CA2274093C - Substituted pyrimidinone and pyridinone compounds and their use - Google Patents

Substituted pyrimidinone and pyridinone compounds and their use Download PDF

Info

Publication number
CA2274093C
CA2274093C CA002274093A CA2274093A CA2274093C CA 2274093 C CA2274093 C CA 2274093C CA 002274093 A CA002274093 A CA 002274093A CA 2274093 A CA2274093 A CA 2274093A CA 2274093 C CA2274093 C CA 2274093C
Authority
CA
Canada
Prior art keywords
radicals
amino
alkyl
alkoxy
radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002274093A
Other languages
French (fr)
Other versions
CA2274093A1 (en
Inventor
Ulrike D. Spohr
Michael J. Malone
Nathan B. Mantlo
Jeffery A. Zablocki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CA2274093A1 publication Critical patent/CA2274093A1/en
Application granted granted Critical
Publication of CA2274093C publication Critical patent/CA2274093C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Selected novel substituted pyrimidinone and pyridone compounds are effective for prophylaxis and treatment of diseases, such as TNF-.alpha., IL-.beta., IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. The invention encompasses novel compounds of the following general formula:
(see formula I) analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for phrophylaxis and treatment of diseases and other maladies or conditions involving inflammation, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Description

., WO 98/24780 PCT/US9'712Z949 SUBSTITUTED PYRIMIDINONE AND PYRIDONE COMPOUNDS AND
METHODS OF USE
BACKGROUND OF THE INVENTION
The present invention comprises a new class of compounds useful in treating diseases, such as TNF-a, IL-lei, IL-6 and/or IL-8 mediated diseases and other maladies, such as pain and diabetes. In particular, the compounds of the invention are useful for the prophylaxis and treatment of diseases or conditions involving inflammation. This invention also relates to intermediates and processes useful in the preparation of such compounds.
Interleukin-1 (IL-1) and Tumor Necrosis Factor Oc (TNF-a) are pro-inflammatory cytokines secreted by a , variety of cells, including monocytes and macrophages, in response to many inflammatory stimuli (e. g., lipopolysaccharide - LPS) or external cellular stress ~(e.g.; osmotic shock and geroxide).
Elevated levels of TNF-a andJor IL-l over basal levels have been implicated in mediating or exacerbating 3C a number of disease states including rheumatoid arthritis; Pagets disease; osteophorosis; multiple myeloma; uveititis; acute and chronic myelogenous , leukemia; pancreatic i~ cell destruction; osteoarthriti.s;
rheumatoid sgondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome CARDS); psoriasis; Crohn's disease; allergic rhinztis;
ulcerative colitis; anaphylaxis; contact dermatitis;
asthma; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; graft vs. host reaction; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection.
HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses (including HSV-1, HSV-2), and herpes zoster are also exacerbated by TNF-a.
It has been reported that TNF-a plays a role in head trauma, stroke, and ischemia. For instance, in animal models of head trauma (rat), TNF-a levels increased in the contused hemisphere (Shohami et al., J.
Cereb. Blood Flow Metab. 14, 615 (1994)). In a rat model of ischemia wherein the middle cerebral artery was occluded, the levels of TNF-a mRNA of TNF-a increased (Feurstein et al., Neurosci. Lett. 164, 125 (1993)).
Administration of TNF-a into the rat cortex has been reported to result in significant neutrophil accumulation in capillaries and adherence in small blood vessels. TNF-a promotes the infiltration of other cytokines (IL-lei, IL-6) and also chemokines, which promote neutrophil infiltration into the infarct area (Feurstein, Stroke 25, 1481 (1994)). TNF-a has also been implicated to play a role in type II diabetes (Endocrinol. 130, 43-52, 1994; and Endocrinol. 13~, 1474-1481, 1995).
TNF-a appears to play a role in promoting certain viral life cycles and disease states associated with them. For in-stance, TNF-a secreted by monocytes induced elevated levels of HIV expression in a chronically infected T cell clone (Clouse et al., J. Immunol. 142, 431 (1989)). Lahdevirta et al., (Am. J. Med. 85, 289 (1988)) discussed the role of TNF-a in the HIV
associated states of cachexia and muscle degradation.

WO 98/24780 PCT/tJS97122949 TNF-oc is upstream in the cytokine cascade of infla_mrnation. As a results elevated levels of TNF-a may 7.ead to elevated levels of other inflammatory and proinflammatory cytokines, such as IL-1, IL-6, and IL-8.
Llevated levels of IL-1 over basal levels have been implicated in mediating or exacerbating a number of disease states including rheumatoid arthritis;
osteoarthritis; rheumatoid spondylitis; gouty arthritis;
inflammatory bowel disease; adult respiratory distress syndrome CARDS); psoriasis; Crohn's disease; ulcerative colitis; anaphylaxis; muscle degeneration; cachexia;
Reiter's syndrome; type I and type II diabetes; bone resorption diseases; ischemia reperfusion injury;
atherosclerosis; brain trauma; multiple sclerosis;
sepsis; septic shock; and toxic shock syndrome. Viruses sensitive to TNF-OC inhibition, e.g., HIV-l, HIV-2, HIV-3, are also affected by IL-1.
TNF-oc and IL-1 appear to play a role in pancreatic f~ cell destruction and diabetes. Pancreatic i3 cells produce insulin which helps mediate blood glucose homeostasis. Deterioration of pancreatic i3 cells often accompanies type I diabetes. Pancreatic Q cell functional abnormalities may occur in patients with type II diabetes. Type II diabetes is characterized by.a functional resistance to insulin: Further, type II
diabetes is also often accompanied by elevated levels of piasna glucagon and increased rates of hepatic glucose production. Glucagon is a regulatory hormone that attenuates Liver gluconeogenesis inhibition by insulin.
Glucagon receptors have been fcund in the liver, kidney and adipose Tissue. Thus glucagon antagonists are useful for attenuating plasma glucose levels (WO
97 / 16442).
By antagonizing the glucagon receptors, it is thought that insulin responsiveness in the liver will improve, thereby decreasing gluconeogenesis and lowering the rate of hepatic glucose production.
In rheumatoid arthritis models in animals, multiple intra-articular injections of IL-1 have led to an acute and destructive form of arthritis (Chandrasekhar et al., Clinical Immunol Immunopathol. 55, 382 (1990)). In studies using cultured rheumatoid synovial cells, IL-1 is a more potent inducer of stromelysin than is TNF-a (Firestein, Am. J. Pathol. 140; 1309 (1992)). At sites of local injection, neutrophil, lymphocyte, and monocyte emigration has been observed. The emigration is attributed to the induction of chemokines (e.g., IL-8), and the up-regulation of adhesion molecules (Dinarello, Eur. Cytokine Netw. 5, 517-531 (1994)) IL-1 also appears to play a role in promoting certain viral life cycles. For example, cytokine-induced increase of HIV expression in a chronically infected macrophage line has been associated with a concomitant and selective increase in IL-1 production (Folks et al., J. Immunol. 136, 40 (1986)). Beutler et al. (J. Immunol. 135, 3969 (1985)) discussed the role of IL-1 in cachexia. Baracos et al. (New Eng. J. Med. 308, 553 (1983)) discussed the role of IL-1 in muscle degeneration.
In rheumatoid arthritis, both IL-1 and TNF-a induce synoviocytes and chondrocytes to produce collagenase and neutral proteases, which leads to tissue destruction within the arthritic joints. In a model of arthritis (collagen-induced arthritis (CIA) in rats and mice), intra-articular administration of TNF-a either prior to or after the induction of CIA led to an accelerated onset of arthritis and a more severe course of the disease (Brahn et al., Lymphokine Cytokine Res. 11, 253 - (1992); and Cooper, Clin. Exp. Immunol. 898, 244 (1992)).
IL-8 has been implicated in exacerbating and/or causing many disease states in which massive neutrophil infiltration into sites of inflammation or injury (e. g., ischemia) is mediated by the chemotactic nature of IL-8, including, but not limited to, the following: asthma, inflammatory bowel disease, psoriasis, adult respiratory 5 distress syndrome, cardiac and renal reperfusion injury, thrombosis and glomerulonephritis. In addition to the chemotaxis effect on neutrophils, IL-8 also has the ability to activate neutrophils. Thus, reduction in IL-8 levels may lead to diminished neutrophil infiltration.
Several approaches have been taken to block the effect of TNF-oc. One approach involves using soluble receptors for TNF-a (e. g., TNFR-55 or TNFR-?5), which have demonstrated efficacy in animal models of TNF-oc-mediated disease states. A second approach to neutralizing TNF-of using a monoclonal antibody specific , to TNF-a, cA2, has demonstrated improvement in swollen joint count in a Phase II human trial of rheumatoid arthritis tFeldmann et al., Immunological Reviews, pp.
195-223 (1995)). These approaches block the effects of TNF-a and IL-1 by either protein sequestration or receptor antagonism.
US 5,100,897 describes pyrimidinone compounds useful as angiotensin II antagonists wherein one of the pyrimidinone ring nitrogen atoms is substituted with a substituted phenylmethyl or pherethyl radical.
US 5,162,325 describes pyrimidinone compounds useful as angiotensin II antagonists wherein one of the pyrimidinone ring nitrogen atoms is substituted with a substituted phenylmethyl radical.
EP 481448 describes pyrimidinone compounds useful as angiotensin II antagonists wherein one of the pyrimidinone ring nitrogen atoms is substituted with a substituted phenyl, phenylmethyl or phenethyl radical.

WO 98/24780 PCTlUS97lZ2949 CA 2,020,370 describes pyrimidinone compounds useful as angiotensin II antagonists wherein one of the pyrimidinone ring nitrogen atoms is substituted with a substituted biphenylaliphatic hydrocarbon radical.
BRIEF DESCRIPTION OF THE INVENTION
The present invention comprises a new class of compounds useful in the prophylaxis and treatment of diseases, such as TNF-OC, IL-1~, IL-6 and/or IL-8 mediated diseases and other maladies, such as pain and diabetes. In particular, the compounds of the invention are useful for the prophylaxis and treatment of diseases or conditions involving inflammation. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds, methods for the prophylaxis and treatment of TNF-OC, IL-lei, IL-6 and/or IL-8 mediated diseases, such as inflammatory, pain and diabetes diseases, using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of the compounds of the invention.
The compounds of the invention are represented by the following general structure:
X

V
~~' wherein the dashed lines represent a double bond between C(R) and V or W (i.e., -V=C(R)- or -W=C(R)-) and V, W, X, R, R" and R'~ are defined below.
.The foregoing merely summarizes certain aspects of the invention and is not intended, nor should it be construed, as limiting the invention in any way.

WO 98!24780 PCT/US97/22949 DETAILED DESCRIPTION OF THE INVENTION
In accordance with the present invention, there is provided compounds of the formula:
X
R1l V

(I) or a pharmaceutically acceptable salt thereof, wherein X is 0, S or NRS; preferably, X is O or S; and most preferably, X is O;
V
' is \y~ ~, R
\N~R3 \N
\N~ R4 \ ~ \N
\Rl \ ~ ~ Rl \ ~ ~R21 R2 N R1 Rq N U
\ N \N
\ \ \N

\ ~ R21 .'' N
n N \
R2i, R2i or R2i ; provided that the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in -VC(R)W- is 0-3, preferably, 0-2, most preferably, 0-1;
a first preferred subgroup of \ / R3 N
V

\W . R R2 a second preferred subgroup of \
N
\V \N~R9 \
; is J\ J\ I R
\W ' R \N R1 or R4 -a third preferred subgroup of N
\V \N N U
is ' ~R21 \ \

\N
\ \N

\ ~ R21 N N
R21 or R21 more preferably, N
\N \N I
\
~1 \ N N"R21 \ ~N N N_R21 N
R21 ~ R
29 or \N ~ _ \N N
R2 i .
most preferably, \N \N
/~ /~ R2a _N ~ i 'N
N ~ N
R2i or R2i - U is NRz1 or CHR~1; preferably, U is NRzl;
n is an integer of 1-3;
R1 and R~ are each independently -Y or -Z-Y, and R3 and R~ are each independently -Z-Y; provided that R4 is other than a substituted-aryl, (substituted-aryl)methyl or lsubstituted-aryl)ethyl radical, and the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Y and -Z-Y is 0-3; preferably, 0-2;
more preferably, 0-1;
preferably, R2 is a radical of hydrogen, C1-C,q alkyl, halo, cyano, hydroxy, CZ-C4 alkoxy, C1-C2 haloalkoxy of 1-3 halo radicals, C1-Cq alkylthio, amino, C1-Cq alkylamino, di-(C1-C4 alkyl)amino or C1-C2 haloalkyl of 1-3 halo radicals; more preferably, R2 is a radical of hydrogen, C1-C4 alkyl, halo, cyano, hydroxy, C1-C4 a'~icoxy, trifluoromethoxy or trifluoromethyl; most preferably, R2 is a hydrogen radical;
preferably, R3 is a hydrogen radical or (1) C1-Cg alkyl or C2-Cg alkenyl radical optionally substituted. by (a) 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-Cq alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl, trifluoromethoxy or trifluoromethyl radicals; or (2) aryl or heteroaryl radical optionally substituted by 5 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, Cl-C4 alkylthio, cyano, halo, C1-C4 alkyl, trifluoromethoxy or trifluoromethyl radicals;
more preferably, R3 is a hydrogen radical or (1) C1-Cg alkyl radical optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di-(C1-Cq alkyl)amino, hydroxy, C1-C4 alkoxy or aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl, trifluoromethoxy or trifluoromethyl radicals; or (2) aryl or heteroaryl radical optionally substituted by-1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C2-C4 alkoxy, C~-C4 alkylthio, cyano, halo, C1-C4 alkyl, trifluoromethoxy or trifluoromethyl radicals;
more preferably, R3 is a hydrogen radical or C1-Cg alkyl 'radical optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, hydroxy, C1-C4 alkoxy or aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C2-C4 alkyl)amino, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl, trifluoromethoxy or trifluoromethyl radicals;
more preferably, R3 is a radical of hydrogen or C1-C4 alkyl; more preferably, R3 is a hydrogen, methyl or ethyl radical;

preferably, R4 is (1) C1-Cg alkyl or C2-Cg alkenyl radical optionally substituted by (a) 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl, trifluoromethoxy or trifluoromethyl radicals; or (2) heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-Cq alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl, trifluoromethoxy or trifluoromethyl radicals;
more preferably, R4 is (1) C1-Cg alkyl radical optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, hydroxy, C1-C4 alkoxy or aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl, trifluoromethoxy or trifluoromethyl radicals; or (2) heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, -Cl-C4 alkyl, trifluoromethoxy or trifluoromethyl radicals;

more preferably, Rg is a C1-Cg alkyl radical optionally substituted by 1-2 radicals of amino, C1-Cg alkylamino, di-(C1-Cg alkyl)amino, hydroxy, C1-Cg alkoxy or aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-Cg alkylamino, di-(C1-Cg alkyl)amino, C1-Cg alkoxy, Cz-Cg alkylthio, halo, Cl-Cg alkyl, trifluoromethoxy or trifluoromethyl radicals;
more preferably, Rg is a C1-Cg alkyl radical; most preferably, Rg is a methyl or ethyl radical;
wherein each Z is independently a (1) alkyl, alkenyl or alkynyl radical optionally substituted by (a) 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, halo, alkyl or haloalkyl;
(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkyl or haloalkyl; or (3) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, halo, alkyl or haloalkyl;
preferably, each Z is independently a (1) C1-Cg alkyl, C2-Cg alkenyl or C2-C8 alkynyl radical optionally substituted by (a) 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-Cg alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-Cg alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 . alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-Cq alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-Cq alkylthio, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
more preferably, each Z is independently a (1) C1-Cg alkyl, C2-Cg alkenyl or C2-Cg alkynyl radical optionally substituted by (a) 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4_ alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 . alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;

(2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C2-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-CQ alkylthio, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
more preferably, each Z is independently a (1) C1-Cg alkyl or C2-Cg alkenyl radical optionally substituted by (a) 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C2-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(C1-C4 alkyl)amino, (C1-C4 _ alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl radicals; or (3) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 -alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;

- . 15 more preferably, each Z is independently a (1) C1-C4 alkyl or C2-C5 alkenyl radical optionally substituted by (a) 1-3 radicals of amino, di-(C1-CZ
alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cz-C2 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(C1-C2 alkyl)amino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio or C1-C4 alkyl radicals; or (3) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
more preferably, each Z is independently a (1) C1-C4 alkyl or C?-C5 alkenyl radical optionally substituted by (a) 1-3 radicals of amino, di-(C1-C2 alkyl)amino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio or halo, and (b) 1-2 radicals of aryl or heteroaryl optionally substituted by 1-2 radicals of amino, di-(C1-C2 alkyl)amino, acetamido, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, halo, C1-C4 alkyl or trifluoromethyl radicals; or (2) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, acetamido, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
more preferably, each Z is independently a C1-Cq alkyl radical optionally substituted by 1-2 radicals of amino, di-(C1-C2 alkyl)amino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, halo or aryl or heteroaryl optionally substituted by 1-2 radicals of hydroxy, C1-C2 alkoxy, C1-C2 al~ylthio, halo, C1-C4 alkyl or trifluoromethyl radicals; and most preferably, each Z is independently a C1-C4 alkyl radical optionally substituted by 1-2 radicals of amino, t-butoxycarbonylamino, dimethylamino, hydroxy, methoxy, methylthio or halo radicals;
each Y is independently a (1) hydrogen radical;
(2) halo or nitro radical;
(3) -C(O)-R2p or -C(NR5)-NR5R21 radical;
4 ) -OR21, -O-C ( O ) -R21, -O-C ( O ) -NR5R21 or -O-C ( O ) -NR22 -S(O)2-R2p radical;
(5) -SR21, -S (O) -R2p, -S (0) 2-R20, -S (0) 2-NR5R21, -S (0) 2-NR22-C (O) -R21, -S (O) 2-NR22-C (O) -OR20 or -S (O) 2-NR22-C (O) -NR5R21 radical; or ( 6 ) -NR5R21, -NR22-C (O) -R21, -NR22-C (O) -OR20, -NR22-C (O) -NR5R21~ -NR22-C (NR5) -NR5R21, -NR22-S (0) 2-R20 or -NR22-S(0)2-NR5R21 radical;
preferably, each Y is independently a (1) hydrogen radical;
(2) halo radical;
(3) -C(O)-R20 or -C(NR5)-NR5R21 radical;
(4) -OR21, -O-C(O)-R21 or -0-C(O)-NR5R21 radical;
(5) -SR21, -S(O)-R2p, -S{0)2-R2p or -S(O)2-NR5R21 radical;
or ( 6 ) -NR5R21, -NR22-C (O) -R21. -NR22-C (O) -OR20. -NR22-C (0) -NR5R21. -NR22-C (NR5 } -NR5R21. -NR22-S (O) 2-R2p or -NR22-S(O)2-NR5R21 radical;
more preferably, each Y is independently a (1) hydrogen radical;
(2 ) -C (O) -R2p radical;
(3) -OR21. -SR21. -S(0)-R2o. -S(O)2-R2p or -S(O)2-NR5R21 radical; or ( 4 ) -NR5R21, -NR22 -C ( O ) -R21. -NR22 -C ( O ) -OR2 0 , -NR22 -C ( O ) NR5R21, -NR22-S(O)2-R20 or -NR22-S(O)2-NR5R21 radical;
more preferably, each Y is independently a (1) hydrogen radical;
(2) -C(O)-R2p radical;
(3) -OR21, -SR21. -S(O)-R20. -S(O)2-R2p or -S(O)2-NR5R21 radical; or (~) -NR5R21, -NR22-C(O)-R21 or -NR22-S(O)2-R20 radical;
more preferably, each Y is independently a (1) -C(O)-R2p radical;
(~) -OR21, -SR21. -S(O)-R2p, -S(O)2-R20 or -S(O)2-NR5R21 :adical; or i'r -NR5R21, -NR22-C(O)-R21 or -NR22-S(O)2-R2p radical.
most preferably, each Y is independently a -OR21, -SR21 or -NR5R21 radical;
wherein each R5 is independently (1) hydrogen radicals;
(2) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, hydroxy, alkoxy, alkylthio, -S03H or halo;
or (3) aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl or cycloalkylalkyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, hydroxy, alkoxy, alkylthio, alkyl or haloalkyl;
preferably, each R5 is independently (1) hydrogen radicals;
(2) C2-Cg alkyl, C2-Cg alkenyl or C2-Cg alkynyl radicals optionally substituted by 1-3 radicals of amino, Cl-Cg alkylamino, di-(C1-C4-alkyl)amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, -S03H or halo; or -(3) aryl, heteroaryl, aryl-C1-C4-alkyl, heteroaryl-C1-C4-alkyl, heterocyclyl; heterocyclyl-C1-C4-alkyl, C3-Cg cycloalkyl or C3-Cg-cycloalkyl-C1-C4-alkyl radicals optionally substituted by 2-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4-alkyl)amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl or C1-Cq haloalkyl of 1-3 halo radicals;
more preferably, each R5 is independently (1) hydrogen radicals;
(2) C1-C4 alkyl, C2-C5 alkenyl or C2-C5 alkynyl radicals optionally subs-tituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4-alkyl)amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, -S03H or halo; or (3) aryl, heteroaryl, aryl-C1-C4-alkyl, heteroaryl-C1-C4-alkyl, heterocyclyl, heterocyclyl-C1-C4-alkyl, C3-Cg cycloalkyl or C3-Cg-cycloalkyl-C1-C4-alkyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4-alkyl)amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
more preferably, each R5 is independently (1) hydrogen radicals;

(2) C1-C4 alkyl or C2-C5 alkenyl radicals optionally substituted by 1-3 radicals of amino, di-(C1-C4-alkyl)amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, -S03H or halo; or (3) phenyl-C1-C2-alkyl, heteroaryl-C1-C2-alkyl, heterocyclyl-C1-C2-alkyl or C3-C6-cycloalkyl-C1-C2-alkyl radicals optionally substituted by 1-3 radicals of amino, di-(C1-C4-alkyl)amino, hydroxy, C1-C4 al~coxy, C1-C4 alkylthio, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
more preferably, each R5 is independently (1) hydrogen radical;
(2) C1-C4 alkyl radical optionally substituted by 1-3 radicals of amino, di-(C1-C2-alkyl)amino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio or halo; or (3) phenyl-C1-C2-alkyl, heteroaryl-C1-C2-alkyl, heterocyclyl-C1-C2-alkyl or C3-C6-cycloalkyl-C1-C2-alkyl radicals optionally substituted by 1-3 radicals of amino, di-(C1-C2-alkyl)amino, hydroxy, C1-C2 alkoxy, C1-CZ alkylthio, methoxy, methylthio, C1-C4 alkyl or trifluoromethyl radicals;
more preferably, each R5 is independently (1) hydrogen radical;
'(2) C1-C4 alkyl radical optionally substituted by 1-3 halo radicals; or (3) phenyl-C1-C2-alkyl or heteroaryl-C1-CZ-alkyl, radicals optionally substituted by 1-3 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, methyl or trifluoromethyl radicals;
more preferably, each R5 is independently hydrogen or C1-C4 alkyl radical; and most preferably, each R5 is a hydrogen radical;

WO 98/247&1 PCT/US97/22949 wherein each R2p is independently (1) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, 5 dialkylamino, alkanoylamino, alkoxycarbonylamino, N-(alkoxycarbonyl)-N-(alkyl)amino, aminocarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, halo or aralkoxy, aralkylthio, aralkylsulfonyl, cycloalkyl, heterocyclyl, 10 aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino,_alkylsulfonylamino, alkanoyl, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, halo, alkyl or haloalkyl;
15 (2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkyl or haloalkyl; or (3) aryl or heteroaryl radicals optionally substituted 20 by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, alkoxycarbonyl, hydroxy, alkoxy, alkylthio, cyano, halo, azido, alkyl or haloalkyl;
preferably, each R2p is independently (1) C1-Cg alkyl, CZ-Cg alkenyl or C2-Cg alkynyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-Cg alkyl)amino, C1-C5 alkanoylamino, (Cl-C4 alkoxy)carbonylamino, N-((C1-C4 alkoxy)carbonyl)-N-(C1-C4 alkyl)amino, aminocarbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo or aryl-C1-C4-alkoxy, aryl-C1-C4-alkylthio, aryl-C1-C4-alkylsulfonyl, C3-Cg cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, C1-C5 alkanoyl, hydroxy, C1-Cq alkoxy, C1-Cq alkylthio, C1-Cq alkylsulfinyl, C1-Cq alkylsulfonyl, halo, C1-Cq alkyl or C1-Cq haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C1-Cq alkylamino, di-(Cl-Cq alkyl)amino, C1-C5 alkanoylamino, (C1-Cq alkoxy)carbonylamino, C1-Cq alkylsulfonylamino, hydroxy, C1-Cq alkoxy, C1-Cq alkylthio, C1-C4 alkyl or C1-Cq haloalkyl of 1-3 halo radicals; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-Cq alkyl)amino, C1-C5 alkanoylamino, (C1-Cq alkoxy)carbonylamino, C1-Cq alkylsulfonylamino, (C1-C4 alkoxy)carbonyl, hydroxy, C1-Cq alkoxy, Cl-Cq alkylthio, cyano, halo, azido, C1-Cq alkyl or C1-Cq haloalkyl of 1-3 halo radicals;
more preferably, each R2p is independently (1) C~-Cg alkyl, C2-C5 alkenyl or C2-C5 alkynyl radicals optionally substituted by 1-3 radicals of amino, C1-Cq alkylamino, di-(Cl-Cq alkyl)amino, C1-C5 alkanoylamino, (C;-Cq alkoxy)carbonylamino, N-((C1-Cq alkoxy)carbonyl)-N-(C1-Cq alkyl)amino, aminocarbonylamino, C1-Cq alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo or aryl-C1-C4-alkoxy, aryl-Cz-Cq-alkylthio, aryl-C1-C4-alkylsulfonyl, C3-Cg cycloalkyl, heterocyclyl, aryl or - 30 heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1 alkoxy)carbonylamino, C1-Cq alkylsulfonylamino, C1-C5 ' alkanoyl, hydroxy, C1-C4 alkoxy, Cl-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C1-C4-alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) aryl or heteroaryl radicals optionally substituted by 1--3 radicals of amino, C1-C4 alkylamino, di-(C1-Cq alkyl)amino, C1-C5 alkanoylamino, (Cl-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
more preferably, each RZp is independently (1) C1-Cg alkyl or C2-C5 alkenyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, N-((C1-C4 alkoxy)carbonyl)-N-(C1-C4 alkyl)amino, aminocarbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo or aryl-C1-CQ-alkoxy, aryl-C1-C4--alkylthio, aryl-C1-C4-alkylsulfonyl, C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkyisulfonylamino, C1-C5 alkanoyl, hydroxy, C1-Cq alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl or C1-CZ haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
more preferably, each R2p is independently (1) C1-Cg alkyl or C2-C5 alkenyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, N-((C1-C4 alkoxy)carbonyl)-N-(C1-Cq alkyl)amino, aminocarbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-Cq alkylsulfonyl, halo or aryl-C1-C4-alkoxy, aryl-C1-C4-alkylthio, aryl-C1-C4-alkylsulfonyl, C3-C6 cycloalkyl, heterocyclyl, aryl, or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, C1-C5 alkanoyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(C1-C4 alkyl)amino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, acetamido, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy)carbonyl, hydroxy, - C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or trifluoromethyl radicals;

more preferably, each R2p is independently (1) C1-Cg alkyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, N-((C1-C4 alkoxy)carbonyl)-N-(C1-C4 alkyl)amino, aminocarbonylamino, hydroxy, C1-C4 alkoxy, Cl-C4 alkylthio, C1-Cq alkylsulfinyl, C2-C4 alkylsulfonyl, halo or C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C~ alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl; or -(3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of (C1-C4 alkoxy)carbonyl, amino, C2-C4 alkylamino, di-(C1-C4 alkyl)amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or trifluoromethyl radicals;
more preferably, each R2p is independently (1) C1-C6 alkyl radicals optionally-substituted by 1-3 radicals of amino, methylamino, dimethylamino, t-butoxycarbonylamino, N-((t-butoxy)carbonyl)-N-(methyl)amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl, methylsulfonyl, halo or C5-C6 cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;

(2) heterocyclyl radical optionally substituted by 1-2 radicals of hydroxy or C1-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, 5 methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
more preferably, each R2o is independently (1) C1-C6 alkyl radicals optionally substituted by 1-3 10 radicals of amino, methylamino, dimethylamino, t-butoxycarbonylamino, N-{(t-butoxy)carbonyl)-N-(methyl)amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl, methylsulfonyl, halo or C5-C6 cycloalkyl., heterocyclyl, 15 phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
(2) heterocyclyl radical; or 20 (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
25 most preferably, each R2p is independently (1) C1-C6 alkyl radicals optionally substituted by 1-3 radicals of amino, methylamino, dimethylamino, hydroxy or phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
(2) heterocyclyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;

each R21 is independently hydrogen radical or R2o: , each R22 is independently (1) hydrogen radical;
(2) alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo, alkyl or haloalkyl; or (3) heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo, alkyl or haloalkyl; provided when Z is a bond and Y is -NR22-C(O)-NH2, then R22 is other then an optionally substituted aryl radical;
preferably, each R22 is independently (1) hydrogen radical;
(2) C1-C4 alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-Cq alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (Cl-Cq alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C2-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, Cl-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of-1-3 halo radicals; provided when Z is a WO 98!24780 PCT/US97/22949 bond and Y is -NR22-C(O)-NH2, then R22 is other then an optionally substituted aryl radical;
more preferably, each R22 is independently (1) hydrogen radical; or (2) C1-Cq alkyl radical optionally substituted by a radical of phenyl or heteroaryl optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
more preferably, each R22 is independently hydrogen or C1-C4 alkyl radical; and most preferably, each R22 is independently hydrogen or methyl radical;
R11 and R12 are each independently an aryl or heteroaryl radical optionally substituted by 1-3 radica-is of (1) R3p;
(2) halo or cyano radicals;
(3 ) -C (O) -R3p, -C (O) -OR2g, -C (O) -NR31R32 or -C (NR31) -NR31R32 radicals;
( 4 ) -OR2 g , -O-C ( 0 ) -R2 g , -O-C ( O ) -NR31R3 2 or -O-C ( O ) -NR3 3 -S(O)2-R3p radicals;
(5) -SR2g, -S(O)-R30~ -S(O)2-R30~ -S(O)2-NR31R32~ -S(0)2-NR33-C (O) -R3o, -S (O) 2-NR33-C (O) -OR3p or -S {O) 2-NR33-C (O) -NR31R32 radicals; or (6) -NR31R32, -NR33-C(0)-R2g, -NR33-C(O)-OR3p. -NR33-C(O)-NR31R32, -NR33-C(NR31)-NR31R32, -NR33-S(0)2-R3p or -NR33-S{O)2-NR31R32 radicals;
provided that (1) R11 is other than a 4-pyridyl, 4-- pyrimidinyl, 4-quinolyl or 6-isoquinolinyl radical optionally substituted by 1-2 substituents; and (2) the _ total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R11 and R12 is 0-1;

preferably, R11 and R12 are each independently an aryl or heteroaryl radical optionally substituted by 1-2 radicals of (1) R3o;
(2) halo or cyano radicals;
(3 ) -C (O) -R3p, -C (0) -OR29, -C (O) -NR31R32 or -C (NR31) -NR31R32 radicals;
( 4 ) -OR2 g , -O-C ( O ) -R2 g , -O-C ( O ) -NR31R32 or -O-C ( O ) -NR3 3 -S(O)2-R3p radicals;
(5) -SR29. -S(O)-R30. -S(O)2-R30. -S(O)2-NR31R32. -S(0)2-NR33-C (O) -R3p, -S (0) 2-NR33-C (O) -OR3p or -S (O) 2-NR33-C (0) -NR31R32 radicals; or ( 6 ) -NR31R32. -NR33-C (0) -R29. -NR33-C (O) -OR30. -NR33-C (O) _ NR31R32. -NR33-~C(NR31)-NR31R32. -NR33-S(O)2-R30 or -NR33-S(O)2-NR31R32 radicals;
provided that (1) R11 is other than a 4-pyridyl, 4-pyrimidinyl, 4-quinolyl or 6-isoquinolinyl radical optionally substituted by 1-2 substituents; and (2) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R11 and R12 is 0-1;
more preferably, R11 and R12 are each independently an aryl or heteroaryl radical optionally substituted by 1-2 radicals of (1) R30;
(2) halo or cyano radicals;
( 3 ) -C (O) -R3p, -C (O) -OR29, -C (O) -NR31R32 or -C (NR~~ ) -NR31R32 radicals; or (4) -OR2g, -SR29. -S (O) -R30. -S (O) 2-R30. -S (0) 2-NR31R32.
-NR31R32. -NR33-C (O) -R29 or -NR33-C (O) -OR30 radicals;
more preferably, Rll is an aryl radical and R12 is a heteroaryl radical, wherein the aryl and heteroaryl --radicals are optionally substituted by 1-2 radicals of (1) R30%
(2) halo or cyano radicals;
( 3 ) -C ( O ) -R3 0 , -C ( O ) -OR2 g , -C ( O ) -NR31R32 or -C ( NR31 ) -NR31R32 radicals; or (4) -OR29, -SR29, -S(O)-R30. -S(O)2-R30, -S(O)2-NR31R32.
-NR31R32 or -NR33-C(O)-R2g radicals;
more preferably, R11 is an aryl radical and R12 is a heteroaryl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of (1) R30%
(2) halo or cyano radicals; or (3) -C(O)-NR31R32~ -OR29, -SR29~ -S(O)-R30. -S(0)2-R3p, _ S(O)2-NR31R32, -NR31R32 or -NR33-C(O)-R2g radicals;
more preferably, R11 is an aryl radical optionally substituted by 1-2 radicals of (1) R30; (2) halo or cyano radicals; or (3) -C(O)-NR31R32~ -OR29. -SR2g, -S (O) -R30 ~ -S (O) 2-R30. -S (O) 2-NR31R32 ~ -NR31R32 fir' -NR33-C(O)-R2g radicals; more preferably, Rll is an aryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl, methylsulfonyl, aminocarbonyl, methyl or trifluoromethyl radicals; more preferably, R11 is an unsubstituted phenyl or naphthyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl, methylsulfonyl, aminocarbonyl, methyl or trifluoromethyl radicals; and most preferably, R11 is an unsubstituted phenyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfonyl, methyl or trifluoromethyl radicals;

more preferably, R12 is a heteroaryl radical optionally substituted by 1-2 radicals of (1) R3p; (2) halo or cyano radicals; or (3) -C(O)-NR31R32, -OR2g, -SR2g, -NR31R32 or -NR33-C(O)-R2g radicals; more preferably, R12 5 is a heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals; more preferably, R12 is a 4-pyridyl, 4-quinolinyl, 4-imidazolyl or 4-pyrimidinyl radical 10 optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals; and most preferably, R12 is a 4-pyridyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, 15 halo, cyano, methoxy, methyl or trifluoromethyl radicals;
wherein each R3p is independently (1) alkyl, alkenyl or alkynyl radicals optionally 20 substituted by 1-3 radicals of -NR31R31~ -C~2R23.
hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo or aralkoxy, aralkylthio, aralkylsulfonyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of 25 amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo, alkyl or haloalkyl;
(2) heterocyclyl radical optionally substituted by 1-3 30 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl;
or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, halo, alkyl or haloalkyl;
preferably, each R3p is-independently (1) C1-C4 alkyl, C2-Cq alkenyl or C2-C4 alkynyl radicals - optionally substituted by 1-3 radicals of -NR31R31, -C02R23, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, cyano, halo or aryl-C1-C4-alkoxy, aryl-C1-C4-alkylthio, aryl-C1-C4-alkylsulfonyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-Cq alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, cyano, halo, C1-C4 alkyl or C1-C.~ haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-Cq -alkoxy)carbonylamino, C1-C~ alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-Cq alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
more preferably, each R3p is independently -- (1) C1-C4 alkyl radical optionally substituted by 1-3 radicals of (a) -NR31R31;
(b) C1-C4 alkoxy-carbonyl or phenoxycarbonyl or phenylmethoxycarbonyl optionally substituted by 1-3 WO 98/2478fl PCT/US97I22949 radicals of amino, alkylamino, di-(C1-C4-alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, CZ-C4 alkyl or trifluoromethyl;
or (c) hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, or phenyl-C1-C4-alkoxy, phenyl-C1-C4-alkylthio, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radical;
(2) C1-Cq haloalkyl of 1-3 halo radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (Cl-C4 alkoxy)carbonylamino, hydroxy, C1-Cq alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
more preferably, each R3p is independently i:) C,-C4 alkyl radical optionally substituted by ~G) amino, C1-Cq alkylamino or di-(C1-C4-alkyl)amino radicals; or (b) hydroxy, C1-C4 alkoxy, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
(2) Cl-C2 haloalkyl of 1-3 halo radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C~ alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
more preferably, each R3p is independently (1) C1-C, alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, acetamido, hydroxy, C1-CZ alkoxy, halo, C1-C4 alkyl or trifluoromethyl radicals;
(2) trifluoromethyl radical; or (3) aryl or heteroaryl radicals optionally substituted by I-3 radicals of amino, di-(C1-C2 alkyl)amino, acetamido, hydroxy, C1-C2 alkoxy, halo, C1-C4 alkyl or tr~~luoromethyl radicals;
more preferably, each R3p is independently (1) C1-Cq alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
(~) trifluoromethyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
most preferably, R3p is independently (1) C1-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
(2) trifluoromethyl radical; or 34 ' (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl -radicals;
each R2g is independently hydrogen radical or R3p; and most preferably, R29 is an aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amin6, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
each R31 is independently (1) hydrogen radicals;
(2) alkyl radical optionally substituted by an cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or (3) aryl, heteroaryl, heterocyclyl or cycloalkyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl;
preferably, each R31 is independently (1) hydrogen radicals;
(2) C1-C4 alkyl radical optionally substituted by an C3-Cg cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-CQ alkyl)amino, Cl-C5 alkanoylamino, (C1-Cq alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C~-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) aryl, heteroaryl, heterocyclyl or C3-Cg cycloalkyl radical optionally substituted by 1-3 radicals of amino, Cl-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyorno, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 5 halo radicals;
more preferably, each R31 is independently (1) hydrogen radicals; or (2) C1-C4 alkyl radical optionally substituted by an 10 phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C2-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-Cq alkylthio, cyorno, C1-C4 alkyl or trifluoromethyl 15 radicals;
more preferably, each R31 is independently hydrogen or C1-C4 alkyl radicals; and most preferably, each R31 is independently hydrogen, methyl or ethyl radicals;
each R32 is independently (1) hydrogen radicals;
(2) alkyl radical optionally substituted by an cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyorno, alkyl or haloalkyl; or (3) aryl, heteroaryl, heterocyclyl or cycloalkyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyorno, alkyl or haloalkyl;
preferably, each R32 is independently (1) hydrogen radicals;

(2) C1-C4 alkyl radical optionally substituted by an C3-Cg cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, Cl-C4 alkylamino, di-(C1-Cq alkyl)amino, C1-C5 alkanoylamino~
(C1-Cq alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-Cq haloalkyl of 1-3 halo radicals; or (3) aryl, heteroaryl, heterocyclyl or C3-Cg cycloalkyl radical optionally substituted by 1-3 radicals of amino, C1-Cq alkylamino, di-(C1-Cg alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-Cq alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
more preferably, each R32 is independently (1) hydrogen radicals;
~2) C1-C4 alkyl radical optionally substituted by an C3-C6 cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C~-Cq alkoxy)carbonylamino, C1-Cq alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-Cq alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) aryl, heteroaryl, heterocyclyi or C3-C6 cycloalkyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C~-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-Cq - 30 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
more preferably, each R32 is independently (1) hydrogen radicals;

(2) C1-C4 alkyl radical optionally substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-Cq alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkyl or trifluoromethyl radicals; or (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-Cq alkoxy, C1-C4 alkyl or trifluoromethyl radicals;
more preferably, each R32 is independently (1) hydrogen radicals;
(2) C1-C4 alkyl radical or C1-C2 alkyl radical substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals; or (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals;
most preferably, R32 is independently (1) hydrogen or C1-C4 alkyl radical; or (2) phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals;
and wherein each_R33 is independently (1) hydrogen radical; or (2) alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl;
preferably, each R33 is independently (1) hydrogen radical; or (2) C1-C4 alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-Cq alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, Cl-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
more preferably, each R33 is independently hydrogen or C1-C4 alkyl radical; and most preferably, eachR33 is independently hydrogen or methyl radical.
The compounds of this invention may have in general several asymmetric centers and are typically depicted in the form of racemic mixtures. This invention is intended to encompass racemic mixtures, partially racemic mixtures and separate enantiomers and diasteromers.
Compounds of interest include the following:
O
R11 ~CH3 wherein Rll, R12, and Rl are one of the combinations given in the following table:
R R R _ Phen 1 4- rid 1 1- i erazin 1 4-fluoro henyl 4- _ 1 1- i erazin 1 rid 3-fluoro hen 1 4- rid 1 1- i erazin 1 2-fluoro hen 1 4- rid 1 1- i erazin 1 4-chlorophen 1 4- rid 1 1- i erazin 1 3-chloro hen 1 4- rid 1 1- iperazinyl 2-chloro hen 1 4- rid 1 1- i erazin 1 4-tol 1 4- ridyl.., 1- i erazin 1 3-tol 1 4- rid 1 1- i erazin 1 2-tol 1 4- rid 1 1- i erazin 1 4-trifluoro- 4-pyridyl 1-piperazinyl meth 1 hen 1 3-trifluoro- 4-pyridyl 1-piperazinyl meth 1 hen 1 2,6- 4-pyridyl 1-piperazinyl dichloro hen 1 2,6-dimethyl 4-pyridyl 1-piperazinyl -hen 1 3,4- 4-pyridyl 1-piperazinyl dichloro hen 1 3,4-dimethyl 4-pyridyl 1-piperazinyl hen 1 2,4- 4-pyridyl 1-piperazinyl dichloro hen 1 2,4-dimethyl 4-pyridyl 1-piperazinyl hen 1 Phenyl 2-amino-4- 1-piperazinyl rid 1 4-fluorophenyl 2-amino-4- 1-piperazinyl rid 1 3-fluorophenyl 2-amino-4- 1-piperazinyl ridyl 2-fluorophenyl 2-amino-4- 1-piperazinyl ridyl 4-chlorophenyl 2-amino-4- 1-piperazinyl rid 1 3-chlorophenyl 2-amino-4- 1-piperazinyl rid 1 2-chlorophenyl 2-amino-4- 1-piperazinyl rid 1 4-tolyl 2-amino-4- 1-piperazinyl rid 1 3-tolyl 2-amino-4- 1-piperazinyl rid 1 ~2-tolyl 2-amino-4- 1-piperazinyl rid 1 4-trifluoro- 2-amino-4- 1-piperazinyl meth 1 hen 1 rid 1 3-trifluoro- 2-amino-4- 1-piperazinyl meth 1 hen 1 rid 1 2,6- 2-amino-4- 1-piperazinyl dichloro hen 1 rid 1 2,6-dimethyl 2-amino-4- 1-piperazinyl hen 1 rid 1 3,4- 2-amino-4- 1-piperazinyl dichloro hen 1 rid 1 3,4-dimethyl 2-amino-4- 1-piperazinyl hen 1 rid 1 2,4- 2-amino-4- 1-piperazinyl dichloro hen 1 rid 1 2,4-dimethyl 2-amino-4- 1-piperazinyl ~

hen 1 rid 1 Phenyl 2-acetamido- 1-piperazinyl 4- rid 1 4-fluorophenyl 2-acetamido- 1-piperazinyl 4- ridyl 3-fluorophenyl 2-acetamido- 1-piperazinyl 4- rid 1 2-fluorophenyl 2-acetamido- 1-piperazinyl 4- rid 1 4-chlorophenyl 2-acetamido- 1-piperazinyl 4- rid 1 3-chlorophenyl 2-acetamido- 1-piperazinyl 4- rid 1 2-chlorophenyl 2-acetamido- 1-piperazinyl 4- rid 1 4-tolyl 2-acetamido- 1-piperazinyl 4- yrid 1 3-tolyl 2-acetamido- 1-piperazinyl 4- rid 1 2-tolyl 2-acetamido- 1-piperazinyl 4-p rid 1 4-trifluoro- 2-acetamido- 1-piperazinyl meth 1 hen 1 4- rid 1 3-trifluoro- 2-acetamido- 1-piperazinyl meth 1 hen 1 4- rid 1 2,6- 2-acetamido- 1-piperazinyl dichloro hen 1 4-pyrid 1 2,6-dimethyl 2-acetamido- 1-piperazinyl hen 1 4- rid 1 3,4- 2-acetamido- 1-piperazinyl dichloro hen 1 4- rid 1 3,4-dimethyl 2-acetamido- 1-piperazinyl hen 1 4- yrid 1 ..,4- 2-acetamido- 1-piperazinyl ,d:chloro hen 4- rid 1 4-dimethyl 2-acetamido- 1-piperazinyl hen 1 4- rid 1 Phenyl 2-amino-4- 1-piperazinyl rimidin 1 4-fluorophenyl 2-amino-4- 1-piperazinyl rimidin 1 3-fluorophenyl 2-amino-4- 1-piperazinyl rimidin 1 2-fluorophenyl 2-amino-4- 1-piperazinyl rimidin 1 4-chlorophenyl 2-amino-4- 1-piperazinyl rimidin 1 3-chlorophenyl 2-amino-4- 1-piperazinyl rimidin 1 2-chlorophenyl 2-amino-4- 1-piperazinyl rimidin 1 4-tolyl 2-amino-4- 1-piperazinyl rimidin 1 3-tolyl 2-amino-4- 1-piperazinyl _ rimidin 1 _ 2-tolyl 2-amino-4- 1 -piperazinyl rimidin1 4-trifluoro- 2-amino-4- 1-piperazinyl meth 1 hen 1 rimidin 1 3-trifluoro- 2-amino-4- 1-piperazinyl meth 1 hen 1 rimidin 1 2 ri 1 piperazinyl dichloro hen 1 midin 1 2,6-dimethyl 2-amino-4- 1-piperazinyl hen 1 rimidin 1 3,4- 2-amino-4- 1-piperazinyl dichloro hen 1 rimidin 1 3,4-dimethyl 2-amino-4- 1-piperazinyl phen 1 rimidin 1 2,4- 2-amino-4- 1-piperazinyl dichloro hen 1 rimidin 1 2,4-dimethyl 2-amino-4- 1-piperazinyl hen 1 rimidin 1 Phenyl 4-pyridyl 2-(2-chlorophenyl) eth lamino 4-fluorophenyl 4-pyridyl 2-(2-chlorophenyl) ethylamino 3-fluorophenyl 4-pyridyl 2-(2-chlorophenyl) eth lamino 2-fluorophenyl 4-pyridyl 2-(2-chlorophenyl) eth lamino 4-chlorophenyl 4-pyridyl 2-(2-chlorophenyl) eth lamino 3-chlorophenyl 4-pyridyl 2-(2-chlorophenyl) eth lamino 2-chlorophenyl 4-pyridyl 2-(2-chlorophenyl) eth lamino 4-tolyl 4-pyridyl 2-(2-chlorophenyl) eth lamino 3-tolyl 4-pyridyl 2-(2-chlorophenyl) eth lamino 2-tolyl 4-pyridyl 2-(2-chlorophenyl) eth lamino 4-trifluoro- 4-pyridyl 2-(2-chlorophenyl) meth 1 hen 1 eth lamino 3-trifluoro- 4-pyridyl 2-(2-chlorophenyl) meth 1 hen 1 eth lamino 2,6- 4-pyridyl 2-(2-chlorophenyl) dichloro hen 1 eth lamino 2,6-dimethyl 4-pyridyl 2-(2-chlorophenyl) hen 1 eth lamino 3,4- 4-pyridyl 2-(2-chlorophenyl) dichloro hen 1 eth lamino 3,4-dimethyl 4-pyridyl 2-(2-chlorophenyl) hen 1 eth lamino 2;4- 4-pyridyl 2-(2-chlorophenyl) dichloro hen 1 eth lamino 2,4-dimethyl 4-pyridyl 2-(2-chlorophenyl) henyl eth lamino 4-fluorophenyl 4-pyridyl 3-(3-fluorophenyl) ro ylamino 4-fluorophenyl 2-amino-4- 3-(3-fluorophenyl) rimidin 1 pro lamino Benz 1 4- rid 1 3-phen 1 ro ylamino benzyl 4-pyridyl 2-(4-fluorophenyl) eth lamino 2-thienyl 4- rid 1 3-phen 1 ro lamino 2-thienyl 4-pyridyl 2-(4-fluorophenyl) ethylamino c clohexyl 4-p rid 1 3- hen lpro lamino cyclohexyl 4-pyridyl 2-(4-fluorophenyl) eth lamino tert-but 1 4-p rid 1 3- hen lpro lamino tert-butyl 4-pyridyl 2-(4-fluorophenyl) ethylamino 4-fluorophenyl 4- 3-phenylpropylamino iperidinyl 4-fluorophenyl 4- 2-(4-fluorophenyl) pi eridin 1 ethylamino 4-fluoro henyl 4- yran 1 3-phen lpro ylamino 4-fluorophenyl 4-pyranyl 2-(4-fluorophenyl) eth lamino Phenyl 2-amino-4- 2-(2-chlorophenyl) yrid 1 ethylamino 4-fluorophenyl 2-amino-4- 2-(2-chlorophenyl) p ridyl eth lamino 3-fluorophenyl 2-amino-4- 2-(2-chlorophenyl) pyrid 1 ethylamino 2-fluorophenyl 2-amino-4- 2-(2-chlorophenyl) rid 1 eth lamino 4-chlorophenyl 2-amino-4- 2-(2-chlorophenyl) rid 1 eth lamino 3-chlorophenyl 2-amino-4- 2-(2-chlorophenyl) pyridyl eth lamino 2-chlorophenyl 2-amino-4- 2-(2-chlorophenyl) rid 1 eth lamino 4-tolyl 2-amino-4- 2-(2-chlorophenyl) rid 1 ethylamino 3-tolyl 2-amino-4- 2-(2-chlorophenyl) p rid 1 eth lamino _ 2-tolyl 2-amino-4- 2-(2-chlorophenyl) rid 1 eth 1amino 4-trifluoro- 2-amino-4- 2-(2-chlorophenyl) meth 1 hen 1 rid 1 eth lamino 3-trifluoro- 2-amino-4- 2-(2-chlorophenyl) methyl hen 1 rid 1 eth lamino 2,6- 2-amino-4- 2-(2-chlorophenyl~

dichloro hen 1 rid 1 eth lamino 2,6-dimethyl 2-amino-4- 2-(2-chlorophenyl) phen 1 p ridyl eth lamino 3,4- 2-amino-4- 2-(2-chlorophenyl) dichloro hen 1 rid 1 eth lamino 3,4-dimethyl 2-amino-4- 2-(2-chlorophenyl) hen 1 rid 1 eth lamino 2,4- 2-amino-4- 2-(2-chlorophenyl) dichlor o eth lamino hen 1 yrid 1 2,4-dimethyl 2-amino-4- 2-(2-chlorophenyl) hen 1 rid 1 eth lamino Phenyl 2-acetamido- 2-(2-chlorophenyl) 4- rid 1 eth lamino 4-fluorophenyl 2-acetamido- 2-(2-chlorophenyl) 4- rid 1 eth lamino 3-fluorophenyl 2-acetamido- 2-(2-chlorophenyl) 4- rid 1 ethlamino 2-fluorophenyl 2-acetamido- 2-(2-chlorophenyl) 4- rid 1 eth lamino 4-chlorophenyl 2-acetamido- 2-(2-.chlorophenyl) 4- rid 1 eth lamino 3-chlorophenyl 2-acetamido- 2-(2-chlorophenyl) 4- rid 1 eth lamino 2-chlorophenyl 2-acetamido- 2-(2-chlorophenyl) 4- rid 1 eth lamino 4-tolyl 2-acetamido- 2-(2-chlorophenyl) 4- rid 1 eth lamino 3-tolyl 2-acetamido- 2-(2-chlorophenyl) 4- rid 1 eth lamino 2-tolyl 2-acetamido- 2-(2-chlorophenyl) 4- rid 1 eth lamino 4-trifluoro- 2-acetamido- 2-(2-chlorophenyl) meth 1 hen 1 4- rid 1 eth lamino 3-trifluoro- 2-acetamido- 2-(2-chlorophenyl) meth 1 hen 1 4- rid 1 eth lamino 2,6- 2-acetamido- 2-(2-chlorophenyl) d:chloro hen 1 4- ridyl eth lamino -dimethyl 2-acetamido- 2-(2-chlorophenyl) 'paeny? 4- rid 1 th lamino e ~.4- 2-acetamido- 2-(2-chlorophenyl) dichloro hen 1 4- rid 1 eth lamino 3,4-dimethyl 2-acetamido- 2-(2-chlorophenyl) hen 1 4- rid 1 eth lamino 2,4- 2-acetamido- 2-(2-chlorophenyl) dichloro hen 1 4- rid 1 eth lamino 2,4-dimethyl 2-acetamido- 2-(2-chlorophenyl) hen 1 4- rid 1 eth lamino Phenyl 2-amino-4- 2-(2-chlorophenyl) rimidin 1 eth lamino 4-fluorophenyl 2-amino-4- 2-(2-chlorophenyl) rimidin 1 eth lamino 3-fluorophenyl 2-amino-4- 2-(2-chlorophenyl) rimidin 1 eth lamino 2-fluorophenyl 2-amino-4- 2-(2-chlorophenyl) rimidin 1 eth lamino 4-chlorophenyl 2-amino-4- 2-(2-chlorophenyl) rimidin 1 eth lamino 3-chlorophenyl 2-amino-4- 2-(2-chloropheny~) rimidinrl ethylamino 2-chlorophenyl 2-amino-4- 2-(2-chlorophenyl) rimidin 1 eth lamino 4-tolyl 2-amino-4- 2-(2-chlorophenyl) rimidin 1 eth lamino 3-tolyl 2-amino-4- 2-(2-chlorophenyl) rimidin 1 ethylamino 2-tolyl 2-amino-4- 2-(2-chlorophenyl) rimidin 1 eth lamino 4-trifluoro- 2-amino-4- 2-(2-chlorophenyl) meth lphen 1 p rimidin 1 eth lamino 3-trifluoro- 2-amino-4- 2-(2-chlorophenyl) meth 1 henyl rimidin 1 eth lamino 2,6- 2-amino-4- 2-(2-chlorophenyl) dichlorophen 1 rimidinyl eth lamino 2,6-dimethyl 2-amino-4- 2-(2-chlorophenyl) phen 1 rimidin 1 ethylamino 3,4- 2-amino-4- 2-(2-chlorophenyl) dichlorophen 1 rimidin 1 ethylamino 3,4-dimethyl 2-amino-4- 2-(2-chlorophenyl) henyl rimidin 1 eth lamino 2,4- 2-amino-4- 2-(2-chlorophenyl) dichloro henyl rimidin 1 eth lamino 2,4-dimethyl 2-amino-4- 2-(2-chlorophenyl) henyl rimidin 1 eth lamino Phenyl 4- rid 1 3-imidazol lpropylamino 4-fluorophen 1 4- yrid 1 3-imidazol 1 ro lamino 3-fluoro hen 1 4- rid 1 3-imidazol 1 ro lamino 2-fluoro hen 1 4- rid 1 3-imidazol 1 ro lamino 4-chloro hen 1 4- rid 1 3-imidazol lpro lamino 3-chloro hen 1 4- yrid 1 3-imidazolyl ro lamino 2-chlorophenyl 4-pyridyl 3-imidazol 1 ro lamino 4-tol 1 4- rid 1 3-imidazol 1 ro lamino 3-tol 1 4- rid 1 3-imidazol lpro lamino 2-tol 1 4- rid 1 3-imidazolyl ro lamino 4-trifluoro- 4-pyridyl 3-imidazolylpropylamino meth 1 hen 1 3-trifluoro- 4-pyridyl 3-imidazolylpropylamino meth 1 hen 1 2,6- 4-pyridyl 3-imidazolylpropylamino dichloro hen 1 2,6-dimethyl 4-pyridyl 3-imidazolylpropylamino hen 1 3,4- 4-pyridyl 3-imidazolylpropylamino dichloro hen 1 3,4-dimethyl 4-pyridyl 3-imidazolylpropylamino hen 1 2,4- 4-pyridyl 3-imidazolylpropylamino dichloro hen 1 2,4-dimethyl 4-pyridyl 3-imidazolylpropylamino hen 1 Phenyl 2-amino-4- 3-imidazolylpropylamino rid 1 WO 98/2478(1 PCT/US97/22949 4-fluorophenyl 2-amino-4- 3-imidazolylpropylamino ~

rid 1 3-fluorophenyl 2-amino-4- 3-imidazolylpropylamino rid 1 2-fluorophenyl 2-amino-4- 3-imidazolylpropylamino rid 1 4-chlorophenyl 2-amino-4- 3-imidazolylpropylamino rid 1 3-chlorophenyl 2-amino-4- 3-imidazolylpropylamino rid 1 2-chlorophenyl 2-amino-4- 3-imidazolylpropylamino rid 1 4-tolyl 2-amino-4- 3-imidazolylpropylamino rid 1 3-tolyl 2-amino-4- 3-imidazolylpropylamino rid 1 2-tolyl 2-amino-4- 3-imidazolylpropylamino rid 1 4-trifluoro- 2-amino-4- 3-imidazolylpropylamino meth 1 hen 1 rid 1 3-trifluoro- 2-amino-4- 3-imidazolylpropylamino meth 1 hen 1 ridyl 2,6- 2-amino-4- 3-imidazolylpropylamino dichloro hen 1 rid 1 2,6-dimethyl 2-amino-4- 3-imidazolylpropylamino hen 1 yrid 1 3,4- 2-amino-4- 3-imidazolylpropylamino dichloro hen 1 rid 1 3,4-dimethyl 2-amino-4- 3-imidazolylpropylamino phenyl rid 1 2,4- 2-amino-4- 3-imidazolylpropylamino dichloro hen 1 rid 1 2,4-dimethyl 2-amino-4- 3-imidazolylpropylamino henyl rid 1 Phenyl 2-acetamido- 3-imidazolylpropylamino 4- rid 1 4-fluorophenyl 2-acetamido- 3-imidazolylpropylamino 4- rid 1 3-fluorophenyl 2-acetamido- 3-imidazolylpropylamino 4- rid 1 2-fluorophenyl 2-acetamido- 3-imidazolylpropylamino 4- rid 1 4-chlorophenyl 2-acetamido- 3-imidazolylpropylamino 4- rid 1 3-chlorophenyl 2-acetamido- 3-imidazolylpropylamino 4- rid 1 2-chlorophenyl 2-acetamido- 3-imidazolylpropylamino 4- rid 1 4-tolyl 2-acetamido- 3-imidazolylpropylamino 4- rid 1 3-tolyl 2-acetamido- 3-imidazolylpropylamino 4- rid 1 2-tolyl 2-acetamido- 3-imidazolylpropylamino 4- rid 1 4-trifluoro- 2-acetamido- 3-imidazolylpropylamino meth 1 hen 1 4- rid 1 3-trifluoro- 2-acetamido- 3-imidazolylpropylamino meth 1 hen 1 4- rid 1 2,6- 2-acetamido- 3-imidazolylpropylamino dichlorophen 1 4- rid 1 2,6-dimethyl 2-acetamido- 3-imidazolylpropylamino phen 1 4- rid 1 3,4- 2-acetamido- 3-imidazolylpropylamino dichlorophen 1 4- yrid 1 3,4-dimethyl 2-acetamido- 3-imidazolylpropylamino hen 1 4- rid 1 2,4- 2-acetamido- 3-imidazolylpropylamino dichloro hen 1 4- yrid 1 2,4-dimethyl 2-acetamido- 3-imidazolylpropylamino hen 1 4- yrid 1 Phenyl 2-amino-4- 3-imidazolylpropylamino rimidin 1 4-fluorophenyl 2-amino-4- 3-imidazolylpropylamino rimidin 1 3-fluorophenyl 2-amino-4- 3-imidazolylpropylamino rimidin 1 2-fluorophenyl 2-amino-4- 3-imidazolylpropylamino yrimidin 1 4-chlorophenyl 2-amino-4- 3-imidazolylpropylamino pyrimidinyl 3-chlorophenyl 2-amino-4- 3-imidazolylpropylamino pyrimidinyl 2-chlorophenyl 2-amino-4- 3-imidazolylpropylamino rimidin 1 4-tolyl 2-amino-4- 3-imidazolylpropylamino yrimidin 1 3-tolyl 2-amino-4- 3-imidazolylpropylamino rimidin 1 ..-tolyl 2-amino-4- 3-imidazolylpropylamino pyrimid_in 4-trifluoro- 2-amino-4- 3-imidazolyipropylamino meth 1 hen 1 rimidin 1 3-trifluoro- 2-amino-4- 3-imidazolylpropylamino meth 1 hen 1 rimidin 1 2,6- 2-amino-4- 3-imidazolylpropylamino dichloro henyl rimidin 1 2,6-dimethyl 2-amino-4- 3-imidazolylpropylamino hen 1 rimidin 1 3,4- 2-amino-4- 3-imidazolylpropylamino dichloro hen 1 rimidin 1 3,4-dimethyl 2-amino-4- 3-imidazolylpropylamino hen 1 rimidin 1 2,4- 2-amino-4- 3-imidazolylpropylamino dichloro hen 1 rimidin 1 2,4-dimethyl 2-amino-4- 3-imidazolylpropylamino hen 1 rimidin 1 4-fluorophenyl 4-pyridyl 2-(2-chlorophenyl-1-meth 1)eth 1)amino 4-fluorophenyl 2-acetamido- 2-(2-chlorophenyl-1-4- rid 1 meth 1)eth 1)amino 4-fluorophenyl 2-amino-4- 2-(2-chlorophenyl-1-rimidin 1 meth 1)eth 1)amino 3-fluorophenyl 4-pyridyl (S)-tetrahydroisoquinol-3- lmeth lenamino 2-fluorophenyl 2-amino-4- (S)-3-benzylpiperazinyl rid 1 3-chlorophenyl 2-acetamido- (S)-2-N-isopropylamino-3-4- rid 1 hen 1 ro lamino 2-chlorophenyl 2-amino-4- (S)-2-N-glycylamino-3-rimidin 1 hen 1 ro lamino 4-tolyl 4-pyridyl (S)-2-amino-3-hen 1 rop lamino 3-tolyl 2-amino-4- (R)-2-amino-3-rid 1 hen 1 ro lamino 2-tolyl 2-acetamido- 3-amino-3- -4- rid 1 hen 1 ro lamino 4-trifluoro- 2-amino-4- (S)-2-amino-3-(2-meth 1 hen 1 rimidin 1 fluoro hen 1) ro lamino 3-trifluoro- 4-pyridyl (S)-2-amino-3-(2-meth 1 henyl meth 1 hen 1) ro lamino 2,6- 2-amino-4- 3-amino-3-(2-dichloro hen 1 rid 1 fluoro hen 1) ro lamino 2,6-dimethyl 2-acetamido- 3-amino-3-(2-hen 1 4- rid 1 meth 1 hen 1) ro lamino 3,4- 2-amino-4- 2-amino-2-methyl-3-dichloro hen 1 rimidin 1 phenyl ro lamino 3,4-dimethyl 4-pyridyl 3-amino-2-methyl-3-hen 1 phen 1 ro lamino 3-fluorophenyl 2-amino-4- (S)-2-amino-3-rid 1 hen 1 ro lamino 2-fluorophenyl 2-acetamido- (S)-2-amino-3-(2-4- rid 1 fluoro hen 1) ro lamino 3-chlorophenyl 2-amino-4- (S)-2-amino-3-(2-rimidin 1 meth 1 hen 1) ro lamino 2-chlorophenyl 4-pyridyl (S)-2-N-isopropylamino-3-hen 1 ro lamino 4-tolyl 2-amino-4- (S)-2-N-glycylamino-3-rid 1 hen 1 ro lamino 3-tolyl 2-acetamido- 2-amino-2-methyl-3-4- rid 1 hen 1 ro lamino 2-tolyl 2-amino-4- (R)-2-amino-3-rimidin 1 hen 1 ro lamino 4-trifluoro- 4-pyridyl 3-amino-3-meth 1 hen 1 hen 1 ro lamino-3-trifluoro- 2-amino-4- 3-amino-3-(2-meth 1 hen 1 rid 1 fluoro hen 1) ro lamino 2,6- 2-acetamido- 3-amino-3-(2-dichloro hen 1 4- rid 1 meth 1 hen 1) ro lamino 2,6-dimethyl 2-amino-4- 3-amino-2-methyl-3-hen 1 rimidin 1 hen 1 ro lamino 3,4- 4-pyridyl (S)-tetrahydroisoquinol-dichloro hen 1 3- lmeth lenamino 1 3, 4-dimethyl 1 4-pyridyl (S) -3-benzylpiperazinyl phenyl O
R11 ~CH3 I N

wherein R1', R'', and R' are one of the coribinations given in the following table:
R.. R.~ R

Phen 1 4- ridyl 4-pyrid 1 4-fluoro hen 1 4- rid 1 4- ridyl 3-fluoro hen 1 4- rid 1 4- rid 1 2-fiuoro hen 1 4- rid 1 4- rid 1 4-chloro hen 1 4- ridyl 4- yrid 1 3-chloro hen 1 4- rid 1 4-pyrid 1 2-chloro hen 1 4- rid 1 4- rid 1 4-tol 1 4- rid 1 4- rid 1 3-tol 1 4- rid 1 4- ridyl 2-tol 1 4- rid 1 4- rid 1 4-trifluoro- 4-pyridyl 4-pyridyl meth 1 hen 1 3-trifluoro- 4-pyridyl 4-pyridyl meth 1 hen 1 2,6- 4-pyridyl 4-pyridyl dichloro hen 1 2,6-dimethyl 4-pyridyl 4-pyridyl hen 1 dichloro hen 1 4 pyridyl 4-pyridyl 3,4-dimethyl 4-pyridyl 4-pyridyl hen 1 2,4- 4-pyridyl 4-pyridyl dichloro hen 1 2,4-dimethyl 4-pyridyl 4-pyridyl hen 1 Phenyl 2-amino-4- 4-pyridyl rid 1 4-fluorophenyl 2-amino-4- 4-pyridyl _ rid 1 3-fluorophenyl 2-amino-4- 4-pyridyl rid 1 2-fluorophenyl 2-amino-4- 4-pyridyl rid 1 4-chlorophenyl 2-amino-4- 4-pyridyl rid 1 3-chlorophenyl 2-amino-4- 4-pyridyl rid 1 2-chlorophenyl 2-amino-4- 4-pyridyl ~ridyl 4-tolyl 2-amino-4- 4-pyridyl rid 1 3-tolyl 2-amino-4- 4-pyridyl rid 1 2-tolyl 2-amino-4- 4-pyridyl rid 1 4-trifluoro- 2-amino-4- 4-pyridyl meth 1 hen 1 rid 1 3-trifluoro- 2-amino-4- 4-pyridyl meth 1 hen 1 rid 1 2,6- 2-amino-4- 4-pyridyl dichloro hen 1 rid 1 2,6-dimethyl 2-amino-4- 4-pyridyl hen 1 p rid 1 3,4- 2-amino-4- 4-pyridyl dichloro hen 1 rid 1 3,4-dimethyl 2-amino-4- 4-pyridyl hen 1 rid 1 2,4- 2-amino-4- 4-pyridyl dichloro hen 1 rid 1 2,4-dimethyl 2-amino-4- 4-pyridyl hen 1 rid 1 Phenyl 2-acetamido- 4-pyridyl 4- rid 1 4-fluorophenyl 2-acetamido- 4-pyridyl 4- rid 1 3-fluorophenyl 2-acetamido- 4-pyridyl 4- rid 1 2-fluorophenyl 2-acetamido- 4-pyridyl 4- rid 1 4-chlorophenyl 2-acetamido- 4-pyridyl 4- rid 1 3-chlorophenyl 2-acetamido- 4-pyridyl 4- ridyl 2-chlorophenyl 2-acetamido- 4-pyridyl 4- rid 1 4-tolyl 2-acetamido- 4-pyridyl 4- rid 1 -3-tolyl 2-acetamido- 4-pyridyl 4- rid 1 2-tolyl 2-acetamido- 4-pyridyl 4- rid 1 4-trifluoro- 2-acetamido- 4-pyridyl meth 1 hen 1_ 4- rid 1 3-trifluoro- 2-acetamido- 4-pyridyl meth 1 hen 1 4- rid 1 2,6- 2-acetamido- 4-pyridyl dichloro hen 1 4- rid 1 2,6-dimethyl 2-acetamido- 4-pyridyl hen 1 4- rid 1 3,4- 2-acetamido- 4-pyridyl dichloro hen 1 4- rid 1 3,4-dimethyl 2-acetamido- 4-pyridyl hen 1 4- rid 1 2,4- 2-acetamido- 4 -pyridyl dichloro hen 1 4- rid 1 2,4-dimethyl 2-acetamido- 4-pyridyl hen 1 4- rid 1 Phenyl 2-amino-4- 4-pyridyl rimidin 1 4-fluorophenyl 2-amino-4- 4-pyridyl rimidinyl 3-fluorophenyl 2-amino-4- 4-pyridyl rimidin 1 2-fluorophenyl 2-amino-4- 4-pyridyl rimidin 1 4-chlorophenyl 2-amino-4- 4-pyridyl rimidin 1 3-chlorophenyl 2-amino-4- 4-pyridyl rimidin 1 2-chlorophenyl 2-amino-4- 4-pyridyl yrimidin 1 4-tolyl 2-amino-4- 4-pyridyl rimidinyl 3-tolyl 2-amino-4- 4-pyridyl rimidin 1 2-tolyl 2-amino-4- 4-pyridyl rimidinyl 4-trifluoro- 2-amino-4- 4-pyridyl meth 1 hen 1 rimidin 1 3-trifluoro- 2-amino-4- 4-pyridyl meth 1 hen 1 rimidin 1 2,6- 2-amino-4- 4-pyridyl dichloro hen 1 yrimidin 1 2,6-dimethyl 2-amino-4- 4-pyridyl hen 1 rimidin 1 3,4- 2-amino-4- 4-pyridyl dichlorophenyl rimidin 1 3,4-dimethyl 2-amino-4- 4-pyridyl hen 1 rimidin 1 2,4- 2-amino-4- 4-pyridyl dichloro hen 1 rimidin 1 2,4-dimethyl 2-amino-4- 4-pyridyl hen l rimidin 1 Phen 1 4- rid 1 4-meth 1 sulfin 1 hen 1 4-fluoro henyl 4- rid 1 4-meth 1 sulfin 1 hen 1 3-fluoro hen 1 4- rid 1 4-meth 1 sulfin 1 hen 1 2-fluoro hen 1 4- rid 1 4-meth 1 sulfin 1 hen 1 4-chloro hen 1 4- rid 1 4-methyl sulfin 1 hen 1 3-chloro hen 1 4- rid 1 4-meth 1 sulfin 1 hen 1 2-chloro hen 1 4- rid 1 4-meth 1 sulfin 1 hen 1 4-tol 1 4- ridyl 4-meth 1 sulfin 1 hen 1 3-tol 1 4- rid 1 4-meth 1 sulfin 1 hen 1 2-tol 1 4- rid 1 4-meth 1 sulfin 1 hen 1 4-trifluoro- 4-pyridyl 4-methyl sulfinylphenyl meth 1 hen 1 -WO 98/24780 PCTlUS97122949 3-trifluoro- 4-pyridyl 4-methyl sulfinylphenyl meth 1 hen 1 2,6- 4-pyridyl 4-methyl sulfinylphenyl dichloro hen 1 2,6-dimethyl 4-pyridyl 4-methyl sulfinylphenyl hen 1 3,4- 4-pyridyl 4-methyl sulfinylphenyl dichloro hen 1 3,4-dimethyl 4-pyridyl 4-methyl sulfinylphenyl phen 1 2,4- 4-pyridyl 4-methyl sulfinylphenyl dichloro hen 1 2,4-dimethyl 4-pyridyl 4-methyl sulfinylphenyl hen 1 Phenyl 2-amino-4- 4-methyl sulfinylphenyl grid 1 4-fluorophenyl 2-amino-4- 4-methyl sulfinylphenyl rid 1 3-fluorophenyl 2-amino-4- 4-methyl sulfinylphenyl rid 1 2-fluorophenyl 2-amino-4- 4-methyl sulfinylphenyl rid 1 4-chlorophenyl 2-amino-4- 4-methyl sulfinylphenyl rid 1 3-chlorophenyl 2-amino-4- 4-methyl sulfinylphenyl rid 1 2-chlorophenyl 2-amino-4- 4-methyl sulfinylphenyl yrid 1 4-tolyl 2-amino-4- 4-methyl sulfinylphenyl rid 1 3-tolyl 2-amino-4- 4-methyl sulfinylphenyl rid 1 2-tolyl 2-amino-4- 4-methyl sulfinylphenyl rid 1 4-trifluoro- 2-amino-4- 4-methyl sulfinylphenyl imeth 1 hen 1 rid 1 3-trifluoro- 2-amino-4- 4-methyl sulfinylphenyl meth 1 hen 1 rid 1 2,6- 2-amino-4- 4-methyl sulfinylphenyl dichloro hen 1 rid 1 2,6-dimethyl 2-amino-4- 4-methyl sulfinylphenyl phen 1 rid 1 3,4- 2-amino-4- 4-methyl sulfinylphenyl dichloro hen 1 rid 1 3,4-dimethyl 2-amino-4- 4-methyl sulfinylphenyl hen 1 rid 1 2,4- 2-amino-4- 4-methyl sulfinylphenyl dichloro hen 1 rid 1 2,4-dimethyl 2-amino-4- 4-methyl sulfinylphenyl hen 1 rid 1 Phenyl 2-acetamido- 4-methyl sulfinylphenyl 4- rid 1 4-fluorophenyl 2-acetamido- 4-methyl sulfinylphenyl 4- rid 1 3-fluorophenyl 2-acetamido- 4~-methyl sulfinylphenyl 4- rid 1 2-fluorophenyl 2-acetamido- 4-methyl sulfinylphenyl 4- rid 1 4-chlorophenyl 2-acetamido- 4-methyl sulfinylphenyl 4- ridyl 3-chlorophenyl 2-acetamido- 4-methyl sulfinylphenyl 4- rid 1 2-chlorophenyl 2-acetamido- 4-methyl sulfinylphenyl 4- yridyl 4-tolyl 2-acetamido- 4-methyl sulfinylphenyl 4- rid 1 3-tolyl 2-acetamido- 4-methyl sulfinylphenyl 4- rid 1 2-tolyl 2-acetamido- 4-methyl sulfinylphenyl 4- rid 1 4-trifluoro- 2-acetamido- 4-methyl sulfinylphenyl meth lphenyl 4-p rid 1 3-trifluoro- 2-acetamido- 4-methyl sulfinylphenyl methylphenyl 4- rid 1 2,6- 2-acetamido- 4-methyl sulfinylphenyl dichloro hen 1 4- ridyl 2,6-dimethyl 2-acetamido- 4-methyl sulfinylphenyl henyl 4- yrid 1 3,4- 2-acetamido- 4-methyl sulfinylphenyl dichloro hen 1 4- rid 1 3,4-dimethyl 2-acetamido- 4-methyl sulfinylphenyl phen 1 4-p ridyl 2,4- 2-acetamido- 4-methyl sulfinylphenyl dichlorophenyl 4- rid 1 2,4-dimethyl 2-acetamido- 4-methyl sulfinylphenyl hen 1 4-p ridyl Phenyl 2-amino-4- 4-methyl sulfinylphenyl rimidin 1 4-fluorophenyl 2-amino-4- 4-methyl sulfinylphenyl rimidin 1 3-fluorophenyl 2-amino-4- 4-methyl sulfinylphenyl p rimidin 1 2-fluorophenyl 2-amino-4- 4-methyl sulfinylphenyl rimidin 1 -4-chlorophenyl 2-amino-4- 4-methyl sulfinylphenyl rimidinyl 3-chlorophenyl 2-amino-4- 4-methyl sulfinylphenyl rimidin 1 2-chlorophenyl 2-amino-4- 4-methyl sulfinylphenyl rimidin 1 4-tolyl 2-amino-4- 4-methyl sulfinylphenyl rimidin 1 3-tolyl 2-amino-4- 4-methyl sulfinylphenyl rimidin 1 2-tolyl 2-amino-4- 4-methyl sulfinylphenyl rimidin 1 4-trifluoro- 2-amino-4- 4-methyl sulfinylphenyl -meth 1 hen 1 rimidinyl 3-trifluoro- 2-amino-4- 4-methyl sulfinylphenyl meth 1 hen 1 rimidin 1 _ 2,6- 2-amino-4- 4-methyl~sulfinylphenyl dichloro hen 1 rimidin 1 2,6-dimethyl 2-amino-4- 4-methyl sulfinylphenyl hen 1 rimidin 1 3,4- 2-amino-4- 4-methyl sulfinylphenyl dichloro hen 1 rimidin 1 3,4-dimethyl 2-amino-4- 4-methyl sulfinylphenyl hen 1 rimidin 1 2,4- 2-amino-4- 4-methyl sulfinylphenyl dichloro hen 1 rimidin 1 2,4-dimethyl 2-amino-4- 4-methyl sulfinylphenyl hen 1 rimidin 1 Phen 1 4- rid 1 2,6-dichlorobenz 1 4-fluorophen 1 4- rid 1 2,6-dichlorobenz 1 3-fluoro hen 1 4- rid 1 2,6-dichlorobenz 1 2-fluoro henyl 4- rid 1 2,6-dichlorobenz 1 4-chloro hen 1 4- rid 1 2,6-dichlorobenz 1 3-chloro hen 1 4- ridyl 2,6-dichlorobenz 1 2-chloro hen 1 4- yrid 1 2,6-dichlorobenz 1 4-tol 1 4- rid 1 2,6-dichlorobenz 1 3-tol 1 4- rid 1 2,6-dichlorobenz 1 2-tol 1 4- rid 1 2,6-dichlorobenz 1 4-trifluoro- 4-pyridyl 2,6-dichlorobenzyl meth 1 hen 1 3-trifluoro- 4-pyridyl 2,6-dichlorobenzyl meth 1 hen 1 2,6- 4-pyridyl 2,6-dichlorobenzyl dichloro hen 1 2,6-dimethyl 4-pyridyl 2,6-dichlorobenzyl hen 1 3,4- 4-pyridyl 2,6-dichlorobenzyl dichloro hen 1 3,4-dimethyl 4-pyridyl 2,6-dichlorobenzyl hen 1 2,4- 4-pyridyl 2,6-dichlorobenzyl dichloro hen 1 2,4-dimethyl 4-pyridyl 2,6-dichlorobenzyl hen 1 Phenyl 2-amino-4- 2,6-dichlorobenzyl rid 1 4-fluorophenyl 2-amino-4- 2,6-dichlorobenzyl rid 1 3-fluorophenyl 2-amino-4- 2,6-dichlorobenzyl rid 1 2-fluorophenyl 2-amino-4- 2,6-dichlorobenzyl rid 1 4-chlorophenyl 2-amino-4- 2,6-dichlorobenzyl rid 1 3-chlorophenyl 2-amino-4- 2,6-dichlorobenzyl rid 1 2-chlorophenyl 2-amino-4- 2,6-dichlorobenzyl rid 1 4-tolyl 2-amino-4- 2,6-dichlorobenzyl rid 1 3-tolyl 2-amino-4- 2,6-dichlorobenzyl rid 1 2-tolyl 2-amino-4- 2,6-dichlorobenzyl p rid 1 4-trifluoro- 2-amino-4- 2,6-dichlorobenzyl meth lphen 1 rid 1 3-trifluoro- 2-amino-4- 2,6-dichlorobenzyl meth lphen 1 rid 1 2,6- 2-amino-4- 2,6-dichlorobenzyl dichloro hen 1 rid 1 2,6-dimethyl 2-amino-4- 2,6-dichlorobenzyl hen 1 yridyl 3,4- 2-amino-4- 2,6-dichlorobenzyl dichloro hen 1 yridyl 3,4-dimethyl 2-amino-4- 2,6-dichlorobenzyl henyl rid 1 2,4- 2-amino-4- 2,6-dichlorobenzyl dichloro hen 1 rid 1 2,4-dimethyl 2-amino-4- 2,6-dichlorobenzyl phen 1 p rid 1 Phenyl 2-acetamido- 2,6-dichlorobenayl 4- yridyl 4-fluorophenyl 2-acetamido- 2,6-dichlorobenzyl 4- yridyl 3-fluorophenyl 2-acetamido- 2,6-dichlorobEnzyl 4-p rid 1 2-fluorophenyl 2-acetamido- 2,6-dichlorobenzyl 4- yrid 1 4-chlorophenyl 2-acetamido- 2,6-dichlorobenzyl 4- rid 1 3-chlorophenyl 2-acetamido- 2,6-dichlorobenzyl 4- rid 1 2-chlorophenyl 2-acetamido- 2,6-dichlorobenzyl 4- rid 1 4-tolyl 2-acetamido- 2,6-dichlorobenzyl 4- rid 1 3-tolyl 2-acetamido- 2,6-dichlorobenzyl 4- rid 1 2-tolyl 2-acetamido- 2,6-dichlorobenzyl 4- rid 1 4-trifluoro- 2-acetamido- 2,6-dichlorobenzyl meth 1 henyl 4- rid 1 3-trifluoro- 2-acetamido- 2,6-dichlorobenzyl methyl hen 1 4- rid 1 2,6- 2-acetamido- 2,6-dichlorobenzyl dichloro henyl 4- rid 1 2,6-dimethyl 2-acetamido- 2,6-dichlorobenzyl hen 1 4- rid 1 3,4- 2-acetamido- 2,6-dichlorobenzyl dichloro hen 1 4- rid 1 3,4-dimethyl 2-acetamido- 2,6-dichlorobenzyl hen 1 4- rid 1 WO 9$/24780 PCT/LTS97/Z2949 2,4- 2-acetamido- 2,6-dichlorobenzyl dichloro hen 1 4- ridyl 2,4-dimethyl 2-acetamido- 2,6-dichlorobenzyl phen 1 4- rid 1 Phenyl 2-amino-4- 2,6-dichlorobenzyl rimidin 1 4-fluorophenyl 2-amino-4- 2,6-dichlorobenzyl rimidin 1 3-fluorophenyl 2-amino-4- 2,6-dichlorobenzyl rimidin 1 2-fluorophenyl 2-amino-4- 2,6-dichlorobenzyl rimidin 1 4-chlorophenyl 2-amino-4- 2,6-dichlorobenzyl rimidin 1 3-chlorophenyl 2-amino-4- 2,6-dichlorobenzyl rimidin 1 2-chlorophenyl 2-amino-4- 2,6-dichlorobenzyl rimidin 1 4-tolyl 2-amino-4- 2,6-dichlorobenzyl rimidin 1 3-tolyl 2-amino-4- 2,6-dichlorobenzyl rimidin 1 2-tolyl 2-amino-4- 2,6-dichlorobenzyl rimidin 1 4-trifluoro- 2-amino-4- 2,6-dichlorobenzyl-meth 1 hen 1 rimidin 1 3-trifluoro- 2-amino-4- 2,6-dichlorobenzyl meth 1 hen 1 rimidinyl 2,6- 2-amino-4- 2,6-dichlorobenzyl dichloro hen 1 rimidin 1 2,6-dimethyl 2-amino-4- 2,6-dichlorobenzyl hen 1 rimidin 1 3,4- 2-amino-4- 2,6-dichlorobenzyl dichloro hen 1 rimidin 1 3,4-dimethyl 2-amino-4- 2,6-dichlorobenzyl hen 1 rimidin 1 2;4- 2-amino-4- 2,6-dichlorobenzyl dichloro hen 1 rimidin 1 2,4-dimethyl 2-amino-4- 2,6-dichlorobenzyl hen 1 rimidin 1 Phenyl 4-pyridyl 2-(4-fluorophenyl) eth lamino 4-fluorophenyl 4-pyridyl 2-(4-fluorophenyl) eth lamino 3-fluorophenyl 4-pyridyl 2-(4-fluorophenyl) eth lamino 2-fluorophenyl 4-pyridyl 2-(4-fluorophenyl) eth lamino 4-chlorophenyl 4-pyridyl 2-(4-fluorophenyl) eth lamino 3-chlorophenyl 4-pyridyl 2-(4-fluorophenyl) eth lamino 2-chlorophenyl 4-pyridyl 2-(4-fluorophenyl) eth lamino WO 98!24780 PCT/US97/22949 4-tolyl 4-pyridyl 2-(4-fluorophenyl) eth !amino 3-tolyl 4-pyridyl 2-(4-fluorophenyl) eth !amino 2-tolyl 4-pyridyl 2-(4-fluorophenyl) eth !amino 4-trifluoro- 4-pyridyl 2-(4-fluorophenyl) meth 1 hen 1 eth !amino 3-trifluoro- 4-pyridyl 2-(4-fluorophenyl) meth 1 hen 1 eth !amino 2,6- 4-pyridyl 2-(4-fluorophenyl) dichloro hen 1 eth !amino 2,6-dimethyl 4-pyridyl 2-(4-fluorophenyl) hen 1 eth !amino 3,4- 4-pyridyl 2-(4-fluorophenyl) dichlorophen 1 eth !amino 3,4-dimethyl 4-pyridyl 2-(4-fluorophenyl) hen 1 ethylamino 2,4- 4-pyridyl 2-(4-fluorophenyl) dichloro hen 1 eth !amino 2,4-dimethyl 4-pyridyl 2-(4-fluorophenyl) hen 1 eth !amino Phenyl 2-amino-4- 2-(4-fluorophenyl) rid 1 eth !amino 4-fluorophenyl 2-amino-4- 2-(4-fluorophenyl) rid 1 ethylamino 3-fluorophenyl 2-amino-4- 2-(4-fluorophenyl) p ridyl ethylamino 2-fluorophenyl 2-amino-4- 2-(4-fluorophenyl) ridyl eth !amino 4-chlorophenyl 2-amino-4- 2-(4-fluorophenyl) yrid 1 eth !amino 3-chlorophenyl 2-amino-4- 2-(4-fluorophenyl) yrid 1 eth !amino 2-chlorophenyl 2-amino-4- 2-(4-fluorophenyl) rid 1 ethylamino 4-tolyl 2-amino-4- 2-(4-fluorophenyl) rid 1 eth !amino 3-tolyl 2-amino-4- 2-(4-fluorophenyl) rid 1 eth !amino 2-tolyl 2-amino-4- 2-(4-fluorophenyl) rid 1 eth !amino 4-trifluoro- 2-amino-4- 2-(4-fluorophenyl) meth lphen 1 rid 1 eth !amino 3-trifluoro- 2-amino-4- 2-(4-fluorophenyl) meth 1 hen 1 ridyl eth !amino 2;6- 2-amino-4- 2-(4-fluorophenyl) dichloro hen 1 rid 1 eth !amino 2,6-dimethyl 2-amino-4- 2-(4-fluorophenyl) hen 1 rid 1 eth !amino 3:4- 2-amino-4- 2-(4-fluorophenyl) dichloro hen 1 rid 1 eth !amino 3,4-dimethyl 2-amino-4- 2-(4-fluorophenyl) hen 1 rid 1 eth !amino 2,4- 2-amino-4- 2-(4-fluorophenyl) dichloro hen 1 ridrl eth lamino 2,4-dimethyl 2-amino-4- 2-(4-fluorophenyl) hen 1 rid 1 eth lamino Phenyl 2-acetamido- 2-(4-fluorophenyl) 4- rid l eth lamino 4-fluorophenyl 2-acetamido- 2-(4-fluorophenyl) 4- ridyl eth lamino 3-fluorophenyl 2-acetamido- 2-(4-fluorophenyl) 4- grid 1 eth lamino 2-fluorophenyl 2-acetamido- 2-(4-fluorophen_yl) 4- rid 1 eth lamino 4-chlorophenyl 2-acetamido- 2-(4-fluorophenyl}

4- rid 1 eth lamino 3-chlorophenyl 2-acetamido- 2-(4-fluorophenyl) 4- rid 1 eth lamino 2-chlorophenyl 2-acetamido- 2-(4-fluorophenyl) 4- rid 1 eth lamino 4-tolyl 2-acetamido- 2-(4-fluorophenyl) 4- rid 1 eth lamino 3-tolyl 2-acetamido- 2-(4-fluorophenyl) 4- rid 1 eth lamino 2-tolyl 2-acetamido- 2-(4-fluorophenyl) 4- rid 1 eth lamino 4-trifluoro- 2-acetamido- 2-(4-fluorophenyl) meth 1 hen 1 4- rid 1 ethylamino 3-trifluoro- 2-acetamido- 2-(4-fluorophenyl) meth 1 hen 1 4- rid 1 eth lamino 2,6- 2-acetamido- 2-(4-fluorophenyl) dichloro hen 1 4- rid 1 eth lamino 2,6-dimethyl 2-acetamido- 2-(4-fluorophenyl) hen 1 4- rid 1 eth lamino 3,4- 2-acetamido- 2-(4-fluorophenyl) dichloro hen 1 4- rid 1 eth lamino 3,4-dimethyl 2-acetamido- 2-(4-fluorophenyl) hen 1 4- rid 1 eth lamino 2,4- 2-acetamido- 2-(4-fluorophenyl}

dichloro hen 1 4- rid 1 eth lamino 2,4-dimethyl 2-acetamido- 2-(4-fluorophenyl) phen 1 4- rid 1 eth lamino Phenyl 2-amino-4- 2-(4-fluorophenyl) rimidin 1 eth lamino 4-fluorophenyl 2-amino-4- 2-(4-fluorophenyl) rimidin 1 eth lamino 3-fluorophenyl 2-amino-4- 2-(4-fluorophenyl) rimidin 1 eth lamino 2-fluorophenyl 2-amino-4- 2-(4-fluorophenyl) rimidin 1 eth lamino 4-chlorophenyl 2-amino-4- 2-(4-fluorophenyl) rimidin 1 eth lamino 3-chlorophenyl 2-amino-4- 2-(4-fluorophenyl) rimidin 1 eth lamino 2-chlorophenyl 2-amino-4- 2-(4-fluorophenyl) rimidin 1 eth lamino 4-tolyl 2-amino-4- 2-(4-fluorophenyl) rimidin 1 eth lamino 3-tolyl 2-amino-4- 2-(4-fluorophenyl) rimidin 1 eth lamino 2-tolyl 2-amino-4- 2-(4-fluorophenyl) rimidin 1 eth lamino 4-trifluoro- 2-amino-4- 2-(4-fluorophenyl) meth 1 hen 1 rimidin 1 eth lamino 3-trifluoro- 2-amino-4- 2-(4-fluorophenyl) methyl hen 1 yrimidin 1 eth lamino -2,6- 2-amino-4- 2-(4-fluorophenyl) dichlorophen 1 rimidinyl eth lamino 2,6-dimethyl 2-amino-4- 2-(4-fluorophenyl) phenyl rimidin 1 eth lamino 3,4- 2-amino-4- 2-(4-fluorophenyl) dichlorophen 1 rimidinyl eth lamino 3,4-dimethyl 2-amino-4- 2-(4-fluorophenyl) phen 1 rimidin 1 eth lamino 2,4- 2-amino-4- 2-(4-fluorophenyl) dichloro hen 1 rimidin 1 eth lamino 2,4-dimethyl 2-amino-4- 2-(4-fluorophenyl) hen 1 rimidin 1 eth lamino Phen 1 4- ridyl 3- henyl- ro lamino 4-fluoro hen 1 4- rid 1 3- hen 1-pro ylamino 3-fluoro hen 1 4- ridyl 3-phenyl- ro lamino 2-fluoro hen 1 4- rid 1 3- hen 1-pro lamino 4-chloro hen 1 4-pyridyl 3-phen 1-pro lamino 3-chloro hen 1 4- rid 1 3- henyl- rop lamino 2-chloro hen 1 4- yrid 1 3- hen 1-pro lamino 4-tol 1 4- ridyl 3-phen 1- ro lamino 3-tol 1 4- rid 1 3- hen 1- ro lamino 2-tol 1 4- rid 1 3-phen 1- ro lamino 4-trifluoro- 4-pyridyl 3-phenyl-propylamino meh 1 henyl _-t:ifluoro- 4-pyridyl 3-phenyl-propylamino meth1 hen 1 ?.,6- 4-pyridyl 3-phenyl-propylamino dichloro henyl 2,6-dimethyl 4-pyridyl 3-phenyl-propylamino hen 1 3,4- 4-pyridyl 3-phenyl-propylamino dichloro hen 1 3,4-dimethyl 4-pyridyl 3-phenyl-propylamino hen 1 2,4- 4-pyridyl 3-phenyl-propylamino dichloro hen 1 2,4-dimethyl 4-pyridyl 3-phenyl-propylamino hen 1 Phenyl 2-amino-4- 3-phenyl-propylamino rid 1 4-fluorophenyl 2-amino-4- 3-phenyl-propylamino rid 1 3-fluorophenyl 2-amino-4- 3-phenyl-propylamino rid 1 WO 98/24780 PCTlUS97/22949 2-fluorophenyl 2-amino-4- 3-phenyl-propylamino rid 1 _ 4-chlorophenyl 2-amino-4- 3-phenyl-propylamino rid 1 3-chlorophenyl 2-amino-4- 3-phenyl-propylamino rid 1 2-chlorophenyl 2-amino-4- 3-phenyl-propylamino rid 1 4-tolyl 2-amino-4- 3-phenyl-propylamino rid 1 3-tolyl 2-amino-4- 3-phenyl-propylamino ridyl 2-tolyl 2-amino-4- 3-phenyl-propylamino rid 1 4-trifluoro- ?.-amino-4- 3-phenyl-propylamino meth 1 hen 1 rid 1 3-trifluoro- 2-amino-4- 3-phenyl-propylamino meth 1 hen 1 rid 1 2,6- 2-amino-4- 3-phenyl-propylamino dichloro hen 1 rid 1 2,6-dimethyl 2-amino-4- 3-phenyl-propylamino hen 1 rid 1 3,4- 2-amino-4- 3-phenyl-propylamino dichloro hen 1 rid 1 3,4-dimethyl 2-amino-4- 3-phenyl-propylamino hen 1 rid 1 2,4- 2-amino-4- 3-phenyl-propylamino dichloro hen 1 rid 1 2,4-dimethyl 2-amino-4- 3-phenyl-propylamino hen 1 rid 1 Phenyl 2-acetamido- 3-phenyl-propylamino 4- rid 1 4-fluorophenyl 2-acetamido- 3-phenyl-propylamino 4- rid 1 3-fluorophenyl 2-acetamido- 3-phenyl-propylamino 4- rid 1 2-fluorophenyl 2-acetamido- 3-phenyl-propylamino 4- rid 1 4-chlorophenyl 2-acetamido- 3-phenyl-propylamino 4- rid 1 3-chlorophenyl 2-acetamido- 3-phenyl-propylamino 4- rid 1 2-chlorophenyl 2-acetamido- 3-phenyl-propylamino 4- rid 1 4-tolyl 2-acetamido- 3-phenyl-propylamino 4- rid 1 3-tolyl 2-acetamido- 3-phenyl-propylamino 4- rid 1 2-tolyl 2-acetamido- 3-phenyl-propylamino 4- rid 1 4-trifluoro- 2-acetamido- 3-phenyl-propylamino meth 1 hen 1 4- rid 1 3-trifluoro- 2-acetamido- 3-phenyl-propylamino meth 1 hen 1 4- rid 1 2,6- 2-acetamido- 3-phenyl-propylamino dichloro henyl 4- rid 1 2,6-dimethyl 2-acetamido- 3-phenyl-propylamino phen 1 4- ridyl 3,4- 2-acetamido- 3-phenyl-propylamino dichloro henyl 4- rid l 3,4-dimethyl 2-acetamido- 3-phenyl-propylamino hen 1 4- rid 1 2,4- 2-acetamido- 3-phenyl-propylamino dichloro hen 1 4- rid 1 2,4-dimethyl 2-acetamido- 3-phenyl-propylamino hen 1 4-pyrid 1 Phenyl 2-amino-4- 3-phenyl-propylamino rimidinyl 4-fluorophenyl 2-amino-4- 3-phenyl-propylamino rimidin 1 3-fluorophenyl 2-amino-4- 3-phenyl-propylamino rimidin 1 2-fluorophenyl 2-amino-4- 3-phenyl-propylamino rimidin 1 4-chlorophenyl 2-amino-4- 3-phenyl-propylamino p rimidin 1 3-chlorophenyl 2-amino-4- 3-phenyl-propylamino yrimidin 1 2-chlorophenyl 2-amino-4- 3-phenyl-propylamino rimidin 1 4-tolyl 2-amino-4- 3-phenyl-propylamino rimidin 1 3-tolyl 2-amino-4- 3-phenyl-propylamino rimidinyl 2-tolyl 2-amino-4- 3-phenyl-propylamino rimidin 1 4-trifluoro- 2-amino-4- 3-phenyl-propylamino methylphen 1 yrimidin 1 3-trifluoro- 2-amino-4- 3-phenyl-propylamino methylphen 1 pyrimidin 1 2,6- 2-amino-4- 3-phenyl-propylamino dichloro hen 1 rimidin 1 2,6-dimethyl 2-amino-4- 3-phenyl-propylamino hen 1 rimidin 1 3,4- 2-amino-4- 3-phenyl-propylamino dichloro henyl rimidin 1 3,4-dimethyl 2-amino-4- 3-phenyl-propylamino hen 1 rimidin 1 2,4- 2-amino-4- 3-phenyl-propylamino dichloro hen 1 rimidin 1 2,4-dimethyl 2-amino-4- 3-phenyl-propylamino henyl rimidin 1 Phenyl 4-pyridyl (1-methyl-3-hen 1) ro lamino 4-fluorophenyl 4-pyridyl (1-methyl-3-hen 1) ro lamino 3-fluorophenyl 4-pyridyl (1-methyl-3-hen 1) ro lamino 2-fluorophenyl 4-pyridyl (1-methyl-3-henyl)propylamino 4-chlorophenyl 4-pyridyl (1-methyl-3-hen 1) ro lamino 3-chlorophenyl 4-pyridyl (1-methyl-3-hen 1) ro lamino 2-chlorophenyl 4-pyridyl (1-methyl-3-hen 1) ro lamino 4-tolyl 4-pyridyl (1-methyl-3-hen 1) ro lamino 3-tolyl 4-pyridyl (1-methyl-3-hen 1)pro lamino 2-tolyl 4-pyridyl (1-methyl-3-hen 1) ro lamino 4-trifluoro- 4-pyridyl (1-methyl-3-meth 1 hen 1 hen 1) ro lamino 3-trifluoro- 4-pyridyl (1-methyl-3-meth 1 hen 1 hen 1) ro lamino 4 pyridyl (1-methyl-3-dichloro hen 1 hen 1) ro lamino 2,6-dimethyl 4-pyridyl (1-methyl-3-hen 1 hen 1) ro lamino 3,4- 4-pyridyl (1-methyl-3-dichloro hen 1 hen 1) ro lamino 3,4-dimethyl 4-pyridyl (1-methyl-3-hen 1 hen 1) ro lamino 2,4- 4-pyridyl (1-methyl-3-dichloro hen 1 hen 1) ro lamino 2,4-dimethyl 4-pyridyl (1-methyl-3-hen 1 hen 1) ro lamino Phenyl 2-amino-4- (1-methyl-3-rid 1 hen 1) ro lamino 4-fluorophenyl 2-amino-4- (1-methyl-3-rid 1 hen 1) ro lamino 3-fluorophenyl 2-amino-4- (1-methyl-3-rid 1 hen 1) ro lamino 2-fluorophenyl 2-amino-4- (1-methyl-3-rid 1 hen 1) ro lamino 4-chlorophenyl 2-amino-4- (1-methyl-3-rid 1 hen 1) ro lamino 3-chlorophenyl 2-amino-4- (1-methyl-3-rid 1 hen 1) ro lamino 2-chlorophenyl 2-amino-4- (1-methyl-3-rid 1 hen 1) ro lamino 4-tolyl 2-amino-4- (1-methyl-3-rid 1 hen 1) ro lamino 3-tolyl 2-amino-4- (1-methyl-3-rid 1 hen 1) ro lamino 2-tolyl 2-amino-4- (1-methyl-3-rid 1 hen 1) ro lamino 4-trifluoro- 2-amino-4- (1-methyl-3-meth 1 hen 1 rid 1 hen 1) ro lamino 3-trifluoro- 2-amino-4- (1-methyl-3-meth 1 hen 1 rid 1 hen 1) ro lamino 2,6- 2-amino-4- (1-methyl-3-dichlorophen 1 yridyl hen 1) ro lamino 2,6-dimethyl 2-amino-4- (1-methyl-3-phen 1 yrid 1 hen 1) ro lamino 3,4- 2-amino-4- (1-methyl-3-dichloro hen 1 rid 1 phen 1) ro lamino 3,4-dimethyl 2-amino-4- (1-methyl-3-phen 1 rid 1 hen 1) ro lamino 2,4- 2-amino-4- (1-methyl-3-dichloro hen 1 rid 1 hen 1) ro lamino 2,4-dimethyl 2-amino-4- (1-methyl-3-hen 1 rid 1 hen 1) rop lamino Phenyl 2-acetamido- (1-methyl-3-4- yrid 1 phen 1) ro lamino 4-fluorophenyl 2-acetamido- (1-methyl-3-4- rid 1 hen 1) ro ylamino 3-fluorophenyl 2-acetamido- (1-methyl-3-4- rid 1 phen 1) rop lamino 2-fluorophenyl 2-acetamido- (1-methyl-3-4- rid 1 hen 1) ro lamino 4-chlorophenyl 2-acetamido- (1-methyl-3-4- rid 1 phen 1) ro lamino 3-chlorophenyl 2-acetamido- (1-methyl-3-4- rid 1 phenyl) ro lamino 2-chlorophenyl 2-acetamido- (1-methyl-3-4- rid 1 hen 1) ro lamino 4-tolyl 2-acetamido- (1-methyl-3-4-p ridyl phen 1) ro lamino 3-tolyl 2-acetamido- (1-methyl-3-4- rid 1 hen 1) ro lamino 2-tolyl 2-acetamido- (1-methyl-3-4- rid 1 henyl) ro lamino 4-trifluoro- 2-acetamido- (1-methyl-3-meth 1 hen 1 4- rid 1 phen 1) ro lamino 3-trifluoro- 2-acetamido- (1-methyl-3-meth 1 hen 1 4- rid 1 phen 1) ro lamino 2,6- 2-acetamido- (1-methyl-3-dichloro hen 1 4- rid 1 hen 1) ro lamino 2,6-dimethyl 2-acetamido- (1-methyl-3-hen 1 4- rid 1 hen 1) ro lamino 3,4- 2-acetamido- (1-methyl-3-dichloro hen 1 4- rid 1 hen 1) ro lamino 3,4-dimethyl 2-acetamido- (1-methyl-3-hen 1 4- rid 1 hen 1) ro lamino 2,4- 2-acetamido- (1-methyl-3-dichlorophen 1 4- rid 1 hen 1) ro lamino 2,4-dimethyl 2-acetamido- (1-methyl-3-hen 1 4- rid 1 hen 1) ro lamino Phenyl 2-amino-4- (1-methyl-3-rimidin 1 hen 1) ro lamino 4-fluorophenyl 2-amino-4- (1-methyl-3-rimidin 1 hen 1) ro lamino 3-fluorophenyl 2-amino-4- (1-methyl-3-rimidin 1 hen 1) ro lamino 2-fluorophenyl 2-amino-4- (1-methyl-3-rimidinyl hen 1) ro lamino _ 4-chlorophenyl 2-amino-4- (1-methyl-3-rimidin 1 hen 1) ro lamino 3-chlorophenyl 2-amino-4- (1-methyl-3-rimidin 1 hen 1) ro lamino 2-chlorophenyl 2-amino-4- (1-methyl-3-rimidin 1 hen 1) ro lamino 4-tolyl 2-amino-4- (1-methyl-3-rimidin 1 hen 1) ro lamino 3-tolyl 2-amino-4- (1-methyl-3-rimidin 1 hen 1) ro lamino 2-tolyl 2-amino-4- (1-methyl-3-rimidin 1 hen 1) ro lamino 4-trifluoro- 2-amino-4- (1-methyl-3-meth 1 hen 1 rimidin 1 hen 1) ro lamino 3-trifluoro- 2-amino-4- (1-methyl-3-meth 1 hen 1 rimidin 1 hen 1) ro lamino 2,6- 2-amino-4- (1-methyl-3-dichloro hen 1 rimidin 1 hen 1) ro lamino 2,6-dimethyl 2-amino-4- (1-methyl-3-hen 1 rimidin 1 hen 1) ro lamino 3,4- 2-amino-4- (1-methyl-3-dichloro hen 1 rimidin 1 hen 1) ro lamino 3,4-dimethyl 2-amino-4- (1-methyl-3-hen 1 rimidin 1 hen 1) ro ylamino 2,4- 2-amino-4- (1-methyl-3- -dichloro hen 1 rimidin 1 hen 1) ro lamino 2,4-dimethyl 2-amino-4- (1-methyl-3-hen 1 rimidin 1 hen 1) ro lamino 4-fluoro hen 1 4- rid 1 4-fluorobenz lamino 4-fluorophenyl 2-acetamido- 4-fluorobenzylamino 4-p rid 1 4-fluorophenyl 2-amino-4- 4-fluorobenzylamino rimidin 1 4-fluorophenyl 4-pyridylnyl (2-(4-fluorophenyl)-1-meth 1-eth 1)amino 4-fluorophenyl 2-acetamido- (2-(4-fluorophenyl)-1-4- rid 1 meth 1-eth 1)amino 4-fluorophenyl 2-amino-4- (2-(4-fluorophenyl)-1-rimidin 1 meth 1-eth 1)amino 4-fluorophenyl 4-pyridyl (1,1-dimethyl-2-(4-fluoro hen 1)-eth 1)amino 4-fluorophenyl _ (1,1-dimethyl-2-(4-2-acetamido-4- rid 1 fluoro hen 1)-eth 1)amino 4-fluorophenyl 2-amino-4- (1,1-dimethyl-2-(4-rimidin 1 fluoro hen 1)-eth 1)amino 4-fluorophenyl 4-pyridyl 2-(4-fluorophenyl)-2-meth 1-eth lamino 4-fluorophenyl 2-acetamido- (2-(4-fluorophenyl)-2-4- rid 1 meth 1-eth 1)amino 4-fluorophenyl 2-amino-4- (2-(4-fluorophenyl)-2-rimidin 1 meth 1-eth 1)amino 4-fluorophenyl 4-pyridyl (2-methyl-2-~hen leth 1)amino 4-fluorophenyl 2-acetamido- (2-methyl-2-4- rid 1 hen leth 1)amino 4-fluorophenyl 2-amino-4- (2-methyl-2-rimidin 1 hen leth 1)amino 4-fluorophenyl 4-pyridyl methyl-(2-hen leth 1)amino 4-fluorophenyl 2-acetamido- methyl-(2-4- rid 1 hen leth 1)amino 4-fluorophenyl 2-amino-4- methyl-(2-rimidin 1 henyleth 1)amino 4-fluorophenyl 4-pyridyl (2-(4-trifluoromethyl hen 1)ethyl)amino 4-fluorophenyl 2-acetamido- (2-(4-trifluoromethyl 4- rid 1 hen 1)eth 1)amino 4-fluorophenyl 2-amino-4- (2-(4-trifluoromethyl rimidin 1 hen 1)eth 1)amino 4-fluoro hen 1 4-p ridyl 2-(4-tol 1)eth lamino 4-fluorophenyl 2-acetamido- 2-(4-tolyl)ethylamino 4- rid 1 4-fluorophenyl 2-amino-4- 2-(4-tolyl)ethylamino rimidin 1 4-fluorophenyl 4-pyridyl (2-(3-fluorophenyl) eth 1)amino 4-fluorophenyl 2-acetamido- (2-(3-fluorophenyl) 4- rid 1 ethyl)amino 4-fluorophenyl 2-amino-4- (2-(3-fluorophenyl) p rimidinyl ethyl)amino 4-fluorophenyl 4-pyridyl (2-(2-fluorophenyl) eth 1)amino 4-fluorophenyl 2-acetamido- (2-(2-fluorophenyl) 4-pyrid 1 eth 1)amino 4-fluorophenyl 2-amino-4- (2-(2-fluorophenyl) rimidin 1 eth 1)amino 4-fluorophenyl 4-pyridyl methyl-(2-(2-rid 1)eth 1)amino 4-fluorophenyl 2-acetamido- methyl-(2-(2-4- rid 1 rid 1)eth 1)amino 4-fluorophenyl 2-amino-4- methyl-(2-(2-rimidin 1 rid 1)eth 1)amino 4-fluorophenyl 4-pyridyl (1,1-dimethyl-3-phenyl-ro 1)amino 4-fluorophenyl 2-acetamido- (1,1-dimethyl-3-phenyl-4- rid 1 ro 1)amino 4-fluorophenyl 2-amino-4- (1,1-dimethyl-3-phenyl-rimidin 1 ro 1)amino 4-fluorophenyl 4-pyridyl (3-(4-fluorophenyl)-ro 1)amino 4-fluorophenyl 2-acetamido- (3-(4-fluorophenyl)-4- rid 1 ro 1)amino 4-fluorophenyl 2-amino-4- (3-(4-fluorophenyl)-rimidin 1 pro 1)amino WO 98/24'780 PGT/US97122949 4-fluorophenyl 4-pyridyl (3-(4-fluorophenyl)-1-meth l~ropyl)amino 4-fluorophenyl 2-acetamido- (3-(4-fluorophenyl)-1-4- rid 1 meth 1- ro 1)amino -4-fluorophenyl 2-amino-4- (3-(4-fluorophenyl)-1-rimidin 1 meth 1- ro 1)amino 4-fluorophenyl 4-pyridyl (1,1-dimethyl-3-(4-fluoro hen 1)- ro 1)amino 4-fluorophenyl 2-acetamido- (1,1-dimethyl-3-(4-fluoro 4- rid 1 hen 1)- ro 1)amino 4-fluorophenyl 2-amino-4- (1,1-dimethyl-3-(4-fluoro rimidin 1 hen 1)- ro 1)amino 4-fluorophenyl 4-pyridyl (3-(2-fluorophenyl)-ro 1)amino 4-fluorophenyl 2-acetamido- (3-(2-fluorophenyl)-4- rid 1 ro 1)amino 4-fluorophenyl 2-amino-4- (3-(2-fluorophenyl)-rimidin 1 ro 1)amino 4-fluorophenyl 4-pyridyl (3-methyl-3-phenyl-ro 1)amino 4-fluorophenyl 2-acetamido- (3-methyl-3-phenyl-4- rid 1 ro 1)amino 4-fluorophenyl 2-amino-4- (3-methyl-3-phenyl-rimidin 1 ro 1)amino 4-fluorophenyl 4-pyridyl (2-methyl-3-phenyl-ro 1)amino 4-fluorophenyl 2-acetamido- (2-methyl-3-phenyl-4- rid 1 ro 1)amino 4-fluorophenyl 2-amino-4- (2-methyl-3-phenyl-rimidin 1 ro 1)amino 4-fluoro hen 1 4- rid 1 (3,3-dimeth lbut 1)amino 4-fluorophenyl 2-acetamido- (3,3-dimethylbutyl)amino 4- rid 1 4-fluorophenyl 2-amino-4- (3,3-dimethylbutyl)amino rimidin 1 4-fluoro hen 1 4- rid 1 isoam lamino 4-fluorophenyl 2-acetamido- isoamylamino 4- rid 1 4-fluorophenyl 2-amino-4- isoamylamino rimidin 1 4-fluoro hen 1 4- rid 1 am lamino 4-fluorophenyl 2-acetamido- amylamino 4- rid 1 4-fluorophenyl 2-amino-4- amylamino rimidin 1 4-fluoro hen 1 4- rid 1 (2,5-dimeth 1) ent lamino 4-fluorophenyl 2-acetamido- (2,5-dimethyl)pentylamino 4- rid 1 4-fluorophenyl 2-amino-4- (2,5-dimethyl)pentylamino rimidin 1 4-fluoro hen 1 4- rid 1 i erazin 1 4-fluorophenyl 2-acetamido- piperazinyl 4- rid 1 4-fluorophenyl 2-amino-4- piperazinyl rrimidin 1 4-fluorophenyl 4-pyridyl (3-(3-fluorophenyl)-ro 1 ) amino 4-fluorophenyl 2-acetamido- (3-(3-fluorophenyl)-4- rid 1 ro 1)amino 4-fluorophenyl 2-amino-4- (3-(3-fluorophenyl)-yrimidinyl ro 1)amino benz 1 4- rid 1 3- hen 1 ro ylamino benzyl 4-pyridyl 2-(4-fluorophenyl) eth laming 2-thienyl 4- rid 1 3- hen 1 rop laming 2-thienyl 4-pyridyl 2-(4-fluorophenyl) eth laming cyclohe 1 4- rid 1 3-phenyl ro laming cyclohexyl 4-pyridyl 2-(4-fluorophenyl) ethylamino tert-but 1 4- rid 1 3-phen lpro ylamino tert-butyl 4-pyridyl 2-(4-fluorophenyl) -- eth laming 4-fluorophenyl 4- 3-phenylpropylamino i eridin 1 4-fluorophenyl 4- 2-(4-fluorophenyl) iperidin 1 eth laming 4-fluoro hen 1 4- yranyl 3-phen lpro ylamino 4-fluorophenyl 4-pyranyl 2-(4-fluorophenyl) eth laming Phenyl 4-pyridyl 3-phenyl-2-amino-pro laming 4-fluorophenyl 4-pyridyl 3-phenyl-2-amino-ro laming 3-fluorophenyl 4-pyridyl 3-phenyl-2-amino-ro laming 2-fluorophenyl 4-pyridyl 3-phenyl-2-amino-rop laming 4-chlorophenyl 4-pyridyl 3-phenyl-2-amino-ro laming 3-chlorophenyl 4-pyridyl 3-phenyl-2-amino-ro laming 2-chlorophenyl 4-pyridyl 3-phenyl-2-amino-ro laming 4-tolyl 4-pyridyl 3-phenyl-2-amino-ro laming 3-tolyl 4-pyridyl 3-phenyl-2-amino-ro laming 2-tolyl 4-pyridyl 3-phenyl-2-amino-pro ylamino 4-trifluoro- 4-pyridyl 3-phenyl-2-amino-meth 1 hen 1 ro laming 3-trifluoro- 4-pyridyl 3-phenyl-2-amino-meth 1 hen 1 ro laming 2,6- 4-pyridyl - 3-phenyl-2-amino-dichloro hen 1 ro laming 2,6-dimethyl 4-pyridyl 3-phenyl-2-amino-hen 1 ro lamino 3,4- 4-pyridyl 3-phenyl-2-amino-dichloro hen 1 ro lamino 3,4-dimethyl 4-pyridyl 3-phenyl-2-amino-hen 1 ro lamino 2,4- 4-pyridyl 3-phenyl-2-amino-dichloro hen 1 ro lamino 2,4-dimethyl 4-pyridyl 3-phenyl-2-amino-hen 1 pro lamino Phenyl 4-pyridyl 3-phenyl-3-amino-ro lamino 4-fluorophenyl 4-pyridyl 3-phenyl-3-amino-ro lamino 3-fluorophenyl 4-pyridyl 3-phenyl-3-amino-ro lamino 2-fluorophenyl 4-pyridyl 3-phenyl-3-amino-ro lamino 4-chlorophenyl 4-pyridyl 3-phenyl-3-amino-ro lamino 3-chlorophenyl 4-pyridyl 3-phenyl-3-amino-ro lamino 2-chlorophenyl 4-pyridyl 3-phenyl-3-amino-ro lamino 4-tolyl 4-pyridyl 3-phenyl-3-amino-ro lamino 3-tolyl 4-pyridyl 3-phenyl-3-amino-ro lamino 2-tolyl 4-pyridyl 3-phenyl-3-amino-ro lamino 4-trifluoro- 4-pyridyl 3-phenyl-3-amino-meth 1 hen 1 ro lamino 3-t:ifluoro- 4-pyridyl 3-phenyl-3-amino-methvl hen 1 ro lamino _,6- 4-pyridyl 3-phenyl-3-amino-d:chloro hen 1 ro lamino ~,6-dimethyl 4-pyridyl 3-phenyl-3-amino-hen 1 ro lamino 3,4- 4-pyridyl 3-phenyl-3-amino-dichloro hen 1 ro lamino 3,4-dimethyl 4-pyridyl 3-phenyl-3-amino-hen 1 ro lamino 2,4- 4-pyridyl 3-phenyl-3-amino-dichloro hen 1 ro lamino 2,4-dimethyl 4-pyridyl 3-phenyl-3-amino-hen 1 ro lamino ana - ~ 68 O
R11 N~CH2CH3 wherein Rll, Rlz, and Rl are one of the combinations given in the following table:

4-fluorophenyl 4-pyridyl (2-(4-fluorophenyl) eth 1)amino 4-fluorophenyl 2-acetamido- (2-(4-fluorophenyl) 4- yrid 1 eth 1)amino 4-fluorophenyl 2-amino-4- (2-(4-fluorophenyl) rimidin 1 eth 1)amino 4-fluoro hen 1 4- rid 1 (3- hen lpro 1)amino 4-fluorophenyl 2-acetamido- (3-phenylpropyl)amino 4- rid 1 4-fluorophenyl 2-amino-4- (3-phenylpropyl)amino rimidin 1 4-fluorophenyl 4-pyridyl (S)-2-amino-3-hen 1 ro lamino 4-fluorophenyl 2-acetamido- (S)-2-amino-3-4- rid 1 hen 1 ropylamino 4-fluorophenyl 2-amino-4- (S)-2-amino-3-rimidinyl hen 1 ro lamino 4-fluorophenyl 4-pyridyl 3-amino-3-hen 1 ro lamino 4-fluorophenyl 2Tacetamido- 3-amino-3-4- rid 1 hen 1 ro lamino 4-fluorophenyl 2-amino-4- 3-amino-3-yrimidin 1 hen 1 ro lamino 4-fluorophenyl 4-pyridyl 3-amino-2-methyl-3-hen 1 ro lamino 4-fluorophenyl 2-acetamido- 3-amino-2-methyl-3-4- rid 1 hen lpro lamino 4-fluorophenyl 2-amino-4- 3-amino-2-methyl-3-rimidin 1 hen 1 ro lamino 4-fluorophenyl 4-pyridyl (S)-tetrahydroisoquinol-3- lmeth lenamino 4-fluorophenyl 2-acetamido- (S)-tetrahydroisoquinol-4- rid 1 3- lmeth lenamino 4-fluorophenyl 2-amino-4- (S)-tetrahydroisoquinol-rimidin 1 3- lmeth lenamino 4-fluoro hen 1 4- rid 1 (S)-3-Benz 1 i erazin 1 4-fluorophenyl 2-acetamido- (S)-3-benzylpiperazinyl 4- rid 1 4-fluorophenyl 2-amino-4- (S)-3-benzylpiperazinyl p rimidin 1 WO 98/24780 PCT/(1S97/22949 69 ' O
R1:
Ri:

in which RZ is H, methyl or benzyl, and R11, Rlz, and R1 are one of the combinations given in the_ following table:
R w-~- -~,..

Phen 1 4- rid 1 he_n 1 4-fluoro hen 1 4- rid 1 hen 1 Phenyl 2-acetamido- phenyl rid 1 4-fluorophenyl 2-acetamido- phenyl rid 1 Phen 1 4- rid 1 4-eth 1 hen 1 4-fluoro hen 1 4- rid 1 4-ethyl hen 1 Phenyl 2-acetamido- 4-ethylphenyl rid 1 4-fluorophenyl 2-acetamido- 4-ethylphenyl rid 1 Phen 1 4- rid 1 2,4-dimeth 1 henyl 4-fluoro hen 1 4-pyridyl 2,4-dimeth 1 hen 1 Phenyl 2-acetamido- 2,4-dimethylphenyl rid 1 4-fluorophenyl 2-acetamido- 2,4-dimethylphenyl ridyl Phen 1 4- rid 1 2,6-dichlorobenz 1 4-fluorophen 1 4- yrid 1 2,6-dichlorobenz 1 Phenyl 2-acetamido- 2,6-dichlorobenzyl rid 1 4-fluorophenyl 2-acetamido- 2,6-dichlorobenzyl rid 1 Phenyl 4-pyridyl 2-(4-fluorophenyl) eth lamino 4-fluorophenyl 4-pyridyl 2-(4-fluorophenyl) eth lamino Phenyl 2-acetamido- 2-(4-fluorophenyl) rid 1 eth lamino 4-fluorophenyl 2-acetamido- 2-(4-fluorophenyl) rid 1 eth lamino -- Phen 1 4- rid 1 3- hen 1 ro lamino 4-fluorophen 1 4- rid 1 3- hen 1 ro lamino Phenyl 2-acetamido- 3-phenylpropylamino rid 1 4-fluorophenyl 2-acetamido- 3-phenylpropylamino rid 1 Phen 1 4- rid 1 1- i erazin 1 p4-fluorophenyl 4-pyridyl 1-piperazinvl ~

Phenyl 2-acetamido- 1 -piperazinyl yrid 1 4-fluorophenyl 2-acetamido- 1-piperazinyl pyrid 1 benz 1 4- rid 1 3- hen 1 ro lamino benzyl 4-pyridyl 2-(4-fluorophenyl) eth lamino 2-thien 1 4- rid 1 3- hen 1 ro lamino 2-thienyl 4-pyridyl 2-(4-fluorophenyl) eth lamino c clohex 1 4- rid 1 3- hen 1 ro ylamino cyclohexyl 4-pyridyl 2-(4-fluorophenyl) eth lamino tert-but 1 4- rid 1 3- hen lpro lamino tert-butyl 4-pyridyl 2-(4-fluorophenyl) ethylamino 4-fluorophenyl 4- 3-phenylpropylamino i eridin 1 4-fluorophenyl 4- 2-(4-fluorophenyl) iperidin 1 eth lamino 4-fluoro hen 1 4- ran 1 3- hen 1 ro lamino 4-fluorophenyl 4-pyranyl 2-(4-fluorophenyl) eth lamino Phenyl 4-pyridyl (S)-2-amino-3-hen lpro lamino 4-fluorophenyl 4-pyridyl (S)-2-amino-3-hen lpro lamino Phenyl 2-acetamido- (S)-2-amino-3-ridyl hen 1 ro lamino 9-fluorophenyl 2-acetamido- (S)-2-amino-3-rid 1 phen lprop lamino Phenyl 4-pyridyl 3-amino-3-hen 1 ro lamino 4-fluorophenyl 4-pyridyl 3-amino-3-hen 1 ro ylamino ;Pnenyl 2-acetamido- _ 3-amino-3-rid 1 phen 1 ropylamino 4-fluorophenyl 2-acetamido- 3-amino-3-rid 1 hen 1 ro lamino Phenyl 4-pyridyl 3-amino-2-methyl-3-hen 1 ro lamino 4-fluorophenyl 4-pyridyl 3-amino-2-methyl-3-hen 1 ro lamino Phenyl 2-acetamido- 3-amino-2-methyl-3-rid 1 hen 1 ro lamino 4-fluorophenyl 2-acetamido- 3-amino-2-methyl-3-rid 1 hen 1 ro lamino Phenyl 4-pyridyl (S)-tetrahydroisoquinol-3- lmeth lenamino 4-fluorophenyl 4-pyridyl (S)-tetrahydroisoquinol-3- lmeth lenamino Phenyl 2-acetamido- (S)-tetrahydroisoquinol-rid 1 3- lmeth lenamino 4-fluorophenyl 2-acetamido- (S)-tetrahydroisoquinol-rid 1 3-ylmethylenamino Phen 1 4- rid 1 (S)-3-benz 1 i erazin 1 4-fluoro hen 1 4- rid 1 S)-3-benz 1 i erazin 1 Phenyl 2-acetamido- S)-3-benzylpiperazinyl rid 1 4-fluorophenyl 2-acetamido- S)-3-benzylpiperazinyl rid 1 Additional preferred compounds are listed in the Examples, infra.
As utilized herein, the following terms shall have the following meanings:
"Alkyl", alone or in combination, means a straight-chain or branched-chain alkyl radical containing preferably 1-carbon atoms (C1-C15), more preferably 1-8 carbon 10 atoms (C1-Cg), even more preferably 1-6 carbon atoms (C1-C6), yet more preferably 1-4 carbon atoms (C1-Cq), still more preferably 1-3 carbon atoms (C1-C3), and most preferably 1-2 carbon atoms (C1-C2). Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, 15 n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl and the like.
"Hydroxyalkyl", alone or in combination, means an alkyl radical as defined above wherein at least one hydrogen radical is replaced with a hydroxyl radical, preferably 1-3 hydrogen radicals are replaced by hydroxyl radicals, more preferably 1-2 hydrogen radicals are replaced by hydroxyl radicals, and most preferably one hydrogen radical is replaced by a hydroxyl radical. Examples of such radicals include hydroxymethyl, 1-, 2-hydroxyethyl, 1-, 2-, 3-hydroxypropyl, 1,3-dihydroxy-2-propyl, 1,3-dihydroxybutyl, 1,2,3,4,5,6-hexahydroxy-2-hexyl and the like.
"Alkenyl", alone or in combination, means a straight-chain or branched-chain hydrocarbon radical having one or more double bonds, preferably 1-2 double bonds and more preferably one double bond, and containing preferably 2-15 carbon atoms (C2-C15), more preferably 2-8 carbon atoms (C2-Cg), even more preferably 2-6 carbon atoms (C2-C6), yet more preferably 2-4 carbon atoms (C2-C4), and still more preferably 2-3 carbon atoms (C2-C3). Examples of such alkenyl radicals include ethenyl, propenyl, 2-methylpropenyl, 1,4-butadienyl and the like.
"Alkoxy", alone or in combination, means a radical of the type "R-O-" wherein "R" is an alkyl radical as defined above and "O" is an oxygen atom. Examples of such alkoxy radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy and the like.
"Alkoxycarbonyl", alone or in combination, means a radical of the type "R-O-C(O)-" wherein "R-O-" is an alkoxy radical as defined above and "C(O)" is a carbonyl radical.
"Alkoxycarbonylamino", alone or in combination, means a radical of the type "R-O-C(O)-NH-" wherein "R-O-C(O)" is an alkoxycarbonyl radical as defined above, wherein the amino radical may optionally be substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl and the like.
"Alkylthio", alone or in combination, means a radical of the type "R-S-" wherein "R" is an alkyl radical as defined above and "S" is a sulfur atom. Examples of such alkylthio radicals include methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, iso-butylthio, sec-butylthio, tert-butylthio and the like.

"Alkylsulfinyl", alone or in combination, means a radical of the type "R-S(O)-" wherein "R" is an alkyl - radical as defined above and "S(0)" is a mono-oxygenated sulfur atom. Examples of such alkylsulfinyl radicals _ 5 include methylsulfinyl, ethylsulfinyl, n-propylsulfinyl, isopropylsulfinyl, n-butylsulfinyl, iso-butylsulfinyl, sec-butylsulfinyl, tert-butylsulfinyl and the like.
"Alkylsulfonyl", alone or in combination, means a radical of the type "R-S(O)z-" wherein "R" is an alkyl radical as defined above and "S(O)z" is a di-oxygenated sulfur atom. Examples of such alkylsulfonyl radicals include methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, iso-butylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl and the like.
"Aryl", alone or in combination, means a phenyl or biphenyl radical, which is optionally benzo fused or heterocyclo fused and which is optionally substituted with one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, azido, nitro, cyano, haloalkyl, carboxy, alkoxycarbonyl, cycloalkyl, alkanoylamino, amido, amidino, alkoxycarbonylamino, N-alkylamidino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, N-alkylamido, N,N-dialkylamido, aralkoxycarbonylamino, alkylthio, alkylsulfinyl, alkylsulfonyl, oxo and the like.
Examples of aryl radicals are phenyl, o-tolyl, 4-methoxyphenyl, 2-(tert-butoxy)phenyl, 3-methyl-4-methoxyphenyl, 2-CF3-phenyl, 2-fluorophenyl, 2-chlorophenyl, 3-nitrophenyl, 3-aminophenyl, 3-acetamidophenyl, 2-amino-3-(aminomethyl)phenyl, 6-methyl-3-acetamidophenyl, 5-methyl-2-aminophenyl, 6-methyl-2,3-diaminophenyl, 2-amino-3-methylphenyl, 4,6-dimethyl-2-aminophenyl, 4-hydroxyphenyl, 3-methyl-4-hydroxyphenyl, 4-(2-methoxyphenyl)phenyl, 2-amino-1-naphthyl, 2-naphthyl, 3-amino-2-naphthyl, 1-methyl-3-amino-2-naphthyl, 2,3-diamino-1-naphthyl, 4,8-dimethoxy-2-naphthyl and the Like.
"Aralkyl" and "arylalkyl", alone or in combination, means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by an aryl radical as defined above, such as benzyl, 1-, 2-phenylethyl, dibenzylmethyl, hydroxyphenylmethyl, methylphenylmethyl, diphenylmethyl, dichlorophenylmethyl, 4-methoxyphenylmethyl and the like.
"Aralkoxy", alone or in combination, means an alkoxy radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by an aryl radical as defined above, such as benzyloxy, 1-, 2-phenylethoxy, dibenzylmethoxy, hydroxyphenylmethoxy, methylphenylmethoxy, dichlorophenylmethoxy, 4-methoxyphenylmethoxy and the like.
"Aralkoxycarbonyl", alone or in combination, means a radical of the type "R-O-C(O)-" wherein "R-O-" is an aralkoxy radical as defined above and "-C(O)-" is a carbonyl radical.
"Alkanoyl", alone or in combination, means a radical of the type "R-C(O)-" wherein "R" is an alkyl radical as defined above and "-C(O)-" is a carbonyl radical.
Examples of such alkanoyl radicals include acetyl, trifluoroacetyl, hydroxyacetyl, propionyl; butyryl, valeryl, 4=methylvaleryl, and the like.
"Alkanoylamino", alone or in combination, means a radical of the type "R-C(O)-NH-" wherein "R-C(O)-" is an alkanoyl radical as defined above, wherein the amino radical may optionally be substituted, such as with WO 98/247$0 PCT/LTS97/22949 alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl and the like.
"Aminocarbonyl", alone or in combination, means an amino 5 substituted carbonyl (carbamoyl) radical, wherein the amino radical may optionally be mono- or di-substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, alkanoyl, alkoxycarbonyl;
aralkoxycarbonyl and the like.
"Aminosulfonyl", alone or in combination, means an amino substituted sulfonyl radical.
"Benzo", alone or in combination, means the divalent radical C6H4= derived from benzene. "Benzo fused" forms a ring system in which benzene and a cycloalkyl or aryl group have two carbons in common, for example tetrahydronaphthylene and the like.
"Bicyclic" as used herein is intended to include both fused ring systems, such as naphthyl and i3-carbolinyl, and substituted ring systems, such as biphenyl, phenylpyridyl and diphenylpiperazinyl.
"Cycloalkyl", alone or in combination, means a saturated or partially saturated, preferably one double bond, monocyclic, bicyclic or tricyclic carbocyclic alkyl radical, preferably monocyclic, containing preferably 5-12 carbon atoms (C5-C12), more preferably 5-10 carbon atoms (C5-Clp), even more preferably 5-7 carbon atoms (C5-C~), which is optionally benzo fused or heterocyclo fused and which is optionally substituted as defined herein with respect to the definition of aryl. Examples of such cycloalkyl radicals include cyclopentyl, cyclohexyl, dihydroxycyclohexyl, ethylenedioxycyclohexyl, cycloheptyl, octahydronaphthyl, --tetrahydronaphthyl, octahydroquinolinyl, dimethoxytetrahydronaphthyl, 2,3-dihydro-1H-indenyl, azabicyclo[3.2.1]octyl and the like.
"Heteroatoms" means nitrogen, oxygen and sulfur heteroatoms.
"Heterocyclo fused" forms a ring system in which a heterocyclyl or heteroaryl group of 5-6 ring members and a cycloalkyl or aryl group have two carbons in common, for example indole, isoquinoline, tetrahydroquinoline, methylenedioxybenzene and the like.
"Heterocyclyl" means a saturated or partially unsaturatEd, preferably one double bond, monocyclic or bicyclic, preferably monocyclic, heterocycle radical containing at least one, preferably 1 to 4, more preferably 1 to 3, even more preferably 1-2, nitrogen, oxygen or sulfur atom ring member and having preferably 3-8 ring members in each ring, more preferably 5-8 ring members in each ring and even more preferably 5-6 ring members in each ring. "Heterocyclyl" is intended to include sulfone and sulfoxide derivatives of sulfur ring members and N-oxides of tertiary nitrogen ring members, and carbocyclic fused, preferably 3-6 ring carbon atoms and more preferably 5-6 ring carbon atoms, and benzo fused ring systems. "Heterocyclyl" radicals may optionally be substituted on at least one, preferably 1-4, more preferably 1-3, even more preferably 1-2, carbon atoms by halogen, alkyl, alkoxy, hydroxy, oxo, thioxo, aryl, aralkyl, heteroaryl, heteroaralkyl, amidino, N-alkylamidino, alkoxycarbonylamino, alkylsulfonylamino and the like, and/or on a secondary nitrogen atom by hydroxy, alkyl, aralkoxycarbonyl, alkanoyl, alkoxycarbonyl, heteroaralkyl, aryl or aralkyl radicals.
More preferably, "heterocyclyl", alone or in combination, is a radical of a monocyclic or bicyclic saturated heterocyclic ring system having 5-8 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally - partially unsaturated or benzo-fused and optionally substituted by 1-2 oxo or thioxo radicals. Examples of such heterocyclyl radicals include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiamorpholinyl, 4-benzyl-piperazin-1-yl, pyrimidinyl, tetrahydrofuryl, pyrazolidonyl, pyrazolinyl, pyridazinonyl, pyrrolidonyl, tetrahydrothienyl and its sulfQxide and sulfone derivatives, 2,3-dihydroindolyl, tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydro-1-oxo-isoquinolinyl, 2,3-dihydrobenzofuryl, benzopyranyl, methylenedioxyphenyl, ethylenedioxyphenyl and the like.
"Heteroaryl" means a monocyclic or bicyclic, preferably monocyclic, aromatic heterocycle radical, having at least one, preferably 1 to 4, more preferably 1 to 3, even more preferably 1-2, nitrogen, oxygen or sulfur atom ring members and having preferably 5-6 ring members in each ring, which is optionally saturated carbocyclic fused, preferably 3-4 carbon atoms (C3-C4) to form 5-6 ring membered rings and which is optionally substituted as defined above with respect to the definitions of aryl. Examples of such heteroaryl groups include imidazolyl, 1-benzyloxycarbonylimidazol-4-yl, pyrrolyl, pyrazolyl, pyridyl, 3-(2-methyl)pyridyl, 3-(4-trifluoromethyl)pyridyl, pyrimidinyl, 5-(4-trifluoromethyl)pyrimidinyl, pyrazinyl, triazolyl, furyl, thienyl, oxazolyl, thiazolyl, indolyl, quinolinyl, 5,6,7,8-tetrahydroquinolyl, 5,6,7,8-tetrahydroisoquinolinyl, quinoxalinyl, benzothiazolyl, benzofuryl, benzimidazolyl, benzoxazolyl and the like.
"Heteroaralkyl" and "heteroarylalkyl," alone or in combination, means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by a heteroaryl radical as defined above, such as 3-furylpropyl, 2-pyrrolyl propyl, chloroquinolinylmethyl, 2-thienylethyl, pyridylmethyl, 1-imidazolylethyl and the like.
"Halogen" and "halo", alone or in combination, means fluoro, chloro, bromo or iodo radicals.
"Haloalkyl", alone or in combination, means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-3, is replaced by a halogen radical, more preferably fluoro or chloro radicals. Examples of such haloalkyl radicals include 1,1,1-trifluoroethyl, chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, bis(trifluoromethyl)methyl and the like.
"Pharmacologically acceptable salt" means a salt prepared by conventional means, and are well known by those skilled in the art. The "pharmacologically acceptable salts" include basic salts of inorganic and organic acids, including but not limited to hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulfonic acid, malic acid, acetic acid, oxalic acid, tartaric acid, citric acid, lactic acid, fumaric acid, succinic acid, malefic acid, salicylic acid, benzoic acid, phenylacetic acid, mandelic acid and the like. When compounds of the invention include an acidic function such as a carboxy group, then suitable pharmaceutically acceptable cation pairs for the carboxy group are well known to those skilled in tl~e art and include alkaline, alkaline earth, ammonium, quaternary ammonium cations and the like. For additional examples of "pharmacologically acceptable salts," see infra and Berge et al,- J. Pharm. Sci. 66, 1 ( 1977 ) .

"Cytokine" means a secreted protein that affects the functions of other cells, particularly as it relates to ' the modulation of interactions between cells of the immune system or cells involved in the inflammatory response. Examples of cytokines include but are not limited to interleukin 1 (IL-1), preferably IL-1i3, interleukin 6 (IL-6), interleukin 8 (IL-8) and TNF, preferably TNF-a (tumor necrosis factor-oc).
"TNF, IL-1, IL-6, and/or IL-8 mediated disease or disease state" means all disease states wherein TNF, IL-1, IL-6, and/or IL-8 plays a role, either directly as TNF, IL-1, IL-6, and/or IL-8 itself, or by TNF, IL-1, IL-6, and/or IL-8 inducing another cytokine to be released. For example, a disease state in which IL-1 plays a major role, but in which the production of or action of IL-1 is a result of TNF, would be considered mediated by TNF.
"Leaving group" generally refers to groups readily displaceable by a nucleophile, such as an amine, a thiol or an alcohol nucleophile. Such leaving groups are well known in the art. Examples of such leaving groups include, but are not limited to, N-hydroxysuccinimide, N-hydroxybenzotriazole, halides, triflates, tosylates and the like. Preferred leaving groups are indicated herein where appropriate.
"Protecting group" generally refers to groups well known in the art which are used to prevent selected reactive groups, such as carboxy, amino, hydroxy, mercapto and the like, from undergoing undesired reactions, such as nucleophilic, electrophilic, oxidation, reduction and the like. Preferred protecting groups are indicated herein where appropriate. Examples of amino protecting groups include, but are not limited to, aralkyl, substituted aralkyl, cycloalkenylalkyl and substituted cycloalkenyl WO 98/24780 PCTlUS97/22949 _ 80 alkyl, allyl, substituted allyl, acyl, alkoxycarbonyl, aralkoxycarbonyl, silyl and the like. Examples of aralkyl include, but are not limited to, benzyl, ortho-methylbenzyl, trityl and benzhydryl, which can be optionally substituted with halogen, alkyl, alkoxy, hydroxy, nitro, acylamino, acyl and the like, and salts, such as phosphonium and ammonium salts. Examples of aryl groups include phenyl, naphthyl, indanyl, anthracenyl, 9-(9-phenylfluorenyl), phenanthrenyl, durenyl and the like.
Examples of cycloalkenylalkyl or substituted cycloalkylenylalkyl radicals, preferably have 6-10 carbon atoms, include, butare not limited to, cyclohexenyl methyl and the like. Suitable acyl, alkoxycarbonyl and aralkoxycarbonyl groups include benzyloxycarbonyl, t-butoxycarbonyl, iso-butoxycarbonyl, benzoyl, substituted benzoyl, butyryl, acetyl, tri-fluoroacetyl, tri-chloro acetyl, phthaloyl and the like. A mixture of protecting groups can be used to protect the same amino group, such as a primary amino group can be protected by both an aralkyl group and an aralkoxycarbonyl group. Amino protecting groups can also form a heterocyclic ring with the nitrogen to which they are attached, for example, 1,2-bis(methylene)benzene, phthalimidyl, succinimidyl, maleimidyl and the like and where these heterocyclic groups can further include adjoining aryl and cycloalkyl rings. In addition, the heterocyclic groups can be mono-, di- or tri-substituted, such as nitrophthalimidyl.
Amino groups may also be protected against undesired reactions, such as oxidation, through the formation of an addition salt, such as hydrochloride, toluenesulfonic acid, trifluoroacetic acid and the like. Many of the amino protecting groups are also suitable for protecting carboxy, hydroxy and mercapto groups. For example, aralkyl groups. Alkyl groups are also sutiable groups for protecting hydroxy and mercapto groups, such as tert-butyl.

81 ' Silyl protecting groups are silicon atoms optionally substituted by one or more alkyl, aryl and aralkyl groups. Suitable silyl protecting groups include,. but are not limited to, trimethylsilyl, . 5 triethylsilyl, tri-isopropylsilyl, tert-butyldimethylsilyl, dimethylphenylsilyl, 1,2-bis(dimethylsilyl)benzene, 1,2-bis(dimethylsilyl)ethane and diphenylmethylsilyl. Silylation of an amino groups provide mono- or di-silylamino groups. Silylation of aminoalcohol compounds can lead to a N,N,O-tri-silyl derivative. Removal of the silyl function from a silyl ether function is readily accomplished by treatment with, for example, a metal hydroxide or ammonium flouride reagent, either as a discrete reaction step or in situ during a reaction with the alcohol group.
Suitable silylating agents are, for example, trimethylsilyl chloride, tert-butt'-dimethylsilyl chloride, phenyldimethylsilyl chloride, diphenylmethyl silyl chloride or their combination products with imidazole or DMF. Methods for silylation of amines and removal of silyl protecting groups are well known to those skilled in the art. Methods of preparation of these amine derivatives from corresponding amino acids, amino acid amides or amino acid esters are also well known to those skilled in the art of organic chemistry including amino acid/amino acid ester or aminoalcohol 'chemistry.
Protecting groups are removed under conditions which will not affect the remaining portion of the molecule. These methods are well known in the art and include acid hydrolysis, hydrogenolysis and the like. A
preferred method involves removal of a protecting group, such as removal of a benzyloxycarbonyl group,by hydrogenolysis utilizing palladium on carbon in a suitable solvent system such as an alcohol, acetic acid, and the like or mixtures thereof. A t-butoxycarbonyl protecting group can be removed utilizing an inorganic WO 98!24780 PCT/US97/22949 or organic acid, such as HC1 or trifluoroacetic acid, in a suitable solvent system, such as dioxane or methylene chloride. The resulting amino salt can readily be neutralized to yield the free amine. Carboxy protecting group, such as methyl, ethyl, benzyl, tert-butyl, 4-methoxyphenylmethyl and the like, can be removed under hydroylsis and hydrogenolysis conditions well known to those skilled in the art.
The symbols used above have the following meanings:
Rx Ry 0 -CRxRy- _ -C(0)- -R
Rx I
-NRxRy - ~-N\ -C (NR) - - N
Ry R
-NR- - ~~N~~ -S (O) 2- _ ,f~ '~~ s~.~
to Prodrugs of the compounds of this invention are also contemplated by this invention. A prodrug is an active or inactive compound that is modified chemically through in vivo physicological action, such as hydrolysis, metabolism and the like, into a compound of this invention following adminstration of the prodrug to a patient. The suitability and techniques involved in making and usingprodrugs are well known by those skilled in the art. For a general discussion of 20 prodrugs involving esters see Svensson and Tunek Drug Metabolism Reviews 165 (1988) and Bundgaard Design of Prodrugs, Elsevier (1985). Examples of a masked carboxylate anion include a variety of esters, such as alkyl (for example, methyl, ethyl), cycloalkyl (for 25 example, cyclohexyl), aralkyl (for example, benzyl, p-methoxybenzyl), and alkylcarbonyloxyalkyl (for example, pivaloyloxymethyl). Amines have been masked as arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases in vivo releasing the free drug and - formaldehyde (Bungaard J. Med. Chem. 2503 (1989)).
Also, drugs containing an acidic NH group, such as imidazole, imide, indole and the like, have been masked with N-acyloxymethyl groups (Bundgaard Design of Prodrugs, Elsevier (1985)). Hydroxy groups have been masked as esters and ethers. EP 039,051 (Sloan and Little, 4/11/81) discloses Mannich-base hydroxamic acid prodrugs, their preparation and use.
Compounds according to the invention can be synthesized according to one or more of the following methods. It should be noted that the general procedures are shown as it relates to preparation of compounds having unspecified stereochemistry. However, such procedures are generally applicable to those compounds of a specific stereochemistry, e.g., where the stereochemistry about a group is (S) or (R). In addition, the compounds having one stereochemistry (e. g., (R)) can often be utilized to produce those having opposite stereochemistry (i.e., (S)) using well-known methods, for example, by inversion.
~ ( 3 H) -Pyrimidinones For the synthesis of 4(3H)-pyrimidinones II (or its tautomer, 4-hydroxy-pyrimidines), the approach displayed in Scheme 1 may be followed (for a review of synthetic methods see: D.J. Brown, Heterocyclic Compounds: the Pyrimidines, supra). This approach involves the cyclization reaction between an acrylic acid ester XII
and an amidine V followed by oxidation of the resulting - dihydropyrimidinone XIII to give II.

84 ' Scheme 1 O H2N R1 si O
R11 ~ R
FOR NH NH
R12 v R12 N~R1 XII
XIII
OH O

N _ ~ \NH
R12 N~R1 R12 N~R1 II
For the synthesis of 2-substituted 5-(4-fluorophenyl)-6-(4-pyridyl)-4-hydroxy-pyrimidines II
(Scheme 2), the disubstituted acrylic acid ester XII may be prepared conveniently by condensation of pyridine-4-carboxaldehyde with 4-fluorophenylacetic acid followed by esterification. XII may be reacted with a variety of amidines V at elevated temperature. As a dehydrogenating agent for the conversion of XIII to II, sodium nitrite/acetic acid is suitable.

WO 98/24780 PCT/US9'7/22949 Scheme 2 F
~H
N
' F ~ / OR
. O
OH

.i R1 HN
F y ~ F
Rm--~,. R1 XIII II
Accordingly, further compounds of formula II may be obtained in which R1z is any other heteroaryl ring within 5 the definition of R'2 by the appropriate choice of starting material. Such starting materials include but are not limited to 2-methylpyridine-4-carboxaldehyde, 2,6-dimethylpyridine-4-carboxaldehyde (Mathes and Sauermilch, Chem. Ber. 88, 1276-1283 (1955)), quinoline-10 4-carboxaldehyde, pyrimidine-4-carboxaldehyde, 6-methylpyrimidine-4-carbox-aldehyde, 2-methylpyrimidine-4-carboxaldehyde, 2,6-dimethylpyrimidine-4-carboxalde-hyde (Bredereck et al., Chem. Ber. 97, 3407-3417 (1964)). The use of 2-nitropyridine-4-carboxaldehyde 15 would lead to a derivative of formula II with R1Z
represented by a 2-vitro-4-pyridyl group. Catalytic reduction of the vitro to an amino group would provide _ the 2-amino-4-pyridyl derivative of II. The approach displayed in Scheme 2 is applicable to the use of other 20 aryl acetic acids leading to compounds of formula II
with different aryl groups as R1'.

Pyrimidinone II (R'= H) may be substituted at the N-3 position by reaction with e.g, an alkyl halide, such as methyl iodide or ethyl bromide in the presence of an appropriate base such as potassium carbonate and the like.
Scheme 3 O

OEt \ O S
F I \ 0 N / / OE t H2N
'OE t ~ ~ \ O
N /
XIV
F \ O F \ O F \
I/ ~ I/ ~ I/ o I --~- I ~ --.~. I '~ 21 N~SH ~ \ N~SMe I \ N~N~R

XV
XVI
II
F \ 0 /
I
\ N~R1 N /
II R1 _ SR2i Another approach (Scheme 3) leading to 5,6-diaryl-4-hydroxy-pyrimidines involves the cyclization of the b-keto ester XIV with thiourea to give the thiouracil derivative XV. XV can be S-monomethylated to XVI.
Reaction of_XVI with primary and secondary amines leads to 2-amino substituted 4-hydroxy-pyrimidines II.
Further 2-thioether derivatives of II with R1 - SRzI can be obtained, for example by alkylation of XV with alkyl halides. Treatment of XV or XVI with Raney nickel and H2 provides compounds of structure II wherein R1 is H.
Although Scheme 3 illustrates syntheses in which R12 is 4-pyridyl, this approach may be equally applied to any other heteroaryl ring within the definition of R'z by the appropriate choice of the starting material. Such starting materials include but are not limited to ethyl 2-methyl isonicotinate (E~imovsky and Rumpf, Bull. Soc.
Chim. FR. 648-649 (1954)), methyl pyrimidine-4-carboxylate, methyl 2-methylpyrimidine-4-carboxylate, methyl 6-methylpyrimidine-4-carboxylate and methyl 2,6-dimethylpyrimidine-4-carboxylate (Sakasi et al., Heterocycles 13, 235 (1978)). Likewise, methyl 2-nitroisonicotinate (Stanonis, J. Org. Chem. 22, 475 (1957)) may be reacted with an aryl acetic acid ester followed by cyclization of the resultant b-keto ester with thiourea analogously to Scheme 3. Subsequent catalytic reduction of the nitro group to an amino group would give a pyrimidinone II in which R12 is represented by a 2-amino-4-pyridyl group (Scheme 4).
Scheme 4 \ O F I \ O 4 / .R4 / ~R
N N
\ I N~R1 \ I N~Ri N~ N
NT02 TNH2 =_ Furthermore, methyl 2-acetamido isonicotinate 2~ (Scheme 5) may be reacted analogously to Scheme 3 after appropriate protection of the amide nitrogen with e.g. a tert-butyldimethylsilyloxymethyl group (Benneche et al., Acta Chem. Scand. B 42 384-389 (1988)), a tert-butyldimethylsilyl group, a benzyloxymethyl group, a benzyl group or the like (P1}.
Scheme 5 C02Me ~ ~ C02Me ~ .\ C02Me N~ ~ N~ ~ N
NH2 NHAc i Ac _ , 88 Removal of the protecting group P1 of the resulting pyrimidine II with a suitable reagent (e. g., tetrabutylammonium fluoride in the case where P1 is t-butyldimethyl-silyloxymethyl) would then lead to a pyrimidinone II with R12 represented by a 2-acetamido-4-pyridyl group. Needless to say, ethyl p-fluorophenyl acetate may be substituted by any alkyl arylacetate in the procedure illustrated in Scheme 3 thus providing compounds of formula II with different R1' aryl substituents.
In a further process, pyrimidinones II may be prepared by coupling_a suitable derivative of XVIII (L
is a leaving group, such as halogen radical and the like) with an appropriate aryl equivalent.
O
L ~ R4 N
R12 N~R1 XVIII
Such aryl/heteroaryl couplings are well known to those skilled in the art and involve an organic-metallic component for reaction with a reactive derivative, e.g., a halogeno derivative, of the second compound in the presence of a catalyst. The metallo-organic species may be provided either by the pyrimidinone in which case the aryl component provides the reactive halogen equivalent or the pyrimidinone may be in the form of a reactive 5-halogeno derivative for reaction with a metallo organic aryl compound. Accordingly, 5-bromo and 5-iodo derivatives of XVIII (L = Br, I) may be treated with arylalkyl tin compounds, e.g., trimethylstannylbenzene, in an inert solvent such as tetrahydrofuran in the presence of a palladium catalyst, such as di(triphenylphosphine)palladium(II)dichloride.~ (Peters et al., J. Heterocyclic Chem. 27, 2165-2173, (1990).
Alternatively, the halogen derivative of XVIII may be converted into a trialkyltin derivative (L = Bu3Sn) by reaction with e.g. tributylstannyl chloride following lithiation with butyllithium and may then be reacted ' with an aryl halide in the presence of a catalyst.
(Sandosham and Undheim, Acta Chem. Stand. 43, 684-689 (1989). Both approaches would lead to pyrimidines II in which R11 is represented by aryl and heteroaryl groups.
As reported in the literature (Kabbe, Lieb. Ann.
Chem. 704, 144 (1967}; German Patent 1271116 (1968)) and displayed in Scheme 6, 5-aryl-2,6-dipyridyl-4(3H)-pyrimidinones II may be prepared in a one step synthesis by reaction of the cyanopyridine with an arylacetyl ester, such as ethyl phenylacetate in the presence of sodium methoxide.
Scheme 6 O
CN Rm~C02Et N
J
N
II
In Scheme 7, compounds of the present invention of formula XXX can be readily prepared by reacting the methylthio intermediate XXXI with the amine NHRSR21, for example by heating the mixture preferably at a temperature greater than 100°C, more preferably 150-210°C. Alternatively, compounds of formula XXX can be readily prepared by reacting the methylsulfonyl intermediate XXXII with the amine NHRSRZ1, for example by heating the mixture preferably at a temperature greater than 40°C, more preferably 50-210°C.
Scheme 7 O O O
Rll Rll 11 NH R NH
12 ~ ~ . R21 R12 N SMe R N N R12 N~S02Me XXXI ~ XXXII

Amines of formula NHRSR21 are commercially available or can be readily prepared by those skilled in the art from commercially available starting materials. For example, an amide, nitro or cyano group can be reduced 5 under reducing conditions, such as in the prescence of a reducing agent like lithium aluminum hydride and the like, to form the corresponding amine. Alkylation and acylation of amino groups are well known in the art.
Chiral and achiral substituted amines can be prepared 10 from chiral amino acids and amino acid amides (for example, alkyl, aryl, heteroaryl, cycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and the like substituted glycine, i3-alanine and the like) using methods well known in the art, such as H. Brunner, P.
15 Hankofer, U. Holzinger, B. Treittinger and H.
Schoenenberger, Eur. J. Med. Chem. 25, 35-44, 1990; M.
Freiberger and R. B. Hasbrouck, J. Am. Chem. Soc. 82, 696-698, 1960; Dornow and Fust, Chem. Ber. 87, 984, 1954; M. Kojima and J. Fujita, Bull. Chem. Soc. Jpn. 55, 20 1454-1459, 1982; W. Wheeler and D. O'Bannon, Journal of Labelled Compounds and Radiopharmaceuticals XXXI, 306, 1992; and S. Davies, N. Garrido, O. Ichihara and I.
Walters, J. Chem. Soc., Chem. Commun. 1153, 1993.
25 Pvridones:
As displayed in Scheme 8, a suitable route to 2(1H)-pyridones III involves the cyclization reaction between an a,b-unsaturated ketone XXII and a sufficiently reactive, substituted acetamide in the 30 presence of base (E1-Rayyes and A1-Hajjar, J.
Heterocycl. Chem. 21, 1473 (1984)) and subsequent dehydrogenation.

_ , 91 Scheme 8 -O
R12~H O

_ ~ 1 ~ R12!~R1 ' XXII ii R
O
R11 _ O

~ NH
Ri2 ~ R1 R1z ~ R1 III
Scheme 9 O
0 ~ i 0 R
~ ~H -' ~ ~ ~~Rl N / N /
XXII ~ j~2 _~~ t Accordingly (Scheme 9), pyridine-4-carboxaldehyde or other heteroaromatic carboxaldehyde-like pyrimidine-4-carboxaldehydes or quinoline-4-carboxyaldehydes may be reacted with acetyl aryl, acetyl heteroaryl or acetyl cycloalkyl derivatives in the presence of piperidine/
' 10 acetic acid at elevated temperature (Bayer and Hartmann, Arch. Pharm. (Weinheim) 324, 815 (1991)) as well as pinacolone (CH3-CO-C(CH~)3) in the presence of sodium hydroxide to provide the unsaturated ketone XXII (or the analogous ketone from the corresponding heteroaromatic-4-carboxyaldehyde). The reaction of XXII with phenylacetamide in the presence of sodium ethoxide then may lead via the 3,4-dihydropyridone to 6-substituted 3-phenyl-4-(heteroaryl)-2(1H)-pyridones of structure III.
In Scheme 10, a feasible route is illustrated leading to 6-chloro-2(1H)-pyridone XXIV, a versatile intermediate for further modifications at the 6-position. This approach (G. Simchen, Chem. Ber. 103, 389-397 (1970) is based on the conversion of the unsaturated g-cyanocarboxylic acid chloride XXIII into XXIV in the presence of hydrogen chloride.
Scheme 10 Eton / o 11 O P\OEt R11 O
R
OR
OEt CN
R12 ~ R12 ~ CN _ O
R = Et XII R = H

~C 1 12~ ~~ 12 ~ CN

XXIV XXIII
Reaction of XXIV with ammonia (Katritzky and Rachwal, J. Heterocylic Chem. 32, 1007 (1995)), primary and secondary amines would lead to 2-amino substituted pyridones III. Furthermore, XXIV may be reacted in a palladium or nickel catalyzed cross-coupling reaction with an alkyl or aryl boronic acid or an alkyl or aryl zinc halide to provide pyridone III wherein R' is alkyl or aryl or heteroaryl.
In addition, pyridone III may be substituted at the N-1 position by reaction with, e.g., an alkyl halide in WO 98!24780 PCT/US97l22949 the presence of an appropriate base such as potassium carbonate.
An approach that may lead to a pyrimidinone of the general formula III is illustrated in Scheme 11.
- 5 Scheme 11 C1 I NCS 2 R N~~Rq R12 OEt ~ R12 OEt ~ ( H
R12 OEt XXVI
XXVII
R11 ~ R11 12~~ ~ ~ 12~~
R N SMe R N S

XXVIII XXIX
According to this approach (Shaw and Warrener, J.
Chem. Soc. 153-156 (1958); Hronowski and Szarek, Can. J.
Chem. 63, 2787 (1985); Agathocleous and Shaw, J. Chem.
Soc. Perkin Trans. I, 2555 (1993)), an ethoxyacryloyl iscthiocyanate XXVI is reacted with a primary amine to give as an addition product the acylthiourea XXVII which_ can be cyclized under basic or acidic conditions to the thiouracil compound XXVIII. XXVIII may be methylated to the methylthio derivative XXIX, a versatile intermediate for further transformations at the 2-position.
Fused 4(3H)-Pvrimidinones:
As displayed in Schemes 12 and 13, introduction of a suitable R' group through the alkylation of XXXIII
affords an intermediate to the fused 5, 6, or 7 membered _ ring systems of Formula I wherein Rl and V or W are joined. The synthesis utilizes a haloalkylamine in which the amino group is protected through reaction with 1,2-bis(chlorodimethylsilyl)ethane affording the cyclic - ~ 94 stabase derivative (see:Basha and Debernardis _ Tetrahedron Lett 5271, 1984) which protects the amine in the subsequent alkylation step (sodium hydride, DMF).
Scheme 12 O iS, O
R11 Br~N' R11 ~ ,S
NH S ~ N
N' \ / v .
m S
R12 N SMe NaH R12 N~SMe m = 2-4 XXXIII
xxxlv ' Rll R11 N ) - Heat N'~H2 m 1 ~ ~ m R12 N' N 12 H R N SMe XXXVI XXXV
Scheme 13 N i N
12 ~ ~ 12 R N ~ R N SMe NH
m_1 ~ 2 m Deprotection of the amine can be accomplished with acid treatment (p-toluenesulfonic acid) or tetrabutylammonium fluoride treatment. The free amine can then be cyclized in an intramolecular fashion by warming to high temperatures. The bromoalkylamines are either commercially available (eg. 3-bromopropylamine hydrobromide, 2-bromoethylamine hydrobromide) or they can be synthesized from the corresponding haloalkylazide followed by reduction of the azide to the amine (see: Hendry et al Tetrahedron Lett 4597 (1987)).
More functionalized haloalkylamines can be used as long as the functional groups are tolerated in the transformations shown in scheme 12 including the bromo derivatives obtained from amino acid precursors as ' described by Baldwin et al (Synlett. 51-53, 1993) and Leanna et al (Tetrahedron Lett. 4485, 1993).
5 Alternatively, the fused ring system can be made through the addition of a hydroxyalkylamine as outlined in Scheme 14. Initially, the amine component of the hydroxyalkylamine displaces the 2-methylthio group to afford compound XXXVII which is followed by conversion 10 of the alcohol to a suitable leaving group (eg.
methanesulfonate or trifluoromethanesulfonate). Closure of the ring can be accomplished by treatment with an excess of sodium hydride in DMF to afford XXXVI.
Scheme 14 O O
1 i OH
R ~ ~NH HO m NHz Rll NH
R1z N~SMe 1z ~ ~ m-1 R N N
H
XXXIII XXXVII
MeS02C1 Et3N
O

R11 OMs m-1 R NH
Rlz N~N
H Riz N~N ~ m-1 H
XXXYI
15 xxxvIII
The 6,5 fused ring systems can be obtained as outlined in Scheme 15. Alkylation of the N-3 nitrogen with 3-bromo-1-trimethylsilylpropyne can be followed by a displacement of the 2-methylthio group with the 20 appropriate amine component exemplified but not limited to a phenylalkylamine. The 2-amino group under the reaction conditions cyclizes onto the acetylene as shown with a loss of the trimethylsilyl group as well. This transformation is illustrated in the examples below wherein 3-phenyl-1-propylamine and benzylamine are reacted with 3-(3-trimethylsilyl-2-propynyl)-5-(4-fluorophenyl)-2-methylthio-6-(4-pyridyl)-4(3H)- -pyrimidinone to afford the corresponding 6, 5 fused system.
Scheme 15 TMS
Br i 'NH ~ N ~ TMS
s2 ~SMe NaH Ri2 N~SMe R N
XXXIX
XXXIII

Rll ~N~

XXXX
Scheme 16 F
R2i OR H2N ~L

L* N n NH ~n ~ R2i Compounds of the invention when U is CHRZ1 can be prepared according to Scheme 2 above wherein R1 contains an leaving group or a group which can be converted into a leaving group (L*) which can be reacted with a primidine nitrogen atoms to form the fused ring (see Scheme 16).
- The following Examples are presented for illustrative purposes only and are not intended, nor should they be construed, as limiting the invention in any manner. Those skilled in the art will appreciate that modifications and variations of the compounds disclosed herein can be made without violating the spirit or scope of the present invention.
EXAMPLES
Exa~qple 1 General procedure for the preparation of 2-substituted 5- (4-fluorophenyl) -6- (4-pyridyl) -4 (3X) -pyrimidones O
I
I \ H F I \ O
F N ~ / OR
\ 0 --s I\
OH N
H2N a. R = H
b. R = Et R
HN
F F
O
I
I~N~Rl N
a. 2-l4-Fluorophenvl)-3-(4-pyridvl)-acrylic acid A
mixture of 4-fluorophenylacetic acid (9 g, 58.4 mmol}, 4-pyridinecarboxaldehyde (5.6 ml, 58.6 mmol), pyridine (6 ml) and acetic anhydride (6 ml) was heated at 150°C
for 1 h followed by evaporation and co-distillation with _ water. The resulting material crystallized on addition of ethanol. The solids were filtered and washed with ethanol and ethyl acetate to provide the title compound.
- MS (m/z) : 244.0 (M+H)'; ClaHIOFN02 requir. 243.2 'H-NMR

WO 98/24780 PCT/US97~2949 (DMSO-d6): d 8.43, 6.98 (2d, each 2H, Pyrid.), 7.73 (s, 2H, CH=), 7.21 (d, 4H, PhF).
b. Ethvl 2-(4-fluorophenyl)-3-(4-pyridyl)-acrvlate~
Conc. sulfuric acid (2.2 ml) was added carefully to a suspension of 2-(4-fluorophenyl)-3-(4-pyridyl}-acrylic acid (6.7 g, 27.5 mmol) in ethanol (120 ml) and the mixture was heated at reflux for 24 h. The solvent was evaporated, the remainder was taken up in dichloromethane and the organic solution was washed with aqueous sodium hydrogencarbonate and water, followed by drying and evaporation. Flash column chromatography on silica gei (hexane-acetone = 2:1) provided the pure title compound. MS (m/z) : 271.8 (M+H)'; C1fiH14FN02 requir.
271.3 'H-NMR (CDC1~): 8.44, 6.88 (2m, each 2H, Pyrid.), 7.72 (s, 1H, CH=), 7.16, 7.06 (2m, each 2H, PhF), 4.28 (q, 2H, CH2) , 1.28 (t, 3H, CH3) .
c. General procedure: A stirred mixture of ethyl 2-(4-fluorophenyl)-3-(4-pyridyl)-acrylate (357 mg, 1.38 mmol), the amidine hydrochloride (2.61 mmol) and sodium methoxide (250 mg, 4.62 mmol) in ethanol (5 ml) was heated in a sealed tube at 120°C for 3 h. It was neutralized with 2N hydrochloric acid prior to evaporation. The residue was taken up in acetic acid (25 ml) and treated with sodium nitrite (670 mg, 9.71 mmol) at 44°C for 20 min. After evaporation, the resultant product was taken up in dichloromethane and the solution was washed with aqueous sodium hydrogencarbonate and water before drying and evaporation. The product was purified by recrystallization from methanol. If the crude product of nitrite oxidation was water soluble, as was found for 5-(4-fluorophenyl)-2-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone, then no aqueous work up was done, but the material obtained on evaporation was applied to a column of silica gel (5~ methanol/dichloromethane) prior to recrystallization.

The following compounds were prepared accordingly using the appropriate amidine hydrochloride:
1-1 5-(4-Fluorophenyl)-2-methyl-6-(4-pyridyl)-4(3H)-_ pvrimidinone: MS (m/z) : 282.2 (M+H)'; C16H1zFN30 requir.
- 5 281.3 1H-NMR (DMSO-ds): d 8.46 (m 2H, Pyrid.), 7.2-7.03 - (m, 6H, PhF, Pyrid. ) . 2.38 (s, 3H, CH3) .
R1 = CH3-1-2 5-(4-Fluorophenyl)-2-isopropyl-6-(4-pyridyl)-4(3H)=
pyrimidinone: MS (m/z) : 310.0 (M+H)'; C18H16FN30 requir.
309.4 1H-NMR (DMSO-ds): 8.45 (m, 2H, Pyrid.), 7.21-7.03 (m, 6H, PhF, Pyrid.), 2.90 (m, 1H, CH(CH3)2,) 1.26, 1.24 (2s, each 3H, 2CHj) .
R1 = ( CH3 ) ZCH-1-3 2-(2,6-Dichlorobenzvl)-5-(4-fluorophenvl)-6-(4-pyridyl)-4(3H)-pyrimidinone: MS (m/z): 426.0 (M)';
Cz~H14C12FN~0 requir. 426.3 1H-NMR (DMSO-d6) : d 8.37 (m, 2H, Pyrid.), 7.50 (d, 2H, PhCl2), 7.35 (t, 1H, PhCl2), 7.18-7.08 (m, 4H, PhF), 6.96 (m, 2H, Pyrid.), 4.36 (s, 2H, CHZ ) .
Cl R1 =
2 0 / Cl 1-4 5-(4-Fluorophenyl)-2-phenyl-6-(4-pyridvl)-4(3H)=
pyrimidinone: MS (m/z) : 344.2 (M+H)'; CZ1H14FN30 requir.
343.4 1H-NMR (DMSO-ds): d 8.49 (d, 2H, Pyrid.), 8,20 (d, 2H, Ph), 7.66-7.50 (m, 3H, Pyrid., Ph), 7.32-7.11 (m, 6H, PhF, Ph).
R1 = I

Example 2 General procedure for the preparation of 2-N substituted 2-amino-5- (4-fluorophenyl) -3-methyl-6- (4-pyridyl) -4 (3H) -pyrimidinones Step A. 5-(4-Fluorophenyl)-3-methyl-2-methylthio-6-(4-pyridyl)-4(3H)-pyrimidinone:
F
NH ~CH3 ~SH ~SCH3 Methyl iodide (418 ml, 6.67 mmol) was added to a stirred mixture of 5-(4-fluorophenyl)-6-(4-pyridyl)-2-thiouracil (1.0 g, 3.34 mmol) and potassium carbonate (923 mg, 6.68 mmol) in N, N-dimethylformamide (30 ml) at room temperature. Stirring was continued for 3 h-, followed by evaporation and flash chromatography on a column of silica gel (hexane-acetone = 3:1, 2:1, 1:1) or IatrobeadsR (chloroform-methanol = 90:7; chloroform-methanol-triethylamine = 90:7:3). The second main fraction provided the title compound as a solid. MS
(m/z) : 328.0 (M+H)'; Cl~HIaFN30S requir. 327.4. 1H-NMR
(DMSO-db): d 8.50, 7.26 (2m, each 2H, Pyrid.), 7.18, 7.14 (2m, each 2H, PhF), 3.52 (s, 3H, NCH3), 2.65 (s, 3H, SCH3 ) . _ Step B. General procedure:
F ~ O F
_ ~ / N~CH3 .CH3 i N ~SCH3 NR5R21 N /
A mixture of 5-(4-fluorophenyl)-3-methyl-2-methylthio-6-(4-pyridyl)-4(3H)-pyrimidinone (103 mg, 0 . 32 mmol ) and the amine HNRSR21 ( 1. 2-3 . 2 mmol ) was heated at 190-200°C for 2-48 h. The resulting product was purified by flash chromatography on a column of silica gel (hexane-acetone or methanol-dichloromethane - or methanol-dichloromethane-conc. ammonium hydroxide) to provide the target compound.
The following compounds were prepared using the above procedure outlined above and an appropriate amine:
2-1 2-(n-Butylamino)-5-(4-fluorophenyl)-3-methyl-6 (4 pyridyl)-4(3H)-pyrimidinone:
The reaction was done in a sealed tube at 190°C for 5 h.
MS (m/z) : 353 .0 (M+H)';
C2oH21FN40 requir. 352.4.
Rl - CHI ( CHz ) 3NH-2-2 5-(4-Fluorophenyl)-3-methyl-2-(pentylamino)-6-(4 pyridyl)-4(3H)-pyrimidinone: The reaction was done in a sealed tube at 190°C for 2.5 h. MS (m/z): 366.8 (M+H)';
Cz1H23FN40 requir . 3 6 6 . 4 .
R1 - CHI ( CHZ ) QNH-2-3 2-(3,3-Dimethylbutylamino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone: The reaction was done in a sealed tube at 190°C for 5 h. MS (m/z):
3 81. 2 ( M+H ) ' ; CzzHz5FNa0 requir . 3 8 0 . 5 .
Rl - ( CHI ) 3C ( CHZ ) zNH-2-4 2-(Benzylamino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone: The reaction was done at 185°C for 6h. MS (m/z) : 387.2 (M+H)'; Cz3H19FNq0 requir.
386.4 i -N
H
R~ _ 2-5 2-(4-Fluorobenzvlamino)-5-(4-fluorophenvl) 3 methyl-6-(4-pyridyl)-4(3H)-pyrimidinone: The reaction was done at 190°C for 24 h. MS (m/z): 405.2 (M+H)';
CZ,H,BF2Na0 requir. 404.4.
~ ~ N~
H
Rl _ F

2-6 2-(3-Fluorobenzylamino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone: The reaction was done at 195°C for 40 h. MS (m/z): 405.0 (M+H)';
C23H18FZN40 requir . 404 . 4 .
\ ~ N~
H
I
Rl - F
2-7 5-(4-Fluorophenvl)-3-methyl-((R-1-phenylethyl)amino)-(4-pyridyl)-4(3H)-pyrimidinone: The reaction was done at 180°C for 4 days. MS (m/z): 401.0 (M+H)~; CZQHZ1FN40 requir. 400.5 N~
H
I
Rl - F -2-8 2-(2-(2-Chlorophenyl)-ethylamino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone:
The reaction was done at 190°C for 5 h. MS (mlz): 435.2 (M+H)'; Cz4HZOC1FNa0 requir. 434.9.
H
N~
R~ -2-9 5-(4-Fluorophenyl)-2-(2-(4-fluorophenyl)-ethylamino)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone:
The reaction was done at 190°C for 5 h. MS (m/z): 419.2 (M+H) ~; CZaH2oF2Nd0 requir. 418. 5 H
\~N~
Rl _ I
2-10 5-(2-Fluorot~henyl)-2-(2-(3-fluorophenyl)-ethylamino)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone:
The reaction was done at 190°C for 24 h. MS (m/z):
419 . 2 ( M+H ) ' ; C,QHZpFzNdO requir . 418 . 5 H
~~N~
Rl - I
F
. 2-11 5-(2-Fluorophenyl)-2-(2-(2-fluorophenyl)-ethylamino)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone:
The reaction was done at 190°C for 12 h. MS (m/z):
419 . 0 (M+H ) ' ; Cz4H2oF,N40 requir . 418 . 5 H
N~
R' -F
2-12 5-(2-Fluorophenyl)-2-((2-hvdroxv-2-phenyl)-ethvlamino)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone:
The reaction was done at 190°C for 1.5 h. MS (m/z):
417 . 0 ( M+H ) ' ; C2aHzIFNaOz requir . 416 . 5 .
OH H
N~
R' _ I
2-13 5-(4-Fluorophenyl)-3-methyl-2-((3-phenylpropyl)-amino)-6-(4-pyridyl)-4(3H) pyrimidinone: The reaction was done at 190°C for 6 h. MS (m/z): 415.0 (M+H)';
C~;Hz~FNaO requir . 414 . 5 . 'H-NMR ( CDC13 ) : d 8 . 49 , 7 . 2 0 ( 2m, each 2H, Pyrid.), 7.35 (t, 2H, Ph), 7.30-7.25 (m, 3H, Ph), 7.12, 6.97 (2m, each 2H, PhF), 4.61 (t, 1H, NH), 3.67 (q, 2H, CHZN), 3.28 (s, 3H, CH3), 2.82 (t, 2H, CH2Ph) , 2 . 12 (m, 2H, CHZ) .
v R~ _ I _ H
2-14 5-(4-F'luoronhenyl)-3-methyl-2-((1-methyl-3-_ phenvlprotwl)-amino)-6-(4-pyridvl)-4(3H)-pyrimidinone:
The reaction was done at 200°C for 48h. MS (m/z): 429.0 (M+H) f ; CZ6H25FNa0 requir. 428 . 5 .

Rl - I v v H
2-15 5-(4-Fluorophenyl)-3-methyl-2-((R-1-methyl-3-phenylpropyl)-amino)-6-(4-pyridyl)-4(3H)-pyrimidinone:
The reaction was done at 200°C for 48 h. MS (m/z):
429.0 (M+H)'; CZ6HzsFNqO requir. 428.5. _ Rl I v v H
2-16 2-((3,3-Diphenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone: The reaction was done at 190°C for 6 h. MS (m/z): 490.8 (M+H)';
C31HZ,FNqO requir . 4 9 0 . 6 .
Rl -i N
H
2-17 5-(4-Fluorophenyl)-3-methyl-2-((2-phenylaminoethyl)-amino)-6-(4-pyridvl)-4(3H)=
pyrimidinone: The reaction was done at 190°C for 4 h.
MS (m/z) : 416.2 (M+H)'; C~QH"FN,O requir. 415.5.
H
N~ N
w Rl - ~ H
2-18 5-(4-Fluorophenvl)-2-((3-imidazolvlpropyl)-amino)-3-methyl-6-(4-pvridyl)-4(3H)-pvrimidinone: The reaction was done at 190°C for 2 h. MS (m/z): 405.0 (M+H)';
2 0 CZZH21FN60 requ i r . 4 0 4 . 5 .
~N~N/
R - N~ H
2-19 5-(4-Fluorophenvl)-3-methyl-2-(2-(piperazin-1-yl)-et~lamino ) -6- ( 4-pyridyl ) -4 ( 3H) -pyrimidinone : The reaction was done at 190°C for 30 min. MS (m/z): 409.2 (M+H) '; CZZH25FNs0 requir. 408 . 5 .
R -HN NN~N~
- 2-20 5-(4-Fluorophenvl)-3-methyl-6-(4-pvridvl)-2-(3-_ 5 (pyrrolidin-1-yl)-propylamino)-4(3H)-pyrimidinone: The reaction was done at 190°C for 2 h. MS (mlz): 408.2 (M+H}'; Cz~Hz~FNsO requir. 407.5.
Rl - N/~N~
H
2-21 2-(((S)-2-Amino-3-phenylpropvl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride: The reaction was done at 190°C for 2.5 h.
MS (m/z): 430.1 (M+H)+; C25H24FN50 requir. 429.5 (free base).
_ i R - H
I ~ N

2-22 2-(((S)-2-N-Ethyl-3-phenvlpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride: The reaction was done at 190°C for 4 h.
MS (m/z): 458.3 (M+H)+; C27H28FN50 requir. 457.6 (free base).
i N
H
R~ - HN

2-23 2-((2-Amino-2-methy-3-phenylpropvl) amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridvl)-4(3H)-pvrimidinone hydrochloride: The reaction was done at 190°C for 4 h.
MS (m/z): 444.0 (M+H)+; C26H26FN50 requir. 443.5 (free base) .
-N
R _ H
~NH
_ ~ 2 2-24 2-((2-Aminomethv-3-phenylpro~yl)-amino)-5-(4 fluorophenvl-3-methyl-6-(4-pyridyl)-4(3H)-bvrimidinone hydrochloride: The reaction was done at 190°C for 1 h.
MS (m/z): 444.0 (M+H)+; C2(H26FN40 requir. 443.5 (free base) .
N
H

Rl _ 2-25 2-((3-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride: The reaction was done at 190°C for 2.5 h. MS (m/z): 430.0 (M+H)+; C25H24FN50 requir. 429.5 (free base) .

\ Ni H

2-26 5-(4-Fluorophenyl)-3-methyl-2-(3-(2-methvlphenvl)propvl)-amino)-6-(4-pvridvl)-4(3H)-pyrimidinone: The reaction was done at 190°C for 4 h.
MS (m/z): 429.5 (M+H)+; C26H25FN40 requir. 428.5.
\ ~ N/
H
Rl - / \ CH3 2-27 5-(4-Fluorophenyl)-3-methyl-2-((R,S)-2-amino-3-(2-fluorophenyl)-propyl-amino)-6-(4-pyridyl)-4(3H)-pyrimidinone Hydrochloride: The reaction was done at 190°C for 7 h. MS (m/z): 448(M+H)'.
N

2 0 Rl - F
2-28 2-(((R)-2-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride: The reaction was done at 190°C for 2 h.
MS (mlz): 430.2 (M+H)+; C25H24FN50 requir. 429.5 (free base).

i I ~ ~ N
R - ~2 H
2-29 2-(((S)-2-N-Methyl-3-phenvlpropvl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pvridyl)-4(3H)-pyrimidinone hydrochloride: The reaction was done at 190°C for 4 h.
MS (m/z): 444.0 (M+H)+; C26H26FN50 requir. 443.5 (free base). -N~
R~ _ I I H
~~ CH

2-30 2-((2-phenylthioethyl)-amino)-5-(4-fluorot~henyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone: The reaction was done at 190°C for 16 h. MS (m/z): 433 (M+H1+_ N~
( H
Rl 2-31 2-((2-hydroxyethyl)-amino)-5-(4-fluorot~henyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone: The reaction was done at 190°C for 16 h. MS (m/z): 341 (M+H)+.
HO~ N ~
R' - H
2-32 2-((2,2-dimethyl-3-hydroxypropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridvl)-4(3H)-pyrimidinone:
The reaction was done at 190°C for 16 h. MS (m/z): 383 (M+H)+.
/~
R' -HO
2-33 2-((2,2-dimethyl-3-phenylthiopropyl)-amino)-5-(4-fluorophenvl)-3-methyl-6-(4-pvridvl)-4(3H)-pyrimidinone:
To a solution of triphenylphosphine (262 mg, 0.29 mmol) in tetrahydofuran (2 mL) at 0 C was added diisopropyl azodicarboxylate (DIAD) (56 ml, 0.29 mmol). After 30 min at 0 C, 2-((2,2-dimethyl-3-hydroxypropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone (50 mg, 0.14 mmol) and 2,6-dichlorothiophenol in tetrahydrofuran (2 mL) was added.

After 16 h, the reaction was concentrated under a stream of nitrogen. The reaction mixture was applied directly to purification via flash chromatography (step gradient ethyl acetate:CHCl3 1:3 then 1:2 then 1:1 then 2:1 then 3:1) to afford the title compound: MS (m/z) 544 (M+H)+.
R~ _ HO ~~ H
2-34 2-((3-Amino-3-(2-fluorophenyl)propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone was prepared from 5-(4-fluorophenyl)-3-methyl-2-methylthio-6-(4-pyridyl)- 4(3H)-pyrimidinone and 1-(2-fluorophenyl)-1,3-propanediamine according to the General Procedure. The reaction was done at 190°C for 3 h. MS (m/z) : 448.1 (M+H)'; Cz5HZ3F2N50 requir. 447.5 (free base).

R1 - / I \/\N/
~ H
2-35 2-((3-Amino-3-(2-methyl~henyl)propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone hvdrochloridewas prepared from 5-(4-fluorophenyl)-3-methyl-2-methylthio-6-(4-pyridyl)- 4(3X)-pyrimidinone and 1-(2-methylphenyl)-1,3-propanediamine according to tae General Procedure. The reaction was done at 185°C ---for 4 h. MS (m/z) : 444.5 (M+H)'; Cz6HzcFN50 requir. 443.5 (free base) .
CH3 ~2 Rl _ ' I \/\N/
H
2-36 2-(((S)-3-amino-3-phenylnropyl)-amino)-5-(4-fluorophenvl)-3-methyl-6-(4-pyridvl)-4(3H)-pvrimidinone hydrochloride was prepared from 5-(4-fluorophenyl)-3-methyl-2-methylthio-6-(4-pyridyl)-4(3H)-pyrimidinone and (S)-1-phenyl-1,3-propanediamine according to the General Procedure. The reaction was done at 190°C for 2.5 h. MS
(m/z) : 430.2 {M+H)'; CZSH2aFN50 requir. 429. 5 (free base) .

R1 _ / I ~N/
H
2-37 2-(((R)-3-amino-3-phenylpropvl)-amino)-5-(4-fluoronhenyl)-3-methyl-6-(4-pvridyl)-4(3H)-pyrimidinone hydrochloride was prepared from 5-(4-fluorophenyl)-3-methyl-2-methylthio-6-(4-pyridyl)-4(3H)-pyrimidinone and (R)-1-phenyl-1,3-propanediamine according to the General Procedure. The reaction was done at 190°C for 3.5 h. MS
(m/~) : 430.7 (M+H)'; CZSHZ4FN50 requir. 429.5 (free base) .
NH~
Ri _ / I /
N
H
2-38 2-(((2R,3R)-3-Amino-2-methyl-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride was prepared from 5-(4-fluorophenyl)-3-methyl-2-methylthio-6-(4-pyridyl)-4(3H)-pyrimidinone and (2R,3R)-2-methyl-3-phenyl-1,3-propanediamine according to the General Procedure. The reaction was done at 190°C for 3 h. MS (m/z): 444.5 (M+H ) ' ; CZ6H26FN50 requir . 443 . 5 ( free base ) .
NHZ
Fi _ / I /
N
H
2-39 2-(((2S,3S)-3-Amino-2-methyl-3-phenylpropvl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pvrimidinone hydrochloride was prepared from 5-(4-fluorophenyl)-3-methyl-2-methylthio-6-(4-pyridyl)-4(3H)-pyrimidinone and (2S,3S)-2-methyl-3-phenyl-1,3-propanediamine according to the General Procedure. The reaction was done at 190°C for 2 h. MS (m/z): 444.4 (M+H)'; C26HzcFNsO requir. 443.5 (free base) .

Ri - / I N/
- H

Analogously, the isomers 2-(((2S,3R)-3-Amino-2-methyl-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone and 2-(((2R,3S)-3-amino-2-methvl-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pvridyl)-4(3H)-pvrimidinone may be prepared from the corresponding diamines.
2-40 5-(4-Fluorophenyl)-2-((-3-hydroxy-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone~ The reaction was done at 190°C for 3 h. MS (m/z): 431.2 (M+H)+; C25H23FN4Oz requir. 430.5.
HO
RZ - / ~ ~N/
H
Example 3 Procedure for the preparation of N-substituted pyrimidinones F ~ I O F ~ I O
NH ~ I N~CH3 i ~ i ~N ~N
N~ ~ N
C1 I ~ C1 C1 I ~ C1 2-(2,6-Dichlorobenzyl)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone: Methyl iodide (41 ml, 0.65 -.mmol) was added to a stirring mixture of 2-(2,6-dichlorobenzyl}-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone (280 mg, 0.61 mmol) and potassium carbonate (181 mg, 1.30 mmol) in N,N-dimethylformamide (2 ml).
Stirring was continued for 2 h, followed by evaporation and flash chromatography of the resulting product on a - 25 column of silica gel (hexane-acetone = 3:1} to yield the title compound as a white solid. MS (m/z): 440.2 (M+H) '; Cz3H1sC12FN30 requir . 440 . 3 .

Example 4 General procedure for the preparation of 2-N and 2'-N
substi tuted 2-amino-5- (4-fluorophenyl) -3-methyl-6- (4- (2 amino)pyridyl) ) -4 (3H) -pyrimidinones F
' I O
/ ,t.CH3 N~NR5R21 N

Step A. 5-(4-Fluorophenyl)-3-methyl-2-methylthio-6-(4-(2-acetamido)pvridvl))-4(3H)-pyrimidinone: To a solution of 5-(4-fluorophenyl)-6-(4-(2-acetamido)pyridyl)-2-thiouracil (600 mg, 1.68 mmol) in DMF (35 mL) was added powdered sodium hydride (60~ oil dispersion, 221 mg, 5.56 mmol) over 1 minute at 23°C.
After 45 min, iodomethane (210 ml, 3.37 mmo1) was added dropwise. After 45 min, the reaction was concentrated in vacuo (rotovap connected to high vac with a bath temperature no greater than 40°C). The residue was applied immediately to flash chromatography purification (step gradient hexane: acetone 4:1; then 3:1; then 2:1;
the 1:1) to afford the desired product.
Step B. 5-!4-Fluorophenyl)-3-methyl-2-((3-phenvlpropvl amino)-6-(4-(2-amino)pyridyl))-4(3H) pyrimidinone: A
neat mixture of 5-(4-Fluorophenyl)-3-methyl-2-methylthio-6-(4-(2-acetamido)pyridyl))-4(3H)-pyrimidinone (50 mg, 0.13 mmol) and 3-phenyl-1-propylamine (88 mg, 0.65 mmol) was warmed to 190°C for 17 h. After cooling to 23°C, the reaction mixture was applied directly to purification via flash chromatography (step gradient l~MeOH:CHC13 then 2~, then 3~; then 4~; then 5~) to afford the desired product: MS
(m/z) 430 (M+H)+.

N
R - I H
R31 _ H
R'z - H
The following compounds were prepared using the above procedure outlined above and an appropriate amine:
4-1 5-(4-Fluorophenyl)-3-methyl-2-((3-phenylpropyl)-amino)-6-(4-(2-acetamido)pyridyl))-4(3H)-pyrimidinone:
To a solution of 5-(4-Fluorophenyl)-3-methyl-2-((3-phenylpropyl)-amino)-6-(4-(2-amino)pyridyl))-4(3H)-pyrimidinone (11 mg, 0.026 mmol) in 600 ~,1 of pyridine was added (5 EL1, 0.064 mmol) of acetyl chloride at 23 C.
After 2 h, the reaction was quenched with water (5 ~1) and the reaction was concentrated under a stream of nitrogen. The reaction mixture was applied directly to purification via flash chromatography (step gradient l~MeOH:CHC13 then 2~, then 3~) to afford the title compound: MS (m/z) 472 (M+H)+.
v R~ _ I _ H
R'z - H
R'1 - Ac 4-2 5-(4-Fluorophenyl)-3-methyl-2-((3-phenylpropyl)-amino)-6-(4-(2-methoxyacetamido)pyridvl))-4(3H)=
pyrimidinone: To a solution of 5-(4-Fluorophenyl)-3-methyl-2-((3-phenylpropyl)-amino)-6-(4-(2-amino)pyridyl))-4(3H)-pyrimidinone (11 mg, 0.026 mmol) in 600 ~.l of pyridine was added (5 ~,1, 0.064 mmol) of methoxyacetyl chloride at 23 C. After 2 h, the reaction was quenched with water (5 ~.1) and the reaction was concentrated under a stream of nitrogen. The reaction mixture was applied directly to purification via flash chromatography (step gradient l~MeOH:CHCl3 then 2~, then 3~) to afford the title compound: MS (m/z) 502 (M+H)+.

N~
R _ I H
R'~ - H
- R'1 - C ( O ) CHZOMe 4-3 5-(4-Fluorophenyl)-3-methyl-2-((3-phenylnropyl)-- 5 amino)-6-(4-(2-acetoxyacetamido)pyridyl))-4(3H)=
pyrimidinone: The reaction was done in the manner of the above substituting acetoxyacetyl chloride for acetyl chloride to afford the title compound after chromatography: MS (m/z) 530 (M+H)+.
v R~ _ I _ H
R3z - H
R" - C ( O ) CH20Ac 4-4 5-(4-Fluorophenyl)-3-methyl-2-((3-phenvlpropyl)-amino)-6-(4-(2-hydroxyacetamido)pyridyl))-4(3H)=
pyrimidinone: To a solution of 5-(4-Fluorophenyl)-3-methyl-2-((3-phenylpropyl)-amino)-6-(4-(2-acetoxyacetamido)pyridyl))-4(3H)-pyrimidinone ( 2 mg, 0.003 mmol) in 900 ~.1 methanol: 100 ~,1 water was added potassium carbonate ( 4 mg, 0.032 mmol) as a solid at 23 C. After 3 h, the reaction was concentrated under a stream of nitrogen. The reaction mixture was diluted with chloroform (20 mL), dried (Na2S04), and concentrated to afford the title compound: MS (m/z) 488 (M+H)+.
R~ _ I w v _ H
Rsa _ H
R'1 - C ( O ) CHZOH
4-5 5-(4-Fluorophenyl)-3-methyl-2-((3-phenylpro~wl)-- amino)-6-(4-(2-methvlsulfonamido)pvridvl))-4(3H)-pyrimidinone: To a solution of 5-(4-Fluorophenyl)-3-methyl-2-((3-phenylpropyl)-amino)-6-(4-(2-WO 98124?80 PCT/IJS9?/22949 amino)pyridyl))-4(3H)-pyrimidinone (11 mg, 0.026 mmol) in 600 )1.1 of pyridine was added methanesulfonyl chloride (4 ~.1, 0.051 mmol) at 23 C. After 2 h, the reaction was quenched with water (5 ~.1} and the reaction was concentrated under a stream of nitrogen. The reaction mixture was applied directly to purification via flash chromatography (step gradient l~MeOH:CHC13 then 2~) to afford the title compound: MS (m/z} 508 (M+H)+.
R1 - I \ v H
R'z - H
R" - SOzMe 4-6 5-(4-Fluorophenyl)-3-methyl-2-((3-phenylpropyl)-aminoL-6-(4-(2-benzylamino)pyridyl))-4(3H)-pyrimidinone:
To a solution of 5-(4-Fluorophenyl)-3-methyl-2-{(3-phenylpropyl)-amino)-6-(4-{2-amino)pyridyl))-4(3H)-pyrimidinone (11 mg, 0.026 mmol) in 600 ~.1 of 1,2-dichloroethane was added benzaldehyde (8.9 mg, 0.084 mmol) and sodium triacetoxyborohydride (14.8 mg, 0.070 mmol) at 23 C. After 16 h, the reaction was quenched with water (15 ~,1) and the reaction was concentrated under a stream of nitrogen. The reaction mixture was applied directly to purification via flash chromatography (step gradient l~MeOH:CHC13 then 2~~, then 3~; then 4~; then 5~) to afford the title compound:
MS (m/z) 458 (M+H)+.
Rl - ~ ~ H
R'2 - H
R'1 - CHZPh 4-7 5-(4-Fluorophenyl)-3-methyl-2-((3-phenylpropyl)-amino)-6-(4-(2-(2-methoxvphenvl)met~lamino)pvridvl))-4(3H}-pyrimidinone: The reaction was done in the manner - ~ 115 of the above substituting 2-methoxybenzaldehyde_.for benzaldehyde to afford the title compound after chromatography: MS (m/z) 550 (M+H)+, v . R~ - ~ H
R'z - H
R'1 _ ~OMe 4-8 5-(4-Fluorophenyl)-3-methyl-2-((3-phenylpropyl)-amino)-6-(4-(2-ethylamino)pyridyl))-4(3H)-pyrimidinone:
The reaction was done in the manner of the above substituting acetaldehyde for benzaldehyde to afford the title compound after chromatography: MS (mlz): 458 (M+H)+.
v R'z - H
R" - Et 4-9 5-(4-Fluorophenyl)-3-methyl-2-((3-phenylpropyl)-amino)-6-(4-(2-(di-(3-methvlbutyl)amino)pyridyl))-4(3H)=
pyrimidinone: The reaction was done in the manner of the above substituting isovaleradehyde for benzaldehyde to afford the title compound after chromatography: MS
(m/z) : 570 (M+H)+.
R~ - ~ v H
R32 - CHZCHZCH ( CH3 ) 2 R'1 - CHZCHzCH ( CH3 ) 2 4-10 5-(4-Fluorophenvl)-3-methyl-2-((3-phenvlpropvl)-amino)-6-(4-(2-diethvlamino)pvridvl))-413H)=
pvrimidinone: The reaction was done in the manner of the above substituting acetaldehyde for benzaldehyde to afford the title compound after chromatography: MS
(m/z): 486 (M+H)+.
v R~ _ I _ H
R'2 - Et R31 - Et 4-11 5-(4-Fluorophenvl)-3-methyl-2-((3-phenvlpropyl)-amino)-6-(4-(2-phenylaminocarbonvl-amino)pyridyl))-4(3H)-twrimidinone: To a solution of 5-(4-Fluorophenyl)-3-methyl-2-((3-phenylpropyl)-amino)-6-{4-(2-amino)pyridyl))-4(3H)-pyrimidinone (.11 mg, 0.026 mmol) in 600 ~,l of dioxane was added phenyl isocyanate (3.3 mg, 0.03 mmol) at 23°C. After 16 h, the reaction was quenched with water (15 ~.1) and the reaction was concentrated under a stream of nitrogen. The reaction mixture was applied directly to purification via flash chromatography (step gradient l~MeOH:CHCl3 then 20, then 3~; then 4%; then 5o) to afford the title compound: MS
(m/z) 549 {M+H) +.
N
R _ I H
R'~ - H
R" - NH(CO)NHPh 4-12 5-(4-Fluorophenyl)-3-methyl-2-((3-phenylpropyl)-amino)-6-(4-(2-methylaminocarbonvl-amino)pyridvl))-4(3H)-pyrimidinone: The reaction was done in the manner of the above substituting methylisocyanate for phenylisocyanate to afford the title compound after chromatography: MS (m/z): 487 (M+H)+.
N
R1 - ~ H

3 0 R'1 - NH ( CO ) NHMe 4-13 5-(4-Fluorophenyl)-3-methyl-2-((3-phenylprotwl)-amino)-6-(4-(2-(2'amino-1'-oxo-ethylamino)pyridyl))-- 4(3H)-pyrimidinone: General Procedure for mixed anhydride coupling - Isobutyl chloroformate (32 ml, 0.24 mmol) was added dropwise to a -20-30 oC solution of N-a-t-Boc-glycine (5.6 mg, 0.05 mmol) and pyridine (0.6 mL).
After 20 min at -20-30°C, 5-(4-fluorophenyl)-3-methyl-2-((3-phenylpropyl)-amino)-6-(4-(2-amino)pyridyl))-4(3H)-pyrimidinone (11 mg, 0.026 mmol) and pyridine (0.6 mL) was added in one portion. The reaction was allowed to warm to 23°C. After 16 h at 23°C, the reaction was poured into saturated bicarbonate (20 mL), extracted with ethyl acetate (2 x 50 mL), washed with brine (1 x 50 mL), and dried (Na2S04). The reaction mixture was applied to purification via flash chromatography (step gradient l~MeOH:CHC13 then 2~~, then 3~; then 4~; then 5~) to afford the N-Boc protected title compound. The crude title compound was obtained after treatment with 50~ trifluoroacetic acid:chloroform (1 mL) for 16 h.
After concentration with a stream of nitrogen, the reaction mixture was applied to purification via flash chromatography (step gradient l~MeOH:CHC13 then 2~, then 3~e; then 4~; then 5~) to afford the title compound: MS
;m ~~) : 487 (M+H)+.
' ~ N
- H
R'~ - H
R" - NH { CO ) CHZNH2 4-14 5-(4-Fluoroohenyl)-3-methyl-2-((3-phenvlpropyl)-amino)-6-(4-(2-(4'amino-1'-oxo-butylamino)pyridyl))-4(3H)-pvrimidinone: The reaction was done in the manner of the above with the following substitution: N-t-Boc-g - aminobutyric acid was used in place of N-a-t-Boc-glycine which after deprotection as above afforded the title compound: MS (m/z): 515 (M+H)+

N~ _ R - H
R'2 - H
R31 - NH ( CO ) CHZCHzCHZNH2 4-15 5-(4-Fluorophenyl)-3-methyl-2-((3-phenylpropyl)-amino)-6-(4-(2-(3'-amino-1'-oxo-propylamino)pyridyl))-4(3H)--pyrimidinone: The reaction was done in the manner of tY~e above with the following substitution: N-t-Boc-~i-alanine was used in place of N-o~-t-Boc-glycine which -afterdeprotection as above afforded the title compound:
MS (m/z): 501 (M+H)+:
v R~ - I H
R'2 - H
R'1 - NH ( CO ) CH2CHZNH2 -16 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-(2-aminopyridyl))-4(3H)-pyrimidinone hydrochloride: The reaction was done at 190°C for 6 h in the above manner with the following substitution of (S)-1, 2-diamino-3-phenylpropane for 3-phenyl-1-propylamine: MS (m/z): 445 (M+H)+;
i i ~ ~ N
R - H

2 0 R,~ - H -R'2 - H
4-17 2-(((S)-2-Dimethylamino-3-phenylpropyl)-amino)-5-(4-fluorophenvl)-3-methyl-6-(4-(2-aminopvridyl))-4(3H)-pyrimidinone hydrochloride: The reaction was done at 190°C for 6 h in the above manner with the following substitution of 1-amino- 2(S)-dirnethylamino-3-phenylpropane for 3-phenyl-1-propylamine: MS (~m/z): 473 (M+H) +;

N/
R~ = I I H
/ N
R'2 - H
- Rsi _ H
4-18 2-(((S)-2-Dimethvlamino-3-phenvlpropvl) amino) 5 - 5 (4-fluorophenyl)-3-methyl-6-(4-(2-acetamidopyridyl)) 4(3H)-pyrimidinone hydrochloride: The reaction was done in the manner of example XX substituting 2-(((S)-2-Dimethylamino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-(2-aminopyridyl))-4(3H)-pyrimidinone hydrochloride for 5-(4-Fluorophenyl)-3-methyl-2-((3-phenylpropyl)-amino)-6-(4-(2-amino)pyridyl))-4(3H)-pyrimidinone which afforded the title compound: MS
(m/z): 515 (M+H)+;
N/
R~ = I ~ H
/
R'z - H
R'1 - Ac 4-19 2-(((R,S)-3-Amino-3-phenvlpropvl)-amino)-5-(4-fluorophenvl)-3-methyl-6-(4-(2-aminopyridvl)) 4(3H)=
pyrimidinone hydrochloride~ The reaction was done at 190°C for 12 h in the above manner with the following substitution of (3 R,S)-1,3-diamino-3-phenylpropane for 3-phenyl-1-propylamine: MS (m/z): 445 (M+H)+;
NH2 _ ~ N~
H
R~ _ /
Rsz - H
R'1 - H
4-20 5-(4-Fluorophenvl)-3-methyl-2-(phenvlmethvlamino) 6-(4-(2-(3'-phenyl-1'-oxo-propvlamino)pvridvl)) (4 (2 amino)pvridvl))-413H)-pyrimidinone: A neat mixture of 5-(4-fluorophenyl)-3-methyl-2-methylthio-6-(4-(2--acetamido)pyridyl))-4(3H)-pyrimidinone (260 mg, 0.13 mmol) and benzylamine (88 mg, 2.71 mmol} was warmed to 190 C for 17 h. After cooling to 23 C, the reaction mixture was applied directly to purification via flash chromatography {step gradient l~MeOH:CHC13 then 2~, then 3~; then 4~; then 5~) to afford 5-(4-Fluorophenyl)-3-methyl-2-(phenylmethylamino)-6-{4-(2-amino)pyridyl))-4(3H)-pyrimidinone. The 5-(4-fluorophenyl)-3-methyl-2-(phenylmethylamino)-6-(4-(2-amino)pyridyl))-4(3H)-pyrimidinone was converted in the manner of the above substituting hydrocinnamoyl chloride for acetyl chloride and 5-(4-fluorophenyl)-3-methyl-2-(phenylmethylamino)-6-(4-(2-amino)pyridyl})-4(3H)-pyrimidinone for 5-(4-fluorophenyl)-3-methyl-2-((3-phenylpropyl)-amino)-6-(4-(2-amino)pyridyl))-4(3H)-pyrimidinone to afford the title compound after chromatography: MS (m/z) 534 (M+H)+.
R1 - NHCHZPh R'2 - H
R'1 - ( CO ) CH2CHzPh Example 5 General procedure for the preparation of 5-(4-fluorophenyl)-6-(4-pyridyl)-2-thioalkyl-4(3H) pyrimidinones Step A. Ethvl 2-(4-fluorophenyl)-3-oxo-3-(4-pyridyl)-propionate:
F

OEt ~ OEt F ~ 0 N
----OEt N /
(According to: Legrand and Lozac~h, Bul~. Soc. Chim. _ Fr., 79-81 (1955)).
A mixture of ethyl 4-fluorophenylacetate (13 g, 71.35 mmol), ethyl isonicotinate (10.7 ml, 71.4 mmol) and sodium spheres (1.64 g, 71.34 mmol) was heated at 90-95°C under argon. The mixture started to reflux and gradually turned into a solid. After 2.5 h, the mixture was neutralized with dil. acetic acid with cooling followed by extraction with dichloromethane. The organic solution was washed with water, dried and evaporated. Flash chromatography on a column of silica gel (hexane-acetone = 4:1, 3:1, 2:1) provided the title compound as an oil . MS (m/z) : 287 . 8 (M+H) i; C16H1aFN03 requir. 287.3 1H-NMR (CDC13), (ketone . mole = 1 .
0.33): d 13.50 (s, 0.3H, OH-E), 8.81 (m, 2H, Pyrid.-K), 8.48 (m, 0.66 H, Pyrid.-E), 7.72 (m, 2H, Pyrid.-K), 7.38 (m, 2H, PhF-K), 7.14-7.04 (m, 2H, PhF-K; ~0.65H, Pyrid.-E; -0.65H, PhF-E), 6.96 (t, 0.64H, PhF-E), 5.51 (s, 1H, CH-K), 4.23-4.2- (m, CHz-K, E), 1.26 (t, CHI-K, E).
Step B. 5-(4-fluoronhenyl)-6-(4-pyridyl)-2-thiouracil-~S
OEt H2N NH
~SH
A stirred mixture of ethyl 2-(4-fluorophenyl)-3-oxo-3-(4-pyridyl)-propionate (22.3 g, 77.6 mmol) and thiourea (5.9 g, 77.6 mmol) was reacted at 190°C under argon for 40 min. The reaction mixture was allowed to reach room temperature, taken up in acetone and the precipitate was filtered to provide the title compound.
MS ( m/z ) : 3 0 0 . 2 (M+H ) '; C15H1oFN30S requir . 2 9 9 . 3 1H-NMR
(DMSO-d6): d 12.74, 12.65 (2s, 2H), 8.51 (m, 2H, Pyrid.), 7.26 (m, 2H, Pyrid.), 7.09 and 7.03 (2m, each 2H, PhF).
Alternatively, ethyl 2-(4-fluorophenyl)-3-oxo-3-(4-pyridyl)-propionate (2.87 g, 10 mmol) and thiourea (2.28 g, 30 mmol) were suspended in anhydrous p-xylene (50 ml) with very efficient stirring. To the mixture pyridinium p-toluenesulfonate (100 mg) was added and refluxed for 12-16 h using a Dean-Stark apparatus with continuous removal of water (0.2 ml). Reaction mixture was cooled WO 98/24780 PCT/US9?/22949 and a dark brown solid was filtered using a Buchner funnel. The collected solid. was suspended in acetone (25 ml) and filtered. The acetone washed product contained a trace of thiourea, which was removed by trituration with hot water (20-30 ml). The product was filtered and airdried.
Step C. General procedure:
The arylalkyl bromide (0.36 mmol) was added dropwise to a stirring mixture of 5-(4-fluorophenyl)-6-(4-pyridyl)-2-thiouracil (100 mg, 0.33 mmol) and potassium carbonate (46 mg, 0.33 mmol) in N,N-dimethylformamide (4.6 ml). Stirring was continued for 3h followed by evaporation. Flash chromatography on a column of silica gel (hexane-acetone = 3:1, 2:1, 1:1) and recrystallization from hot methanol provided the target compound.
The following compounds were obtained using the appropriate arylalkyl bromide according to the above procedure:
5-1 5-(4-Fluorophenyl)-2-(2-phenylethyl)thio-6-(4-pyridyl) -4 (3H) -pyrimidinone: MS (m/z) : 404.2 (M+H)';
C23H18FN30S requir. 403.4. 1H-NMR (DMSO-ds) : d 13.08 (bs, 0.7H), 8.49 (m, 2H, Pyrid.), 7.30-7.06 (m, 11H, Pyrid., Ph, PhF), 3.41 (dd, 2H, CH2S), 3.00 (t, 2H, CH2).

' 5-2 5-(4-Fluorophenyl)-2-(3-phenvlpropvl)thio-6-f4-pyridyl)-4(3H)-pyrimidinone: MS (m/z): 418.0 (M+H).';
C24HZOFN30S requir . 417 . 5 . 1H-NMR ( DMSO-ds ) : d 13 . 10 (bs , 0.7H), 8.47 (m, 2H, Pyrid.), 7.29-7.06 (m, 11H, Pyrid., Ph, PhF), 3.18 (t, 2H, CHZS), 2.71 (t, 2H, CHZPh), 2.03 (m, 2H, CHz ) .
_ S~
R~ - I

5-3 5-(4-Fluoronhenyl)-2-(2-phenoxyethvl)thio-6-(4-pyridyl,Z 4 (3H) -pyrimidinone: MS (m/z) : 420. 0 (M+H)~;
Cz3H1eFN302S requir . 419 . 5 . 1H-NMR ( DMSO-ds ) : d 13 . 2 0 ( bs , 0.7H), 8.46 (m, 2H, Pyrid.), 7.24-7.07 (m, 8H, Pyrid., PhF, Ph), 6.95 (d, 2H, Ph), 6.92 (t, overlapped, 1H, Ph) , 4.30 (t, 2H,_ CHzO) , 3.58 (t, 2H, CHzS) .
o~ ~
R~ -5-4 5-(4-Fluorophenyl)-2-(2-phenylaminoethvl)thio-6-(4-pyridyl)-4(3H)-pyrimidinone: MS (m/z): 419.0 (M+H)';
C23H19FNaOS requir . 418 : 5 . 1H-NMR ( DMSO-d6 ) : d 13 . 2 0 ( bs , 0.8H), 8.48, 7.22 (2m, each 2H, Pyrid.), 7.16, 7.10 (2m, each 2H, PhF), 6.89 (t, 2H, Ph), 6.54 (d, 2H, Ph), 6.48 (t, 1H, Ph), 5.90 (bs, 0.6H, NH), 3.43-3.25 (m, 2CH2).
H
N~S~
R - I
Example 6 General procedure for the preparation of 2-N substituted 2-amino-5- (4-fluorophenyl ) -6- (4-pyridyl ) -4 (3H) pyrimidinones:
Step A. 5-(4-Fluorophenyl)-2-methylthio-6-(4-pyridyl)-4 ( 3H) -pyrimidinone F F
NH
SH
~SCH3 Methyl iodide (90 ml, 1.44 mmol) was added dropwise to a stirred mixture of 5-(4-fluorophenyl)-6-(4-pyridyl)-2-thiouracil (430 mg, 1.44 mmol) and potassium carbonate (198 mg, 1.43 mmol) in N,N-dimethylformamide (13 ml) at ice-bath temperature. After 40 min, it was evaporated and the crude product purified by flash chromatography on a column of silica gel (hexane-acetone - 2:1, 1:1, 1:2) to provide the title compound as a solid. MS (m/z) : 314.2 (M+H)'; C16H1zFN30S requir. 313 .3 .
1H-NMR (DMSO-db): d 13.10 (bs), 8.47, 7.22 (2m, each 2H, Pyrid.), 7.16, 7.10 (2m, each 2H, PhF), 2.56 (s, 3H, CH3 ) .
Step B. General procedure' F F
NH
SCH3 ~NR5R21 A mixture of 5-(4-fluorophenyl)-2-methylthio-6-(4-pyridyl)-4(3H)-pyrimidinone (100 mg, 0.32 mmol) and an amine HNR'R2' (1 mmol) was heated at 180°C for 2 h. The resulting product was purified by flash chromatography on a column of silica gel (hexane-acetone or methanol-dichloromethane or dichloromethane-methanol-conc.
ammonium hydroxide) to provide the target compound.
The following compounds were prepared using the general procedure outlined above and an appropriate amine:
6-1 2-(2-(2-Chlorophenyl)ethyl-amino)-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone: MS
(m/z) : 421 .2 (M+H) ~; C23H18C1FNa0 requir. 420 . 9 . 1H-NMR
(DMSO-d6): d 11.24 (bs), 8.44, 7.16 (2m, each 2H, Pyrid.), 7.43, 7.38 (2dd, each 1H, PhCl), 7.30, 7.26 (2dt, each 1H, PhCl), 7.10-7.00 (m, 2H, PhF), 6.74 (bs, 1H, NH), 3.60 {q, 2H, CH2N), 3.03 (t, 2H, CHZ).
H
N~

2 5 ~ C1 6-2 5-(4-Fluorophenyl)-2-((3-phenylpropyl)-amino) 6 (4 pyridvl) -4 (3H) -pyrimidinone: MS (m/z) : 401.2 (M+H)';
CzaH21FNa0 requir . 4 0 0 . 5 . 1H-NMR ( DMSO-d6 ) : d 11.16 ( bs ) , 8.44, 7.14 (2m, each 2H, Pyrid.), 7.32-7.01 (m, 9H, Ph, PhF), 6.78 (bs, NH), 3.36 (q, 2H, CHZN), 2.67 (t, 2H, CH2Ph) , 1.89 (m, 2H, CHZ) .
- ~ i Rl - I v v H
. /
6-3 5-(4-Fluorophenyl)-2-((1-methyl-3-phenylpropyl)-amino)-6-(4-pvridvl)-4(3H)-pvrimidinone: A reaction time of 15 h at 180_ C was required. MS (mlz): 415.0 ( M+H ) ' ; CZSHZ~FN40 requir . 414 . 5 . 1H-NMR ( CDC 13 ) : d 8 . 4 8 (m, 2H, Pyrid.), 7.28-7.08 (m, 9H, Pyrid., Ph, PhF), 6.94 (m, 2H, PhF), 5.67 (bs, 1H, NH), 4.08 (m, 1H, CHCH~), 2.61 (t, 2H, CHzPh), 1.67 (m, 2H, CHZ), 1.08 (d, 3H, CHI ) .

i 1 ~ N
R - ~ H
6-4 5-(4-Fluorophenyl)-2-((3-imidazolylpropyl)-amino)-6-(4-pyridyl)-4(3H)-pyrimidinone: MS (m/z): 391.0 ( M+H ) ' ; CZ1H19FN60 requir . 3 9 0 . 4 . 1H-NMR ( DMSO-db ) : d 11. 2 4 (bs), 8.42, 7.12 (2m, each 2H, Pyrid.), 7.62, 7.18 (2s, each 1H, Imid.), 7.08-6.99 (m, 4H, PhF), 6.88 (s, 1H, Imid.), 4.02 (t, 2H, CHZN), 3.28 (overlapped by water signal, CHZNH) , 2.00 (m, 2H, CHz) .
R~ - ~N~N~
N' H
6-5 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4=
fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride: The reaction was done at 170°C for 7 h.
MS (m/z): 416.1 (M+H)+; C26H22FN50 requir. 415.5.
Ri _ / I N/
' NH2 H

Example 7 5- (4-Fluorophenyl) -2-hydrazino-6- (4-pyridyl) -4 (3H) -pyrimidinone A mixture of 5-(4-fluorophenyl)-6-(4-pyridyl)-2-thiouracil (500 mg, 1.66 mmol) and hydrazine hydrate (800 ml, ~14 mmol) was heated at 120°C for 60 min. It was evaporated and the reaction product was recrystallized from hot methanol to provide the title compound. MS (m/z) : 298.0 (M+H)~; C15H1zFN50 requir.
297.3. 1H-NMR (DMSO-d6): d 8.41, 7.12 (2m, each 2H, Pyrid.), 7.05, 7.00 (2m, each 2H, PhF).
R1 = NH-NHZ
Example 8 General procedure for the preparation of 5-aryl-2,6-dipyridyl- (3H) -pyrimidinones s-i H /
I O
/ CN H ~ ~
2 N~~ + I / O ~ ~ NH
OEt N~ ~N
J iN

F
r/ CN F
2 N~~ + ( / O
~/
OEt N J ~~ N
8-3 N , O
/ CN N ~ O
2 N~ + I / ~ ~ NH
OEt I ~ N
N / ~N
8_4 F
~~CN F ~ _ + ~ / O
N OEt These compounds were prepared according to_the literature (Kabbe, supra; German Patent 1271116 (1968)) - as follows:
A stirred mixture of the ethyl phenylacetate (3.13 mmol), cyanopyridine (6.24 mmol) and sodium methoxide (3.5 mmol) in n-butanol (1.2 ml) was heated at 110°C for ' 2h. The reaction mixture was concentrated and dissolved in water (4 ml), followed by the addition of aqueous sat. ammonium chloride (2 ml). The precipitate was filtered and recrystallized from hot methanol.
The following compounds were prepared according to this procedure using the appropriate starting materials:
8-1 5-Phenvl-2,6-bis-(4-pyridyl)-4-(3H)pyrimidinone: MS
(m/z) : 327.2 (M+H)~; C2oH1aN40 requir. 326.4. 1H-NMR (DMSO-ds): d 8.78, 8.47, 8.13 (3m, each 2H, Pyrid.), 7.40-7.14 (m, 7H, Ph, Pyrid.).
8-2 5-(4-Fluorophenvl)-2,6-bis-(4-pyridvl)-4(3H)=
pyrimidinone : MS (m/z) : 345 . 2 (M+H) r; CzoH13F1Va0 requir .
344.4 1H-NMR (DMSO-d6): d 8.80, 8.49, 8.13 (3m, each 2H, Pyrid.), 7.40-7.08 (m, 6H, PhF, Pyrid.).
8-3 2,5,6-Tris-l4-pyridyl)-4(3H)-pyrimidinone was prepared according to the general procedure by reacting ethyl 4-pyridylacetate and 4-cyanopyridine in the presence of sodium methoxide. MS (m/z): 328.2 (M+H)';
C19H~~N50 requir. 327.4 1H-NMR (DMSO-db) : 8.65, 8.45, 8.35, 8.18, 7.25, 7.13 (6m, each 2H, Pyrid.).
8-4 5-(4-Fluorophenyl)-2,6-bis-(3-pvridvl)-4(3H~=
pyrimidinone: MS (m/z) : 345.2 (M+H)~; C2oH13FN,0 requir.
344.4 1H-NMR (DMSO-ds): d 9.34, 8.77, 8.54, 8.48, 7.78, 7.60, 7.34 (7m, 3xlH, 2H, 3xlH, Pyrid.), 7.26, 7.15 (2m, each 2H, PhF).

Example 9 3- (3-trimethylsilyl-2-propynyl) -5- (4-fluorophenyl) -2 methylthio-6- (4-pyridyl) -4 (3H) -pyrimidinone F
~\~~ TMS
SMe The preparation of the tile compound was carried out in the same manner as 3-ethyl-5-(4-fluorophenyl)-2-methylthio-6-(4-pyridyl)-4(3H)-pyrimidinone with the following substitution: 3-bromo-1-(trimethylsilyl)-1-propyne was used in place of ethyl bromide.
Example 10 6-(4-Fluorophenyl)-2-methyl-1-(3-phenylpropyl)-7 pyridin-4-y1-1H-imidazo(1,2-a)pyrimidin-5-one F
N
--N
Ph A neat mixture of 3-(3-trimethylsilyl-2-propynyl)-5-(4-fluorophenyl)-2-methylthio-6-(4-pyridyl)-4(3H)-pyrimidinone (50 mg, 0.12 mmol) and 3-phenyl-1-propylamine (67 mg, 0.47 mmol) was warmed to 190°C for 17 h. After cooling to 23°C, the reaction mixture was applied directly to purification via flash chromatography (step gradient l~MeOH:CHC13 then 2~, then 3~; ) to afford the desired product: MS (m/z) 439 (M+H)+.

Example 11 6-(4-Fluorophenyl)-2-methyl-1-benzyl-7-pyridin-4-yl-1H
- imidazo(1,2-a)pyrimidin-5-one F ~ I. o \ ~N~
I \ N~N
N J '~" Ph The preparation of the title compound was carried out in the same manner as 6-(4-Fluorophenyl)-2-methyl-1-(3-phenyl propyl)-7-pyridin-4-yl-1H-imidazo(1,2-a)pyrimidin-5-one with the following substitution:
benzylamine for 3-phenyl-1-propylamine; MS (mlz): 411 (M+H)+.
Example 12 General procedure for the preparation of 6-substituted 3-phenyl-4- (4-pyridyl) -2 (1H) -pyridones Step A. General procedure for the preparation of 1-aryl-3-(4-pyridyl)-2-propene-1-one H O
I \ O + O ~ ' Rl N / ~R1 N
At ice-bath temperature, piperidine (206 ml), acetic acid (206 ml) and 4-pyridinecarboxaldehyde (1.6 mi, 16.6 mmol) were mixed. Then the acetophenone (12.0 mmol) was added at rom temperature and the mixture was heated at 130°C for 1.5 h. The reaction mixture was diluted with dichloromethane, washed with aqueous sodium hydrogencarbonate and water followed by drying and evaporation. The crude product was purified by column chromatography on silica gel (hexane-acetone = 3:1).
The following compounds were prepared according to this procedure using the apropriate acetophenone derivative:
1-Phenyl-3-(4-pyridyl)-2-propene-1-one: MS (m/z): 210.1 (M+H)'; ClaHiiNO requir. 209.3.

1-(4-Methylphenyl)-3-(4-pyridyl)-2-propene-1-one_: MS -(m/z) : 224.2 (M+H)'; C15H13N0 requir. 223 .3 .
1-(4-Ethylphenyl)-3-(4-pyridyl}-2-propene-1-one: MS
(m/z) : 237.8 (M+H)'; C16H15N0 requir. 237.3 .
1-(4-Isopropylphenyl)-3-(4-pyridyl)-2-propene-1-one: MS
(m/z) : 252.0 (M+H)'; C1~H1~N0 requir. 251.3 .
1-(2-Methylphenyl)-3-(4-pyridyl)-3-propene-1-one: MS
(m/z) : 223 . 8 (M+H)'; C15H13N0 requir. 223 .3 .
1-(2,4-Dimethylphenyl)-3-(4-pyridyl)-2-propene-1-one: MS
(mlz) : 238. 0 (M+H)'; C16H15N0 requir. 237.3 . _ 1-(2-Methoxyphenyl)-3-(4-pyridyl)-2-propene-1-one: MS
(m/z) : 240.0 (M+H)'; C15H13N02 requir._ 239.3 1-(4-Chlorophenyl}-3-(4-pyridyl)-2-propene-1-one: MS
(m/z) : 244. 0 (M+H)'; ClaHIOCINO requir. 243 :7.
1-(4-Cyanophenyl)-3-(4-pyridyl)-2-propene-1-one: MS
(mlz) : 235.1 (M+H)'; C15H1oN20 requir. 234.3 .
1-(a-Naphthyl)-3-(4-pyridyl)-2-propene-1-one: MS (m/z):
260.0 (M+H)'; C18H13N0 requir. 259.3.
1,3-Bis-(4-pyridyl)-2-propene-1-one: MS (m/z): 211.0 (M+H)': C13H1oNZ0 requir. 210.2.
3-(4-Pyridy-1-(2-thienyl)-2-propene-1-one: MS (m/z):
216. 0 (M+H)'; ClzH9NOS requir. 215.3.
1-(2-Furyl-3-(4-pyridyl)-2-propene-1-one: MS (mlz):
200.0 (M+H)'; C12H9N02 requir. 199.2.
1-Cyclohexyl-3-(4-pyridyl)-2-propene-1-one was prepared in the same way using acetylcyclohexane: MS (m/z):
216.2 (M+H)'; C14H1~N0 requir. 215.3.
1-tert-Butyl-3-(4-pyridyl)-2-propene-1-one: A mixture of 3,3-dimethyl-2-butanone (2.5 ml, 20.0 mmol), 4-pyridinecarboxaldehyde (2.15 ml, 22.3 mmol), ethanol (7.6 ml), and 4.5~ aqueous sodium hydroxide (4.6 ml) was kept at room temperature for 12 h. It was diluted with dichloromethane, washed with aqueous hydrochloric acid and water, dried and evaporated. Subsequent column chromatography (hexane - ethyl acetate = 3:1) provided the title compound. MS (m/z) : 190.4 (M+H)'; C1zH15N0 requir.189.3.

WO 98124'780 PCT/US97/22949 Step B. General procedure for the preparation of 6-substituted 3-phenyl-4-(4-pyridyl)-2(1H)-pyridones:
- O
\ \ Ri NJ

\ NH2 R
I I
/ O -Sodium (40 mg, 1.74 mmol) was dissolved in a stirring mixture of phenylacetamide (880 mg, 6.51 mmol) and ethanol (5m1). If solubility allowed, the 1-substituted 3-(4-pyridyl)-2-propene-1-one (5.4 mmol) was added portionwise as an ethanolic solution (20 ml) to the refluxing phenylacetamide solution or it was added at room temperature as a solid. The mixture was kept under reflux for 1.5 h and was then allowed to reach room temperature. 2N Hydrochloric acid was added to a pH value of 5 followed by the addition of a few ml of water. The product that crystallized from this mixture was filtered, washed subsequently with ethanol, water, ethanol and recrystallized from methanol. If the product did not crystallize from the reaction mixture on addition of hydrochloric acid, then the mixture was evaporated and the remainder taken up in dichloromethane. The organic solution was washed with water, dried and evaporated. The resultant product was crystallized from hot acetone and recrystallized from methanol.
The following compounds were prepared according to this procedure using the 2-(4-pyridyl)-2-propene-1-one derivatives described in Example 12.a:
- 12-1 3,6-Diphenvl-4-(4-pyridyl)-2(1H)-pyridone: MS
(m/z) : 325.4 (M+H)~; CZZH16Nz0 requir. 324.4. 1H-NMR (DMSO-d6): d 8.63 (m, 2H, Pyrid.), 7.86 (m, 2H), 7.58-7.45, 7.29-7.08 (2m).

R~ - I \ /
12-2 6-(4-Methylphenyl)-3-phenyl-4-(4-pyridyl)-2(1H)-pyridone: MS (m/z) : 339.2 (M+H)'; Cz3H18N20 requir. 338.4.
1H-NMR (DMSO-d6): d 8.44 (m, 2H, Pyrid.), 7.79 (d, 2H), 7.32 (d, 2H), 7.26-7.01 (m, 7H, Ph, Pyrid.), 6.67 (bs, 1H ) .
R~ ~ /

12-3 6-(4-Ethvlphenvl)-3-phenyl-4-(4-pvridvl)-2(1H)-pyridone: MS (m/z) : 353.0 (M+H)'; CZ9HzoN20 requir. 352.4.
1H-NMR (DMSO-db): d 8.42 (m, 2H, Pyrid.), 7.79 (d, 2H), 7.33 (d, 2H), 7.24-7.06 (m, 7H, Ph, Pyrid.), 6.65 (bs, 1H, CH=), 2.66 (q, 2H, CHZ), 1.21 (t, 3H, CH3).

Et 12-4 6-(4-Isopropylphenyl)-3-phenyl-4-(4-pyridyl)-2(1H)-pyridone: MS (m/z) : 367.0 (M+H)'; CZSHZZN20 requir. 366.5.
iH-NMR (DMSO-d6): d 8.45 (m, 2H, Pyrid.), 7.82 (d, 2H), 7.39 (d, 2H), 7.28-7.10 (m, 7H, Ph, Pyrid.), 6.67 (bs, 1H. CH=), 2.98 (m, 1H, CH(CH3)2), 1.27, 1.25 (2s, each 3H, 2CH3) .
i Rl - H3C

12-5 6-(2-Methylphenvl)-3-phenyl-4-(4-pvridvl)-2(1H)-pyridone: MS (m/z) : 339.2 {M+H)'; C23H18N20 requir. 338.4.
1H-NMR {DMSO-ds): d 8.40 (m, 2H, Pyrid.), 7.45-7.09 (m, 11H, Ph, Pyrid.), 6.21 (bs, 1H, CH=), 2.39 (s, 3H, CH3).
R1 _ I
2 5 \ CH3 12-6 ~2,4-Dimethvlphenyl)-3-phenyl-4-(4-twridyl)-2 (1H) -pyridone: MS (m/z) : 353 . 0 (M+H)'; C24HZON20 requir.
352.4. 1H-NMR (DMSO-ds): d 8.42 (m, 2H, Pyrid.), 7.29 (d, 1H), 7.23-7.06 (m, 9H, Ph, Pyrid.), 6.17 (bs, 1H, CH=), 2.34, 2.31 (2s, each 3H, 2CH3).
R~ - I ~

12-7 6-(2-Methoxyphenyl)-3-phenyl-4-(4-pyridyl)-2(1H)-pyridone: MS (m/z) : 355.0 (M+H)'; Cz3H18NzO2 requir. 354.4.
1H-NNiR (DMSO-db) : d 8.41 (m, 2H, Pyrid. ) , 7.49 (bd, 1H) , 7.44 (m, 1H), 7.24-7.06 (m, 8H, Ph, Pyrid.), 7.02 (dt, 1H), 6.32 (bs, 1H, CH=), 3.82 (s, 3H, CH3).
R1 _ I
OCH~
12-8 6-(4-Chlorophenyl)-3-phenyl-4-(4-pvridvl)-2(1H
pyridone: MS (m/z) : 359.2 (M+H)'; Cz2H15C1N20 requir.
358.8. 'H-NMR (DMSO-db): d 8.42 (m, 2H, Pyrid.), 7.93 (bd, 2H), 7.54 (m, 2H), 7.26-7.08 (m, 7H, Ph, Pyrid.), 6.80 (bs, 1H, CH=).
R' -Cl 12-9 6-(4-Cyanophenyl)-3-phenyl-4-(4-pyridyl)-2(1HL
pyridone: MS (m/z) : 350.2 (M+H)+; C23H15N30 requir. 349.4.
1H-NMR (DMSO-db): d 8.45 (m, 2H, Pyrid.), 8.16 (bd, 2H), 7.98 (d, 2H), 7.32-7.00 (m, 8H, Ph, Pyrid., CH=).
R' -12-10 6-(a-Naphthvl)-3-phenyl-4-(4-pvridyl)-2(1H)-pyridone: MS (m/z) : 375.0 (M+H)'; CZ6H18N20 requir. 374.5.
1H-NMR (DMSO-ds): d 8.38 (m, 2H, Pyrid.), 8.06-7.98 (m, 3H), 7.67 (dd, 1H), 7.62-7.54 (m, 3H), 7.25-7.11 (m, 7H, Ph, Pyrid.), 6.38 (bs, 1H, CH=).
R1- ~ I
12-11 3-Phenyl-4,6-bis-(4-pvridvl)-2(1H)-~vridone~
MS (m/z) : 326.0 (M+H)'; CZIH1sN30 requir. 325.4. 1H-NMR

134 ' (DMSO-ds: d 8.69, 8.43 (2m, each 2H, Pyrid.), 7.92 (bs, 2H), 7.28-7.05 (m, 8H).

N
12-12 3-Phenyl-4-(4-pyridyl)-6-(2-thienyl)-2(1H) pyridone: MS (m/z) : 331.0 (M+H)'; CzoH1aN20S requir. 330.4.
1H-NMR (DMSO-ds): d 8.44 (m, 2H, Pyrid.), 7.90, 7.70 (2bd, each 1H), 7.28-7.08 (m, 9H).
S
R~ ~ /\
12-13 6-(2-Furyl)-3-phenyl-4-(4-pyridvl)-2(1H
pyridone: MS (m/z) : 315.0 (M+H)'; CzoH1aN202 requir. 314.4.
1H-NMR (DMSO-ds): d 8.44 (m, 2H, Pyrid.), 7.90 (s, 1H), 7.43 {bs, 1H), 7.27-7.08 (m, 7H, Ph, Pyrid.), 6.71 (m, 2H).
RI - I O\-12-14 6-Cvclohexvl-3-phenyl-4-(4-pvridvl)-2(1H)-pyridone: MS (m/z) : 331.2 (M+H)'; CZZHZZN20 requir. 330.4.
1H-NMR (DMSO-d6): d 8.40 (m, 2H, Pyrid.), 7.22-7.13, 7.10-7.03 (2m, 7H, Ph, Pyrid.), 6.04 (bs, 1H, CH=), 1.95-1.15 (m, 11H, cyclohex.).
R' -'12-15 6-tent-Butyl-3-phenyl-4-(4-pyridyl)-2(1H)-pyridone: MS (m/z) : 305. 0 (M+H)'; CzoHzoN20 requir. 304.4.
1H-NMR (DMSO-ds): d 8.39 (m, 2H, Pyrid.), 7.20-7.12, 7.10-7.02 (2m, 7H, Ph, Pyrid.), 6.02 (bs, 1H, CH=), 1.31 (s, 9H, 3CH3) .
Rl - ( CH3 ) 3C-Example 13 Procedure for the preparation of (S)-2,2 Benzylethylendiamine - 5 (S)-1,2-Benzvlethylendiamine: The diamine was prepared according to the literature (H. Brunner, P. Hankofer, U.
Holzinger, B. Treittinger and H. Schoenenberger, Eur. J.
Med. Chem. 25, 35-44, (1990)) by reduction of L-phenylalanine amide with lithium aluminium hydride. The (R)-enantiomer was prepared in the same manner from D-phenylalanine amide.
Example 14 Procedure for the preparation of 2-(((S)-2-Acetamido-3 phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4 pyridyl ) -4 (3H) -pyrimidinone F ~ O F /
O
\ I N/ \ I N/
I I
J. \ -.,.~ J~ \
N H __ ( / ~ \ N N _ I /
N / NHz N / H NHAc 2-(((S)-2-Acetamido-3-phenvlpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pvrimidinone:
A solution of 2-(((S)-2-amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone (25 mg, 0.058 mmol) and acetic anhydride (200 ml) in methanol (2 ml) was kept at room temperature for 1 h. Evaporation followed by chromatography of the resultant product on a column of silica gel (10~
methanol/dichloromethane) provided the title compound.
MS (m/z): 472.3 (M+H)+; C27H26FN502 requir. 471.5.

Example 15 Procedure for the preparation of 5-(4-Fluorophenyl)-2-(((S)-2-N-isopropylamino-3-phenylpropyl)-amino)-3-methyl-6- (4-pyridyl ) -4 (3H) -pyrimidinone hydrochloride F F /
\ I 0 , \ I ON/
N
I
I \ I NJ~N I \ I \ N~N I /
N J H IVH ~ N / H NH

5-(4-Fluorophenyl)-2-(((S)-2-N-isopropylamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride~ Sodium triacetoxyborohydride (23 mg, 0.109 mmol) was added to a strirring mixture of 2-(((S)-2-amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride (50 mg, 0.107 mmol), triethylamine (15 ml, 0.108 mmol) and acetone (7.9 ml, 0.108 mmol) in 1,2-dichloroethane (0.8 ml). _ After 4h, the reaction was quenched by the addition of sat. aqu.
sodium hydrogencarbo-nate, followed by extraction with dichloromethane, drying of the organic solution and evaporation. Chromatography on a column of silica gel (10o methanol/chloroform) provided the title compound as a free base which was converted into the monohydrochloride by the addition of 4N hydrochloric acid/dioxane (21 mml, 0.08 mmol) to its methanolic solution (1 ml) and subsequent evaporation. MS (m/z):
472.1 (M+H)+; C28H30FN50 requir. 471.6 (free base).

Example 16 Procedure for the preparation of 5-(4-Fluorophenyl)-2-- (((S)-2-N-cyclohexylamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride F / O F / I O
\ I / \ N/
I N~N I \ ~.I \ I NON I \
I - ~ N / H NH

5-(4-Fluorophenvl)-2-(((S)-2-N-cvclohexvlamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride: Utilizing cyclohexanone, 5-(4-fluorophenyl)-2-(((S)-2-N-cyclohexylamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone was prepared in the same manner as 5-(4-fluorophenyl)-2-(((S)-2-N-isopropylamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone: MS (m/z): 511.6 (M)+; C31H34FN50 requir.
511.6 (free base).
Example 17 Procedure for the preparation of 2-(((S)-2-N-n Butylamino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3 methyl-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride F ~ 0 F / O \ I N/
I
---~ I
\ I J' _ \ I \ NJ'N - I \
N N = ~ NJ H

2-(((S)-2-N-n-Butylamino-3-phenvlpropvl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pvridvl)-4(3H)-pyrimidinone hydrochloride: Sodium triacetoxyborohydride (28 mg, 0.13 mmol) was added to a strirring mixture of 2-(((S)-2-amino-3-phenylpropyl)-amino}-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone (41 mg, 0.095 mmol) and butyraldehyde (8.5 ml, 0.094 mmol) in 1,2-dichloroethane (0.8 ml). After 2 h, the reaction was quenched by the addition of sat. aqu, sodium hydrogencarbonate, followed by extraction with dichloromethane, drying of the organic solution and evaporation. Chromatography on a column of silica gel (5~ methanol/chloroform) provided the title compound as a free base which was converted into the monohydrochloride by the addition of 4N hydrochloric acid/dioxane (12 mml, 0.048 mmol) to its methanolic solution (1 ml) and subsequent evaporation. MS (m/z):
486.2 (M+H)+; C2gH32FN50 requir. 485.6 (free base).
Example 18 Procedure for the preparation of (S)-2-N,N-Dimethylamino-3-phenylpropylamine O
O
\ H2N ~ \ H2N
H2N ~/ ~ --~ _- / ~ N
N

(S)-2-N,N-Dimethylamino-3-phenvlpropylamine: Sodium triacetoxyhydride (13.0 g, 61.3 mmol) was added to a stirring mixture of phenylalanine amide (3.6 g, 21.9 mmol) and 37~ formaldehyde solution (4.4 ml, 58.7 mmol) in 1,2-dichloroethane (77 ml). After stirring for 2 h, the reaction was quenched by the addition of sat. aqu.
sodium hydrogencarbonate. Then potassium hydroxide pellets were added followed by extraction with dichloromethane, drying of the organic solution and evaporation. The resulting (S)-2-N,N-dimethylamino-3-phenylpropylamide was reduced with lithium aluminium hydride according to the literature (H. Brunner, P.
Hankofer, U. Holzinger, B. Treittinger and H. _ Schoenenberger, Eur. J. Med. Chem. 25, 35-44, (1990)) to provide the title compound.

Exaraple 19 Procedure for the preparation of 2-(((S)-2-N,N
Dimethylamino-3-phenylpropyl)-amino)-5-(4-fluorophenyl 3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride _ F ~ I ~ ~ F ~I 0 I 'N \
I \ N~S~CH3 '~ \ I N~~~CHg N J -O
F
I ° \
\ I N/ H2N __ I \ N~N I \ /N\
H
NJ__ ~N~\
Step A. 5-(4-Fluorophenyl)-3-methyl-.2-methvlsulfonvl-6-~4-pyridyl)-4(3H)-pyrimidinone: A mixture of 5-(4-fluorophenyl)-3-methyl-2-methylthio-6-(4-pyridyl)-4(3H)-pyrimidinone (400 mg, 1.22 mmol) and OxoneR (potassium peroxymonosulfate, 2.3 g, 3.74 mmol) in methanol (100 ml) and water (45 ml) was stirred for 13 h. The solvent was concentrated to about 50 ml, followed by extraction with dichloromethane, drying of the organic solution and evaporation. The resulting white solid was used without purification in the next step.
Step B. 2-(((S)-2-N N-Dimethvlamino-3-phenylpropvl)-amino)-5-(4-fluoromhenyl-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride: A mixture of crude 5-(4-fluorophenyl)-3-methyl-2-methylsulfonyl-6-(4-pyridyl)-4(3H)-pyrimidinone (430 mg g, 1.19 mmol) and (S)-2-N,N-dimethylamino-3-phenylpropylamine (600 mml, ~3.4 mmol) was stirred at room temperature for 1h and then briefly warmed at 50 C. Column chromatography on silica gel (3-5~ methanol/chloroform) provided the title compound as a free base which was converted into the monohydrochloride by the addition of 4N hydrochloric acid/dioxane (160 mml, 0.64 mmol) to its methanolic solution (4 ml) and subsequent evaporation. MS (m/z): 458.0 (M+H)+;
C27H28~50 requir. 457.5 (free base).
Example 20 5- (4-fluorophenyl) -&- (4- (2-acetami do) -pyridyl) -2-thioalkyl-4 (3H) -pyrimidinones Step A. Ethyl 2-(4-fluorophenyl)-3-oxo-3-(4 (2 acetamido)-pyridyl))-propionate A solution of 2-chloroisonicotinic acid (25.Og, 0.16 mol) in 65 mL of concentrated ammonium hydroxide was warmed to 205 Celsius in a steel bomb for 72 h. After cooling to 23 C, the solution was acidified to a pH of 1 using 6N HC1 and subsequently filtered to remove unreacted starting material. The solution was concentrated to one fourth the original volume (approx 200 mL) in vacuo, and carefully adjusted to a pH of 6 using 1 N NaOH. After storing the cloudy solution at 0 C for 20 h, the desired 2-aminoisonicotinic acid was filtered off. To a suspension of 2-aminoisonicotinic acid in ethanol (600 mL) was added 47.1 mL of 4 N
anhdrous HC1 in dioxane. After warming to achieve reflux for 20 h, an additional 47.1 mL of 4 N anhdrous HC1 in dioxane was added and the reaction was warmed to reflux for an additional 20 h. Concentration with a stream of nitrogen in the hood was followed by further concentration in vacuo, the remaining solid was diluted with saturated bicarbonate (200 mL), extracted with ethyl acetate (2 x 200mL), dried (Na2S04). After concentration in vacuo, the desired ethyl 2-aminoisonicotinate was obtained. To a solution of ethyl 2-aminoisonicotinic acid in pyridine (45 mL) at 0 C
undr an argon atmosphere was added acetyl chloride dropwise over 5 min. After 2 h at 0 C, the reaction was pored into over ice 300 g, extracted with ethyl acetate (2 x300 mL), washed with water (2 x100 ml) followed by brine ( 2 x 100 mL), and dried (Na2S04). After concentration in vacuo, the residue was purified by - . 141 application of flash chromatography ( step gradient ethyl acetate: hexane 1:4 then ethyl acetate: hexane 1:1) to afford ethyl 2-acetamidoisonicotinate.
To a solution of diisopropylamine (14.15 mL, 101 mmol) and THF (40 mL) at -78 C was added n-butyl lithium (38.1 mL, 95 mmol) dropwise over 5 min. After - 10 min, ethyl 4-fluorophenylacetate (17.3 g, 95 mmol) was added in 40 mL of dry THF. After 10 min, ethyl 2-acetamidoisonicotinate (6.0 g, 29 mmol) was added in 20 ml of dry THF. The reaction was allowed to warm to 23 G
overnight, and then acetic acid (95 mmol) was added in one portion. The reaction was concentrated in vacuo, then partitioned repeatedly between saturated bicarbonate (200 ml) and ether (300 mL), the combined bicarbonate layers were neutralized with 10~ citric acid, and extracted with ethyl acetate (2 x 300 mL).
The organic layers were dried (Na2S04), concentrated in vacuo to afford the Ethyl 2-(4-fluorophenyl)-3-oxo-3-(4-(2-acetamido)-pyridyl)-propionate.
Step B. 5-(4-fluorophenyl)-6-(4-(2-acetamido)pyridyl))-2-thiouracil:
Ethyl 2-(4-fluorophenyl)-3-oxo-3-(4-(2-acetamido)pyridyl)-propionate (1.3 g, 3.78 mmol) and thiourea (863 mg, 11.3 mmol) were suspended in anhydrous p-xylene (15 ml) with very efficient stirring.
To the mixture pyridinium p-toluenesulfonate (38 mg) was added and refluxed for 12-16 h using a Dean-Stark apparatus with continuous removal of water (0.1 ml).
Reaction mixture was cooled and a dark brown solid was filtered using a Buchner funnel. The collected solid was suspended in acetone (25 ml) and filtered. The acetone washed product contained a trace of thiourea, - which was removed by trituration with hot water (20-30 ml). The product was filtered and air dried followed by azeotroping with toluene.

WO 98/24780 PCTlIJS97/22949 Example 21 Procedure for the preparation of (S)-2-N-Ethylamino-3-phenylpropylamine O
O
\ H2N __ ~ / H2N ~ \
H2N ~_ ~ / ~ O NH ~ - /

~S)-2-N-Ethylamino-3-phenylpropylamine: Acetic anhydride (1.2 ml, 12.7 mmol) was added to a stirring solution of L-phenylalanine amide (1.0 g, 6.10 mmol) in methanol (25 ml). After 1.5 h at room temperature, it was evaporat-ed followed by drying in an oil pump vacuum.
The resultant L-N-ethylphenylalanine amide (6.1 mmol) was reduced with lithium aluminium hydride (570 mg, 15.0 mmol ) in tetrahydrofuran ( 65 mml ) at 55°C for 4 h. The reaction mixture was poured into sat. aqu. sodium hydrogencarbonate followed by extraction with dichloromethane, drying and evaporation. Column chromatography on silica gel (chloroform . methanol .
triethylamine = 90:7:3) provided the amine as a yellowish oil. MS (mlz): 179.1 (M+H)+; C11H18N2 requir.
178.3.
Exat~ple 22 Procedure for the preparation of 2-Amino-2-methyl-3-phenylpropylamine /~ 'NH2 2-Amino-2-methyl-3-phenylpropylamine: A solution of commercially available D,L-a-methyl phenylalanine methyl ester (5.0 g, 25.7 mmol) in aqu. 28~ ammonium hydroxide (50 ml) was kept at room temperature for 3 d. The resulting white precipitate of D,L-a-methyl phenylalanine amide was filtered and dried (2.5 g).

This material (2.0 g, 11.22 mmol) was reduced with lithium aluminium hydride (1.3 g, 34.26 mmol) in boiling tetrahydrofuran for 24 h. The reaction was quenched by the addition of sodium sulfate decahydrate at ice-bath temperature. The salts were filtered off, followed by evaporation to leave the title compound as an oil. MS
(m/z): 165.1 (M+H)+; C1pH16N2 requir. 164.2. An alternative preparation was reported by M. Freiberger and R. B. Hasbrouck, J. Am. Chem. Soc. 82, 696-698 (1960).
Example 23 Procedure for the preparation of 2-Methyl-3-phenylpropylamine ~NH2 2-Methyl-3-phenvlpropylamine: A mixture of commercially available 2-methyl-3-phenylpropylamide (4.32 g, 26.5 mmol) and lithium aluminium hydride (1.3 g, 34.3 mmol) in tetrahydrofuran (184 ml) was stirred at room temperature for 5 h. It was poured into aqu. sat.
sodium sulfate and extracted with dichloromethane followed by drying of the organic solution and evaporation to provide the amine as an oil. Other syntheses have been reported, e.g. Dornow and Fust, Chem. Ber. 87, 984 (1954).

Example 24 Procedure for the preparation of 5-(4-Fluorophenyl)-3 methyl-2-((2-methy-3-phenylpropyl) amino)-6-(4-pyridyl) 4 (3H) -pyrimidinone hydrochloride F ~ O
\ I i N O
N~S~CH3 F / 0 N / O \ I N/
+ --w ~\ ~ N~N ~\
H2N ~ NJ H CH

5-(4-Fluorophenvl)-3-methvl-2-((2-methv-3-phenvlpropvl) amino)-6-(4-pvridyl)-4(3H)-pyrimidinone hydrochloride:
A mixture of crude 5-(4-fluorophenyl)-3-methyl-2-methylsulfonyl-6-(4-pyridyl)-4(3H)-pyrimidinone (520 mg g, 1.45 mmol) and 2-methyl-3-phenylpropylamine (1.5 g, 10.1 mmol) was heated at 50°C for 30 min. Column chromatography on silica gel (2-5~
methanol/dichloromethane; hexane-acetone= 2 . 1) provided the title compound. MS (mlz): 429.4 (M+H)+;
C26H25FN40 requir. 428.5 (free base).
Example 25 Procedure for the preparation of 1-Phenyl-1,3 propanediamine 1-Phenvl-1,3-propanediamine: 3-Phenyl-3-aminopropionic acid (S. G. Cohen and S. Y. Weinstein, J. Am. Chem. Soc.
86, 725-728, 1964) was converted into 1-phenyl-1,3-propanediamine as reported in the literature (M. Kojima and J. Fujita, Bull. Chem. Soc. Jpn. 55, 1454-1459 (1982)), Analogously, 1-(2-fluorophenyl)-1,3-propanediamine, 1-(2-methylphenvl)-1,3-propanediamine and 1-(2-- chlorophenyl)-1,3-propanediamine have been prepared.
- Example 26 Procedure for the preparation of 3-Ethyl-5-(4 fluorophenyl) -2-methylthio-6- (4-pyridyl) -4 (3H) pyrimidinone F / ( O F / I O
NH ' N~
N~S~CH3 ----~ I ~ I N~S~CH3 N / N
3-Ethvl-5-(4-fluorophenyl)-2-methylthio-6-(4-pvridvl 4(3H)~wrimidinone: Ethyl bromide (600 ml, 8.03 mmol) was added to a stirred mixture of 5-(4-fluorophenyl)-2-methylthio-6-(4-pyridyl)-4(3H)-pyrimidinone (1.8 g, 5.97 mmol) and sodium hydride (60~ oily suspension, 320 mg, 8 mmol) in N,N-dimethylformamide (60 ml) at room temperature. More ethyl bromide (2x 600 ml, 2x8.03 mmol) was added after 2 and 3.5 h. After 8 h, the reaction mixture was neutralized with acetic acid and evaporated. The remainder was taken up in d;chloromethane, the organic solution was washed with water, dried and evaporated. Flash chromatography on a column of silica gel (hexane-acetone = 3:1, 2:1).
provided in the second main fraction the title compound as a solid.
Example 27 Procedure for the preparation of 3-Ethyl-5-(4-fluorophenyl) -2-methylsulfonyl-6- (4-pyridyl) -4 (3H) -' pyrimidinone F / O F / O
__ ~ I N~ ~ I N~
I
N~S~CH3 '.~' I ' I N J\p~CH3 N / N J il O

3-Ethyl-5-(4-fluorophenyl)-2-methvlsulfonyl-6 (4 pvridvl)-4(3H)-pyrimidinone: A mixture of 3-ethyl-5-(4-fluorophenyl)-2-methylthio-6-(4-pyridyl)-4(3H)-pyrimidinone (300 mg, 0.88 mmol) and OxoneR (potassium peroxymonosulfate, 2.54 g, 4.14 mmol) in methanol (71 ml) and water (33 ml) was stirred for 14 h. The solvent was concentrated to about 35 ml, followed by extraction with dichloromethane, drying and evaporation. The resulting white solid was used without purification in the next step.
Example 28 Procedure for the preparation of 2-(((S)-2-Amino-3 phenylpropyl) -amino) -3-ethyl-5- (4-fluorophenyl) -6- (4 pyridyl)-4(3H)-pyrimidinone hydrochloride O
N
NJwN - ~ \
NJ H ~2 2-(((S)-2-Amino-3-phenylpropyl)-amino)-3-ethyl-5-(4 fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride: A mixture of 3-ethyl-5-(4-fluorophenyl)-2-methylthio-6-(4-pyridyl)-4(3H)-pyrimidinone (150 mg, 0.44 mmol) and (S)-1,2-benzylethylendiamine (200 ml, ~1.3 mmol) was heated at 190-C for 4.5 h. Column -.chromatography on IatrobeadsR (chloroform . methanol .
triethylamine = 90 . 7 . 3) provided the title compound as a free base which was converted into the crystallizing monohydrochloride by the addition of 2N
hydrochloric acid (165 ml, 0.33 mmol) and methanol (1.5 ml). Filtration provided the title compound. MS (m/z):
444.0 (M+H)+; C265H27FN50 requir. 443.5 (free, base).

Txample 29 Procedure for the preparation of 3-Ethyl-5-(4 fluorophenyl) -2- ( (2-methy-3-phenylpropyl) amino) -6- (4 pyridyl)-4(3H)-pyrimidinone hydrochloride \ I N~
\ I NJ~N I \

3-Ethyl-5-(4-fluorophenyl)-2-((2-methy-3-phenylpropyl) amino)-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride:
A mixture of crude 3-ethyl-5-(4-fluorophenyl)-2-methylsulfonyl-6-(4-pyridyl)-4(3H)-pyrimidinone (320 mg g, 0.89 mmol) and 2-methyl-3-phenylpropylamine (600 ml, ~4 mmol) was heated at 60°C for 2 h. Column chromatography on silica gel (hexane-acetone= 2 . 1; 2-5~ methanol/dichloromethane) provided the title compound. MS (m/z): 443.2 (M+H)+; C27H27FN40 requir.
442.5.
Example 30 Procedure for the preparation of 3-(2-Methylphenyl)propylamine ~ ~NHZ

3-(2-Methvlphenvl)propvlamine: Diethyl cyanomethylphosphonate (5.0 ml, 30.9 mmol) was added to' a stirring suspension of sodium hydride (60~ oily suspension, 1.24 g, 31 mmol) in tetrahydrofuran (50 ml) under argon. After 3o min, 2-methylbenzaldehyde (3.6 ml, 31.1 mmol) was added and stirring continued for 1 h.
The reaction was quenched by the addition of water and ' extracted with dichloromethane followed by drying and evaporation of the organic solution. Column chromatography (hexane; hexane . ethylacetate = 3 . 1) WO 98/24780 PCT/fJS97/22949 provided 2-(2-methylphenyl)acrylonitrile as an oil.
This material (3.8 g), 10~ palladium on carbon (3.8 g) and 12 N hydrochloric acid (11.8 ml, 142 mmol) in methanol (125 ml) were hydrogenated with hydrogen at atmospheric pressure for 2 d. The catalyst was removed by filtration and the solvent was evaporated. The resultant material was partitioned between dichloromethane and water. The aqueous layer was made basic with 10 N sodium hydroxide and extracted with dichloromethane, followed by drying and evaporation.
The resultant material was purified on a silica gel column (chloroform . methaol . triethylamine = 85 . 10 .
5) to provide the title compound as an oil.
Example 31 Procedure for the preparation of 2-amino-3-(2-fluorophenyl)-propylamine \NH2 Step A. Methyl 2-amino-3-(2-fluorophenyl)propionate:
5g (27.3 mmol) of (D,L)-(2-fluoro-phenyl)alanine was suspended in 50 ml methanolic HC1 and stirred at room temperature for 3 days. The reaction mixture was concentrated in vacuo and dried to give a yellow oil.
MS (m/z) : 198 (M+H)' ; CloHIZFN02 requir. 297.2.
Step B. 2-Amino-3-(2-fluorophenyl)propionamide: Methyl 2-amino-3-(2-fluorophenyl) propionate was suspended in 50 ml 30~ ammonium hydroxide and stirred at room temperature-for 18 hrs. The mixture was filtered, washed with cold water and 2-amino-3-(2-fluorophenyl) propionamide was collected as a white solid. MS (m/z):
183.1 (M+H)' ; C9H11FN20 requir. 182.2.
Step C. 2-Amino-3-(2-fluoronhenvl)-propvlamine: 2-Amino-3-{2-fluorophenyl)propionamide was added carefully to a chilled (5°) mixture of LAH (l.Og, 26.3 mmol) and 20 ml THF under argon. The reaction was then heated at reflux for 10 hrs. The reaction was cooled to 5°C and carefully treated with Na2S04~10 H20. The resulting mixture was stirred for 18 hrs, then filtered to remove the solids. The filtrate was concentrated in vacuo to give an amber oil. MS (m/z) : 169 (M+H)' ; C9H13FN2 requir. 168.19 Example 32 Procedure for the preparation of 5-(4-Fluorophenyl)-2 (((S)-2-N-glycylamino-3-phenylpropyl)-amino)-3-methyl-6 (4-pyridyl ) -4 (3H) -pyrimidinone hydrochloride F ~ O
N~N I \
N ~ _ H NH
0 "NH2 5-(4-Fluorophenvl).-2-(((S)-2-N-ctlvcvlamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4(3H) pyrimidinone hydrochloride: Ethyl chloroformate (56.8 ~1, 0.59 mmol) was added at ice-bath temperature to a stirring mixture of N-(tert.-butoxycarbonyl)glycine (104 mg, 0.59 mmol) and 4-methylmorpholine (65.3 ~1, 0.59 mmol) in tetrahydrofuran (9 ml). After 50 min, a solution of 2-(((S)-2-amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone (250 mg, 0.58 mmol) in tetrahydrofuran (9 ml) was added at ice-bath temperature. Within 2 h, the mixture was allowed to reach room temperature. It was diluted with dichloromethane, washed with aqueous sodium hydrogencarbonate, followed by drying of the organic solution and evaporation. The resulting material was - dissolved in methanol (1.2 ml) and 4N hydrogen chloride/dioxane (1.2 ml) was added. After 1 h at room temperature, it was evaporated and the remainder taken up in dichloromethane followed by washing with aqueous sodium hydrogencarbonate, drying of the organic solution and evaporation. Column chromatography on silica gel (dichloromethane - methanol - conc. ammonium hydroxide =
93 . 7 . 0.7) provided the title compound as the free base which was converted into the hydrochloride by the addition of 4N hydrogen chloride/dioxane (112 ~.I,1, 0.45 mmol) to its methanolic solution (3 ml) followed by evaporation. MS (m/z) : 487.1 (M+H)'; Cz~H2~FN60z requir.
486.6 (free base).
Accordingly, 2-(((S)-2-N-alycylamino-3-phenylpropyl)-amino)-3-methyl-5-(3-methylphenyl)-6-(4-pvridvl)-4(3H) pyrimidinone hydrochloride was prepared from 2-(((S)-2-amino-3-phenylpropyl)-amino))-3-methyl-5-(3-methylphenyl 6-(4-pyridyl)-4(3H)-pyrimidinone.
Example 33 Procedure for the preparation of 5-(4-Fluorophenyl)-2 (((S)-2-hydroxyacetamido-3-phenylpropyl)-amino)-3 methyl-6- (4-pyridyl) -4 (3H) -pyrimidinone F ~ O
I N
N~N
N ~ H NH
O~ OH
5-(4-Fluorophenvl)-2-(((S)-2-hydroxyacetamido-3-phenvlpropvl)-amino)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone: Acetoxyacetyl chloride (55 ~.1, 0.51 mmol) was added at ice-bath temperature to a stirring solution of 2-(((S)-2-amino-3-phenylpropyl)-amino)-5-(4-fluoro phenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone (200 mg, 0.466 mmol) and triethylamine (130 ~1, 0.93 mmol) in dichloromethane (4 ml). After 50 min, the reaction was quenched by the addition of a drop of methanol followed by evaporation. The resultant material was taken up in a 1:1:1 mixture of methanol/water/triethylamine (3 ml) and 151 ' left overnight. Evaporation and subsequent column chromatography (3-7~ methanol/chloroforme) provided the title compound. MS (m/z) : 488.3 (M+H)~; CZ,HZ6FN503 requir.
487.5.
Example 34 - Procedure for the preparation of 5-(4-fluorophenyl)-2 (2-((3-N-methylureido)-3-phenylpropyl)-amino)-3-methyl 6- (4-pyridyl) -4 (3H) -pyrimidinone F / O
~' /
I N
N~N _ I - /
N ~ H NH
O' NHCH3 5-(4-Fluorot~henyl)-2-(2-((3-N-methvlureido)-3-phenvlpropyl)-amino)-3-methvl-6-(4-pyridvl)-4(3H)-pyrimidinone: Methyl isocyanate (6 ~1, 0.102 mmol) was added to a solution of 2-(((S)-2-amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone (43.6 mg, 0.102 mmol) in dioxane (1.5 ml) at 15°C. After 15 min, the solvent was evaporated and the reaction product applied to a silica gel column (5-7~ methanol/chloroform) to provide the title compound.
MS (m/z) : 486.6 (M+H)'; C~,HZ~FN602 requir. 486.6.
Example 35 Procedure for the preparation of 5-(4-fluorophenyl)-3 methyl-6-(4-pyridyl)-2-((2-pyrrolidinyl-3-phenylpropyl) amino)-4(3H)-pyrimidinone hydrochloride F / O
. ~I /
N
_ I ~ I N~N I ~
NJ H N
U

5-(4-Fluorophenyl)-3-methyl-6-(4-pyridyl)-2-(((S)-2-pyrrolidinyl-3-phenylprotwl)-amino)-4(3H)-pvrimidinone hydrochloride: Sodium hydride (60~ oily suspension, 84 mg, 2.1 mmol> was added to a solution of 2-(((S)-2-amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone (300 mg, 0.70 mmol) in N,N-dimethylformamide (8 ml) at ice-bath temperature. After 30 min, 1,4-dibromobutane (108 ~1, 0.91 mmol) was added. Stirring was continued for 30 min at ice-bath temperature, then 20 h at room temperature.
It was neutralized with acetic acid, followed by evaporation. The crude product was--purified on a column of silica gel (dichloromethane - methanol = 93 . 7;
dichloromethane - methanol - conc. ammonium hydroxide =
93 . 7 . 0.7). The resultant product was converted into the hydrochloride by the addition of 4N hydrogen chloride/dioxane (37 ~.l) to its methanolic solution (2 ml) and subsequent evaporation. MS (m/z): 484.6 (M+H)';
C~9H~oFN~O requir . 483 . 6 ( free base ) .
Example 36 Procedure for the preparation of 5-(4-fluorophenyl)-2 (((S)-3-N-isopropylamino-3-phenylpropyl)-amino)-3 methyl-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride F ~ O
NH
I N
~ N~N
H
5-(4-Fluorophenvl)-2-(((S)-3-N-isopropvlamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride~ Sodium triacetoxyborohydride (12.9 mg, 0.061 mmol) was added to a strirring mixture of 2-(((S)-3-amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone (21.8 mg, 0.051 mmol) and acetone (4.5 ~.1, 0.061 mmol) in 1,2-dichloroethane (0.4 ml). After 2.5 h, the reaction was quenched by the addition of sat. aqu.
- sodium hydrogencarbonate, followed by extraction with dichloromethane, drying of the organic solution and evaporation. Chromatography on a column of silica gel (10~ methanol/chloroform) provided the title compound as - a free base which was converted into the monohydrochloride by the addition of 4N hydrochloric acid/dioxane (12.2 E11) to its methanolic solution (1 ml) and subsequent evaporation. MS (m/z): 472.0 (M+H)+;
C2gH3pFN50 requir. 471.6 (free base).
Example 37 Procedure for the preparation of 5-(4-fluorophenyl)-2 (((R)-3-N-isopropylamino-3-phenylpropyl)-amino)-3 methyl-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride F / O
/ NH
N
I ~ I N J.N
N ~ H
5-(4-Fluorophenyl)-2-(((R)-3-N-isopropvlamino-3 phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride was prepared from 5-(4-fluorophenyl)-2-(((R)-3-N-isopropylamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone as described above for its S-enantiomer. MS
(m/z): 472.1 (M+H}+; CZgH3pFN50 requir. 471.6 (free base).
Exaa~le 38 Procedure for the preparation of 2-(((S)-3-acetamido-3-- phenylpropyl)-amino)-5-(4-fluorophenyl)- 3-methyl-6-(4-- pyridyl ) -4 (3H) -pyrimidino.ne F / 0 O' \
NH
I ~N -N~N
N J H U
2-(((S)-3-Acetamido-3-phenylpropyl)-amino)-5 (4 fluorophenyl)- 3-methyl-6-(4-pyridyl)-4(3H) pyrimidinone: A solutiont of 2=(((S)-3-amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone (23.8 mg, 0.055 mmol) and acetic anhydride (20 E1.1, 0.21 mmol) in methanol(1 ml) was kept for 30 min at room temperature. Evaporation was followed by column chromatography (dichloromethane -methanol - ammonium hydroxide = 93 . 7 . 0.7) to provide the title compound. MS (m/z): 472.2 (M+H)+; C2~I-i26FN502 requir. 471.5.
Example 39 Procedure for the preparation of(S)-1-Phenyl-1,3-propanediamine NH-tBOC NHZ
N --~ \ I v wNH2 (S)-1-Phenyl-1 3-propanediamine~ S-3-N-tert.--Butoxycarbonylamino-3-phenylpropionitrile was prepared according to the literature (W. J. Wheeler and D.D.
O'Bannon, J. Label.Compds. Radiopharm. XBXI (4), 305-315, 1992) from D-(-)-a-phenylglycinol. For reduction (D. Mitchell and T.M. Koenig, Synth. Comm. 25 (8), 1231-1238, 1995), borane-methyl sulfide complex (2N, 3 ml, 5 mmol) was added dropwise to a solution of the nitrile (1 g, 4.06 mmol) in tetrahydrofuran (6 ml). Methyl sulfide was distilled off and the resulting solution refluxed for 2.5 h. With ice-cooling, methanolic hydrogen chloride (1N, 3 ml) was added followed by evaporation.

The remainder was taken up in methanol (10 ml) and 4N
hydrogen chloride/dioxane (10 ml) was added. After 1 h at room temperature, it was evaporated and the aqueous solution of the resultant-product was washed with ,~ 5 dichloromethane. The aqueous solution was made basic by the addition of solid potassium hydroxide followed by repeated dichloromethane extractions. Drying and evaporation of the dichloromethane solution left the crude diamine as an oil. MS (m/z) : 150.8 (M+H)'; C9H1aN2 requir. 150.2.
Enantiomeric fR)-1-phenyl-1,3-propanediamine was prepared analogously from L-(+)-o~,-phenylglycinol. MS
(m/z) : 150.9 (M+H)'; C9HlaNz requir. 150.2.
Example 40 Procedure for the preparation of (2R,3R)-2-methyl-3-phenyl-1,3-propanediamine _ Ph NH2 NJ o 0 Phi --~. ( ~ OMe -OMe ~
NH2 ~2 0 NH2 1; ~ , ~2 Step A: Methyl f2S,3R,aS)-3-(N-benzvl-N-a methvlbenzylamino)-2-methyl-3-phenylpropionate was prepared as reported for the 2R,3S,ocR-enantiomer (S. G.
Davies and I.A.S. Walters, J. Chem. Soc. Perkin Trans.I, - 1129-1139 (1994).
' Step B: Methyl (2S,3R)-3-amino-2-methyl-3-phenvlpropionate: A mixturte of methyl (2S,3R,ocS)-3-(N-benzyl-N-a-methylbenzylamino)-2-methyl-3-phenylpropionate (13.0 g, 33.55 mmol) and 10~ palladium-on-carbon (13.0 g) in glacial acetic acid (260 ml) was hydrogenated under a balloon of hydrogen for 24 h. The catalyst was removed by filtration followed by evaporation and co-distillation with toluene to provide the title compound as a white solid. MS (mlz): 194.2 (M+H)'; C11H1sNCz requir. 193.3.
Step C: (2S,3R)-3-Amino-2-methyl-3-phenylpropionamide A solution of methyl (2S,3R)-3-amino-2-methyl-3-phenylpropionate (6.3 g, 33 mmol) in 2N methanolic ammonia (20 ml) and ammonium hydroxide (28-30~, 40 ml) was stirred at room temperature. After 4d, it was evaporated followed by chromatography on a short column of silica gel (dichloromethane - methanol - conc.
ammonium hydroxide = 93 . 7 . 0.7; 90 . 10 . 0.8) to provide the amide as a white solid. MS (m/z): 179.2 (M+H)'; CloH1qN20 requir. 178.2 .
Step D: (2R,3R)-2-methyl-3-phenyl-1 3-propanediamine:
Lithium aluminium hydride (2.3 g, 60.60 mmol) was added in portions to a stirring solution of (2S,3R)-3-amino-2-methyl-3-phenylpropionamide (2.6 g, 14.59 mmol) in tetrahydrofuran (54 ml) at ice-bath temperature. After 45 min, the mixture was heated at reflux for 16 h. With ice-bath cooling, the reaction was quenched by the portionwise addition of sodium sulfate decahydrate and some methanol until hydrogen evolution ceased. The solids were removed by filtration and washed with dichloromethane. The combined filtrates were evaporated to provide the title compound. MS (m/z): 165.2 (M+H)';
CloH16N2 requir . 164 . 3 .
Accordingly, the enantiomer (2S,3S)-2-methyl-3-phenyl-1s3-propanediamine was prepared from methyl (2R,3S,aR)-3-(N-benzyl-N-a-methylbenzylamino)-2-methyl-3-phenylpropionate . MS (m/z) : 165 . 3 (M+H) '; C1oH16Nz requir.
164.3.

157 ' Analogously, the enantiomers (2R,3S)-2-methyl-3-phenvl-1,3-prot~anediamine and (2S,3R)-2-methyl-3-phenyl-1 3-propanediamine may be prepared from tert.butyl (2S, 3S, ocR) - and - (2R, 3R, otS) -3- (N-benzyl-N-a-methylbenzylamino)-2-methyl-3-phenylpropionate (S.
Davies et al., J. Chem. Soc. Chem. Commun. 1153-1155, 1993 ) .
Example 41 Procedure for the preparation of 2-((S)-3-Benzylpiperaziny)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride O F ~ ~ O
\ /
\ \ N
HN ~ I / ,~ H ~~ ' / + \ I N~,O,/
S
O N ~ 0 F
\ ~ O /
I N
\ N ~N I \
N / ~ NH
Step A: (S)-2-Benzylpiperazine~ At ice-bath temperature, lithium aluminium hydride (1.6 g, 42.16 mmol) was added in portions to a stirring mixture of (S)-2-benzylpiperazine-3,6-dione (3.0 g, 14.70 mmol) ,.(comm. avail.) and tetrahydrofuran (80 ml). After 30 min at ice-bath temperature, the mixture was refluxed for 4 h with stirring. The reaction was quenched by the portionwise addition of sodium sulfate decahydrate and some methanol until hydrogen evolution ceased. It was filtered and the solids were washed several times with - dichloromethane. The combined filtrates were evaporated " , to leave a white solid.MS (m/z) : 177.1 (M+H)'; CI1H16Nz requir. 176.3.
Step B: 2-((S)-3-Benzvlpiperaziny)-5-(4-fluorophenvl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride:

WO 98/24780 PCT/US9'7/22949 A mixture of crude 5-(4-fluorophenyl)-3-methyl-2-methylsulfonyl-6-(4-pyridyl)-4(3H)-pyrimidinone (434 mg, 1.21 mmol) and (S)-2-benzylpiperazine_(426 mg, 2.42 mmol) was heated at 105°C for 1 h. The crude reaction product was purified by column chromatography on silica gel (dichloromethane - methane = 93 . 7; dichloromethane methanol - conc. ammonium hydroxide = 93 . 7: 0.7).
The resulting material was converted into its hydrochloride by the addition of 4N hydrogen chloride/dioxane (75 ~.1) to its methanolic solution (3 ml) followed by evaporation. MS (m/z): 456.5 (M+H)';
Cz.,Hz6FN50 requir. 455.5 (free base) .
Example 42 Procedure for the preparation of 5-(4-fluorophenyl)-3-methyl-2- (3-phenylpropoxy) -6- (4-pyridyl) -4 (3H) -pyrimidinone F

\ I
I N
N ~0 \
N
5-(~-fluorophenyl)-3-methyl-2-(3-phenylpropoxy) 6 (4 ~~,~-idyl)-4(3H)-pyrimidinone: Sodium hydride (60~ oily __ suspension, 111 mg, 2.79 mmol) was added to a stirred solution of 3-phenylpropanol (387 mg, 2.85 mmol) in tetrahydrofuran (1 ml). After gas evolution ceased, 5-(4-fluorophenyl)-3-methyl-2-methylsulfonyl-6-(4-pyridyl)-4(3H)-pyrimidinone (100 mg, 0.279 mmol) was added and the mixture was heated at 60°C for 30 min.
The reaction mixture was partitioned between dichloromethane and water. The organic solution was washed with brine, dried and evaporated. Column chromatography on silica gel (hexane - ethyl acetate = 2 . 1) provided the title compound. MS (m/z): 416.1 (M+H)+; C25H22FN302 requir. 415.5.

Example 43 Procedure for the preparation of 5-(4-fluorophenyl)-3 methyl-2- (4-phenylbutyl) -6- (4-pyridyl) -4 (3H) pyrimidinone F
/
Step A: 5-(4-Fluorophenvl)-2-(4-phenylbutyl)-6-(4-pyridyl)-4~3H)-pyrimidinone: Ethyl 2-(4-fluorophenyl)-3-oxo-3-(4-pyridyl)-propionate (293 mg, 1.02 mmol), 4-phenylbutanecarboxamidine (315 mg, 1.79 mmol) and pyridinium p-toluenesulfonate (10 mg) were suspended in p-xylene (10 ml). With efficient stirring, the mixture was heated to reflux using a Dean-Stark apparatus with continuous removal of water. After 16 h, the solvent was evaporated and the product purified by column chromatography on silica gel (3~
methanol/dichloromethane) followed by recrystallization from acetone. MS (m/z): 400.3 (M+H)+; C25H22FN30 requir.
399.5.
Step B: 5-(4-Fluorophenyl)-3-methyl-2-(4-phenylbutyl)-6-(4-pyridyl)-4(3H)-pyrimidinone: Methyl iodide (22 ~,1, 0.351 mmol) was added to a stirring mixture of 5-(4-fluorophenyl)-2-(4-phenylbutyl)-6-(4-pyridyl)-4(3H)-pyrimidinone (140 mg, 0.351 mmol) and potassium carbonate (49 mg, 0.351 mmol) in N,N-dimethylformamide (5 ml). After 75 min, it was evaporated and the resultant product purified on a silica gel column (hexane - acetone = 3 . 1; 2 . 1) to provide the title -compound. MS (m/z): 414.3 (M+H)+; C26H24FN30 requir.
413.5.

Example 44 The compounds shown in Table I were prepared using the procedures of Examples 1-43.
TABLE I
F
O F I \ O
/ N
C 1 / I N' I \ N N I \ I \ N~N ./

MS (m/~): 464.0 (M)+; MS (m/z): 479.7 (M)+;
C25H23FN50 requir. 463.9 C2gH26FN50 requir. 479.6 F \ O F I \ O
N' / N
I \ N~N \ Cl \ ~ N~N
N / H NH2 ~Cl N ~ H NH2 MS (m/z): 498.0 (M)+; MS (m/z): 416.1 (M+H)+;
C25H2~FN50 requir. 498.4 C24H22FN50 requir. 415 F
O F ( ~ O
N~ / N
N~N ~ I \ N~N~Sw N H NH2 ~Cl N J H NH

MS (m/z): 464.1 (M)+; MS (m/z): 414.0 (M+H)+;
C25H~3C1FN50 requir. 463.9 C21H24FN50S requir. 413.5 F
O F I \ O
/ N
F / N
N~N _ ~ \ I \ I N~N _ N / H NH2 ~ N / H NH2 MS (m/z): 448.3 (M+H)+; MS (m/z): 436.2 (M+H)+;
C25H23FzN502 requir. 447.5 C25H3pFN50 requir. 435.6 F
0 F ~ \ O
/ N, / N
N~N ~ I \ N~N ' \
N H ~2 ~F N / H HN--MS (m/z): 448.2 (M+H)+; MS (m/z): 428.1 (M+H)+;
C25H22FZN50 requir. 447.3 C25H22FN50 requir. 427.5 F I \ O F I \ 0 / N~ / N
I \ I N~N~ I I \ I \ I N~N \
N / H~~ N / H ~ I /

MS (m/z): 486.1 (M+H)+; MS (m/z): 442.1 (M+H)+;
C2~H24FN50S requir. 485.4 C26H24FN50 requir. 413.5 Example 45 The compounds shown in Table II can be prepared using the procedures of Examples 1-43, wherein R11 represents 3-methylphenyl, 3-chlorophenyl, 3-trifluoromethylphenyl, 4-fluorophenyl, 4-methylphenyl, 4-chlorophenyl and 3,4-dimethylphenyl.
TABLE II
O O

R N~ C1 R N
i \ I NON _ I ~ I \ I NON _ I
N ~ H NH2 / N ~ H NH2 Rll ONE R110N~
I \ I N~.N I \ Cl I \ I N~.N~ \
N / H NH2 / Cl N / H NH

R11 ~ ~ R11 ~ i I N ~N
I \ N~N \ C1 \ I N~N \
N ~ H NH2 ~ N / H NH2 I N
11 ~ 11 \ I J~~ \ R I JL
I~ N N __ ~ I \ N N _= I \

Rll O ~ Rll I N I ~N
I \ N~N I \ I \ N~~N I \
N / H NH' ~F N / H HN--WO 98/2478(1 PCT/US97/22949 11 O R11 O i R I N~ F N
I \ N~N -_ ~I ~\ I \ I N~N I \
N ~ H NH2 " F N / H NH I /

R11 O ~ R11 O ~
I N _ I ~IV
I \ N~N lI \ I \ N~N _ N / H NH2 ~CN N / H NH2 \ I N J~ N _ \ I JL _ I = - I N N _ I S

\ INS . \ I ~ _ I N I N N _ N / H ~2 N y NH N / H NH

O O
Rll ~ Rll \ I N~N \ \ I \ I N~N _ I
N / H ~2 I / / N / H

Example 46 Procedure for the preparation of 3-methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(3-trifluoromethyl phenyl)-6-(4-pyridyl ) -4 (3H) -pyrimidinone F
Stets A. 6-(4-pyridyl)-2-thiouracil: Ethyl isonicotinoylacetate (5g, 25.89 mmol) and thiourea (5.94 g, 77.64 mmol) were suspended in anhydrous p-xylene (100m1) with vigorous stirring. To the mixture, pyridinium p-toluenesulfonate (150mg) was added and refluxed for 12-16 h using a Dean-Stark apparatus with continuous removal of water (0.5m1). The reaction mixture was cooled and a dark brown solid was filtered.
The collected solid was suspended in acetone (25 ml) and filtered. The acetone washed product contain trace of thiourea, which was removed by trituration with hot water (20-30m1). The title compound was isolated by filtration. MS (m/z): 206.2 C9H~N30S requir. 205.3. 1H-NMR (DMSO-d6): d 12.65 (bm, 2H, NH and SH), 8.71(m, 2H, pryid.), 7.66(m, 2H, Pyrid.), 6:25 (s, 1H, H-5).
Step B. 3-Methyl-6-(4-pyridyl)-2-methylthio-4(3H)-pvrimidinone: 6-(4-Pyridyl)-2-thiouracil (1.5g 7.299 mmol) was dissolved in DMF (50 ml) and the mixture was cooled to 0°C. Sodium hydride (0.437 g, 0.7308 60~ in oil, 18.25 mmol) was added and the reaction mixture was stirred for 30 minutes. Methyl iodide (1.2 ml, 2.68, 18.25 mmol) was added dropwise over 15 minutes.
Formation of dimethyl compound was monitored by TLC.
Reaction mixture was concentrated and the residue chromatographed on silica gel column using hexane:
acetone (9:1, 4:1 and 2:1) to obtain the title compound as a solid: MS (m/z) :234.1 CIlHmN30S requir. 233 .2; 1H-NMR(CDCls):d 8.75 (m, 2H, pyridyl), 7.8 (m, 2H, pyridyl), 6.75 (s, 1H), 3.58 (s, 3H, N-CH3), 2.72 (s, 3H, S-CHI) .
Stets C. 3-Methyl-5-bromo-6-(4-pyridyl)-2-methylthio-4(3H)-pvrimidinone: 3-Methyl-6-!4-pyridyl)-2-methylthio-4(3H)-pyrimidinone (1.008 4.29 mmol) was dispersed in acetic acid (24 ml) and to the clear solution Bromine (0.5m1, 1.58 9.38 mmol) was added. The reaction mixture stirred at room temperature for 24 h. The mixture was concentrated and the residue was co-evaporated with toluene until all bromine is removed. The crude _ compound is ready to use in next step. MS(m/z): 312 and 314 . C11H1oBrN30S requir . 311 and 313 . 1H-NMR ( DMSO-d6 ) : d 8.75 (m, 2H, pyridyl) 8.19 (m, 2H, pyridyl), 3.67 (s, 3H, N-CH3) , 2.80 (s, 3H, S-CH3) .

Step D. 3-Methyl-5-(3-trifluoromethylphenyl)-6-(4-pyridyl)-2-thiomethyl-4(3H)-pvrimidinone: 3-Methyl-5-bromo-6-(4-pyridyl)-2-methylthio-4(3H)-pyrimidinone (1.2g, 3.8 mmol) was dipersed in 2M sodium carbonate solution (30 ml) and the pale yellow colour of the adhered bromine disappeared to give colourless precipitate in the reaction mixture. 3-Trifluromethylbenzene boronic acid (1.00 g, 5.27 mmol) and toluene (30m1) were added to the above mixture and the reaction mixture was degassed. Tetrakis triphenyl phosphine Pd(0) {350 mg) was added. The reaction mixture was refluxed for 8-12h. The formation of the product was monitored by TLC. The mixture was cooled, diluted with toluene(20m1) and washed with water. The organic layer was dried over sodium sulfate, concentrated and product isolated by silica gel chromatgraphy to give the titled compoud. MS (m/z) : 378.4 C18H14F3N30S requir.
377.39; 1H-NMR(CDCl~):d 8.5 (m, 2H, pyridyl), 7.45 (s,lH), 7.17-7.25 (m, 3H, pyridyl and Ph-CF3), 6.95 (d, 2 0 1H, Ph-CF3 ) , 3 . 67 (N-CH3 ) , 2 . 8 ( S-CH3 ) .
Step E. 3-methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(3-trifluoromethylphenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone: 3-Methyl-5-(3-trifluoromethylphenyl)-6-(4-pyridyl)-2-thiomethyl-4(3H)-pyrimidinone (0.7g, 1.85 mmol) and (S)-2-amino-3-phenyl-1-propylamine {0.9 ml, 6.00 mmol) were mixed in a round bottom flask and heated at 185°C for 3h. The mixture was separated on silica gel (dichloromethane: methanol: ammonium hydroxide 92:7:1) to obtain compound titled compound. MS(m/z):
480, CZ6HZaF3N50 requir 479.51; 1H-NMR(CDC13) :d 8.49 (m, 2H, pyridyl), 7.51-7.17 (m, 11H, Ph and pyridyl), 5.81 {bm, 1H, NH), 3.91 (m, 1H, CH), 3.53 (s, 3H, N-CHI), 3 .35 (m, 2H, CHz) , 2.94 {dd, 1H, CHZ) , 2.82 (dd, 1H, CHZ ) .

Exa~m~ple 47 Using the corresponding starting materials, the following compounds of Table III were prepared using the procedure for 3-methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(3-trifluoromethylphenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone.
TABLE III

MS (m/z) 4-tolyl 2(S)-amino-3-phenyl-propyl 426 4-trifluoromethyl 2(S)-amino-3-phenyl-propyl 480 phenyl 3-isopropylphenyl 2(S)-amino-3-phenyl-propyl 454 3-chloro-4-fluoro 2(S)-amino-3-phenyl-propyl 464 phenyl 3,5-bis(trifluoro 2(S)-amino-3-phenyl-propyl 548 methyl)phenyl 3,4-dichloro 2(S)-amino-3-phenyl-propyl 482 phenyl 1-naphthyl 2(S)-amino-3-phenyl-propyl 462 3-fluorophenyl 2(S)-amino-3-phenyl-propyl 430 3-chlorophenyl 2(S)-amino-3-phenyl-propyl 3-methylphenyl 2(S)-amino-3-phenyl-propyl 4-chlorophenyl 2(S)-amino-3-phenyl-propyl 2-chlorophenyl 2(S}-amino-3-phenyl-propyl 2-thienyl 2(S)-amino-3-phenyl-propyl 3,4-dimethylphenyl 2(S)-amino-3-phenyl-propyl 440.6 3,5-dichloro 3-phenylpropyl 467 phenyl 4-tolyl 3-phenylpropyl 411 3-trifluoromethyl 3-phenylpropyl 465 . phenyl 4-methoxyphenyl 3-phenylpropyl 427 4-trifluoromethyl 3-phenylpropyl 465 phenyl 3-chlorophenyl 3-phenyl-propyl 3-methylphenyl 3-phenyl-propyl 4-chlorophenyl 3-phenyl-propyl 2-chlorophenyl 3-phenyl-propyl 3-nitrophenyl 3-phenyl-propyl 3-methoxyphenyl 3-phenyl-propyl 2-fluorophenyl 3-phenyl-propyl benzothienyl 3-phenyl-propyl 3-fluorophenyl 2-methyl-3-phenyl-propyl 429 1-naphthyl 2-methyl-3-phenyl-propyl 461 3-trifluoromethyl 2(S)-dimethylamino-phenyl 3-phenylpropyl 3-methylphenyl 2(S)-dimethylamino-3-phenylpropyl 3-chlorophenyl 2(S)-N,N-dimethylamino-3-phenylpropyl 3-nitrophenyl 2(S)-N,N-dimethylamino-3-phenylpro~yl 3-methoxyphenyl 2(S)-N,N-dimethylamino-3-phenylpropyl 2-fluorophenyl 2(S)-N,N-dimethylamino-3-phenylpropyl 3-trifluoromethyl (S)-tetrahydroisoquinol-3- 492.1 phenyl ylmethylenamino 3-methylphenyl (S)-tetrahydroisoquinol-3- 438 ylmethylenamino 3,4-dimethylphenyl 3-amino-3-phenylpropylamine 440.6 3-methylphenyl 3-amino-3-phenylpropylamine benzothienyl 3-amino-3-phenylpropylamine benzofuranyl 3-amino-3-phenylpropylamine Example 48 3-Methyl-5-(4-methylsulfinylphenyl)-6-(4-pyridyl) 2 thiomethvl-4(3H)-pyrimidinone: The title compound was prepared in the ng manner of example 4-34-D substituti methylsulfinylbenzene boronic acid for trifluoromethylbenzene boronic.

Example 4s 3-methyl-2-(3(S)-(1 2 3 4-tetrahydroisoctuinolinyl)methyl amino)-5-(4-methvlthiophenvl)-6-(4-pvridvl)-4(3H) pyrimidinone: The title compound was prepared in the manner of example 34 step D with the following substitutions of 3-methyl-5-(4-methylsulfinylphenyl)-6-(4-pyridyl)-2-thiomethyl-4(3H)-pyrimidinone for 3-methyl-5-(3-trifluoromethylphenyl)-6-(4-pyridyl)-2-thiomethyl-4(3H)-pyrimidinone and 3(S)-(1,2,3,4-tetrahydroisoquinolinyl)methylamine for (S)-2-amino-3-phenyl-1-propylamine: MS (m/z) 470 (M+H)+.

Example 50 3-methyl-2-(3(S)-(1.2,3,4-tetrahvdroisoauinolinvl)methvl - amino)-5-(4-methylsulfonvlphenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone: To a solution of 3-methyl-2-(3(S)-(1,2,3,4-tetrahydroisoquinolinyl)methylamino)-5-(4-methylthiophenyl).-6-(4-pyridyl)-4(3H)-pyrimidinone (50 ' mg, 0.11 mmol) in methanol: water (15 mL:lO mL) was added oxone (127 mg, 0.21 mmol) as a solid in one portion at 23°C. After 16 h, the reaction was concentrated under a stream of nitrogen. The reaction mixture was applied directly to purification via preparative plate chromatography (3 silica gel 2mm thick plates; 5~
methanol in methylene chloride) to afford the title compound . MS (m/z) 502 (M+H)+.
Example 51 -2-(((S)-3-Amino-3-phenvlpropvl)-amino)-3-methyl-6=l4-pyridyl)-5-(3-trifluoromethylphenyl)-4(3H)-pyrimidinone hydrochloride was prepared from 3-methyl-2-methylthio-6-(4-pyridyl)-5-(3-trifluoromethylphenyl)-4(3H)-pyrimidinone and (S)-1-phenyl-1,3-propanediamine according to the General Procedure. The reaction was at 190°C for 1 h. MS (m/z) : 480.0 (M+H)'; CZ6HZaF~NsO requir.
479.5 (free base).
Example 52 2-(((R)-3-Amino-3-phenvlpropvl)-amino)-3-methyl-6-~4-pyridvl)-5-(3-trifluoromethvlphenyl)-4(3H)-pyrimidinone hydrochloride was prepared from 3-methyl-2-methylthio-6-(4-pyridyl)-5-(3-trifluoromethylphenyl)-4(3H)-pyrimidinone and (R)-1-phenyl-1,3-propanediamine according to the General Procedure. The reaction was done at 190°C for 3.5 h. MS (m/z) : 480.4 (M+H)'; CZ6Hz4F,N50 requir. 479.5 (free base).

Exaanple 53 Procedure for the preparation of 2-chloro-3-methyl-5-(3 methylphenyl ) -6- (4-pyridyl ) -4 (3H) -pyrimidinone O / I O / I O
N~ ~ i ~ i ---~ N ~N
N~S/ I ~ I N~OH ~ I ~ I N~C1 N / N~ NJ
Step A: 3-Methyl-5-(3-methylphenyl)-6-(4-pyridyl) 2,4(1H,3H)-pyrimidindione: 10 N Sodium hydroxide (25 ml) and water (50 ml) was added to a solution of 3-methyl-5-(3-methylphenyl)-2-methylthio-6-(4-pyridyl)-4(3H)-pyrimidindione (16.17 g, 0.05 mol) in dixoxane (65 ml). The mixture was heated at 80°C for 16 h under argon. The mixture was allowed to reach room temperature and the pH value was adjusted to 9 with 1 N
hydrochloric acid. The precipitate was filtered, washed with water and dried to give the title compound. MS
(m/z) : 292 (M-H)+; C1~H15N302 requir. 293.3.
Step B: 2-Chloro-3-methyl-5-(3-methylphenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone: A mixture of 3-methyl-5-(3-methylphenyl)-6-(4-pyridyl)-2,4(1H,3H)-pyrimidindione (12.5 g, 0.043 mol) and phosphorus oxychloride (65 ml) was refluxed for 16 h. The excess of phosphorus oxychloride was evaporated followed by co-distillation with toluene. The remainder was carefully partitioned between dichloromethane and aqueous sodium hydrogencarbonate. The organic solution was washed with water, dried and evaporated to leave the title compound.
- MS (m/z) : 312 (M)+; C1~H14C1N30 requir. 311.8.
2-Chloro-3-methyl-6-(4-pvridyl)-5-(3-trifluoromethylphenyl)-4(3H)-pyrimidinone was prepared according to the same procedure.

Example 54 Procedure for the preparation of 2-(((S)-2-amino-3-- phenylpropyl) -amino) -3-methyl-5- (3-methylphenyl) -6- (4-pyridyl) -4 (3H) -pyrimidinone hydrochloride 1 NH2 \ I
2-(((S)-2-Amino-3-phenylpropyl)-amino)-3-methyl-5-(3-methylphenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride: A solution of 2-chloro-3-methyl-5-(3-methylphenyl}-6-(4-pyridyl)-4(3H)-pyrimidinone (3.34 g, 10.71 mmol) and (S)-1-benzyl-1,2-ethanediamine (2.3 g, 15.31 mmol} in ethanol (50 ml) was stirred at room temperature for 16 h. The solvent was evaporated and the crude product recrystallized from methanol. MS
(m/z) : 426 (M+H)+; C26H2~N5O requir. 425.5 (free base) .
Example 55 Procedure for the preparation of 2-((3-amino-2,2-dimethyl-3-phenylpropyl)-amino)-3-methyl-5-(3-methylphenyl) -6- (4-pyridyl) -4 (3H) -pyrimidinone hydrochloride O
\I
I N ~2 N ~ H
2-((-3-.Amino-2 2-dimethyl-3-phenylpropvl)-amino)-3-- methyl-5-(3-methvlphenyl)-6-(4-pvridvl)-4(3H)-pvrimidinone hydrochloride: A solution of 2-chloro-3-methyl-5-(3-methylphenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone (228 mg, 0.73 mmol) and 3-phenyl-2,2-' dimethyl-1,3-propanediamine (178 mg, 1 mmol} (prepared according to: W. Ten Hoeve and H. Wynberg, Synth. Commun.

24 (15), 2215-2221, 1994) in ethanol (4 ml) was stirred at room temperature for 16 h. The solvent was evaporated and the crude product purified by column chromatography on silica gel. MS (m/z): 454 (M+H)+;
C2gH31N50 requir. 453.6 (free base).
Accordingly, 2-((-3-Amino-2 2-dimethyl-3-phenylpropyl) amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethyl phenyl)-4(3H)-pyrimidinone hydrochloride was prepared.
MS {m/z) : 508 (M+H)'; CzeHz8F3N50 requir. 507. 6 (free base) .
Example 56 Procedure for the preparation of ~-(((S)-3-amino-3-phenylpropyl ) -amino) -3-methyl-6- (4-pyridyl ) -5- (3-trifluoromethylphenyl)-4(3H)-pyrimidinone hydrochloride O
N~ NH2 N~N
N / H \ I
2-(((S)-3-Amino-3-phenvlpropyl)-amino)-3-methyl-6-(4 pyridvl)-5-(3-trifluoromethvlphenvl)-4(3H)-pyrimidinone hydrochloride: Aqueous sat. sodium carbonate (2 ml) was ad~ed to a solution of 2-chloro-3-methyl-6-(4-pyridyl)-_-c3-trifluoromethylphenyl)-4(3H)-pyrimidinone hydrochloride (730 mg, 2 mmol) and (S)-1-phenyl-1,3-propanediamine {360 mg, 2.4 mmol) in ethanol (10 ml).
The mixture was stirred for 4 h at room temperature. It was evaporated and the remainder partitioned between dichloromethane and water. The organic solution was dried and evaporated followed by column chroatography on silica gel (dichloromethane . methanol . conc. ammonium hydroxide = 93 . 7 . 0.7). MS (m/z): 480 (M+H)';
C26HZQF3N5O requir. 479.5 (free base) .

Examwple 57 Procedure for the preparation of 3-methyl-2-methylthio 5- (3-methylphenyl) -6- (4-pyridyl) -4 (3H) -pyrimidinone _ ~ O
\I
_ I N
N~SCH3 N
3-Methyl-2-methvlthio-5-(3-methylphenyl)-6-(4-pyridyl)-4(3Fi)-pyrimidinone: A solution of potassium t-butoxide (1M in t-butanol, 11, 1 mol) was added dropwise to a stirring solution of ethyl 3-methylphenyl acetate (178 g, 1 mol) in N,N-dimethylformamide (2 1). A solution of 4-cyanopyridine (104.11 g, 1 mol) in N,N-dimethylformamide (1 1) was pumped into the reaction mixture over a period of about 4.5 h. The mixture was then stirred at room temperature for 3 h, before the dropwise addition of a solution of methyl isothiocyanate (68.4 ml, 1 mol) in N,N-dimethylformamide (50 ml) over a period of 10 min. After stirring for 1 h at room temperature, the reaction mixture was cooled to 3 C and methyl iodide (62.3 ml, 1 mol) was added dropwise over a period of 10 min. Stirring was continued at room temperature overnight. The mixture was cooled to 3 C
and water (4 1) was pumped into the reaction mixture over a period of 6 h. The precipitate was removed by filtration, washed with water and dried in a vacuum oven to give the title compound. MS (m/z): 324 (M+H)';
C18H1~N30S requir. 323.4.
~xaa~ple 58 Using the corresponding starting materials, the following compounds of Table IV may be prepared using the procedure for 6-(4-fluorophenyl)-2-methyl-1-(3-phenylpropyl)-7-pyridin-4-yl-1H-imidazo(1,2-a)pyrimidin-5-one. The required pyrimidinones with the varied R'~

WO 98/24780 PCT/tJS97/22949 substituents can be prepared using the general procedures described above.
TABLE IV
O
R11 ~ ''N[ /
N~N
N, J R21 Rll 3,5-dichlorophenyl 2(S)-amino-3-phenyl-propyl 4-methoxyphenyl 2(S)-amino-3-phenyl-propyl 3-tolyl 2(S)-amino-3-phenyl-propyl 3-chlorophenyl 2(S)-amino-3-phenyl-propyl 4-fluorophenyl 2(S)-amino-3-phenyl-propyl 2-naphthyl 2(S)-amino-3-phenyl-propyl n-butyl 2(S)-amino-3-phenyl-propyl 2-thiophene 2(S)-amino-3-phenyl-propyl 3-thiophene 2(S)-amino-3-phenyl-propyl 3-aminophenyl 2(S)-amino-3-phenyl-propyl 2-(5-chlorothiophene) 2(S)-amino-3-phenyl-propyl 3-isopropylphenyl 3-phenylpropyl 3-tolyl 3-phenylpropyl 3-chlorophenyl 3-phenylpropyl 3-chloro-4-fluorophenyl 3-phenylpropyl 3,5-Ditrifluoromethylphenyl 3-phenylpropyl 4-fluorophenyl 3-phenylpropyl 3,4-dichlorophenyl 3-phenylpropyl 1-naphthyl 3-phenylpropyl 3-fluorophenyl 3-phenylpropyl 2-naphthyl 3-phenylpropyl n-butyl 3-phenylpropyl '2-thiophene 3-phenylpropyl 3-thiophene 3-phenylpropyl 3-aminophenyl 3-phenylpropyl 2-(5-chlorothiophene) 3-phenylpropyl 3,5-dichlorophenyl 3-methyl-3-phenyl-propyl 4-tolyl 3-methyl-3-phenyl-propyl 3-trifluoromethylphenyl 3-methyl-3-phenyl-propyl 4-methoxyphenyl 3-methyl-3-phenyl-propyl 4-trifluoromethylphenyl 3-methyl-3-phenyl-propyl 3-isopropylphenyl 3-methyl-3-phenyl-propyl 3-tolyl 3-methyl-3-phenyl-propyl 3-chlorophenyl 3-methyl-3-phenyl-propyl 3-chloro-4-fluorophenyl 3-methyl-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 3-methyl-3-phenyl-propyl 4-fluorophenyl 3-methyl-3-phenyl-propyl 3,4-dichlorophenyl 3-methyl-3-phenyl-propyl 2-naphthyl 3-methyl-3-phenyl-propyl n-butyl 3-methyl-3-phenyl-propyl 2-thiophene 3-methyl-3-phenyl-propyl 3-thiophene 3-methyl-3-phenyl-propyl 3-aminophenyl 3-methyl-3-phenyl-propyl 2-(5-chlorothiophene) 3-methyl-3-phenyl-propyl 3,5-dichlorophenyl 3-amino-3-phenyl-propyl 4-tolyl 3-amino-3-phenyl-propyl 3-trifluoromethylphenyl 3-amino-3-phenyl-propyl ' 10 4-methoxyphenyl 3-amino-3-phenyl-propyl 4-trifluoromethylphenyl 3-amino-3-phenyl-propyl 3-isopropylphenyl 3-amino-3-phenyl-propyl 3-tolyl 3-amino-3-phenyl-propyl 3-chlorophenyl 3-amino-3-phenyl-propyl 3-chloro-4-fluorophenyl 3-amino-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 3-amino-3-phenyl-propyl 4-fluorophenyl 3-amino-3-phenyl-propyl 3,4-dichlorophenyl 3-amino-3-phenyl-propyl 1-naphthyl 3-amino-3-phenyl-propyl 3-fluorophenyl 3-amino-3-phenyl-propyl 2-naphthyl 3-amino-3-phenyl-propyl n-butyl 3-amino-3-phenyl-propyl 2-thiophene 3-amino-3-phenyl-propyl 3-thiophene 3-amino-3-phenyl-propyl 3-aminophenyl 3-amino-3-phenyl-propyl 2-(5-chlorothiophene) 3-amino-3-phenyl-propyl 3,5-dichlorophenyl 2(R)-amino-3-phenyl-propyl 4-tolyl 2(R)-amino-3-phenyl-propyl 3-trifluoromethylphenyl 2(R)-amino-3-phenyl-propyl 4-methoxyphenyl 2(R)-amino-3-phenyl-propyl 4-trifluoromethylphenyl 2(R)-amino-3-phenyl-propyl 3-isopropylphenyl 2(R)-amino-3-phenyl-propyl 3-tolyl 2(R)-amino-3-phenyl-propyl 3-chlorophenyl 2(R)-amino-3-phenyl-propyl 3-chloro-4-fluorophenyl 2(R)-amino-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 2(R)-amino-3-phenyl-propyl 4-fluorophenyl 2(R)-amino-3-phenyl-propyl 3,4-dichlorophenyl 2(R)-amino-3-phenyl-propyl 1-naphthyl 2(R)-amino-3-phenyl-propyl 3-fluorophenyl 2(R)-amino-3-phenyl-propyl 2-naphthyl 2(R)-amino-3-phenyl-propyl n-butyl 2(R)-amino-3-phenyl-propyl 2-thiophene 2(R)-amino-3-phenyl-propyl 3-thiophene 2(R)-amino-3-phenyl-propyl 3-aminophenyl 2(R)-amino-3-phenyl-propyl 2-(5-chlorothiophene) 2(R)-amino-3-phenyl-propyl 3,5-dichlorophenyl 2-methyl-2-amino-3-phenyl-propyl 4-tolyl 2-methyl-2-amino-3-phenyl-propyl 3-trifluoromethylphenyl 2-methyl-2-amino-3-phenyl-propyl 4-methoxyphenyl 2-methyl-2-amino-3-phenyl-propyl 4-trifluoromethylphenyl 2-methyl-2-amino-3-phenyl-_ propyl 3-isopropylphenyl 2-methyl-2-amino-3-phenyl-propyl 3-tolyl 2-methyl-2-amino-3-phenyl-propyl 3-chlorophenyl 2-methyl-2-amino-3-phenyl-propyl 3-chloro-4-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 2-methyl-2-amino-3-phenyl-propyl 4-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl 3,4-dichlorophenyl 2-methyl-2-amino-3-phenyl-propyl 1-naphthyl 2-methyl-2-amino-3-phenyl-propyl 3-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl 2-naphthyl 2-methyl-2-amino-3-phenyl-propyl n-butyl 2-methyl-2-amino-3-phenyl-propyl 2-thiophene 2-methyl-2-amino-3-phenyl-propyl 3-thiophene 2-methyl-2-amino-3-phenyl-propyl 3-aminophenyl 2-methyl-2-amino-3-phenyl-propyl 2-(5-chlorothiophene) 2-methyl-2-amino-3-phenyl-propyl 3,5-dichlorophenyl 2-methyl-3-phenyl-propyl 4-tolyl 2-methyl-3-phenyl-propyl 3-trifluoromethylphenyl 2-methyl-3-phenyl-propyl 4-methoxyphenyl 2-methyl-3-phenyl-propyl 4-trifluoromethylphenyl 2-methyl-3-phenyl-propyl 3-isopropylphenyl 2-methyl-3-phenyl-propyl 3-tolyl 2-methyl-3-phenyl-propyl 3-chlorophenyl 2-methyl-3-phenyl-propyl 3-chloro-4-fluorophenyl 2-methyl-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 2-methyl-3-phenyl-propyl 4-fluorophenyl 2-methyl-3-phenyl-propyl 3,4-dichlorophenyl 2-methyl-3-phenyl-propyl 1-naphthyl 2-methyl-3-phenyl-propyl 3-fluorophenyl 2-methyl-3-phenyl-propyl 2-naphthyl 2-methyl-3-phenyl-propyl n-butyl ~ 2-methyl-3-phenyl-propyl 2-thiophene 2-methyl-3-phenyl-propyl 3-thiophene 2-methyl-3-phenyl-propyl 3-aminophenyl 2-methyl-3-phenyl-propyl 2-(5-chlorothiophene) 2-methyl-3-phenyl-propyl 3,5-dichlorophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 4-tolyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3-trifluoromethylphenyl 2-(N,N-dimethylamino}-3-phenyl-propyl 4-methoxyphenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 4-trifluoromethylphenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3-isopropylphenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3-tolyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3-chlorophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3-chloro-4-fluorophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 4-fluorophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3,4-dichlorophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 1-naphthyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3-fluorophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 2-naphthyl 2-(N,N-dimethylamino)-3-phenyl-propyl n-butyl 2-(N,N-dimethylamino)-3-phenyl-propyl 2-thiophene 2-(N,N-dimethylamino)-3-phenyl-propyl 3-thiophene 2-(N,N-dimethylamino)-3-phenyl-propyl 3-aminophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 2-(5-chlorothiophene) 2-(N,N-dimethylamino)-3-phenyl-propyl 3,5-dichlorophenyl 2-(N-methylamino)-3-phenyl-propyl 4-tolyl 2-(N-methylamino)-3-phenyl-propyl 3-trifluoromethylphenyl 2-(N-methylamino)-3-phen 1 y -propyl 4-methoxyphenyl 2-(N-methylamino)-3-phenyl-propyl 4-trifluoromethylphenyl 2-(N-methylamino)-3-h y 3-isopropylphenyl 2 (N
mephylamino)-3-phenyl-propyl 3-tolyl 2-(N-methylamino)-3-phenyl-propyl 3-chlorophenyl 2-(N-methylamino)-3-phenyl-propyl 3-chloro-4-fluorophenyl 2-(N-methylamino)-3-h y 3,5-Ditrifluoromethylphenyl 2 (N
mephylamino)-3-h y 3,4-dichlorophenyl 2 (N
methylamino)-3-phenyl-propyl 4-fluorophenyl 2-(N-methylamino)-3-phenyl-propyl 1-naphthyl 2-(N-methylamino)-3-phenyl-propyl 3-fluorophenyl 2-(N-methylamino)-3-h y 2-naphthyl 2 (N
mephypamino)-3-phenyl-propyl n-butyl 2-(N-methylamino)-3-h y 2-thiophene . p (N
mephypamino)-3-phenyl-propyl 3-thiophene 2-(N-methylamino)-3-phenyl-propyl 3-aminophenyl 2-(N-methylamino)-3-phenyl-propyl 2-(5-chlorothiophene) 2-(N-methylamino)-3-phenyl-propyl Exaraple 59 The compounds in table V can be prepared using the appropriate starting materials and the following procedures: The required pyrimidinones with the varied R11 substituents can be prepared using the general procedures described above. The fused 6, 5 ring system can be prepared as described above affording R~1 as a hydrogen radical. Other R21 groups can be introduced through a reductive amination process using the corresponding aldehyde with appropriate amino protection (Boc group). For example, N-Boc-phenylalanal can be prepared from the corresponding Weinreb amide through reduction with lithium aluminum hydride as described in the literature (Konieczny and Cushman Tetrahedron Lett 6939, 1992). The N-Boc-phenylalanal can then be reacted with the amino group using sodium triacetoxyborohydride.
Alternatively, the alcohol of N-Boc-phenylalanol can be activated under Mitsunobu conditions (triphenylphosphine, diiisopropyl azodicarboxylate) and reacted with the amino group of the 6, 5 fused system followed by removal of the Boc group (trifluoroacetic acid).

TABLE V
O

N~N

Rll Rz i 3,5-dichlorophenyl 2(S)-amino-3-phenyl-propyl 4-methoxyphenyl 2(S)-amino-3-phenyl-propyl 3-tolyl 2(S)-amino-3-phenyl-propyl 3-chlorophenyl 2(S)-amino-3-phenyl-propyl 4-fluorophenyl 2(S)-amino-3-phenyl-propyl 2-naphthyl 2(S)-amino-3-phenyl-propyl n-butyl 2(S)-amino-3-phenyl-propyl 2-thiophene 2(S)-amino-3-phenyl-propyl 3-thiophene 2(S)-amino-3-phenyl-propyl 3-aminophenyl 2(S)-amino-3-phenyl-propyl 2-(5-chlorothiophene) 2(S)-amino-3-phenyl-propyl 3-isopropylphenyl 3-phenylpropyl 3-tolyl 3-phenylpropyl 3-chlorophenyl 3-phenylpropyl 3-chloro-4-fluorophenyl 3-phenylpropyl 3,5-Ditrifluoromethylphenyl 3-phenylpropyl 4-fluorophenyl 3-phenylpropyl 3,4-dichlorophenyl 3-phenylpropyl 1-naphthyl 3-phenylpropyl 3-fluorophenyl 3-phenylpropyl 2-naphthyl 3-phenylpropyl n-butyl 3-phenylpropyl 2-thiophene 3-phenylpropyl 3-thiophene 3-phenylpropyl 3-aminophenyl 3-phenylpropyl 2-(5-chlorothiophene) 3-phenylpropyl 3,5-dichlorophenyl 3-methyl-3-phenyl-propyl 4-tolyl 3-methyl-3-phenyl-propyl 3-trifluoromethylphenyl 3-methyl-3-phenyl-propyl 4-methoxyphenyl 3-methyl-3-phenyl-propyl 4-trifluoromethylphenyl 3-methyl-3-phenyl-propyl 3-isopropylphenyl 3-methyl-3-phenyl-propyl 3-tolyl 3-methyl-3-phenyl-propyl 3-chlorophenyl 3-methyl-3-phenyl-propyl 3-chloro-4-fluorophenyl 3-methyl-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 3-methyl-3-phenyl-propyl 4-fluorophenyl 3-methyl-3-phenyl-propyl 3,4-dichlorophenyl 3-methyl-3-phenyl-propyl 2-naphthyl 3-methyl-3-phenyl-propyl n-butyl 3-methyl-3-phenyl-propyl 2-thiophene 3-methyl-3-phenyl-propyl 3-thiophene 3-methyl-3-phenyl-propyl 3-aminophenyl 3-methyl-3-phenyl-propyl 2-(5-chlorothiophene) 3-methyl-3-phenyl-propyl 3,5-dichlorophenyl 3-amino-3-phenyl-propyl 4-tolyl 3-amino-3-phenyl-propyl 3-trifluoromethylphenyl 3-amino-3-phenyl-propyl 4-methoxyphenyl 3-amino-3-phenyl-pro 1 PY

4-trifluoromethylphenyl 3-amino-3-phenyl-propyl 3-isopropylphenyl 3-amino-3-phenyl-propyl 3-tolyl 3-amino-3-phenyl-propyl 3-chlorophenyl 3-amino-3-phenyl-pro 1 PY

3-chloro-4-fluorophenyl 3-amino-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 3-amino-3-phenyl-propyl 4-fluorophenyl 3-amino-3-phenyl-pro 1 PY

3,4-dichlorophenyl 3-amino-3-phenyl-propyl 1-naphthyl 3-amino-3-phenyl-propyl 3-fluorophenyl 3-amino-3-phenyl-pro 1 y 2-naphthyl 3-amino-3-phenyl-pro l PY

n-butyl 3-amino-3-phenyl-propyl 2-thiophene 3-amino-3-phenyl-propyl 3-thiophene 3-amino-3-phenyl-pro 1 pY

3-aminophenyl 3-amino-3 propyl P
y 2-(5-chlorothiophene) 3-amino-3 hen l -p y -propyl 3,5-dichlorophenyl 2(R)-amino-3-phenyl-propyl 4-tolyl 2(R)-amino-3 hen 1 P Y Propyl 3-trifluoromethylphenyl 2(R)-amino-3 propyl P
Y

4-methoxyphenyl l_ 2(R)-amino-3 hen propyl p y 4-trifluoromethylphenyl 2(R)-amino-3 hen l -p y -propyl 3-isopropylphenyl 2(R)-amino-3-phenyl-propyl 3-tolyl 2(R)-amino-3-phenyl-pro 1 PY

3-chlorophenyl 2(R)-amino-3-phenyl-propyl 3-chloro-4-fluorophenyl 2(R)-amino-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 2(R)-amino-3-phenyl-propyl 4-fluorophenyl 2(R)-amino-3-phenyl-propyl 3,4-dichlorophenyl 2(R)-amino-3-phenyl-propyl 1-naphthyl 2(R)-amino-3-phenyl-propyl 3-fluorophenyl 2(R)-amino-3-phenyl-propyl 2-naphthyl 2(R)-amino-3-phenyl-propyl n-butyl 2(R)-amino-3-phenyl-propyl 2-thiophene 2(R)-amino-3-phenyl-pro 1 PY

3-thiophene 2(R)-amino-3-phenyl-propyl 3-aminophenyl 2(R)-amino-3-phenyl-propyl 2-(5-chlorothiophene) 2(R)-amino-3-phenyl-propyl 3,5-dichlorophenyl 2-methyl-2-amino-3-phenyl-propyl 4-tolyl 2-methyl-2-amino-3-phenyl-propyl 3-trifluoromethylphenyl 2-methyl-2-amino-3-phenyl-propyl 4-methoxyphenyl 2-methyl-2-amino-3-phenyl-propyl 4-trifluoromethylphenyl 2-methyl-2-amino-3-phenyl-propyl 3-isopropylphenyl 2-methyl-2-amino-3-phenyl-propyl 3-tolyl 2-methyl-2-amino-3-phenyl-propyl 3-chlorophenyl 2-methyl-2-amino-3-phenyl-propyl 3-chloro-4-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl.

3,5-Ditrifluoromethylphenyl 2-methyl-2-amino-3-phenyl-propyl 4-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl 3,4-dichlorophenyl 2-methyl-2-amino-3-phenyl-propyl 1-naphthyl 2-methyl-2-amino-3-phenyl-propyl 3-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl 2-naphthyl 2-methyl-2-amino-3-phenyl-propyl n-butyl 2-methyl-2-amino-3-phenyl-propyl 2-thiophene 2-methyl-2-amino-3-phenyl-propyl 3-thiophene 2-methyl-2-amino-3-phenyl-propyl 3-aminophenyl 2-methyl-2-amino-3-phenyl-propyl 2-(5-chlorothiophene) 2-methyl-2-amino-3-phenyl-propyl 3,5-dichlorophenyl 2-methyl-3-phenyl-propyl 4-tolyl 2-methyl-3-phenyl-propyl 3-trifluoromethylphenyl 2-methyl-3-phenyl-propyl 4-methoxyphenyl 2-methyl-3-phenyl-propyl 4-trifluoromethylphenyl 2-methyl-3-phenyl-propyl 3-isopropylphenyl 2-methyl-3-phenyl-propyl 3-tolyl 2-methyl-3-phenyl-propyl 3-chlorophenyl 2-methyl-3-phenyl-propyl 3-chloro-4-fluorophenyl 2-methyl-3-phenyl-propyl i,5-Ditrifluoromethylphenyl 2-methyl-3-phenyl-propyl _ 4-fluorophenyl 2-methyl-3-phenyl-propyl 3,4-dichlorophenyl 2-methyl-3-phenyl-propyl 1-naphthyl 2-methyl-3-phenyl-propyl 3-fluorophenyl 2-methyl-3-phenyl-propyl 2-naphthyl 2-methyl-3-phenyl-propyl n-butyl 2-methyl-3-phenyl-propyl 2-thiophene 2-methyl-3-phenyl-propyl 3-thiophene 2-methyl-3-phenyl-propyl 3-aminophenyl 2-methyl-3-phenyl-propyl 2-(5-chlorothiophene) 2-methyl-3-phenyl-propyl 3,5-dichlorophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 4-tolyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3-trifluoromethylphenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 4-methoxyphenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 4-trifluoromethylphenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3-isopropylphenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3-tolyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3-chlorophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3-chloro-4-fluorophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 2-(N;N-dimethylamino)-3-h 4-fluorophenyl p (NyN-dimethylamino)-3-phenyl-propyl 3,4-dichlorophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 1-naphthyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3-fluorophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 2-naphthyl 2-(N,N-dimethylamino)-3-phenyl-propyl n-butyl 2-(N,N-dimethylamino)-3-phenyl-propyl 2-thiophene 2-(N,N-dimethylamino)-3-phenyl-propyl 3-thiophene 2-(N,N-dimethylamino)-3-h 3-aminophenyl p (NyN-dimethylamino)-3-2-(5-chlorothiophene) ph(NyN-dimethylamino)-3-phenyl-propyl 3,5-dichlorophenyl 2-(N-methylamino)-3-phenyl-propyl 4-tolyl 2-(N-methylamino)-3-phenyl-propyl 3-trifluoromethylphenyl 2-(N-methylamino)-3-h y 4-methoxyphenyl p (N
mephylamino)-3-phenyl-propyl 4-trifluoromethylphenyl 2-(N-methylamino)-3-phenyl-propyl 3-isopropylphenyl 2-(N-methylamino)-3-phenyl-propyl 3-tolyl 2-(N-methylamino)-3-3-chlorophenyl ph(Nymephypamino)-3-phenyl-propyl 3-chloro-4-fluorophenyl 2-(N-methylamino)-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 2-(N-methylamino)-3-phenyl-propyl 3,4-dichlorophenyl 2-(N-methylamino)-3-phenyl-propyl 4-fluorophenyl 2-(N-methylamino)-3-phenyl-propyl 1-naphthyl - 2-(N-methylamino)-3-phenyl-propyl 3-fluorophenyl 2-(N-methylamino)-3-phenyl-propyl 2-naphthyl 2-(N-methylamino)-3-phenyl-propyl n-butyl 2-(N-methylamino)-3-phenyl-propyl _ 2-thiophene 2-(N-methylamino)-3-phenyl-propyl 3-thiophene 2-(N-methylamino)-3-' 10 phenyl-propyl 3-aminophenyl 2-(N-methylamino )-3-_ phenyl-propyl 2-(5-chlorothiophene) 2-(N-methylamino)-3-phenyl-propyl Example 60 The compounds in table VI can be prepared using the appropriate starting materials and procedures as described above.
TABLE VI
O
R11 I wN
N~N
N J R2i 3,5-dichlorophenyl 2(S)-amino-3-phenyl-propyl 4-methoxyphenyl 2(S)-amino-3-phenyl-propyl 3-tolyl 2(S)-amino-3-phenyl-propyl 3-chlorophenyl 2(S)-amino-3-phenyl-propyl 4-fluorophenyl 2(S)-amino-3-phenyl-propyl 2-naphthyl 2(S)-amino-3-phenyl-propyl n-butyl 2(S)-amino-3-phenyl-propyl 2-thiophene 2(S)-amino-3-phenyl-propyl 3-thiophene 2(S)-amino-3-phenyl-propyl 3-aminophenyl 2(S)-amino-3-phenyl-propyl 2-(5-chlorothiophene) 2(S)-amino-3-phenyl-propyl 3-isopropylphenyl 3-phenylpropyl 3-tolyl 3-phenylpropyl 3-chlorophenyl 3-phenylpropyl _ 3-chloro-4-fluorophenyl 3-phenylpropyl 3,5-Ditrifluoromethylphenyl 3-phenylpropyl 4-fluorophenyl 3-phenylpropyl 3,4-dichlorophenyl 3-phenylpropyl 1-naphthyl 3-phenylpropyl 3-fluorophenyl 3-phenylpropyl 2-naphthyl 3-phenylpropyl n-butyl 3-phenylpropyl 2-thiophene 3-phenylpropyl 3-thiophene 3-phenylpropyl 3-aminophenyl 3-phenylpropyl 2-(5-chlorothiophene) 3-phen-ylpropyl 3,5-dichlorophenyl 3-methyl-3-phenyl-propyl 4-tolyl 3-methyl-3-phenyl-propyl 3-trifluoromethylphenyl 3-methyl-3-phenyl-propyl 4-methoxyphenyl 3-methyl-3-phenyl-propyl 4-trifluoromethylphenyl 3-methyl-3-phenyl-propyl 3-isopropylphenyl 3-methyl-3-phenyl-propyl 3-tolyl 3-methyl-3-phenyl-propyl 3-chlorophenyl 3-methyl-3-phenyl-propyl 3-chloro-4-fluorophenyl 3-methyl-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 3-methyl-3-phenyl-propyl 4-fluorophenyl 3-methyl-3-phenyl-propyl 3,4-dichlorophenyl 3-methyl-3-phenyl-propyl 2-naphthyl 3-meth 1-3 Propyl y P
y n-butyl 3-meth l-3 hen l Y -P y -propyl 2-thiophene 3-methyl-3-phenyl-propyl 3-thiophene 3-meth 1-3 phenyl-propyl y 3-aminophenyl 3-meth l-3 phenyl-propyl y 2-(5-chlorothiophene) l-3 3-meth l propyl n 3,5-dichlorophenyl 3-amino-3 hen l -p y -propyl 4-tolyl 3-amino-3-phenyl-pro 1 PY

3-trifluoromethylphenyl 3-amino-3-phenyl-propyl 4-methoxyphenyl 3-amino-3-phenyl-propyl 4-trifluoromethylphenyl 3-amino-3-phenyl-propyl 3-isopropylphenyl 3-amino-3-phenyl-propyl 3-tolyl 3-amino-3-phenyl-propyl 3-chlorophenyl 3-amino-3-phenyl-pro 1 y 3-chloro-4-fluorophenyl 3-amino-3-phenyl-pro l PY

3,5-Ditrifluoromethylphenyl 3-amino-3-phenyl-propyl 4-fluorophenyl 3-amino-3-phenyl-pro 1 PY

3,4-dichlorophenyl 3-amino-3-phenyl-propyl :-naphthyl 3-amino-3-phenyl-pro 1 py ?-fluorophenyl 3-amino-3 Propyl P
y ..-naphthyl _._ 3-amino-3 hen l -p y -propyl n-butyl 3-amino-3-phenyl-propyl 2-thiophene 3-amino-3-phenyl-propyl 3-thiophene 3-amino-3-phenyl-propyl 3-aminophenyl 3-amino-3-phenyl-propyl 2-(5-chlorothiophene) 3-amino-3-phenyl-propyl 3,5-dichlorophenyl 2(R}-amino-3-phenyl-propyl 4-tolyl 2(R}-amino-3-phenyl-propyl 3-trifluoromethylphenyl 2(R)-amino-3-phenyl-propyl 4-methoxyphenyl 2(R)-amino-3-phenyl-propyl 4-trifluoromethylphenyl 2(R)-amino-3-phenyl-propyl 3-isopropylphenyl 2(R)-amino-3-phenyl-propyl 3-tolyl 2(R)-amino-3-phenyl-propyl 3-chlorophenyl 2(R)-amino-3-phenyl-propyl 3-chloro-4-fluorophenyl 2(R)-amino-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 2(R)-amino-3-phenyl-propyl 4-fluorophenyl 2(R)-amino-3-phenyl-propyl 3,4-dichlorophenyl 2(R)-amino-3-phenyl-propyl 1-naphthyl 2(R)-amino-3-phenyl-propyl 3-fluorophenyl 2(R)-amino-3-phenyl-propyl 2-naphthyl 2(R)-amino-3-phenyl-propyl n-butyl 2(R)-amino-3-phenyl-propyl 2-thiophene 2(R)-amino-3-phenyl-propyl a 3-thiophene 2(R)-amino-3-phenyl-propyl 3-aminophenyl 2(R)-amino-3-phenyl-propyl 2-(5-chlorothiophene) 2(R)-amino-3-phenyl-propyl 3,5-dichlorophenyl 2-methyl-2-amino-3-phenyl-propyl 4-tolyl 2-methyl-2-amino-3-phenyl-propyl 3-trifluoromethylphenyl 2-methyl-2-amino-3-phenyl-Px'oPYl 4-methoxyphenyl 2-methyl-2-amino-3-phenyl-propyl 4-trifluoromethylphenyl 2-methyl-2-amino-3-phenyl-propyl 3-isopropylphenyl 2-methyl-2-amino-3-phenyl-propyl 3-tolyl 2-methyl-2-amino-3-phenyl-propyl 3-chloroghenyl 2-methyl-2-amino-3-phenyl-propyl 3-chloro-4-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 2-methyl-2-amino-3-phenyl-propyl 4-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl 3,4-dichlorophenyl 2-methyl-2-amino-3-phenyl-propyl 1-naphthyl 2-methyl-2-amino-3-phenyl-propyl 3-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl 2-naphthyl 2-methyl-2-amino-3-phenyl-propyl n-butyl 2-methyl-2-amino-3-phenyl-propyl 2-thiophene 2-methyl-2-amino-3-phenyl-propyl 3-thiophene 2-methyl-2-amino-3-phenyl-propyl 3-aminophenyl 2-methyl-2-amino-3-phenyl-propyl 2-(5-chlorothiophene) 2-methyl-2-amino-3-phenyl-propyl 3,5-dichlorophenyl 2-methyl-3-phenyl-propyl - 4-tolyl 2-methyl-3-phenyl-propyl 3-trifluoromethylphenyl 2-methyl-3-phenyl-propyl 4-methoxyphenyl 2-methyl-3-phenyl-propyl 4-trifluoromethylphenyl 2-methyl-3-phenyl-propyl 3-isopropylphenyl 2-methyl-3-phenyl-propyl 3-tolyl 2-methyl-3-phenyl-propyl 3-chlorophenyl 2-methyl-3-phenyl-propyl 3-chloro-4-fluorophenyl 2-methyl-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 2-methyl-3-phenyl-propyl 4-fluorophenyl 2-methyl-3-phenyl-propyl 3,4-dichlorophenyl 2-methyl-3-phenyl-propyl 1-naphthyl 2-methyl-3-phenyl-propyl 3-fluorophenyl 2-methyl-3-phenyl-propyl 2-naphthyl 2-methyl-3-phenyl-propyl n-butyl 2-methyl-3-phenyl-propyl 2-thiophene 2-methyl-3-phenyl-propyl 3-thiophene 2-meth 1-3 y -phenyl-propyl 3-aminophenyl 2-methyl-3-phenyl-propyl 2-(5-chlorothiophene) 2-methyl-3-phenyl-propyl 3,5-dichlorophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 4-tolyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3-trifluoromethylphenyl 2-(N,N-dimethylamino)-3-h 4-methoxyphenyl p (NyN-dimethylamino)-3-phenyl-propyl 4-trifluoromethylphenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3-isopropylphenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3-tolyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3-chlorophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3-chloro-4-fluorophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 4-fluorophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3,4-dichlorophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 1-naphthyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3-fluorophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 2-naphthyl 2-(N,N-dimethylamino)-3-phen 1 n-butyl 2-(NyN-dimethylami~no)-3-phenyl-propyl 2-thiophene 2-(N,N-dimethylamino)-3-h 3-thiophene 2 (NyN-dimethylamino)-3-h 3-aminophenyl 2 (NYN-dimethylamino)-3-phenyl-propyl 2-(5-chlorothiophene) 2-(N,N-dimethylamino)-3-phenyl-propyl 3,5-dichlorophenyl 2-(N-methylamino)-3-n y 4-tolyl 2 (N
mephylamino)-3-phenyl-propyl 3-trifluoromethylphenyl 2-(N-methylamino)-3---phenyl-propyl WO 98/24780 PCT/U$97122949 4-methoxyphenyl 2-(N-methylamino)-3-phenyl-propyl 4-trifluoromethylphenyl 2-(N-methylamino)-3-- phenyl-propyl 3-isopropylphenyl 2-(N-methylamino)-3-phenyl-propyl 3-tolyl 2-(N-methylamino)-3-phenyl-propyl 3-chlorophenyl ~ 2-(N-methylamino)-3-- 10 phenyl-propyl 3-chloro-4-fluorophenyl 2-(N-methylamino)-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 2-(N-methylamino)-3-phenyl-propyl 3,4-dichlorophenyl 2-(N-methylamino)-3-h y 4-fluorophenyl p (N
mephylamino)-3-phenyl-propyl 1-naphthyl 2-(N-methylamino)-3-phenyl-propyl 3-fluorophenyl 2-(N-methylamino)-3-phenyl-propyl 2-naphthyl 2-(N-methylamino)-3-phenyl-propyl n-butyl 2-(N-methylamino)-3-phenyl-propyl 2-thiophene 2-(N-methylamino)-3-phenyl-propyl 3-thiophene 2-(N-methylamino)-3-phenyl-propyl 3-aminophenyl 2-(N-methylamino)-3-phenyl-propyl 2-(5-chlorothiophene) 2-(N-methylamino)-3-phenyl-propyl Example 61 The compounds in table VII can be prepared using the appropriate starting materials and procedures as described above.
TABLE VII
N
i Rll R'21 3,5-dichlorophenyl 2(S)-amino-3-phenyl-propyl 4-methoxyphenyl 2(S)-amino-3-phenyl-propyl 3-tolyl 2(S)-amino-3-phenyl-propyl WO 98/24780 PCT/US97l22949 3-chlorophenyl 2(S)-amino-3-phenyl-pro 1 pY

4-fluorophenyl 2(S)-amino-3-phenyl-propyl 2-naphthyl 2(S)-amino-3-phenyl-propyl n-butyl 2(S)-amino-3-phenyl-propyl 2-thiophene 2(S)-amino-3-phenyl-propyl 3-thiophene 2(S)-amino-3-phenyl-propyl 3-aminophenyl 2(S)-amino-3-phenyl-propyl 2-(5-chlorothiophene) 2(S)-amino-3-phenyl-propyl 3-isopropylphenyl 3-phenylpropyl 3-tolyl 3-phenylpropyl 3-chlorophenyl 3-phenylpropyl 3-chloro-4-fluorophenyl 3-phenylpropyl 3,5-Ditrifluoromethylphenyl 3-phenylpropyl 4-fluorophenyl 3-phenylpropyl 3,4-dichlorophenyl 3-phenylpropyl 1-naphthyl 3-phenylpropyl 3-fluorophenyl 3-phenylpropyl 2-naphthyl 3-phenylpropyl n-butyl 3-phenylpropyl 2-thiophene 3-phenylpropyl 3-thiophene 3-phenylpropyl 3-aminophenyl 3-phenylpropyl 2-t5-chlorothiophene) 3-phenylpropyl 3,5-dichlorophenyl 3-methyl-3-phenyl-propyl 4-tolyl 3-methyl-3-phenyl-propyl 3-trifluoromethylphenyl 3-methyl-3-phenyl-propyl 4-methoxyphenyl 3-methyl-3-phenyl-propyl 4-trifluoromethylphenyl 3-methyl-3-phenyl-propyl 3-isopropylphenyl 3-methyl-3-phenyl-propyl 3-tolyl 3-methyl-3-phenyl-propyl 3-chlorophenyl 3-methyl-3-phenyl-propyl 3-chloro-4-fluorophenyl 3-methyl-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 3-methyl-3-phenyl-propyl 4-fluorophenyl 3-methyl-3-phenyl-propyl 3,4-dichlorophenyl 3-methyl-3-phenyl-propyl 2-naphthyl 3-methyl-3-phenyl-propyl n-butyl 3-methyl-3-phenyl-propyl 2-thiophene 3-methyl-3-phenyl-propyl 3-thiophene 3-methyl-3-phenyl-propyl 3-aminophenyl 3-methyl-3-phenyl-propyl 2-(5-chlorothiophene) 3-methyl-3-phenyl-propyl 3,5-dichlorophenyl 3-amino-3-phenyl-propyl 4-tolyl 3-amino-3-phenyl-propyl 3-trifluoromethylphenyl 3-amino-3-phenyl-propyl 4-methoxyphenyl 3-amino-3-phenyl-propyl 4-trifluoromethylphenyl 3-amino-3-phenyl-propyl 3-isopropylphenyl 3-amino-3-phenyl-propyl 3-tolyl 3-amino-3-phenyl-propyl 3-chlorophenyl 3-amino-3-phenyl-propyl 3-chloro-4-fluorophenyl 3-amino-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 3-amino-3-phenyl-propyl 4-fluorophenyl 3-amino-3-phenyl-propyl 3,4-dichlorophenyl 3-amino-3-phenyl-propyl 1-naphthyl 3-amino-3-phenyl-propyl 3-fluorophenyl 3-amino-3-phenyl-propyl 2-naphthyl 3-amino-3-phenyl-propyl n-butyl 3-amino-3-phenyl-propyl 2-thiophene 3-amino-3-phenyl-propyl 3-thiophene 3-amino-3-phenyl-propyl 3-aminophenyl 3-amino-3-phenyl-propyl 2-(5-chlorothiophene) 3-amino-3-phenyl-propyl 3,5-dichlorophenyl 2(R)-amino-3-phenyl-propyl 4-tolyl 2(R)-amino-3-phenyl-propyl 3-trifluoromethylphenyl 2(R)-amino-3-phenyl-propyl 4-methoxyphenyl 2(R)-amino-3-phenyl-propyl 4-trifluoromethylphenyl 2(R)-amino-3-phenyl-propyl 3-isopropylphenyl 2(R)-amino-3-phenyl-propyl 3-tolyl 2(R)-amino-3-phenyl-propyl 3-chlorophenyl 2(R)-amino-3-phenyl-propyl 3-chloro-4-fluorophenyl 2(R)-amino-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 2(R)-amino-3-phenyl-propyl 4-fluorophenyl 2(R)-amino-3-phenyl-propyl 3,4-dichlorophenyl 2(R)-amino-3-phenyl-propyl 1-naphthyl 2(R)-amino-3-phenyl-propyl 3-fluorophenyl 2(R)-amino-3-phenyl-propyl 2-naphthyl 2(R)-amino-3-phenyl-propyl n-butyl 2(R)-amino-3-phenyl-propyl 2-thiophene 2(R)-amino-3-phenyl-propyl 3-thiophene 2(R)-amino-3-phenyl-propyl 3-aminophenyl 2(R)-amino-3-phenyl-propyl 2-(5-chlorothiophene) 2(R)-amino-3-phenyl-propyl 3,5-dichlorophenyl 2-methyl-2-amino-3-phenyl-propyl 4-tolyl 2-methyl-2-amino-3-phenyl-propyl 3-trifluoromethylphenyl 2-methyl-2-amino-3-phenyl-propyl 4-methoxyphenyl 2-methyl-2-amino-3-phenyl-propyl 4-trifluoromethylphenyl 2-methyl-2-amino-3-phenyl-propyl 3-isopropylphenyl 2-methyl-2-amino-3-phenyl-propyl 3-tolyl 2-methyl-2-amino-3-phenyl-propyl 3-chlorophenyl 2-methyl-2-amino-3-phenyl-propyl 3-chloro-4-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 2-methyl-2-amino-3-phenyl-propyl 4-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl 3,4-dichlorophenyl 2-methyl-2-amino-3-phenyl-propyl 1-naphthyl 2-methyl-2-amino-3-phenyl-propyl 3-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl 2-naphthyl 2-methyl-2-amino-3-phenyl-propyl n-butyl 2-methyl-2-amino-3-phenyl-propyl 2-thiophene 2-methyl-2-amino-3-phenyl-propyl 3-thiophene 2-methyl-2-amino-3-phenyl-propyl 3-aminophenyl 2-methyl-2-amino-3-phenyl-propyl 2-(5-chlorothiophene) 2-methyl-2-amino-3-phenyl-propyl 3,5-dichlorophenyl 2-methyl-3-phenyl-propyl 4-tolyl 2-methyl-3-phenyl-propyl 3-trifluoromethylphenyl 2-methyl-3-phenyl-propyl 4-methoxyphenyl 2-methyl-3-phenyl-propyl 4-trifluoromethylphenyl 2-methyl-3-phenyl-propyl 3-isopropylphenyl 2-methyl-3-phenyl-propyl 3-tolyl 2-meth 1-3 propyl y P
y 3-chlorophenyl 2-meth l-3 hen l Y -P y -propyl 3-chloro-4-fluorophenyl 2-methyl-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 2-methyl-3-phenyl-propyl 4-fluorophenyl 2-methyl-3-phenyl-propyl 3,4-dichlorophenyl 2-methyl-3-phenyl-propyl 1-naphthyl 2-meth 1-3 y -Ph~Yl-propyl 3-fluoro hen 1 2-methyl-3-phenyl-propyl P Y

2-naphthyl 2-methyl-3-phenyl-propyl n-butyl 2-methyl-3-phenyl-propyl 2-thiophene 2-meth 1-3 propyl y p y 3-thiophene 2-meth l-3 hen l Y -p y -propyl 3-aminophenyl 2-methyl-3-phenyl-propyl 2-(5-chlorothiophene) 2-methyl-3-phenyl-propyl 3,5-dichlorophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 4-tolyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3-trifluoromethylphenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 4-methoxyphenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 4-trifluoromethylphenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3-isopropylphenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3-tolyl 2-(N,N-dimethylamino)-3-h 3-chlorophenyl p (NyN-dimethylamino)-3-phenyl-propyl 3-chloro-4-fluorophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 4-fluorophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3,4-dichlorophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 1-naphthyl 2-(N,N-dimethylamino)-3-phenyl-propyl 3-fluorophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 2-naphthyl 2-(N,N-dimethylamino)-3-phenyl-propyl n-butyl 2-(N,N-dimethylamino)-3-phenyl-propyl 2-thiophene 2-(N,N-dimethylamino)-3-phenyl-propyl 3-thiophene 2-(N,N-dimethylamino)-3-phenyl-propyl 3-aminophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 2-(5-chlorothiophene) 2-(N,N-dimethylamino)-3-phenyl-propyl 3,5-dichlorophenyl 2-(N-methylamino)-3-phenyl-propyl 4-tolyl 2-(N-methylamino)-3-phenyl-propyl 3-trifluoromethylphenyl 2-(N-methylamino)-3-phenyl-propyl 4-methoxyphenyl 2-(N-methylamino)-3-phenyl-propyl 4-trifluoromethylphenyl 2-(N-methylamino)-3-phenyl-propyl 3-isopropylphenyl 2-(N-methylamino)-3-phenyl-propyl 3-tolyl 2-(N-methylamino)-3-phenyl-propyl-3-chlorophenyl 2-(N-methylamino)-3-phen 1 y -propyl 3-chloro-4-fluorophenyl 2-(N-methylamino)-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 2-(N-methylamino)-3-phenyl-propyl 3,4-dichlorophenyl 2-(N-methylamino)-3-phenyl-propyl 4-fluorophenyl 2-(N-methylamino)-3-phenyl-propyl 1-naphthyl 2-(N-methylamino)-3-phenyl-propyl 3-fluorophenyl 2-(N-methylamino)-3-phenyl-propyl 2-naphthyl 2-(N-methylamino)-3-phenyl-propyl n-butyl 2-(N-methylamino)-3-phenyl-propyl 2-thiophene 2-(N-methylamino)-3-phenyl-propyl 3-thiophene 2-(N-methylamino)-3-phenyl-propyl 3-aminophenyl 2-(N-methylamino)-3-phenyl-propyl 2-(5-chlorothiophene) 2-(N-methylamino)-3-phenyl-propyl Example 62 Using the corresponding starting materials, the following compounds of Table VIII may be prepared using the procedure for 3-methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(3-trifluoromethylphenyl)-6-(4-pyridyl)-4{3H)-pyrimidinone.
TABLE VIII

Rii Rzl 3,5-dichlorophenyl 2(S)-amino-3-phenyl-propyl 4-methoxyphenyl 2(S)-amino-3-phenyl-propyl 3-tolyl 2(S)-amino-3-phenyl-propyl 3-chlorophenyl 2(S)-amino-3-phenyl-propyl 4-fluorophenyl 2(S)-amino-3-phenyl-propyl 2-naphthyl 2(S)-amino-3-phenyl-propyl n-butyl 2(S)-amino-3-phenyl-propyl 2-thiophene 2(S)-amino-3-phenyl-propyl 3-thiophene 2(S)-amino-3-phenyl-propyl 3-aminophenyl 2(S)-amino-3-phenyl-propyl 2-(5-chlorothiophene) 2(S)-amino-3-phenyl-propyl 3-isopropylphenyl 3-phenylpropyl 3-tolyl 3-phenylpropyl 3-chlorophenyl 3-phenylpropyl 3-chloro-4-fluorophenyl 3-phenylpropyl 3,5-Ditrifluoromethylphenyl 3-phenylpropyl 4-fluorophenyl 3-phenylpropyl 3,4-dichlorophenyl 3-phenylpropyl 1-naphthyl 3-phenylpropyl 3-fluorophenyl 3-phenylpropyl _ 2-naphthyl 3-phenylpropyl n-butyl 3-phenylpropyl 2-thiophene 3-phenylpropyl 3-thiophene 3-phenylpropyl 3-aminophenyl 3-phenylpropyl 2-(5-chlorothiophene) 3-phenylpropyl 3,5-dichlorophenyl 3-methyl-3-phenyl-propyl 4-tolyl 3-methyl-3-phenyl-propyl 3-trifluoromethylphenyl 3-methyl-3-phenyl-propyl 4-methoxyphenyl 3-methyl-3-phenyl-propyl 4-trifluoromethylphenyl 3-methyl-3-phenyl-propyl 3-isopropylphenyl 3-methyl-3-phenyl-propyl 3-tolyl 3-methyl-3-phenyl-propyl 3-chlorophenyl 3-methyl-3-phenyl-propyl 3-chloro-4-fluorophenyl 3-methyl-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 3-methyl-3-phenyl-propyl 4-fluorophenyl 3-methyl-3-phenyl-propyl 3,4-dichlorophenyl 3-methyl-3-phenyl-propyl 2-naphthyl 3-methyl-3-phenyl-propyl n-butyl 3-methyl-3-phenyl-propyl 2-thiophene 3-methyl-3-phenyl-propyl 3-thiophene 3-methyl-3-phenyl-propyl 3-aminophenyl 3-methyl-3-phenyl-propyl 2-(5-chlorothiophene) 3-methyl-3-phenyl-propyl 3,5-dichlorophenyl 3-amino-3-phenyl-propyl 4-tolyl 3-amino-3-phenyl-propyl 3-trifluoromethylphenyl 3-amino-3-phenyl-propyl 4-methoxyphenyl 3-amino-3-phenyl-propyl 4-trifluoromethylphenyl 3-amino-3-phenyl-propyl 3-isopropylphenyl 3-amino-3-phenyl-propyl 3-tolyl 3-amino-3-phenyl-propyl 3-chlorophenyl 3-amino-3-phenyl-propyl 3-chloro-4-fluorophenyl 3-amino-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 3-amino-3-phenyl-propyl 4-fluorophenyl 3-amino-3-phenyl-propyl 3,4-dichlorophenyl 3-amino-3-phenyl-propyl 1-naphthyl 3-amino-3-phenyl-propyl 3-fluorophenyl 3-amino-3-phenyl-propyl 2-naphthyl 3-amino-3-phenyl-propyl n-butyl 3-amino-3-phenyl-propyl 2-thiophene 3-amino-3-phenyl-propyl 3-thiophene 3-amino-3-phenyl-propyl 3-aminophenyl 3-amino-3-phenyl-propyl 2-(5-chlorothiophene) 3-amino-3-phenyl-propyl 3,5-dichlorophenyl 2(R)-amino-3-phenyl-propyl 4-tolyl 2(R)-amino-3-phenyl-propyl 3-trifluoromethylphenyl 2(R)-amino-3-phenyl-propyl 4-methoxyphenyl 2(R)-amino-3-phenyl-propyl 4-trifluoromethylphenyl 2(R)-amino-3-phenyl-propyl 3-isopropylphenyl 2(R)-amino-3-phenyl-propyl ?-tolyl 2(R)-amino-3-phenyl-propyl ~-chlorophenyl 2(R)-amino-3-phenyl-propyl 3-chloro-4-fluorophenyl 2(R)-amino-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 2(R)-amino-3-phenyl-propyl 4-fluorophenyl 2(R)-amino-3-phenyl-propyl 3,4-dichlorophenyl 2(R)-amino-3-phenyl-propyl 1-naphthyl 2(R)-amino-3-phenyl-propyl 3-fluorophenyl 2(R)-amino-3-phenyl-propyl 2-naphthyl 2(R)-amino-3-phenyl-propyl n-butyl 2(R)-amino-3-phenyl-propyl 2-thiophene 2(R)-amino-3-phenyl-propyl 3-thiophene 2(R)-amino-3-phenyl-propyl 3-aminophenyl 2(R)-amino-3-phenyl-propyl 2-(5-chlorothiophene) 2(R)-amino-3-phenyl-propyl 3,5-dichlorophenyl 2-methyl-2-amino-3-phenyl-propyl 4-tolyl 2-methyl-2-amino-3-phenyl-propyl 3-trifluoromethylphenyl 2-methyl-2-amino-3-phenyl-propyl 4-methoxyphenyl 2-methyl-2-amino-_3-phenyl-propyl 4-trifluoromethylphenyl 2-methyl-2-amino-3-phenyl-propyl 3-isopropylphenyl 2-methyl-2-amino-3-phenyl-propyl 3-tolyl 2-methyl-2-amino-3-phen 1 Y _ propyl 3-chlorophenyl 2-methyl-2-amino-3-phenyl-propyl 3-chloro-4-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 2-methyl-2-amino-3-phenyl-propyl 4-fluorophenyl 2-methyl-2-amino-3-phenyl=

propyl 3,4-dichlorophenyl 2-methyl-2-amino-3-phenyl-propyl 1-naphthyl 2-methyl-2-amino-3-phenyl-propyl 3-fluorophenyl 2-methyl-2-amino-3-phenyl-propyl 2-naphthyl 2-methyl-2-amino-3-phenyl-propyl n-butyl 2-methyl-2-amino-3-phenyl-propyl 2-thiophene 2-methyl-2-amino-3-phenyl-propyl 3-thiophene 2-methyl-2-amino-3-phenyl-propyl 3-aminophenyl 2-methyl-2-amino-3-phenyl-propyl 2-(5-chlorothiophene) 2-methyl-2-amino-3-phenyl-propyl 3,5-dichlorophenyl 2-methyl-3-phenyl-propyl 4-tolyl 2-methyl-3-phenyl-propyl 3-trifluoromethylphenyl 2-methyl-3-phenyl-propyl 4-methoxyphenyl 2-methyl-3-phenyl-propyl 4-trifluoromethylphenyl 2-methyl-3-phenyl-propyl 3-isopropylphenyl 2-methyl-3-phenyl-propyl 3-tolyl 2-methyl-3-phenyl-propyl 3-chlorophenyl 2-methyl-3-phenyl-propyl 3-chloro-4-fluorophenyl 2-methyl-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 2-methyl-3-phenyl-propyl 4-fluorophenyl 2-methyl-3-phenyl-propyl 3,4-dichlorophenyl 2-methyl-3-phenyl-propyl 1-naphthyl 2-methyl-3-phenyl-propyl 3-fluorophenyl 2-methyl-3-phenyl-propyl 2-naphthyl 2-methyl-3-phenyl-propyl n-butyl 2-methyl-3-phenyl-propyl 2-thiophene 2-methyl-3-phenyl-propyl 3-thiophene 2-methyl-3-phenyl-propyl 3-aminophenyl 2-methyl-3-phenyl-propyl 2-(5-chlorothiophene) 2-methyl-3-phenyl-propyl 3,5-dichlorophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 4-tolyl 2-(N,N-dimethylamino)-3-h 3-trifluoromethylphenyl 2 (NyN-dimethylamino)-3-h 4-methoxyphenyl p (NyN-dimethylamino)-3-h 4-trifluoromethylphenyl 2 (NyN-dimethylamino)-3-h 3-isopropylphenyl 2 (NYN-dimethylamino)-3-phenyl-propyl 3-tolyl 2-(N,N-dimethyla mino)-3-_ phenyl-propyl 3-chlorophenyl 2-(N,N-dimethylamino)-3-h 3-chloro-4-fluorophenyl 2 (NyN-dimethylamino)-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 2-(N,N-dimethylamino)-3-h 4-fluorophenyl p (NyN-dimethylamino)-3-phenyl-propyl 3,4-dichlorophenyl 2-(N,N-dimethylamino)-3-phenyl-propyl 1-naphthyl 2-(N,N-dimethylamino)-3-h 3-fluorophenyl p (NyN-dimethylamino)-3-phenyl-propyl 2-naphthyl 2-(N,N-dimethylamino)-3-phenyl-propyl n-butyl 2-(N,N-dimethylamino)-3-h 2-thiophene p (NyN-dimethylamino)-3-h 3-thiophene p (NYN-dimethylamino)-3-h 3-aminophenyl p (NyN-dimethylamino)-3-phenyl-propyl 2-(5-chlorothiophene) 2-(N,N-dimethylamino)-3-h y 3,5-dichlorophenyl p (N
mephylamino)-3-~ phenyl-propyl 4-tolyl 2-(N-methylamino)-3-h Y

3-trifluoromethylphenyl 2 (N
methylamino)-3-h Y

4-methoxyphenyl 2 (N
methylamino)-3-h y 4-trifluoromethylphenyl 2 (N
methylamino)-3-h y - 3-isopropylphenyl 2 (N
methylamino)-3-phenyl-propyl 3-tolyl 2-(N-methylamino)-3-phenyl-propyl 3-chlorophenyl 2-(N-methylamino)-3-h y 3-chloro-4-fluorophenyl 2 (N
methylamino)-3-phenyl-propyl 3,5-Ditrifluoromethylphenyl 2-(N-methylamino)-3-ph y 3,4-dichlorophenyl 2 (N
methylamino)-3-h y 4-fluorophenyl p (N
mephylamino)-3-h y 1-naphthyl 2 (N
mephypamino)-3-h y 3-fluorophenyl p (N
mephypamino)-3-phenyl-propyl 2-naphthyl 2-(N-methylamino)-3-phenyl-propyl n-butyl 2-(N-methylamino)-3-h Y

2-thiophene p (N
methylamino)-3-phenyl-propyl 3-thiophene 2-(N-methylamino)-3-h y 3-aminophenyl 2 (N
mephylamino)-3-phenyl-propyl 2-(5-chlorothiophene) 2-(N-methylamino)-3-phenyl-propyl Example 63 Procedure for the preparation of 2-((2-(3-trifluoromethylphenyl)phenylmethyl)amino)-3-methyl-5-(4-fluorophenyl) -6- (4-pyridyl) -4 (3H) -pyrimidinone F

NCH-.
N
H
Step A. 2-((2-bromophenylmethyl)amino)-5-(4-fluorophenyl)-6-(4-pyridvl)-3-methvl-4(3H)-pvrimidinone:
The compound, 3-methyl-5-(4-fluorophenyl)-6-(4-pyridyl)-2-thiomethyl-4(3H)-pyrimidinone (470 mg, 1.44 mmol) was dissolved-in methanol:water mixture(1.8:1, 40m1 and 22.5m1). Potasssium peroxymonosulfate (OXONE Aldrich Chem Co., 2.5g 4.1 mmol) was added to a cooled (4°C) reaction mixture and then the reaction was continued for 16h at room-temperature. The reaction mixture was concentrated and extracted with dichloromethane and the organic layer was washed with water, dried over NaZSOd and was concentrated. The residue (500mg) and o-bromobenzylamine were mixed in 1,4-dioxane (20 ml). The clear solution was heated at 85°C for 18 h and progress of the reaction monitored by TLC. The reaction mixture was concentrated and chromatographed on a silica gel column to obtain the titled compound. MS(m/z): 466.9 CZ,HIpBrFN,O requirs: 465.33 1H-NMR (CDC1~) :d 8.49 (dd, 2H, pyridyl), 7.67-6.81 (m, 12H, Ph and pyridyl), 5.44 (t, 1H, NH), 4.92 (d 2H, CHZ-Ph), 3.6 (s, 3H, N-CH3).
Step A. 2-((2-(3-trifluoromethylphenyl)phenylmethyl) amino)-3-methyl-5-(4-fluorophenyl)-6-(4-pvridvl)-4(3H)-pyrimidinone: 2-((2-bromophenylmethyl)amino)-5-(4-fluorophenyl)-6-(4-pyridyl)-3-methyl-4(3H)-pyrimidinone (175 mg, 0.38 mmol) was dipersed in 2M sodium carbonate solution (12 ml) and 3-trifluromethylbenzene- boronic acid (170 mg, 0.89 mmol), toluene (l2ml) were added to the above mixture and the reaction mixture was degassed and catalyst tetrakistriphenylphosphine Pd(0) (50 mg) was added. The reaction mixture was refluxed for 16 h.
The formation of the product was monitored by TLC. Then it was cooled, diluted with toluene (12 ml) and washed with water. The organic layer was dried over sodium sulfate, concentrated and the product was purified by silica gel chromatgraphy to give the title compound.
MS ( m/ z ) : 531 . 1 C~aH2zF4Na0 requir . 53 0 . 53 ; 1H-NMR ( CDC13 ) : d 8.43 (m, 2H, pyridyl), 7.69-7.12 (m,8H, Ph), 7.11-6.88 (m, 6H, pyridyl and Ph-CF,), 4.85 (m, 3H, CHZ-Ph and NH), 3 . 3 2 ( N-CH3 ) .
Example 64 Using the corresponding starting materials, the following compounds of Table IX may be prepared using the procedure for 2-((2-(3-trifluoromethylphenyl) phenylmethyl)amino)-3-methyl-5-(4-fluorophenyl)-6-(4-' pyridyl)-4(3H)-pyrimidinone.

TABLE IX

N~N
N J H
Rii Rso 4-fluorophenyl 3,5-dichlorophenyl -4-fluorophenyl 4-tolyl 4-fluorophenyl 4-methoxyphenyl 4-fluorophenyl 4-trifluoromethylphenyl 4-fluorophenyl 3-isopropylphenyl 4-fluorophenyl 3-tolyl 4-fluorophenyl 3-chlorophenyl 4-fluorophenyl 3-chloro-4-fluorophenyl 4-fluorophenyl 3,5-Ditrifluoromethylphenyl 4-fluorophenyl 4-fluorophenyl 4-fluorophenyl 3,4-dichlorophenyl 4-fluorophenyl 1-naphthyl 4-fluorophenyl 3-fluorophenyl 4-fluorophenyl 2-naphthyl 4-fluorophenyl n-butyl 4-fluorophenyl 2-thiophene 4-fluorophenyl 3-thiophene 4-fluorophenyl 3-aminophenyl 4-fluorophenyl 2-(5-chlorothiophene) 3-trifluoromethylphenyl 3,5-dichlorophenyl 3-trifluoromethylphenyl 4-tolyl 3-trifluoromethylphenyl 3-trifluoromethylphenyl 3-trifluoromethylphenyl 4-methoxyphenyl 3-trifluoromethylphenyl 4-trifluoromethylphenyl 3-trifluoromethylphenyl 3-isopropylphenyl 3-trifluoromethylphenyl 3-tolyl 3-trifluoromethylphenyl 3-chlorophenyl 3-trifluoromethylphenyl 3-chloro-4-fluorophenyl - .3-trifluoromethylphenyl 3,5-Ditrifluoromethylphenyl 3-trifluoromethylphenyl 4-fluorophenyl 3-trifluoromethylphenyl 3,4-dichlorophenyl 3-trifluoromethylphenyl 1-naphthyl 3-trifluoromethylphenyl 3-fluorophenyl 3-trifluoromethylphenyl 2-naphthyl 3-trifluoromethylphenyl n-butyl 3-trifluoromethylphenyl 2-thiophene 3-trifluoromethylphenyl 3-thiophene - 3-trifluoromethylphenyl 3-aminophenyl 3-trifluoromethylphenyl 2-(5-chlorothiophene) Example 65 Using the corresponding starting materials, the following compounds of Table X may be prepared using the procedure for 2-((2-(3-trifluoromethylphenyl) phenylmethyl)amino)-3-methyl-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone.
TABLE X
O

\ N i 'N
NJ H ~ /
Rll Rao 4-fluorophenyl 3,5-dichlorophenyl 4-fluorophenyl 4-tolyl 4-fluorophenyl 4-methoxyphenyl 4-fluorophenyl 4-trifluoromethylphenyl 4-fluorophenyl 3-isopropylphenyl 4-fluorophenyl 3-tolyl 4-fluorophenyl 3-chlorophenyl 4-fluorophenyl 3-chloro-4-fluorophenyl 4-fluorophenyl 3,5-Ditrifluoromethylphenyl 4-fluorophenyl 4-fluorophenyl 4-fluorophenyl 3,4-dichlorophenyl 4-fluorophenyl 1-naphthyl 4-fluorophenyl 3-fluorophenyl 4-fluorophenyl 2-naphthyl 4-fluorophenyl n-butyl 4-fluorophenyl 2-thiophene 4-fluorophenyl 3-thiophene 4-fluorophenyl 3-aminophenyl 4-fluorophenyl 2-(5-chlorothiophene) 3-trifluoromethylphenyl 3,5-dichlorophenyl 3-trifluoromethylphenyl 4-tolyl 3-trifluoromethylphenyl 3-trifluoromethylphenyl 3-trifluoromethylphenyl 4-methoxyphenyl 3-trifluoromethylphenyl 4-trifluoromethylphenyl 3-trifluoromethylphenyl 3-isopropylphenyl 3-trifluoromethylphenyl 3-tolyl 3-trifluoromethylphenyl 3-chlorophenyl 3-trifluoromethylphenyl 3-chloro-4-fluorophenyl 3-trifluoromethylphenyl 3,5-Ditrifluoromethylphenyl 3-trifluoromethylphenyl 4-fluorophenyl 3-trifluoromethylphenyl 3,4-dichlorophenyl 3-trifluoromethylphenyl 1-naphthyl 3-trifluoromethylphenyl 3-fluorophenyl 3-trifluoromethylphenyl 2-naphthyl 3-trifluoromethylphenyl n-butyl 3-trifluoromethylphenyl 2-thiophene 3-trifluoromethylphenyl 3-thiophene 3-trifluoromethylphenyl 3-aminophenyl 3-trifluoromethylphenyl 2-(5-chlorothiophene) 8xample 66 Using the corresponding starting materials, the following compounds of Table XI may be prepared using the procedure for 2-((2-(3-trifluoromethylphenyl) phenylmethyl)amino)-3-methyl-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone.
TABLE XI
O

i N~N
NJ H ~ /
R4o R" Ra o 4-fluorophenyl 3,5-dichlorophenyl 4-fluorophenyl 4-tolyl 9-fluorophenyl 4-methoxyphenyl 4-fluorophenyl 4-trifluoromethylphenyl 4-fluorophenyl 3-isopropylphenyl 4-fluorophenyl 3-tolyl 4-fluorophenyl 3-chlorophenyl 4-fluorophenyl 3-chloro-4-fluorophenyl 4-fluorophenyl 3,5-Ditrifluoromethylphenyl 4-fluorophenyl 4-fluorophenyl 4-fluorophenyl 3,4-dichlorophenyl 4-fluorophenyl 1-naphthyl 4-fluorophenyl 3-fluorophenyl 4-fluorophenyl 2-naphthyl 4-fluorophenyl n-butyl 4-fluorophenyl 2-thiophene 4-fluorophenyl 3-thiophene 4-fluorophenyl 3-aminophenyl 4-fluorophenyl 2-(5-chlorothiophene) 3-trifluoromethylphenyl 3,5-dichlorophenyl 3-trifluoromethylphenyl 4-tolyl 3-trifluoromethylphenyl 3-trifluoromethylphenyl 3-trifluoromethylphenyl 4-methoxyphenyl 3-trifluoromethylphenyl 4-trifluoromethylphenyl 3-trifluoromethylphenyl 3-isopropylphenyl 3-trifluoromethylphenyl 3-tolyl 3-trifluoromethylphenyl 3-chlorophenyl 3-trifluoromethylphenyl 3-chloro-4-fluorophenyl 3-trifluoromethylphenyl 3,5-Ditrifluoromethylphenyl 3-trifluoromethylphenyl 4-fluorophenyl 3-trifluoromethylphenyl 3,4-dichlorophenyl 3-trifluoromethylphenyl 1-naphthyl 3=trifluoromethylphenyl 3-fluorophenyl 3-trifluoromethylphenyl 2-naphthyl 3-trifluoromethylphenyl n-butyl 3-trifluoromethylphenyl 2-thiophene WO 98/24780 '~ ~ PCT/US9~/22949 3-trifluoromethylphenyl 3-thiophene 3-trifluoromethylphenyl 3-arninophenyl 3-trifluoromethylphenyl 2-(5-chlorothiophene) ale 67 Biological Assays The following assays were used to characterize the ability of compounds of the invention to inhibit the production of TNF-a and IL-1-(3. The second assay measured the inhibition of TNF-a and/or IL-1-~i in mice after oral administration of the test compounds. The third assay, a glucagon binding inhibition in vitro assay, can be used to characterize the ability of compounds of the invention to inhibit glucagon binding.
The fourth assay, a Cyclooxygenase enzyme (COX-1 and COX-2) inhibition activity in vitro assay, can be used to characterize the ability of compounds of the invention to inhibit COX-1 and/or COX-2.
Lipopolysaccharide-activated moaocyte TNF production assay Isolation of monocytes Test compounds were evaluated in vitro for the ability to inhibit the production of TNF by monocytes activated with bacterial lipopolysaccharide (LPS).
Fresh residual source leukocytes (a byproduct of plateletpheresis) were obtained from a local blood bank, and peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation on Ficol-Paque~'Plus (Pharmacia). PBMCs were suspended at 2 x 106/ml in DMEM supplemented to contain 2$ FCS, 10 mM, 0.3 mg/ml glutamate, 100 U/ml penicillin G and 100 mg/ml streptomycin sulfate (complete media). Cells were plated into Falcon*flat bottom, 96 well culture plates (200 ul/well) and cultured overnight at 37°C and 6~ COz.
Non-adherent cells were removed by washing with 200 -ul/well of fresh medium. Wells containing adherent cells (~70~ monocytes) were replenished with I00 ul of fresh medium.
*Trade-mark WO 98~I24780 ~~ ~~~ PG"TIUS97722949 Preparation of test compound stock solutions Test compounds were dissolved in DMZ. Compound stock solutions were prepared to an initial concentration of 10 - 50 uM. Stocks were diluted initially to 20 - 200 uNi in complete media. Nine two-fold serial dilutions of each compound were then prepared in complete medium.
Treatment of cells with test compounds and activation of TNF production with 3ipopolysaccharide One hundred microliters of each test compound dilution were added to microtiter wells containing adherent monocytes and 100 ul complete medium.
Monocytes were cultured with test compounds for 60 min at which time 25 ul of complete medium containing 30 ng/ml lipopolysaccharide from E. coli K532 were added to each well. Cells were cultured an additional 4 hrs.
Culture supernatants were then removed and TNF presence in the supernatants was quantified using an ELISA.
TNF ELISA
Flat bottom, 96 well Corning High Binding ELISA
plates were coated overnight (4°C) with 150 uL/well of 3 ug/ml murine anti-human TNF-a MAb (R&D Systems #MAB210).
Wells were then blocked for 1 hr at room temperature with 200 uL/well of CaClz-free ELISA buffer supplemented to contain 20 mg/ml BSA (standard ELISA buffer: 20 mM, °1,50 mM NaCl, 2 mM CaCl2, O.I5 mM thimerosal~, pH 7.4).
Plates were washed and replenished with 100 ul of test supernatants (diluted 1:3) or standards. Standards consisted of eleven 1.5-fold serial dilutions from a stock of 1 ng/ml recombinant human TNF (R&D Systems).
Plates were incubated at room temperature for 1 hr on - orbital shaker (300 rpm), washed and replenished with 100 ul/well of 0.5 ug/ml goat anti-human TNF-a (R&D
systems #AB-210-NA) biotinylated at a 4:1 ratio. Plates were incubated for 40 min, washed and replenished with 100 ul/well of alkaline phosphatase-conjugated *Trade-mark streptavidin (Jackson ImmunoResearch #016-050-084) at 0.02 ~,zg/ml. Plates were incubated 30 min, washed and - replenished with 200 ul/well of 1 mg/ml of p-nitrophenyl phosphate. After 30 min, plates were read at 405 nm on a V~ plate reader.
Data analysis Standard curve data were fit to a second order polynomial and unknown TNF-a concentrations determined from their OD by solving this equation for concentration. TNF concentrations were then plotted vs.
test compound concentration using a second order polynomial. This equation was then used to calculate the concentration of test compounds causing a 50~
reduction in TNF production.
Compounds of the invention can also be shown to inhibit LPS-induced release of IL-1(3, IL-6 and/or IL-8 from monocytes by measuring concentrations of IL-l~i, IL-6 and/or IL-8 by methods well known to those-skilled in the art. In a similar manner to the above described assay involving the LPS induced release of TNF-a from monocytes, compounds of this invention can also be shown to inhibit LPS induced release of IL-1(3, IL-6 and/or IL-8 from monocytes by measuring concentrations of IL-1(3, IL-6 and/or IL-8 by methods well known to those skilled in the art. Thus, the compounds of the invention may lower elevated levels of TNF-a, IL-1, IL-6, and IL-8 levels. Reducing elevated levels of these inflammatory cytokines to basal levels or below is favorable in controlling, slowing progression, and alleviating many disease states. All of the compounds are useful in the methods of treating disease states in which TNF-a, IL-1(3, IL-6, and IL-8 play a role to the full extent of the definition of TNF-a-mediated diseases described herein.
Inhibition of LPS-Induced TNF-a production in mice Male DBA/1LACJ mice were dosed with vehicle or test compounds in a vehicle (the vehicle consisting of 0.5~
tragacanth in 0.03 N HC1) 30 minutes prior to lipopolysaccharide (2 mg/kg, I.V.) injection. Ninety minutes after LPS injection, blood was collected and the serum was analyzed by ELISA for TNF levels.
The following compounds exhibit activities in the monocyte assay (LPS induced TNF release) with ICSO values of 20 ~1M or less:
2-(2,6-Dichlorobenzyl)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 2-(Butylamino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 2-(Benzylamino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 5-(4-Fluorophenyl)-3-methyl-((R-1-phenylethyl)amino)-(4-pyridyl)-4(3H)-pyrimidinone 2-(2-(2-Chlorophenyl)-ethylamino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 5-(4-Fluorophenyl)-2-(2-(4-fluorophenyl)-ethylamino)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 5-(4-Fluorophenyl)-2-((2-hydroxy-2-phenyl)-ethylamino)-3-methyl-6-(4-pyridyl)-4(3H}-pyrimidinone 5-(4-Fluorophenyl)-3-methyl-2-((3-phenylpropyl)-amino)-6-(4-pyridyl)-4(3H)-pyrimidinone 5-(4-Fluorophenyl)-3-methyl-2-((1-methyl-3-phenylpropyl)-amino)-6-(4-pyridyl)-4(3H)-pyrimidinone 5-(4-Fluorophenyl)-3-methyl-2-((R-1-methyl-3-phenylpropyl)-amino}-6-(4-pyridyl)-4(3H)-pyrimidinone 5-(4-Fluorophenyl)-3-methyl-2-((2-phenylaminoethyl}-amino)-6-(4-pyridyl)-4{3H)-pyrimidinone 5-(4-Fluorophenyl)-2-((3-imidazolylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 5-{4-Fluorophenyl)-3-methyl-6-(4-pyridyl)-2-(3-(pyrrolidin-1-yl)-propylamino)-4(3H)-pyrimidinone 3,6-biphenyl=4-(4-pyridyl)-2{1H)-pyridone 6-(4-Methylphenyl)-3-phenyl-4-(4-pyridyl)-2(2H)-pyridone 6-(4-Ethylphenyl)-3-phenyl-4-(4-pyridyl}-2(1H)-pyridone 6-(2,4-Dimethylphenyl)-3-phenyl-4=(4-pyridyl)-2{1H)-pyridone 3-Phenyl-4-{4-pyridyl)-6-{2-thienyl)-2(1H)-pyridone 6-(2-Furyl)-3-phenyl-4-(4-pyridyl)-2(1H)-pyridone 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4- _ fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 2-(((R)-2-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 2-(((S)-2-N-Ethyl-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 2-((2-Amino-2-methy-3-phenylpropyl)amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 2-((2-Aminomethy-3-phenylpropyl)-amino)-5-(4-fluorophenyl-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 2-((3-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 5-(4-Fluorophenyl)-3-methyl-2-(3-(2-methylphenyl)propyl)-amino)-6-(4-pyridyl)-4(3H)-pyrimidinone 5-(4-Fluorophenyl)-3-methyl-2-((R,S)-2-amino-3-(2'-fluorophenyl)-propyl-amino)-6-(4-pyridyl)-4(3H)-pyrimidinone 2-(((S)-2-Acetamido-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 5-(4-Fluorophenyl}-2-(((S)-2-N-isopropylamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 2-(((S)-2-N-n-Butylamino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-5-(4-fluorophenyl-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 5-(4-Fluorophenyl)-3-methyl-2-((2-methy-3-phenylpropyl) amino)-6-(4-pyridyl)-4(3H)-pyrimidinone 2-(((S)-2-Amino-3-phenylpropyl)-amino)-3-ethyl-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Ethyl-5-(4-fluorophenyl)-2-((2-methy-3-phenylpropyl) amino)-6-(4-pyridyl)-4(3H)-pyrimidinone 2-((2-(3-trifluoromethylphenyl)phenylmethyl)amino)-3-methyl-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(4-tolyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(4-trifluoromethylphenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(3-isopropylphenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(3-chloro-4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(3,5-bis(trifluoromethyl)phenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(3,4-dichlorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(2(S)-amino-3-phenylpropylamino)-5-{1-naphthyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(3-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(3-trifluoromethylphenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(3-phenylpropylamino)-5-(3,5-dichlorophenyl)-6-(4-pyridyl)-4(3H}-pyrimidinone 3-Methyl-2-(3-phenylpropylamino)-5-(4-tolyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(3-phenylpropylaminoj-5-(3-trifluoromethylphenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(3-phenylpropylamino)-5-{4-methoxyphenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(3-phenylpropylamino)-5-(4-trifluoromethylphenyl)-6-(4-pyridyl}-4(3H)-pyrimidinone 3-Methyl-2-(2-methyl-3-phenylpropylamino)-5-(3-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(2-methyl-3-phenylpropylamino)-5-(1-naphthyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 5-(4-Fluorophenyl)-2-({(S)-2-N-glycylamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-(((S)-2-N-Glycylamino-3-phenylpropyl)-amino)-3-methyl-5-(3-methylphenyl)-6-(4-pyridyl)-4-(3H)-pyrimidinone 5-(4-Fluorophenyl)-2-(((S)-2-hydroxyacetamido-3-phenylpropyl)-amino)-3-methyl-6-{4-pyridyl)-4-(3H)-pyrimidinone 5-(4-Fluorophenyl)-2-(((S)-2-pyrrolidinyl-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-((S)-3-Benzylpiperazinyl)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-((3-Amino-3-(2-fluorophenyl)propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-((3-Amino-3-(2-methylphenyl)propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-(((S)-3-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-(((R)-3-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone WO 98/24'780 PCT/I1S97/22949 2-(((S)-3-Amino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)5-(3-trifluoromethylphenyl)-4-(3H)-pyrimidinone 2-(((R)-3-Amino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)5-(3-trifluoromethylphenyl)-4--(3H)-pyrimidinone 2-((3-Amino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)5-(3-trifluoromethylphenyl)-4-(3H)-pyrimidinone 2-((3-Amino-3-(2-methylphenyl)propyl)-amino)-3-methyl-6-(4-pyridyl)5-(3-trifluoromethylphenyl)-4-(3H)-pyrimidinone 2-((3-Amino-3-(2-fluorophenyl)propyl)-amino)-3-methyl-6-(4-pyridyl)5-(3-trifluoromethylphenyl)-4-(3H)-pyrimidinone 2-((3-Amino-3-phenylpropyl)-amino}-3-methyl-5-(3-methylphenyl)-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-((3-Amino-3-(2-fluorophenyl)propyl)-amino)-3-methyl-5-(3-methylphenyl)-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-((3-Amino-3-(2-chlorophenyl)propyl)-amino)-3-methyl-5-(3-methylphenyl)-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-(((S)-3-Amino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)5-(3,4-dimethylphenyl)-4-(3H)-pyrimidinone 2-(((2R,3R)-3-Amino-2-methyl-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-(((2S,3S)-3-Amino-2-methyl-3-phenylpropyl)-amino}-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 5-(4-Fluorophenyl)-2-(((S)-3-N-isopropylamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 3G 5-(4-Fluorophenyl)-2-(((R)-3-N-isopropylamino-3-phenyipropyl)-amino)-3-methyl-6-(4-pyridyl)-4-(3H)- ----pyrimidinone 5-(4-Fluorophenyl)-3-methyl-6-(4-pyridyl)-2-((S)-tetrahydroisoquinol-3-ylmethylenamino)-4-(3H)-pyrimidinone 3-Methyl-6-(4-pyridyl)-2-((S)-tetrahydroisoquinol-3-ylmethylenamino)- 5-(3-trifluoromethylphenyl)-4-(3H)-pyrimidinone 3-Methyl-5-(3-methylphenyl)-6-(4-pyridyl)-2-((S)-tetrahydroisoquinol-3-ylmethylenamino)-4-(3H)-pyrimidinone 3-Methyl-5-(4-methylthiophenyl)-6-(4-pyridyl)-2-((S)-tetrahydroisoquinol-3-ylmethylenamino)-4-(3H)-pyrimidinone 2-(((S)-2-Amino-3-phenylpropyl)-amino)-3-methyl-5-(3-methylphenyl)-6-(4-pyridyl)-4-(3H)-pyrimidinone 5-(4-Fluorophenyl)-2-((3-hydroxy-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-6-{4-pyridyl)-4-(3H)-pyrimidinone 2-(((S}-2-Amino-3-(2-fluorophenyl)propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-(((S)-2-Amino-3-(4-fluorophenyl)propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-(((S)-2-Amino-3-(2-chlorophenyl)propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-({(S)-2-N-Isopropylamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethylphenyl)-4-(3H)=
pyrimidinone 2-(((S)-2-N-Isopropylamino-3-phenylpropyl)-amino)-3-methyl-5-(3-methylphenyl)-6-(4-pyridyl)-4-(3H)-pyrimidinone 5-(3-Chlorophenyl-2-(((S)-2-N-isopropylamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-(((S}-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-3-methyl-5-(3-methylphenyl)-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-3-methyl-5-(3-chlorophenyl)-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluorophenyl)-4-(3H)-pyrimidinone 5-(4-Fluorophenyl)-3-methyl-2-(((S)-2-N-methylamino-3-phenylpropyl)-amino)-6-(4-pyridyl)-4-(3H)-pyrimidinone.
The following compounds exhibit activities in the monocyte assay (LPS induced TNF release) with ICSO values of 5 ~,4M or less 2-(2,6-Dichlorobenzyl)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 2-(Benzylamino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 5-(4-Fluorophenyl)-3-methyl-((R-1-phenylethyl)amino)-(4-pyridyl)-4(3H}-pyrimidinone 2-(2-(2-Chlorophenyl)-ethylamino)-5-(4-fluorophenyl}-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 5-(4-Fluorophenyl)-2-(2-(4-fluorophenyl}-ethylamino)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 5-(4-Fluorophenyl)-3-methyl-2-((3-phenylpropyl)-amino)-6-(4-pyridyl)-4(3H)-pyrimidinone 5-(4-Fluorophenyl)-3-methyl-2-((1-methyl-3-phenylpropyl)-amino)-6-(4-pyridyl)-4(3H)-pyrimidinone 5-(4-Fluorophenyl)-3-methyl-2-((R-1-methyl-3-phenylpropyl)-amino)-6-(4-pyridyl)-4(3H)-pyrimidinone 5-(4-Fluorophenyl)-3-methyl-2-((2-phenylaminoethyl)-amino)-6-(4-pyridyl)-4(3X)-pyrimidinone 5-(4-Fluorophenyl)-3-methyl-6-(4-pyridyl)-2-(3-(pyrrolidin-1-yl)-propylamino)-4(3H)-pyrimidinone 6-(4-Ethylphenyl)-3-phenyl-4-(4-pyridyl)-2(1H)-pyridone 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 2-(((R)-2-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 2-(((S)-2-N-Ethyl-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 2-((2-Amino-2-methy-3-phenylpropyl) amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 2-((2-Aminomethy-3-phenylpropyl)-amino)-5-(4-fluorophenyl-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 2-((3-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 5-(4-Fluorophenyl)-3-methyl-2-(3-(2-methylphenyl)propyl)-amino)-6-(4-pyridyl)-4(3H)-pyrimidinone 5-(4-Fluorophenyl)-3-methyl-2-((R,S)-2-amino-3-(2'-fluorophenyl)-propyl-amino)-6-(4-pyridyl)-4(3H)-pyrimidinone 2-(((S)-2-Acetamido-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 5-(4-Fluorophenyl)-2-(((S)-2-N-isopropylamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 2-(((S)-2-N-n-Butylamino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-5-(4-fluorophenyl-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone 5-(4-Fluorophenyl)-3-methyl-2-((2-methy-3-phenylpropyl) amino)-6-(4-pyridyl)-4(3H)-pyrimidinone 2-(((S)-2-Amino-3-phenylpropyl)-amino)-3-ethyl-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone _ 3-Ethyl-5-(4-fluorophenyl)-2-((2-methy-3-phenylpropyl) amino)-6-(4-pyridyl)-4(3H)-pyrimidinone 2-((2-(3-trifluoromethylphenyl)phenylmethyl)amino)-3-methyl-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(2{S)-amino-3-phenylpropylamino)-5-(4-tolyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(4-trifluoromethylphenyl)-6-{4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(2(S)-amino-3=phenylpropylamino)-5-(3-isopropylphenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-{2(S)-amino-3-phenylpropylamino)-5-(3-chloro-4-fluorophenyl)-6-{4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(3,5-bis{trifluoromethyl)phenyl)-6-(4-pyridyl)-4(3H~-pyrimidinone 3-Methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(3,4-dichlorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(2{S)-amino-3-phenylpropylamino)-5-(1-naphthyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(2(S)=amino-3-phenylpropylamino)-5-(3-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(3-trifluoromethylphenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(3-phenylpropylamino)-5-(3,5-dichlorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(3-phenylpropylamino)-5-(4-tolyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(3-phenylpropylamino)-5-(3-trifluoromethylphenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(3-phenylpropylamino)-5-(4-methoxyphenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(3-phenylpropylamino)-5-(4-trifluoromethylphenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(2-methyl-3-phenylpropylamino)-5-(3-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 3-Methyl-2-(2-methyl-3-phenylpropylamino)-5-(1-'naphthyl)-6-(4-pyridyl)-4(3H)-pyrimidinone 5-{4-Fluorophenyl)-2-(((S)-2-N-glycylamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-(((S)-2-N-Glycylamino-3-phenylpropyl)-amino)-3-methyl-5-(3-methylphenyl)-6-(4-pyridyl)-4-(3H)-pyrimidinone 5-(4-Fluorophenyl)-2-(((S)-2-hydroxyacetamido-3-- 40 phenylpropyl)-amino)-3-methyl-6-{4-pyridyl)-4-(3H)-pyrimidinone 5-{4-Fluorophenyl)-2-(((S)-2-pyrrolidinyl-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4-{3H)-pyrimidinone 2-((S)-3-Benzylpiperazinyl)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone WO 98/24780 PCTlUS97/22949 2-((3-Amino-3-(2-fluorophenyl)propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-((3-Amino-3-(2-methylphenyl)propyl)-amino)-5-(4-fluorophenyl}-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-(((S)-3-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl}-4-(3H)-pyrimidinone 2-(((R)-3-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-{3H)-pyrimidinone 2-(((S)-3-Amino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)5-(3-trifluoromethylphenyl)-4-(3H)-pyrimidinone 2-(((R)-3-Amino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)5-(3-trifluoromethylphenyl)-4-(3H)-pyrimidinone 2-((3-Amino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)5-(3-trifluoromethylphenyl)-4-(3H)-pyrimidinone 2-((3-Amino-3-(2-methylphenyl)propyl)-amino)-3-methyl-6-(4-pyridyl)5-(3-trifluoromethylphenyl)-4-(3H}-pyrimidinone 2-((3-Amino-3-(2-fluorophenyl)propyl)-amino)-3-methyl-6-(4-pyridyl)5-(3-trifluoromethylphenyl)-4-(3H)-pyrimidinone 2-((3-Amino-3-phenylpropyl)-amino)-3-methyl-5-(3-methylphenyl}-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-((3-Amino-3-(2-fluorophenyl)propyl)-amino)-3-methyl-5-(3-methylphenyl)-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-((3-Amino-3-(2-chlorophenyl)propyl)-amino)-3-methyl-5-(3-methylphenyl)-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-(((S)-3-Amino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)5-(3,4-dimethylphenyl)-4-{3H)-pyrimidinone 2-(((2R,3R)-3-Amino-2-methyl-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-(((2S,3S)-3-Amino-2-methyl-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 5-(4-Fluorophenyl)-2-(((S)-3-N-isopropylamino-3-phenylpropyl)-amino)-3-methyl-6-{4-pyridyl)-4-(3H)-pyrimidinone 5-(4-Fluorophenyl)-2-(((R)-3-N-isopropylamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 5-(4-Fluorophenyl)-3-methyl-6-(4-pyridyl)-2-((S)-tetrahydroisoquinol-3-ylmethylenamino)-4-(3H)-pyrimidinone 3-Methyl-6-(4-pyridyl)-2-((S)-tetrahydroisoquinol-3-ylmethylenamino)- 5-(3-trifluoromethylphenyl)-4-(3H)-pyrimidinone 3-Methyl-5-(3-methylphenyl)-6-(4-pyridyl)-2-((S)-tetrahydroisoquinol-3-ylmethylenamino)-4-(3H)-pyrimidinone 3-Methyl-5-(4-methylthiophenyl)-6-(4-pyridyl)-2-((S)-tetrahydroisoquinol-3-ylmethylenamino}-4-(3H)-pyrimidinone 2-(((S)-2-Amino-3-phenylpropyl)-amino)-3-methyl-5-(3-methylphenyl}-6-(4-pyridyl)-4-(3H)-pyrimidinone 5-(4-Fluorophenyl)-2-((3-hydroxy-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-6-(4-pyridyl)-4-{3H)-pyrimidinone 2-(((S)-2-Amino-3-(2-fluorophenyl)propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-(((S)-2-Amino-3-(4-fluorophenyl)propyl)-amino}-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-(((S)-2-Amino-3-(2-chlorophenyl)propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-(((S)-2-N-Isopropylamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethylphenyl)-4-(3H)-pyrimidinone 2-(((S)-2-N-Isopropylamino-3-phenylpropyl)-amino)-3-methyl-5-(3-methylphenyl)-6-(4-pyridyl)-4-(3H)-pyrimidinone S-(3-Chlorophenyl-2-(((S)-2-N-isopropylamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl}-amino)-3-methyl-5-(3-methylphenyl)-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-3-methyl-5-(3-chlorophenyl)-6-(4-pyridyl)-4-(3H)-pyrimidinone 2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluorophenyl)-4-(3H)-pyrimidinone 5-(4-Fluorophenyl)-3-methyl-2-(((S)-2-N-methylamino-3-phenylpropyl)-amino)-6-(4-pyridyl)-4-(3H)-pyrimidinone - 40 Compounds of the invention may be shown to have anti-inflammatory properties in animal models of inflammation, including carageenan paw edema, collagen induced arthritis and adjuvant arthritis, such as the carageenan paw edema model (C. A. Winter et al Proc.
Soc. Exp. Biol. Med. (1962) vol 111, p 544; K. F.

WO 98124'180 _~ ~ PCTlLTS97122949 Swingle, in R. A. Scherrer and M. W. Whitehouse, Eds., Antiinflammatory Agents, Chemistry and Pharmacology, Vol. 13-II, Academic, New York, 1974, p. 33) and collagen induced arthritis (D. E. Trentham et al J. Exp.
Med. (1977) vol. 146, p 857; J. S. Courtenay, Nature (New Biol.) (1980), Vol 283, p 666).
~"I-Glucagon Handing Screen with CSO/hGLUR Cells The assay is described in WO 97/16442.
Reagents The reagents can be prepared as follows: (a) prepare fresh 1M o-Phenanthroline (Aldrich) (198.2 mg/ml ethanol); (b) prepare fresh 0.5M DTT (Sigma); (c) Protease Inhibitor Mix (1000X): 5 mg leupeptin, 10 mg benzamidine, 40 mg bacitracin and 5 mg soybean trypsin inhibitor per ml DMSO and store aliquots at -20°C; (d) 250 E1M human glucagon (Peninsula): solubilize 0.5 mg vial in 575 ~.1 O.1N acetic acid (1 ~.1 yields 1 ).tM final concentration in assay for non-specific binding) and store in aliquots at -20°C; (e) Assay Buffer: 20mM Tris (pH 7.8), 1 mM DTT and 3 mM o-phenanthroline; (f) Assay Buffer with 0.1~ BSA (for dilution of label only; 0.01 final in assay): 10 ~.ll 10~ BSA (heat-inactivated) and 990 ail Assay Buffer; (g) 1~SI-Glucagon (NF.N, receptor-grade, 2200 Ci/m~nol) : dilute to 50, 000 cpml25 ~,1 in assay buffer with BSA (about 50pM final concentration in assay).
Harvestincr of CHO/hGLUR Cells for Assav 1. Remove media from confluent flask then rinse once each with PBS (Ca, Mg-free) and Enzyme-free Dissociation Fluid (Specialty Media, Inc.).
2. Add 10 ml Enzyme-free Dissoc. Fluid and hold for about 4 min. at 37°C.

3. Gently tap cells free, triturate, take aliquot for counting and centrifuge remainder for 5 min. at 1000 rpm.
4. Resuspend pellet in Assay Buffer at 75000 cells per 100 ~1.
Membrane preparations of CHO/hGLUR cells can be used in place of whole cells at the same assay volume.
Final protein concentration of a membrane preparation is determined on a per batch basis.
Assay The determination of inhibition of glucagon binding can be carried out by measuring the reduction of I125-glucagon binding in the presence of compounds of Formula I. The reagents are combined as follows:
Compound/ 250 ).l.M 125I- CHO/hGLUR
Vehicle Glucagon Glucagon Cells Total --/5 ~,l -- 25 ~,l 100 ~.1 Binding 5 ~,l/-- '- 25 ~,1 100 ~,1 Compound Nonspecif I --/5 ~.~,1 1 ~,1 25 )..1,1 100 ~.1 Binding The mixture is incubated for 60 min. at 22°C on a shaker at 275 rpm. The mixture is filtered over pre-soaked (0.5~ polyethylimine (PEI)) GF/C filtermat using an Innotech Harvester or Tomtec Harvester with four washes of ice-cold 20mM Tris buffer (pH 7.8). The radioactivity in the filters is determined by a gamma-scintillation counter.
Thus, compounds of the invention may also be shown to inhibit the binding of glucagon to glucagon receptors.
Cyclooxygeaase Enzyme Activity Assay The human monocytic leukemia cell line, THP-1, differentiated by exposure to phorbol esters expresses only COX-1; the human osteosarcoma cell line 143B
expresses predominantly COX-2. THP-1 cells are routinely cultured in RPMI complete media supplemented with 10o FBS and human osteosarcoma cells (HOSC) are cultured in minimal essential media supplemented with 10~ fetal bovine serum (MEM-10~FBS); all cell incubations are at 37°C in a humidified environment containing 5~ COz.
COX-1 Assay In preparation for the COX-1 assay, THP-1 cells are grown to confluency, split 1:3 into RPMI containing 2~
FBS and 10 mM pr~orbol 12-myristate 13-acetate (TPA), and incubated for 48 hours on a shaker to prevent attachment. Cells are pelleted and resuspended in Hank's Buffered Saline (HBS) at a concentration of 2.5 x 106 cells/mL and plated in 96-well culture plates at a density of 5 x 105 cells/mL. Test compounds are diluted in HBS and added to the desired final concentration and the cells are incubated for an additional 4 hours.
Arachidonic acid is added to a final concentration of 30 mM, the cells incubated for 20 minutes at 37°C, and enzyme activity determined as described below.
COX-2 Assav For the COX-2 assay, subconfluent HOSC are trypsinized and resuspended at 3 x 106 cells/mL in MEM-FBS containing 1 ng human IL-1b/mL, plated in 96-well tissue culture plates at a density of 3 x 10' cells per well, incubated on a shaker for 1 hour to evenly _ distribute cells, followed by an additional 2 hour static incubation to allow attachment. The media is then replaced with MEM containing 2~ FBS (MEM-2~FBS) and 1 ng human IL-1b/mL, and the cells incubated for 18-22 WO 98/24780 PG"T/US97/22949 hours. Following replacement of media with 190 mL MEM, mL of test compound diluted in HBS is added to achieve the desired concentration and the cells incubated for 4 hours. The supernatants are removed and 5 replaced with MEM containing 30 mM arachidonic acid, the cells incubated for 20 minutes at 37°C, and enzyme activity determined as described below.
COX Activity Determined 10 After incubation with arachidonic acid, the reactions are stopped by the addition of 1 N HC1, followed by neutralization with 1 N NaOH and centrifugation to pellet cell debris. Cyclooxygenase enzyme activity in both HOSC and THP-1 cell supernatants is determined by measuring the concentration of PGE2 using a commercially available ELISA (Neogen #404110).
A standard curve.of PGEZ is used for calibration, and commercially available COX-1 and COX-2 inhibitors are included as standard controls.
Accordingly, the compounds of the invention or a pharmaceutical composition thereof are useful for prophylaxis and treatment of rheumatoid arthritis;
Pagets disease; osteophorosis; multiple myeloma;
uveititis; acute and chronic myelogenous leukemia;
pancreatic i~ cell destruction; osteoarthritis;
rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome CARDS); psoriasis; Crohn's disease; allergic rhinitis;
ulcerative colitis; anaphylaxis; contact dermatitis;
asthma; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; graft vs. host reaction; ischemia reperfusion injury; atherosclerosis; brain trauma; Alzheimer's disease; stroke; myocardial infarction; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection.
HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, CA 02274093 2003-02-20 I~
WD 98IZ4T80 ~ ~ PCT/US97i22949 adenovirus, the herpes viruses (including HSV-1, HSV-2), and herpes zoster, all of which are sensitive to TNF-oc and/or IL-1 inhibition or glucagon antagonism, will also be positively effected by the compounds and methods of the invention.
The compounds of the present invention also may possess analgesic properties and may be useful for the treatment of pain disorders, such as hyperalgesia due to excessive IL-1. The compounds of the present invention may also prevent the production of prostaglandins by inhibition of enzymes in the human arachidonic acid/prostaglandin pathway, including cyclooxygenase (WO
96/0338T~.
Because of their ability to lower TNF-a and IL-1 concentrations or inhibit glucagon binding to its receptor, the compounds of the invention are also useful research tools for studying the physiology associated with blocking these effects.
The methods of the invention comprise administering an effective dose of a compound of the invention, a pharmaceutical salt thereof, or a pharmaceutical composition of either, to a subject (i.e., an animal, preferably a mammal, most preferably a human) in need of a reduction in the level of TNF-a, TL-1, IL-6, and/or IL-8 levels and/or reduction in plasma glucose levels and/or which subject may be suffering from rheumatoid arthritis; Pagets disease; osteophorosis; multiple myeloma; uveititis; acute and chronic myelogeno s leukemia; pancreatic Q cell destruction; osteoarthritis;
rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS)~; psoriasis; Crohn's disease; allergic rhinitis;
ulcerative colitis; anaphylaxis; contact dermatitis;
asthma; muscle degeneration; cachexia; Reiter~s syndrome; type I and type II diabetes; bone resorption diseases; graft vs. host reaction; Alzheimer's disease;

216 ' stroke; myocardial infarction; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection, or which subject is infected by HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses (including HSV-1, HSV-2), or herpes zoster.
In another aspect, this invention comprises the use of a compound of the invention, or pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment either acutely or chronically of a TNF-oc, IL-1(3, IL-6, and/or IL-8 mediated disease state, including those described previously.
Also, the compounds of this invention are useful in the manufacture of a analgesic medicament and a medicament for treating pain disorders, such as hyperalgesia. The compounds of the present invention also are useful in the manufacture of a medicament to prevent the production of prostaglandins by inhibition of enzymes in the human arachidonic acid/prostaglandin pathway.
In still another aspect, this invention provides a pharmaceutical composition comprising an effective TNF-oc, IL-l~i, IL-6, and/or IL-8 lowering amount and/or effective plasma glucose level lowering amount of a compound of the invention and a pharmaceutically acceptable carrier or diluent, and if desired other "active ingredients. The compounds of the invention are administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. Therapeutically effective doses of the compounds of the present invention required to arrest the progress or prevent tissue damage associated with the disease are readily ascertained by one of ordinary skill in the art using standard methods.
For the treatment of TNF-OC, IL-1~3, IL-6, and IL-8 mediated diseases and/or hyperglycemia, the compounds of the present invention may be administered orally, parentally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles. The term parenteral as used herein includes, subcutaneous, intravenous, intramuscular, intrasternal, infusion techniques or intraperitoneally.
The dosage regimen for treating a TNF-OC, IL-1, IL
6, and IL-8 mediated diseases and/or hyperglycemia with the compounds of this invention and/or compositions of this invention is based on a variety of factors, including the type of disease, the age, weight, sex, medical condition of the patient, the severity of the condition, the route of administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely using standard methods. Dosage levels of the order from about 0.01 mg to 30 mg per kilogram of body weight per day, preferably from about 0.1 mg to 10 mg/kg, more preferably from about 0.25 mg to 1 mg/kg are useful for all methods of use disclosed herein.
The pharmaceutically active compounds of this invention can be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, including humans and other mammals .
For oral administration, the pharmaceutical composition may be in the form of, for example, a capsule, a tablet, a suspension, or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a given amount of the active ingredient. For example, these may contain an amount of active ingredient from about 1 to 2000 mg, - preferably from about 1 to 500 mg, more preferably from about 5 to 150 mg. A suitable daily dose for a human or other mammal may vary widely depending on the condition WO 98/24780 PCT/~1597/22949 - . 218 of the patient and other factors, but, once again, can be determined using routine methods.
The active ingredient may also be administered by injection as a composition with suitable carriers including saline, dextrose, or water. The daily parenteral dosage regimen will be from about 0.1 to about 30 mg/kg of total body weight, preferably from about 0.1 to about 10 mg/kg, and more preferably from about 0.25 mg to 1 mg/kg.
Injectable preparations, such as sterile injectabl~
aqueous or oleaginous suspensions, may be formulated according to the known are using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable non-irritating excipient such as cocoa butter and polyethylene glycQls that are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.
A suitable topical dose of active ingredient of a compound of the invention is 0.1 mg to 150 mg administered one to four, preferably one or two times daily. For topical administration, the active ingredient may comprise from 0.001 to 10~ w/w, e.g., from 1~ to 2~ by weight of the formulation, although it may comprise as much as 10~ w/w, but preferably not more than 5~ w/w, and more preferably from 0.1~ to 1~ of the - formulation.
Formulations suitable for topical administration . 5 include liquid or semi-liquid preparations suitable for penetration through the skin (e. g., liniments, lotions, ointments, creams, or pastes) and drops suitable for administration to the eye, ear, or nose.
For administration, the compounds of this invention are ordinarily combined with one or more adjuvants appropriate for the indicated route of administration.
The compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, stearic acid, talc, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, acacia, gelatin, sodium alginate, polyvinyl-pyrrolidine, and/or polyvinyl alcohol, and tableted or encapsulated for conventional administration.
Alternatively, the compounds of this invention may be dissolved in saline, water, polyethylene glycol, propylene glycol, ethanol, corn oil, peanut oil, cottonseed oil, sesame oil, tragacanth gum, and/or various buffers. Other adjuvants and modes of administration are well known in the pharmaceutical art.
The carrier or diluent may include time delay material, such as glyceryl monostearate or glyceryl distearate -.alone or with a wax, or other materials well known in the art.
The pharmaceutical compositions may be made up in a solid form (including granules, powders or suppositories) or in a liquid form (e.g., solutions, suspensions, or emulsions). The pharmaceutical compositions may be w subjected to conventional pharmaceutical operations such - as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc.

WO 98/24780 PCTlUS97J22949 Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules.
In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose, lactose, or starch. Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water.
Such compositions may also comprise adjuvants, such as wetting, sweetening, flavoring, and perfuming agents.
Compounds of the present invention can possess one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers as well as in the form of racemic or non-racemic mixtures thereof. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, e.g., by formation of diastereoisomeric salts, by =. treatment with an optically active acid or base.
Examples of appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric, and camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts. A different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers. Still another available method involves synthesis of covalent diastereoisomeric molecules by reacting compounds of the invention with an optically pure acid in an activated form or an optically pure isocyanate. The synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically pure compound.
The optically active compounds of the invention can likewise be obtained by using active starting materials.
These isomers may be in the form of a free acid, a free base, an ester or a salt.
The compounds of the present invention can be used in the form of salts derived from inorganic or organic acids. The salts include, but are not limited to, the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hyroxy-ethanesulfonate, lactate, maleate, methansulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 2-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble-or dispersible products are thereby obtained.
Examples of acids that may be employed to from pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, malefic acid, succinic acid and citric acid.
Other examples include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases.
While the compounds of the invention can be administered as the sole. active pharmaceutical agent, they can also be used in combination with one or more compounds of the invention or other agents. When administered as a combination, the therapeutic agents can be formulated as separate compositions that are given at the same time or different times, or the therapeutic agents can be given as a single composition.
The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims.
From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

Claims

WHAT IS CLAIMED IS:

1. ~A compound of formula or a pharmacutically acceptable salt thereof, wherein X is O, S Or NR5;
provided that the combined total number of aryl; heteroaryl, cycloalkyl and heterocyclyl radicals in -VC(R)W- is 0-3;
U is NR21 or CHR21; and n is an integer of 1-3;
R1 and R2 are each independently -Y or -Z-Y, and R3 and R4 are each independently -Z-Y; provided that R4 is other than substituted-aryl, (substituted-aryl)methyl or (substituted-aryl)ethyl radical, and the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Y and -Z-Y is 0-3;

wherein each Z is independently a (1) C1-C8 alkyl, C2-C8 alkenyl or C2-C8 alkynyl radical optionally substituted by (a) 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano or halo and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (Cl-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo. C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-3 radicals- of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo. C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;

each Y is independently a (1) hydrogen radical;
(2) halo, cyano or nitro radical;
(3) -C(O) -R20, -C(O)-OR21, -C(O)-NR5R21 or -C(NR5)-NR5R21-radical;
(4) -OR21, -O-C(O)-R21, -O-C(O)-NR5R21 or -O-C(O)-NR22-S(O)2-R21 radical;
(5) -SR21, -S(O)-R20, -S(O)2-R20, -S(O)2-NR5R21, -S(O)2-NR22-C(O)-R21, -S(O)2-NR22-C(O)-OR20 or -S(O)2-NR22-C(O)-NR5R21 radical; or (6) -NR5R21, -NR22-C(O)-R21, -NR22-C(O)-OR20, -NR22-C(O)-NR5R21, -NR22-C(NR5)-NR5R21, -NR22-S(O)2-R20 or -NR22-S(O)2-NR5R21 radical;
wherein each R5 is independently (1) hydrogen radicals;
(2) C1-C8 alkyl, C2-C8 alkenyl or C2-C8 alkynyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4-alkyl)amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano or halo; or (3) aryl, heteroaryl, aryl-C1-C4-alkyl, heteroaryl-C1-C4-alkyl, heterocyclyl, heterocyclyl-C1-C4-alkyl, C3-C8 cycloalkyl or C3-C8-cycloalkyl-C1-C4-alkyl radicals optionally substituted by-1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4-alkyl)amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; and wherein each R20 is independently (1) C1-C8 alkyl, C2-C8 alkenyl or C2-C8 alkynyl radicals optionally substituted by 1-3 radicals of -CO2R23, amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, N-((C1-C4 alkoxy)carbonyl)-N-(C1-C4 alkyl)amino, aminocarbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, cyano, halo or aryl-C1-C4-alkoxy, aryl-C1-C4-alkylthio, aryl-C1-C4-alkylsulfonyl, C3-C8 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, C1-C4 alkanoyl, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;

each R21 is independently hydrogen radical or R20;

each R22 is independently (1) hydrogen radical;
(2) C1-C4 alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C2-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;

each R23 is independently hydrogen or C1-C4 alkyl, or aryl, heteroaryl, aryl-C1-C4-alkyl or heteroaryl-C1-C4-alkyl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;

R11 is an aryl radical and R12 is a heteroaryl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of;
(1) R30;
(2) halo or cyano radicals;
(3) -C(O)-R30, -C(O)-OR29, -C(O)-NR31R32 or -C(NR31)-NR31R32 radicals; or (4) -OR29, -SR29, -S(O)-R30, -S(O)2-R30, -S(O)2-NR31R32, -NR31R32 or -NR33-C(O)-R29 radicals;
provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R11 and R12 is 0 - 1;
wherein each R30 is independently (1) C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl radicals optionally substituted by 1-3 radicals of -NR31R31, -CO2R23, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, cyano, halo or aryl-C1-C4-alkoxy, aryl-C1-C4-alkylthio, aryl-C1-C4-alkylsulfonyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;

(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
each R29 is independently hydrogen radical or R30:
each R31 and R32 are each independently (1) hydrogen radicals;
(2) C1-C4 alkyl radical optionally substituted by an C3-C8 cycloalkyl, aryl, heterocyclyl ar heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) aryl, heteroaryl, heterocyclyl or C3-C8 cycloalkyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; and wherein each R33 is independently (1) hydrogen radical; or (2) C1-C4 alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; and wherein heterocyclyl is a radical of a monocyclic or bicyclic saturated heterocyclic ring system having 5-8 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally partially unsaturated or benzo-fused and optionally substituted by 1-2 oxo or thioxo radicals;
aryl is a phenyl or naphthyl radical; and heteroaryl is radical of a monocyclic or bicyclic aromatic heterocyclic ring system having 5-6 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused or saturated C3-C4-carbocyclic-fused.

2. A compound of formula or a pharmacutically acceptable salt thereof, wherein X is O, S or NR5;

230a provided that the combined total number of aryl; heteroaryl, cycloalkyl and heterocyclyl radicals in -VC(R)W- is 0-3;
U is NR21 or CHR21; and n is an integer of 1-3;
R1 and R2 are each independently -Y or -Z-Y, and R3 and R4 are each independently -Z-Y; provided that R4 is other than substituted-aryl, (substituted-aryl)methyl or (substituted-aryl)ethyl radical, and the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Y and -Z-Y is 0-3;
each Z is independently a (1) C1-C8 alkyl, C2-C8 alkenyl or C2-C8 alkynyl radical optionally substituted by (a) 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino; C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or halo and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C5 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
each Y is independently a (1) hydrogen radical;
(2) halo, cyano or nitro radical;
(3) -C(O)-R20, -C(O)-OR21, -C(O)-NR5R21 or -C(NR5)-NR5R21 radical;
(4) -OR21, -O-C(O)-R21, -O-C(O)-NR5R21 or -O-C(O)-NR22-S(O)2-R20 radical;
(5) -SR21, -S(O)-R20, -S(O)2-R20, -S(O)2-NR5R21, -S(O)2-NR22-C(O)-R21, -S(O)2-NR22-C(O)-OR20 or -S(O)2-NR22-C(O)-NR5R21 radical; or (6) -NR5R21, -NR22-C(O)-R21, -NR22-C(O)-OR20, -NR22-C(O)-NR5R21, -NR22-C(NR5)-NR5R21, -NR22-S(O)2-R20 or -NR22-S(O)2-NR5R21 radical;

231a each R5 is independently (1) hydrogen radicals;
(2) C1-C4 alkyl, C2-C5 alkenyl or C2-C5 alkynyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4-alkyl)amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or halo; or (3) aryl, heteroaryl, aryl-C1-C4-alkyl, heteroaryl-C1-C4-alkyl, heterocyclyl, heterocyclyl-C2-C4-alkyl, C3-C8 cycloalkyl or C3-C8-cycloalkyl-C1-C4-alkyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4-alkyl)amino, hydroxy, C1-C4 alkoxy, -C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
each R20 is independently (1) C1-C8 alkyl, C2-C5 alkenyl or C2-C5 alkynyl radicals optionally substituted by 1-3 radicals of -CO2R23, amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, N-((C1-C4 alkoxy)carbonyl)-N-(C1-C4 alkyl)amino, aminocarbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo or aryl-C1-C4-alkoxy, aryl-C1-C4-alkylthio, aryl-C1-C4-alkylsulfonyl, C3-C8 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, C1-C5 alkanoyl, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl-radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C2-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
each R21 is independently hydrogen radical or R20;
each R22 is independently (1) hydrogen radical;
(2) C1-C4 alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or 232a (3) heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
each R23 is independently hydrogen or C1-C4 alkyl, or aryl, heteroaryl, -aryl-C1-C4-alkyl or heteroaryl-C1-C4-alkyl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4~alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
R11 is an aryl radical and R12 is a heteroaryl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of (1) R30;
(2) halo or cyano radicals;
(3) -C(O)-R30, -C(O)-OR29, -C(O)-NR31R32 or -C(NR31)-NR31R32 radicals; or (4) -OR29, -SR29, -S(O)-R30, -S(O)2-R30, -S(O)2-NR31R32, -NR31R32 or -NR33-C(O)-R29 radicals;
provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R11 and R12 is 0 - 1;
each R30 is independently (1) C1-C4 alkyl radical optionally substituted by 1-3 radicals of (a) -NR31R31:
(b) C1-C4 alkoxy-carbonyl or phenoxycarbonyl or phenylmethoxycarbonyl optionally substituted by 1-3 radicals of amino, alkylamino, di-(C1-C4-alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl;
or (c) hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, or phenyl-C1-C4-alkoxy, phenyl-C1-C4-alkylthio, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
(2) C1-C4 haloalkyl of 1-3 halo radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
each R29 is independently hydrogen radical or R30;
each R31 is independently (1) hydrogen radicals; or (2) C1-C4 alkyl radical optionally substituted by an phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or trifluoromethyl radicals; and each R32 is independently (1) hydrogen radicals;

(2) C1-C4 alkyl radical optionally substituted by an C3-C6 cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) aryl, heteroaryl, heterocyclyl or C3-C6 cycloalkyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; and each R33 is independently hydrogen or C1-C4 alkyl radical, and wherein heterocyclyl is a radical of a monocyclic or bicyclic saturated heterocyclic ring system having 5-8 ring-members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally partially unsaturated or benzo-fused and optionally substituted by 1-2 oxo or thioxo radicals;
aryl is a phenyl or naphthyl radical; and heteroaryl is radical of a monocyclic or bicyclic aromatic heterocyclic ring system having 5-6 ring members per ring, wherein 2-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused or saturated C3-C4-carbocyclic-fused.

234a 3. The compound of Claim 2 or a pharmaceutically acceptable salt thereof, wherein X is O or S;

provided that the. combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in -VC(R)W- is 0-2;
wherein R1, is -Y or -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R1 is 0-3;

Z is a (1) C1-C8 alkyl or C2-C8 alkenyl radical optionally substituted by (a) 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or halo and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(C1-C4 alkyl)amino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl radicals; or (3) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
Y is a (1) hydrogen radical;
(2) halo radical;
(3) -C(O)-R20, -C(O)-OR21, -C(O)-NR5R21 or -C(NR5)-NR5R21 radical;
(4) -OR21, -O-C(O)-R21 or -O-C(O)-NR5R21 radical;
(5) -SR21, -S(O)-R20, -S(O)2-R20 or -S(O)2-NR5R21 radical;
or (6) -NR5R21, -NR22-C(O)-R21, -NR22-C(O)-OR20, -NR22-C(O)-NR5R21, -NR22-C(NR5)-NR5R21, -NR22-S(O)2-R20 or -NR22-S(O)2-NR5R21 radical;

each R5 is independently (1) hydrogen radicals;
(2) C1-C4 alkyl or C2-C5 alkenyl radicals optionally substituted by 1-3 radicals of amino, di-(C1-C4-alkyl)amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or halo; or (3) phenyl-C1-C2-alkyl, heteroaryl-C1-C2-alkyl, heterocyclyl-C1-C2-alkyl or C3-C6-cycloalkyl-C1-C2-alkyl radicals optionally substituted by 1-3 radicals of amino, di-(C1-C4-alkyl)amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
each R24 is independently (1) C1-C8 alkyl or C2-C5 alkenyl radicals optionally substituted by 1-3 radicals of -CO2R23, amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, N-((C1-C4 alkoxy)carbonyl)-N-(C1-C4 alkyl)amino, aminocarbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo or aryl-C1-C4-alkoxy, aryl-C1-C4-alkylthio, aryl-C1-C4-alkylsulfonyl, C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, C2-C5 alkanoyl, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
each R21 is independently hydrogen radical or R20;
each R22 is independently (1) hydrogen radical; or (2) C1-C4 alkyl radical optionally substituted by a radical of phenyl or heteroaryl optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, C2-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
each R23 is independently hydrogen or C1-C4 alkyl, or phenyl, heteroaryl, phenyl-C1-C2-alkyl or heteroaryl-C1-C2-alkyl optionally substituted by 1-3 radicals of amino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
R2 is a radical of hydrogen, C1-C4 alkyl, halo, cyano, hydroxy, C1-C4 alkoxy, C1-C2 haloalkoxy of 1-3 halo radicals, C1-C4 alkylthio, amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino or C1-C2 haloalkyl of 1-3 halo radicals;

(1) C1-C8 alkyl or C2-C8 alkenyl radical optionally substituted by (a) 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl, trifluoromethoxy or trifluoromethyl radicals; or (2) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl, trifluoromethoxy or trifluoromethyl radicals;
R11 is an aryl radical and R12 is a heteroaryl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of (1) R30:
(2) halo or cyano radicals;
(3) -C(O)-R30, -C(O)-OR29, -C(O)-NR31R32 or -C(NR31)-NR31R32 radicals; or (4) -OR29, -SR29, -S(O)-R30, -S(O)2-R30, -S(O)2-NR31R32, -NR31R32, or -NR33-C(O)-R29 radicals;
provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R11 and R12 is 0-1;
each R30 is independently (1) C1-C4 alkyl radical optionally substituted by (a) amino, C1-C4 alkylamino or di-(C1-C4-alkyl)amino radicals; or (b) hydroxy, C1-C4 alkoxy, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
(2) C1-C2 haloalkyl of 1-3 halo radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
each R29 is independently hydrogen radical or R30;
each R31 is independently hydrogen or C1-C4 alkyl radicals; and each R32 is independently (1) hydrogen radicals;
(2) C1-C4 alkyl radical optionally substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkyl or trifluoromethyl radicals; or (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkyl or trifluoromethyl radicals; and each R33 is independently hydrogen or methyl radical;
and wherein heterocyclyl is a radical of a monocyclic saturated heterocyclic ring system having 5-6 ring members, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused and optionally substituted by 1-2 oxo or thioxo radicals; aryl is a phenyl or naphthyl radical; and heteroaryl is radical of a monocyclic aromatic heterocyclic ring system having 5-6 ring members, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused or saturated C3-C4-carbocyclic-fused.

4. The compound of Claim 3 or a pharmaceutically acceptable salt thereof, wherein Z is a (1) C1-C4 alkyl or C2-C5 alkenyl radical optionally substituted by (a) 1-3 radicals of amino, di-(C1-C2 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio or halo and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C2 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(C1-C2 alkyl)amino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio or C1-C4 alkyl radicals; or (3) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
each R5 is independently (1) hydrogen radical;
(2) C1-C4 alkyl radical optionally substituted by 1-3 radicals of amino, di-(C1-C2-alkyl)amino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio or halo; or (3) phenyl-C1-C2-alkyl, heteroaryl-C1-C2-alkyl, heterocyclyl-C1-C2-alkyl or C3-C6-cycloalkyl-C1-C2-alkyl radicals optionally substituted by 1-3 radicals of amino, di-(C1-C2-alkyl)amino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, methoxy, methylthio, cyano, C1-C4 alkyl or trifluoromethyl radicals;
each R22 is independently hydrogen or C1-C4 alkyl radical;
each R23 is independently hydrogen or C1-C4 alkyl, or phenyl, heteroaryl, phenyl-C1-C2-alkyl or heteroaryl-C1-C2-alkyl optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
R3 is (1) C1-C8 alkyl radical optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, hydroxy, C1-C4 alkoxy or aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl, trifluoromethoxy or trifluoromethyl radicals; or (2) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl, trifluoromethoxy or trifluoromethyl radicals;
R11 is an aryl radical and R12 is a heteroaryl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of (1) R30:
(2) halo or cyano radicals;
(3) -C(O)-R30, -C(O)-OR29, -C(O)-NR31R32 or -C(NR31)-NR31R32 radicals; or (4) -OR29, -SR29, -S(O)-R30, -S(O)2-R30, -S(O)2-NR31R32, -NR31R32 or -NR33-C(O)-R29 radicals;
provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R11 and R12 is 0-1;
each R30 is independently (1) C1-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, acetamido, hydroxy, C1-C2 alkoxy, halo, C1-C4 alkyl or trifluoromethyl radicals;
(2) trifluoromethyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, acetamido, hydroxy, C1-C2 alkoxy, halo, C1-C4 alkyl or trifluoromethyl radicals;
each R29 is independently hydrogen radical or R30; and each R32 is independently (1) hydrogen radicals;
(2) C1-C4 alkyl radical or C1-C2 alkyl radical substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, acetamido, hydroxy, C1-C2 alkoxy, C1-C4 alkyl or trifluoromethyl radicals; or (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino-, acetamido, hydroxy, C1-C2 alkoxy, C1-C4 alkyl or trifluoromethyl radicals; and wherein heterocyclyl is a radical of a monocyclic saturated heterocyclic ring system having 5-6 ring members, wherein 1-2 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused and optionally substituted by 1-2 oxo or thioxo radicals; aryl is a phenyl or naphthyl radical; and heteroaryl is radical of a monocyclic aromatic heterocyclic ring system having 5-6 ring members, wherein 1-2 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused.

5. The compound of Claim 4 or a pharmaceutically acceptable salt thereof, wherein wherein R1 is -Y or -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R1 is 0-2;
Z is a (1) C1-C4 alkyl or C2-C5 alkenyl radical optionally substituted by (a) 1-3 radicals of amino, di-(C1-C2 alkyl)amino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio or halo and (b) 1-2 radicals of aryl or heteroaryl optionally substituted by 1-2 radicals of amino, di-(C1-C2 alkyl)amino, acetamido, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals; or (2) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, acetamido, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
Y is a (1) hydrogen radical;
(2) -C(O)-R20, -C(O)-OR21 or -C(O)-NR5R21 radical;
(3) -OR21, -SR21, -S(O)-R20, -S(O)2-R20 or -S(O)2-NR5R21 radical; or (4) -NR5R21, -NR22-C(O)-R21, -NR22-C(O)-OR20, -NR22-C(O)-NR5R21, -NR22-S(O)2-R20 or -NR22-S(O)2-NR5R21 radical;
each R5 is independently (1) hydrogen radical;
(2) C1-C4 alkyl radical optionally substituted by 1-3 halo radicals; or (3) phenyl-C1-C2-alkyl or heteroaryl-C1-C2-alkyl, radicals optionally substituted by 1-3 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, methyl or trifluoromethyl radicals;
each R20 is independently (1) C1-C8 alkyl or C2-C5 alkenyl radicals optionally substituted by 1-3 radicals of -CO2R23, amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, N-((C1-C4 alkoxy)carbonyl)-N-(C1-C4 alkyl)amino, aminocarbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo or aryl-C1-C4-alkoxy, aryl-C1-C4-alkylthio, aryl-C1-C4-alkylsulfonyl, C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, C1-C5-alkanoyl, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4-alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(C1-C4 alkyl)amino, (C1-C4 alkoxy)carbonylamino, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, acetamido, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or trifluoromethyl radicals;
each R21 is independently hydrogen radical or R20;
each R23 is independently hydrogen or C1-C4 alkyl, or phenyl-C1-C2-alkyl or heteroaryl-C1-C2-alkyl optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, acetamido, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
R2 is a radical of hydrogen, C1-C4 alkyl, halo, cyano, hydroxy, C1-C4 alkoxy, trifluoromethoxy or trifluoromethyl;
R3 is C1-C8 alkyl radical optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, hydroxy, C1-C4 alkoxy or aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl, trifluoromethoxy or trifluoromethyl radicals;
R11 is an aryl radical and R12 is a heteroaryl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of (1) R30;
(2) halo or cyano radicals; or -C(O)-NR31R32, -OR29, -SR29, -S(O)-R30, -S(O)2-R30, -S(O)2-NR31R32, -NR31R32 or -NR33-C(O)-R29 radicals;
provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R11 and R12 is 0-1;
each R30 is independently (1) C1-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
(2) trifluoromethyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
each R29 is independently hydrogen radical or R30;
each R31 is independently hydrogen, methyl or ethyl radicals; and each R32 is independently (1) hydrogen radicals;
(2) C1-C4 alkyl radical or C1-C2 alkyl radical substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl on trifluoromethyl radicals; or (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals.
6. The compound of Claim 5 or a pharmaceutically acceptable salt thereof, wherein R3 is a C1-C4 alkyl radial;
R11 is an aryl radical optionally substituted by 1-2 radicals of (1) R30;
(2) halo or cyano radicals; or (3) -C(O)-NR31R32, -OR29, -SR29, -S(O)-R30, -S(O)2-R30, -S(O)2-NR31R32, -NR31R32 or -NR33-C(O)-R29 radicals; and R12 is a heteroaryl radical optionally substituted by 1-2 radicals of (1) R30;
(2) halo or cyano radicals;
(3) -C(O)-NR31R32, -OR29, -SR29, -NR33R32 or -NR33-C(O)-R29 radicals;
provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R11 and R12 is 0-2;
R30 is independently (1) C1-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;

(2) trifluoromethyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
R29 is an aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals; and R32 is independently (1) hydrogen or C1-C4 alkyl radical; or (2) phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals.
7. The compound of Claim 6 or a pharmaceutically acceptable salt thereof, wherein wherein R1 is -Y or -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R1 is 0-1;
Z is a C1-C4 alkyl radical optionally substituted by 1-2 radicals of amino, di-(C1-C2 alkyl)amino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, halo, or aryl or heteroaryl optionally substituted by 1-2 radicals of hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
each R5 is independently hydrogen or C1-C4 alkyl radical;

each R20 is independently (1) C1-C8 alkyl radicals optionally substituted by 1-3 radicals of -CO2R23, amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, N-((C1-C4 alkoxy)carbonyl)-N-(C1-C4 alkyl)amino, aminocarbonylamino; hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo or C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of (C1-C4 alkoxy)carbonyl, amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or trifluoromethyl radicals;
each R21 is independently hydrogen radical or R20:
each R23 is independently. hydrogen or C1-C4 alkyl, or phenyl-C1-C2-alkyl optionally substituted by 1-2 radicals of hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
R2 is a hydrogen radical;
R3 is a methyl or ethyl radical;

R11 is an aryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl, methylsulfonyl, aminocarbonyl, methyl or trifluoromethyl radicals; and R12 is a heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals.
8. The compound of Claim 7 or a pharmaceutically acceptable salt thereof, wherein Z is C1-C4 alkyl radical optionally substituted by 1-2 radicals of amino, t-butoxycarbonylamino, dimethylamino, hydroxy, methoxy, methylthio or halo radicals;
Y is a (1) hydrogen radical;
(2) -C(O)-R20, -C(O)-OR21 or -C(O)-NR5R21 radical;
(3) -OR21, -SR21, -S(O)-R20, -S(O)2-R20 or -S(O)2-NR5R21 radical; or (4) -NR5R21, -NR22-C(O)-R21 or -NR22-S(O)2-R20 radical;
R5 is a hydrogen radical;
each R20 is independently (1) C1-C6 alkyl radicals optionally substituted by 1-3 radicals of -CO2R23, amino, methylamino, dimethylamino, t-butoxycarbonylamino, N-((t-butoxy)carbonyl)-N-(methyl)amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl, methylsulfonyl, halo or C5-C6 cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals:
(2) heterocyclyl radical optionally substituted by 1-2 radicals of t-butoxycarbonyl, hydroxy, or C1-C4 alkyl;
or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
each R21 is independently hydrogen radical or R20;
each R22 is independently hydrogen or methyl radical;
each R23 is independently hydrogen or C1-C4 alkyl radicals;
R11 is an unsubstituted phenyl,or naphthyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamiao, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl, methylsulfonyl, aminocarbonyl, methyl or trifluoromethyl radicals; and R12 is a 4-pyridyl, 4-quinolinyl, 4-imidazolyl or 4-pyrimidinyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals.
g. The compound of Claim 8 or a pharmaceutically acceptable salt thereof, wherein Y is a (1) -C(O)-R2 p or -C(O)-NR5R21 radical;
(2) -OR21, -SR21, -S (O) -R20, -S(O)2-R20 or -S(O)2-NR5R21 radical; or (3) -NR5R21, -NR22-C(O)-R21 or -NR22-S(O)2-R20 radical ;
each R20 is independently (1) C1-C6 alkyl radicals optionally substituted by 1-3 radicals of -CO2R23, amino, methylamino, dimethylamino, t-butoxycarbonylamino, N-((t-butoxy)carbonyl)-N-(methyl)amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl, methylsulfonyl, halo or C5-C6 cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by t-butoxycarbonyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals; and each R21 is independently hydrogen radical or R20 10. The compound of Claim 9 or a pharmaceutically acceptable salt thereof, wherein Y is a -OR21, -SR21 or -NR5R21 radical;
each R20 is independently (1) C1-C6 alkyl radicals optionally substituted by 1-3 radicals of amino, methylamino, dimethylamino, hydroxy or phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
(2) heterocyclyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
each R21 is independently hydrogen radical or R20;
R11 is an unsubstituted phenyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfonyl, methyl or trifluoromethyl radicals; and R12 is a 4-pyridyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals.
11. The compound of Claim 2 or a pharmaceutically acceptable salt thereof, wherein X is O or S;
provided that the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in -VC(R)W- is 0-2;
wherein R1 is -Y or -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R1 is 0-3;
Z is a (1) C1-C8 alkyl or C2-C8 alkenyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, or heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(C1-C4 alkyl)amino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl radicals; or (3) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
Y is a (1) hydrogen radical;
(2) halo radical;
(3) -C(O)-R20, -C(O)-OR21, -C(O)-NR5R21 or -C(NR5)-NR5R21 radical;
(4) -OR21, -O-C(O)-R21 or -O-C(O)-NR5R21 radical;
(5) -SR21, -S(O)-R20, -S(O)2-R20 or -S(O)2-NR5R21 radical;
or (6) -NR5R21, -NR22-C(O)-R21, -NR22-C(O)-OR20, -NR22-C(O)-NR5R21, -NR22-C(NR5) -NR5R21, -NR22-S(O)2-R20 or -NR22-S(O)2-NR5R21 radical;
each R5 is independently (1) hydrogen radicals;

(2) C1-C4 alkyl or C2-C5 alkenyl radicals optionally substituted by 1-3 radicals of amino, di-(C1-C4-alkyl)amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or halo; or (3) phenyl-C1-C2-alkyl, heteroaryl-C1-C2-alkyl, heterocyclyl-C1-C2-alkyl or C3-C6-cycloalkyl-C1-C2-alkyl radicals optionally substituted by 1-3 radicals of amino, di-(C1-C4-alkyl)amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
each R20 is independently (1) C1-C8 alkyl or C2-C5 alkenyl radicals optionally substituted by 1-3 radicals of -CO2R23, amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, N-((C1-C4 alkoxy)carbonyl)-N-(C1-C4 alkyl)amino, aminocarbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo or aryl-C1-C4-alkoxy, aryl-C1-C4-alkylthio, aryl-C1-C4-alkylsulfonyl, C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C5 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, C1-C5 alkanoyl, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or Cl-C2 haloalkyl of 1-3 halo radicals;
each R21 is independently hydrogen radical or R2o:
each R22 is independently (1) hydrogen radical; or (2) C1-C4 alkyl radical optionally substituted by a radical of phenyl or heteroaryl optionally substituted by 1-3 radicals of amino, di-(C1-C2-alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
each R23 is independently hydrogen or C1-C4 alkyl, or phenyl, heteroaryl, phenyl-C1-C2-alkyl or heteroaryl-C1-C2-alkyl optionally substituted by 1-3 radicals of amino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
R4 is (1) C1-C8 alkyl or C2-C8 alkenyl radical optionally substituted by (a) 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl, trifluoromethoxy or trifluoromethyl radicals; or (2) heteroaryl radical optionally substituted by 2-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl, trifluoromethoxy or trifluoromethyl radicals;
R11 is an aryl radical and R12 is a heteroaryl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of (1) R30;
(2) halo or cyano radicals;
(3 ) -C(O)-R30, -C(O)-OR29, -C(O)-NR31R32 or -C(NR31)-NR31R32 radicals; or (4) -OR29, -SR29, -S(O)-R30, -S(O)2-R30, -S(O)2-NR31R32, -NR31R32 or -NR33-C(O)-R29 radicals;
provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R11 and R12 i s 0-1;
each R30 is independently (1) C1-C4 alkyl radical optionally substituted by (a) amino, C1-C4 alkylamino or di-(C1-C4-alkyl)amino radicals; or (b) hydroxy, C1-C4 alkoxy, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;

(2) C1-C2 haloalkyl of 1-3 halo radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
each R29 is independently hydrogen radical or R30;
each R31 is independently hydrogen or C1-C4 alkyl radicals; and each R32 is independently (1) hydrogen radicals;
(2) C1-C4 alkyl radical optionally substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkyl or trifluoromethyl radicals; or (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkyl or trifluoromethyl radicals; and each R33 is independently hydrogen or methyl radical;
and wherein heterocyclyl is a radical of a monocyclic saturated heterocyclic ring system having 5-6 ring members, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused and optionally substituted by 1-2 oxo or thioxo radicals; aryl is a phenyl or naphthyl radical; and heteroaryl is radical of a monocyclic aromatic heterocyclic ring system having 5-6 ring members, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused or saturated C3-C4-carbocyclic-fused.
12. The compound of Claim 11 or a pharmaceutically acceptable salt thereof, wherein Z is a (1) C1-C4 alkyl or C2-C5 alkenyl radical optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, halo, or heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C2 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(C1-C2 alkyl)amino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio or C1-C4 alkyl radicals; or (3) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
each R5 is independently (1) hydrogen radical;
(2) C1-C4 alkyl radical optionally substituted by 1-3 radicals of amino, di-(C1-C2-alkyl)amino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio or halo; or (3) phenyl-C1-C2-alkyl, heteroaryl-C1-C2-alkyl, heterocyclyl-C1-C2-alkyl or C3-C6-cycloalkyl-C1-C2-alkyl radicals optionally substituted by 1-3 radicals of amino, di-(C1-C2-alkyl)amino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, methoxy, methylthio, cyano, C1-C4 alkyl or trifluoromethyl radicals;
each R22 is independently hydrogen or C1-C4 alkyl radical;
each R23 is independently hydrogen or C1-C4 alkyl, or phenyl, heteroaryl, phenyl-C1-C2-alkyl or heteroaryl-C1-C2-alkyl optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
R4 is (1) C1-C8 alkyl radical optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, hydroxy, C1-C4 alkoxy or aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl, trifluoromethoxy or trifluoromethyl radicals; or (2) heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl, trifluoromethoxy or trifluoromethyl radicals;
R11 is an aryl radical and R12 is a heteroaryl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of (1) R30:
(2) halo or cyano radicals;
(3) -C(O)-R30, -C(O)-OR29, -C(O)-NR31R32 or -C(NR31)-NR31R32 radicals; or (4) -OR29, -SR29, -S(O)-R30, -S(O)2-R30, -S(O)2-NR31R32, -NR31R32 or NR33-C(O)-R29 radicals;
provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R11 and R12 is 0-1;
each R30 is independently (1) C1-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, acetamido, hydroxy, C1-C2 alkoxy, halo, C1-C4 alkyl or trifluoromethyl radicals;
(2) trifluoromethyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, acetamido, hydroxy, C1-C2 alkoxy, halo, C1-C4 alkyl or trifluoromethyl radicals;
each R29 is independently hydrogen radical or R30; and each R32 is independently (1) hydrogen radicals;
(2) C1-C4 alkyl radical or C1-C2 alkyl radical substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, acetamido, hydroxy, C1-C2 alkoxy, C1-C4 alkyl or trifluoromethyl radicals; or (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, acetamido, hydroxy, C1-C2 alkoxy, C1-C4 alkyl or trifluoromethyl radicals; and wherein heterocyclyl is a radical of a monocyclic saturated heterocyclic ring system having 5-6 ring members, wherein 1-2 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused and optionally substituted by 1-2 oxo or thioxo, radicals; aryl is a phenyl or naphthyl radical; and heteroaryl is radical of a monocyclic aromatic heterocyclic ring system having 5-6 ring members, wherein 1-2 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused.
13. The compound of Claim 12 or a pharmaceutically acceptable salt thereof, wherein wherein R1 is -Y or -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R1 is 0-2;
Z is a (1) C1-C4 alkyl or C2-C5 alkenyl radical optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, halo, or aryl or heteroaryl optionally substituted by 1-2 radicals of amino, di-(C1-C2 alkyl)amino, acetamido, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals; or (2) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, acetamido, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
Y is a (1) hydrogen radical;

(2) -C(O)-R20, -C(O)-OR21 or -C(O)-NR5R21 radical;
(3) -OR21, -SR21, -S(O)-R20, -S(O)2-R20 or -S(O)2-NR5R21 radical; or (4) -NR5R21, -NR22-C(O)-R21, -NR22-C(O)-OR20, -NR22-C(O)-NR5R21, -NR22-S(O)2-R20 or -NR22-S(O)2-NR5R21 radical;
each R5 is independently (1) hydrogen radical;
(2) C1-C4 alkyl radical optionally substituted by 1-3 halo radicals; or (3) phenyl-C1-C2-alkyl or heteroaryl-C1-C2-alkyl, radicals optionally substituted by 1-3 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, methyl or trifluoromethyl radicals;
each R20 is independently (1) C1-C8 alkyl or C2-C5 alkenyl radicals optionally substituted by 1-3 radicals of -CO2R23, amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, N-((C1-C4 alkoxy)carbonyl)-N-(C1-C4 alkyl)amino, aminocarbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo or aryl-C1-C4-alkoxy, aryl-C1-C4-alkylthio, aryl-C1-C4-alkylsulfonyl, C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted. by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, C1-C5 alkanoyl, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(C1-C4 alkyl)amino, (C1-C4 alkoxy)carbonylamino, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, acetamido, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or trifluoromethyl radicals;
each R21 is independently hydrogen radical or R20;
each R23 is independently hydrogen or C1-C4 alkyl, or phenyl-C1-C2-alkyl or heteroaryl-C1-C2-alkyl optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, acetamido, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
R4 is a C1-C8 alkyl radical optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, hydroxy, C1-C4 alkoxy or aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C4 alkoxy, C1-C4 alkylthio, halo, C1-C4 alkyl, trifluoromethoxy or trifluoromethyl radicals;
R11 is an aryl radical and R12 is a heteroaryl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of (1) R30;
(2) halo or cyano radicals; or (3) -C(O)-NR31R32, -OR29, -SR29, -S(O)-R30, -S(O)2-R30, S(O)2-NR31R32, -NR31R32 or NR33-C(O)-R29 radicals;
provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R11 and R12 is 0-1;

each R30 is independently (1) C1-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
(2) trifluoromethyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
each R29 is independently hydrogen radical or R30;
each R31 is independently hydrogen, methyl or ethyl radicals; and each R32 is independently (1) hydrogen radicals;
(2) C1-C4 alkyl radical or C1-C2 alkyl radical substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals; or (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals.
14. The compound of Claim 13 or a pharmaceutically acceptable salt thereof, wherein R4 is a C1-C4 alkyl radical;
R11 is an aryl radical optionally substituted by 1-2 radicals of (1) R30;
(2) halo or cyano radicals; or (3) -C(O)-NR31R32, -OR29, -SR29, -S(O)-R30, -S(O)2-R30, -S(O)2-NR31R32, -NR31R32 or NR33-C(O)-R29 radicals; and R12 is a heteroaryl radical optionally substituted by 1-2 radicals of (1) R30;
(2) halo or cyano radicals; or (3) -C(O)-NR31R32, -OR29, -SR29, -NR31R32 or -NR33-C(O)-R29 radicals;
provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R11 and R12 is 0-1;
R30 is independently (1) C1-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
(2) trifluoromethyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
each R29 is independently hydrogen radical or R30;
R32 is independently (1) hydrogen or C1-C4 alkyl radical; or (2) phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals.
15. The compound of Claim 14 or a pharmaceutically acceptable salt thereof, wherein wherein R1 is -Y or -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R1 is 0-1;
Z is a C1-C4 alkyl radical optionally substituted by 1-2 radicals of amino, di-(C1-C2 alkyl)amino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, halo, or aryl or heteroaryl optionally substituted by 1-2 radicals of hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
each R5 is independently hydrogen or C1-C4 alkyl radical;
each R20 is independently (1) C1-C8 alkyl radicals optionally substituted by 1-3 radicals of -CO2R23, amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, N-((C1-C4 alkoxy)carbonyl)-N-(C1-C4 alkyl)amino, aminocarbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo or C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of (C1-C4 alkoxy)carbonyl, amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or trifluoromethyl radicals;
each R21 is independently hydrogen radical or R20;
each R23 is independently hydrogen or C1-C4 alkyl, or phenyl-C1-C2-alkyl optionally substituted by 1-2 radicals of hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
R4 is a methyl or ethyl radical;
R11 is an aryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl, methylsulfonyl, aminocarbonyl, methyl or trifluoromethyl radicals; and R12 is a heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals.
16. The compound of Claim 15 or a pharmaceutically acceptable salt thereof, wherein Z is C1-C4 alkyl radical optionally substituted by 1-2 radicals of amino, t-butoxycarbonylamino, dimethylamino, hydroxy, methoxy, methylthio or halo radicals;
Y is a (1) hydrogen radical;
(2) -C(O)-R20, -C(O)-OR21 or -C(O)-NR5R21 radical;
(3) -OR21, -SR21, -S(O)-R20, -S(O)2-R20 or -S(O)2-NR5R21 radical; or (4) -NR5R21, -NR22-C(O)-R21 or -NR22-S(O)2-R20 radical;
R5 is a hydrogen radical;
each R20 is independently (1) C1-C6 alkyl radicals optionally substituted by 1-3 radicals of -CO2R23, amino, methylamino, dimethylamino, t-butoxycarbonylamino, N-((t-butoxy)carbonyl)-N-(methyl)amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl, methylsulfonyl, halo or C5-C6 cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of t-butoxycarbonyl, hydroxy, or C1-C4 alkyl;
or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
each R21 is independently hydrogen radical or R20;
each R22 is independently hydrogen or methyl radical;

each R23 is independently hydrogen or C1-C4 alkyl radicals;
R11 is an unsubstituted phenyl or naphthyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl, methylsulfonyl, aminocarbonyl, methyl or trifluoromethyl radicals; and R12 is a 4-pyridyl, 4-quinolinyl, 4-imidazolyl or 4-pyrimidinyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals.
17. The compound of Claim 16 or a pharmaceutically acceptable salt thereof, wherein Y is a (1) -C(O)-R20 or -C(O)-NR5R21 radical;
(2) -OR21, -SR21, -S(O)-R20, -S(O)2-R20 or -S(O)2-NR5R21 radical; or (3) -NR5R21, -NR22-C(O)-R21 or -NR22-S(O)2-R20 radical;
each R20 is independently (1) C1-C6 alkyl radicals optionally substituted by 1-3 radicals of -CO2R23, amino, methylamino, dimethylamino, t-butoxycarbonylamino, N-((t-butoxy)carbonyl)-N-(methyl)amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl, methylsulfonyl, halo or C5-C6 cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by t-butoxycarbonyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals; and each R21 is independently hydrogen radical or R20.
18. The compound of Claim 17 or a pharmaceutically acceptable salt thereof, wherein Y is a -OR21, -SR21 or -NR5R21 radical;
each R20 is independently (1) C1-C6 alkyl radicals optionally substituted by 1-3 radicals of amino, methylamino, dimethylamino, hydroxy or phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
(2) heterocyclyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
each R21 is independently hydrogen radical or R20;
R11 is an unsubstituted phenyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfonyl, methyl or trifluoromethyl radicals; and R12 is a 4-pyridyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals.

19. The compound of Claim 2 or a pharmaceutically acceptable salt thereof, wherein X is O or S;

provided that the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in -VC(R)W- is 0-2;

each R21 is independently a hydrogen radical or (1) C1-C8 alkyl or C2-C5 alkenyl radicals optionally substituted by 1-3 radicals of -CO2R23, amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, N-((C1-C4 alkoxy)carbonyl)-N-(C1-C4 alkyl)amino, aminocarbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo or aryl-C1-C4-alkoxy, aryl-C1-C4-alkylthio, aryl-C1-C4-alkylsulfonyl, C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, C1-C5 alkanoyl, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;

(2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy)carbonyl,-hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;

each R23 is independently hydrogen or C1-C4 alkyl, or phenyl, heteroaryl; phenyl-C1-C2-alkyl or heteroaryl-C1-C2-alkyl optionally substituted by 1-3 radicals of amino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;

R11 is an aryl radical and R12 is a heteroaryl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of (1) R30;

(2) halo or cyano radicals;

(3) -C (O) R30, -C (O) -OR29, -C (O) -NR31R32 or -C (NR31) -NR31R32 radicals; or (4) -OR29, -SR29, -S (O) -R30, -S (O) 2-R30, -S (O) 2-NR31R32, -NR31R32 or -NR33-C (O) -R29 radicals;

provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R11 and R12 is 0-1;

each R30 is independently (1) C1-C4 alkyl radical optionally substituted by (a) amino, C1-C4 alkylamino or di-(C1-C4-alkyl)amino radicals; or (b) hydroxy. C1-C4 alkoxy, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl) amino, C1-C5 alkanoylamino, (-C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;

(2) C1-C2 haloalkyl of 1-3 halo radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;

each R29 is independently hydrogen radical or R30 each R31, is independently hydrogen or C1-C4 alkyl-radicals; and each R32 is independently (1) hydrogen radicals;

(2) C1-C4 alkyl radical optionally substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkyl or trifluoromethyl radicals; or (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkyl or trifluoromethyl radicals; and each R33 is independently hydrogen or methyl radical;
and wherein heterocyclyl is a radical of a monocyclic saturated heterocyclic ring system having 5-6 ring members, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused and optionally substituted by 1-2 oxo or thioxo radicals; aryl is a phenyl or naphthyl radical; and heteroaryl is radical of a monocyclic aromatic heterocyclic ring system having 5-6 ring members, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused or saturated C3-C4-carbocyclic-fused.

20. The compound of Claim 19 or a pharmaceutically acceptable salt thereof, wherein U is NR21;

each R23 is independently hydrogen or C1-C4 alkyl, or phenyl, heteroaryl, phenyl-C1-C2-alkyl or heteroaryl-C1-C2-alkyl optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;

R11 is an aryl radical and R12 is a heteroaryl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of (1) R30:
(2) halo or cyano radicals;
(3) -C (0) -R30 -C (O) -OR29 , -C (O) -NR31R32 or -C (NR31)-NR31R32 radicals; or (4) -OR29, -SR29, -S(O)-R30, -S (O) 2-R30. -S (O) 2-NR31R32.
-NR31R32 or NR33-C (O) -R29 radicals;
provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R11 and R12 is 4-1;

each R30 is independently (1) C1-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, acetamido, hydroxy, C1-C2 alkoxy, halo, C1-C4 alkyl or trifluoromethyl radicals;

(2) trifluoromethyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, acetamido, hydroxy, C1-C2 alkoxy, halo, C1-C4 alkyl or trifluoromethyl radicals;

each R29 is independently hydrogen radical or R30; and each R32 is independently (1) hydrogen radicals;

(2) C1-C4 alkyl radical or C1-C2 alkyl radical substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino; di-(C1-C2 alkyl)amino, acetamido, hydroxy, C1-C2 alkoxy, C1-C4 alkyl or trifluoromethyl radicals; or (3) phenyl or heteroaryl radical optionally substituted -by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, acetamido, hydroxy, C1-C2 alkoxy, C1-C4 alkyl or trifluoromethyl radicals; and wherein heterocyclyl is a radical of a monocyclic saturated heterocyclic ring system having 5-6 ring members, wherein 1-2 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused and optionally substituted by 1-2 oxo or thioxo radicals; aryl is a phenyl or naphthyl radical; and heteroaryl is radical of a monocyclic aromatic heterocyclic ring system having 5-6 ring members, wherein 1-2 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused.

21. The compound of Claim 20 or a pharmaceutically acceptable salt thereof, wherein each R21 is independently a hydrogen radical or (1) C1-C8 alkyl or C2-C5 alkenyl radicals optionally substituted by 1-3 radicals of -CO2R23, amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, N-((C1-C4 alkoxy)carbonyl)-N-(C1-C4 alkyl)amino, aminocarbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo or aryl-C1-C4-alkoxy, aryl-C1-C4-alkylthio, aryl-C1-C4-alkylsulfonyl, C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, C1-C5 alkanoyl, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;

(2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(C1-C4 alkyl)amino, (C1-C4 alkoxy)carbonylamino, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, acetamido, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or trifluoromethyl radicals;

each R23 is independently hydrogen or C1-C4 alkyl, or phenyl-C1-C2-alkyl or heteroaryl-C1-C2-alkyl optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, acetamido, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;

each R24 is independently a hydrogen or C1-C4 alkyl radical;

R11 is an aryl radical and R12 is a heteroaryl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of (1) R30:

(2) halo or cyano radicals; or (3) -C(O)-NR31R32, -OR29, -SR29; -S(O)-R30, -S(O)2-R30,-S (O) 2-NR31R32. NR31R32 or -NR33-C (O) -R29 radicals;

provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R11 and R12 is 0-1%;

each R30 is independently (1) C1-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;

(2) trifluoromethyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;

each R29 is independently hydrogen radical or R30;

each R31 is independently hydrogen, methyl or ethyl radicals; and each R32 is independently (1) hydrogen radicals;

(2) C1-C4 alkyl radical or C1-C2 alkyl radical substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals; -or (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals.

22. The compound of Claim 21 or a pharmaceutically acceptable salt thereof, wherein R11 is an aryl radical optionally substituted by 1-2 radicals of (1) R30;

(2) halo or cyano radicals; or (3) -C (O) -NR31R32, -OR29. -SR29, -S (O) -R30, -S (O) 2-R30,-S(O) 2-NR31R32, -NR31R32 or -NR33-C (O) -R29 radicals; and R12 is a heteroaryl radical optionally substituted by 1-2 radicals of (1) R30:
(2) halo or cyano radicals; or (3) -C (O) -NR31R32, -OR29, -SR29. -NR31R32 or -NR33-C (O) -R29 radicals;

provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R11 and R12 is 0-1;

R30 is independently (1) C1-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;

(2) trifluoromethyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;

each R29 is independently hydrogen radical or R30;

R32 is independently (1) hydrogen or C1-C4 alkyl radical; or (2) phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals 23. The compound of Claim 22 or a pharmaceutically acceptable salt thereof, wherein each R21 is independently a hydrogen radical or (1) C1-C8 alkyl radicals optionally substituted by 1-3 radicals of -CO2R23, amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, N-((C1-C4 alkoxy)carbonyl)-N-(C1-C4 alkyl)amino, aminocarbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, halo or C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;

(2) heterocyclyl radical optionally substituted by 1-2 radicals of (C1-C4 alkoxy)carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of (C1-C4 alkoxy)carbonyl, amino, C1-C4 alkylamino, di- (C1-C4 alkyl ) amino, hydroxy, C1-C4, alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or trifluoromethyl radicals;

each R23 is independently hydrogen or C1-C4 alkyl, or phenyl-C1-C2-alkyl optionally substituted by 1-2 radicals of hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;

R11 is an aryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl, methylsulfonyl, aminocarbonyl, methyl or trifluoromethyl radicals; and R12 is a heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals.

24. The compound of Claim 23 or a pharmaceutically acceptable salt thereof, wherein each R21 is independently a hydrogen radical or (1) C1-C6 alkyl radicals optionally substituted by 1-3 radicals of -CO2R23, amino, methylamino, dimethylamino, t-butoxycarbonylamino, N-((t-butoxy)carbonyl)-N-(methyl)amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl, methylsulfonyl, halo or C5-C6 cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;

(2) heterocyclyl radical optionally substituted by t-butoxycarbonyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;

each R23 is independently hydrogen or C1-C4 alkyl radicals;

R11 is an unsubstituted phenyl or naphthyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl, methylsulfonyl, aminocarbonyl, methyl or trifluoromethyl radicals; and R12 is a 4-pyridyl, 4-quinolinyl, 4-imidazolyl or 4-pyrimidinyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals.

25. The compound of Claim 24 or a pharmaceutically acceptable salt thereof, wherein each R21 is independently a hydrogen radical or (1) C1-C6 alkyl radicals optionally substituted by 1-3 radicals of amino, methylamino, dimethylamino, hydroxy or phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino,-hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;

(2) heterocyclyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;

R11 is an unsubstituted phenyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfonyl, methyl or trifluoromethyl radicals; and R12 is a 4-pyridyl radical optionally substituted by-a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals.

26. The compound of Claim 1 which is:

2-(2,6-Dichlorobenzyl)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone, 2-(Butylamino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone, 2-(Benzylamino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone, 5-(4-Fluorophenyl)-3-methyl-((R-1-phenylethyl)amino)-(4-pyridyl)-4(3H)-pyrimidinone, 2-(2-(2-Chlorophenyl)-ethylamino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(8H)-pyrimidinone, 5-(4-Fluorophenyl)-2-(2-(4-fluorophenyl)-ethylamino)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone, 5-(4-Fluorophenyl)-2-((2-hydroxy-2-phenyl)-ethylamino)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone, 5-(4-Fluorophenyl)-3-methyl-2-((3-phenylpropyl)-amino)-6-(4-pyridyl) -4 (3H) -pyrimidinone, 5-(4-Fluorophenyl)-3-methyl-2-((1-methyl-3-phenylpropyl)-amino)-6-(4-pyridyl)-4(3H)-pyrimidinone, 5-(4-Fluorophenyl)-3-methyl-2-((R-1-methyl-3-phenylpropyl)-amino)-6-(4-pyridyl)-4(3H)-pyrimidinone, 5-(4-Fluorophenyl)-3-methyl-2-((2-phenylaminoethyl)-amino)-6-(4-pyridyl)-4(3H)-pyrimidinone, 5-(4-Fluorophenyl)-2-((3-imidazolylpropyl).-amino)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone.
5-(4-Fluorophenyl)-3-methyl-6-t4-pyridyl)-2-(3-(pyrrolidin-1-yl)-propylamino)-4(3H)-pyrimidinone, 3,6-biphenyl-4-(4-pyridyl)-2(1H)-pyridone, 6-(4-Methylphenyl)-3-phenyl-4-(4-pyridyl)-2(1H)-pyridone, 6-(4-Ethyiphenyl)-3-phenyl-4-(4-pyridyl)-2(1H)-pyridone, 6-(2,4-Dimethylphenyl)-3-phenyl-4-(4-pyridyl)-2(1H)-pyridone, 3-Phenyl-4-(4-pyridyl)-6-(2-thienyl)-2(1H)-pyridone, 6-(2-Furyl)-3-phenyl-4-(4-pyridyl)-2(1H)-pyridone, 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone, 2-(((R)-2-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone, 2-(((S)-2-N-Ethyl-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone, 2-((2-Amino-2-methy-3-phehylpropyl)amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone, 2-((2-Aminomethy-3-phenylpropyl)-amino)-5-(4-fluorophenyl-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone, 2-((3-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone, 5-(4-Fluorophenyl)-3-methyl-2-(3-(2- .
methylphenyl)propyl)-amino)-6.-(4-pyridyl)-4(3H)-pyrimidinone, 5-(4-Fluorophenyl)-3-methyl-2-((R,S)-2-amino-3-(2'-fluorophenyl)-propyl-amino)-6-(4-pyridyl)-4(3H)-pyrimidinone, 2-(((S)-2-Acetamido-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone, 5-(4-Fluorophenyl)-2-(((S)-2-N-isopropylamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone, 2-(((S)-2-N-N-Butylamino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone, 2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-5-(4-fluorophenyl-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone, 5-(4-Fluorophenyl)-3-methyl-2-((2-methy-3-phenylpropyl) amino)-6-(4-pyridyl)-4(3H)-pyrimidinone, 2-(((S)-2-Amino-3-phenylpropyl)-amino)-3-ethyl-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone, 3-Ethyl-5-(4-fluorophenyl)-2-((2-methy-3-phenylpropyl) amino)-6-(4-pyridyl)-4(3H)-pyrimidinone, 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine, 2-((2-(3-trifluoromethylphenyl)phenylmethyl)amino)-3-methyl-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone, 3-Methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(4-tolyl)-6-(4-pyridyl)-4(3H)-pyrimidinone, 3-Methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(4-trifluoromethylphenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone, 3-Methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(3-isopropylphenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone, 3-Methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(3-chloro-4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone, 3-Methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(3,5-bis(trifluoromethyl)phenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone, 3-Methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(3,4-dichlorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone, 3-Methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(1-naphthyl)-6-(4-pyridyl)-4(3H)-pyrimidinone, 3-Methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(3-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone, 3-Methyl-2-(2(S)-amino-3-phenylpropylamino)-5-(3-trifluoromethylphenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone, 3-Methyl-2-(3-phenylpropylamino)-5-(3,5-dichlorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone, 3-Methyl-2-(3-phenylpropylamino)-5-(4-tolyl)-6-(4-pyridyl)-4(3H)-pyrimidinone, 3-Methyl-2-(3-phenylpropylamino)-5-(3-trifluoromethylphenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone, 3-Methyl-2-(3-phenylpropylamino)-5-(4-methoxyphenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone, 3-Methyl-2-(3-phenylpropylamino)-5-(4-trifluoromethylphenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone, 3-Methyl-2-(2-methyl-3-phenylpropylamino)-5-(3-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone, 3-Methyl-2-(2-methyl-3-phenylpropylamino)-5-(1-naphthyl)-6-(4-pyridyl)-4(3H)-pyrimidinone, 5-(4-Fluorophenyl)-2-(((S)-2-N-glycylamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone, 2-(((S)-2-N-Glycylamino-3-phenylpropyl)-amino)-3-methyl-5-(3-methylphenyl)-6-(4-pyridyl)-4-(3H)-pyrimidinone, 5-(4-Fluorophenyl)-2-(((S)-2-hydroxyacetamido-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone, 5-(4-Fluorophenyl)-2-(((S)-2-pyrrolidinyl-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4-(3H-)-pyrimidinone, 2-((S)-3-Benzylpiperazinyl)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone, 2-((3-Amino-3-(2-fluorophenyl)propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone, 2-((3-Amino-3-(2-methylphenyl)propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone, 2-(((S)-3-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone, 2-(((R)-3-Amino-3-phenylpropyl}-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone, 2-(((S)-3-Amino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)5-(3-trifluoromethylphenyl)-4-(3H)-pyrimidinone, 2-(((R)-3-Amino-3-phenylpropyl)-amino)-3-methyl-5-(4-pyridyl)5-(3-trifluoromethylphenyl)-4-(3H)-pyrimidinone, 2-((3-Amino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)5-(3-trifluoromethylphenyl)-4-(3H)-pyrimidinone, 2-((3-Amino-3-(2-methylphenyl)propyl)-amino)-3-methyl-6-(4-pyridyl)5-(3-trifluoromethylphenyl)-4-(3H)-pyrimidinone;
2-((3-Amino-3-(2-fluorophenyl)propyl)-amino)-3-methyl-6-(4-pyridyl)5-(3-trifluoromethylphenyl)-4-(3H)-pyrimidinone, 2-((3-Amino-3-phenylpropyl)-amino)-3-methyl-5-(3-methylphenyl)-6-(4-pyridyl)-4-(3H)-pyrimidinone, 2-((3-Amino-3-(2-fluorophenyl)propyl)-amino)-3-methyl-5-(3-methylphenyl)-6-(4-pyridyl)-4-(3H)-pyrimidinone, 2-((3-Amino-3-(2-chlorophenyl)propyl)-amino)-3-methyl-5-(3-methylphenyl)-6-(4-pyridyl)-4-(3H)-pyrimidinone, 2-(((S)-3-Amino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)5-(3,4-dimethylphenyl)-4-(3H)-pyrimidinone, 2-(((2R,3R)-3-Amino-2-methyl-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone, 2-(((2S,3S)-3-Amino-2-methyl-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone, 5-(4-Fluorophenyl)-2-(((S)-3-N-isopropylamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone, 5-(4-Fluorophenyl)-2-(((R)-3-N-isopropylamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone, 5-(4-Fluorophenyl)-3-methyl-6-(4-pyridyl)-2-((S)-tetrahydroisoguinol-3-ylmethylenamino)-4-(3H)-pyrimidinone, 3-Methyl-6-(4-pyridyl)-2-((S)-tetrahydroisoquinol-3-ylmethylenamino)- 5-(3-trifluoromethylphenyl)-4-(3H}-pyrimidinone, 3-Methyl-5-(3-methylphenyl)-6-(4-pyridyl)-2-((S)-tetrahydroisoquinol-3-ylmethylenamino)-4-(3H)-pyrimidinone, 3-Methyl-5-(4-methylthiophenyl)-6-(4-pyridyl)-2-((S)-tetrahydroisoquinol-3-ylmethylenamino)-4-(3H)-pyrimidinone, 2-(((S)-2-Amino-3-phenylpropyl)-amino)-3-methyl-5-(3-methylphenyl)-6-(4-pyridyl)-4-(3H)-pyrimidinone, 5-(4-Fluorophenyl)-2-((3-hydroxy-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone, 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-6-(4-pyridyl)-4-(3H)-pyrimidinone, 2-(((S)-2-Amino-3-(2-fluorophenyl)propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone, 2-(((S)-2-Amino-3-(4-fluorophenyl)propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone, 2-(((S)-2-Amino-3-(2-chlorophenyl)propyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone, 2-(((S)-2-N-Isopropylamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluoromethylphenyl)-4-(3H)-pyrimidinone, 2-(((S)-2-N-Isopropylamino-3-phenylpropyl)-amino)-3-methyl-5-(3-methylphenyl)-6-(4-pyridyl)-4-(3H)-pyrimidinone, 5-(3-Chlorophenyl-2-(((S)-2-N-isopropylamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-4-(3H)-pyrimidinone, 2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-3-methyl-5-(3-methylphenyl)-6-(4-pyridyl)-4-(3H)-pyrimidinone, 2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-3-methyl-5-(3-chlorophenyl)-6-(4-pyridyl)-4-(3H)-pyrimidinone, 2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-3-methyl-6-(4-pyridyl)-5-(3-trifluorophenyl)-4-(3H)-pyrimidinone or 5-(4-Fluorophenyl)-3-methyl-2-(((S)-2-N-methylamino-3-phenylpropyl)-amino)-6-(4-pyridyl)-4-(3H)-pyrimidinone or a pharmaceutically acceptable salt thereof.

27. A pharmaceutical composition comprising a compound of any one of Claims 1 to 26 and a pharmaceutically acceptable carrier.

28. A use of an effective amount of a compound of any one of Claims 1 to 26 for prophylaxis or treatment of inflammation.

29. A use of an effective amount of a compound of any one of Claims 1 to 26 for the production of a medicament for prophylaxis or treatment of inflammation.

30. A use of an effective amount of a composition of Claim 27 for prophylaxis or treatment of inflammation.

31. A use of an effective amount of a composition of Claim 27 for the production of a medicament for prophylaxis or treatment of inflammation.

32. A use of an effective amount of a compound of any one of Claims 1 to 26 for lowering plasma concentrations of either or both TNF-.alpha.-wand IL-1.

33. A use of an effective amount of a compound of any one of Claims 1 to 26 for the production of a medicament for lowering plasma concentrations of either or both TNF-.alpha. and IL-1.

34. A use of an effective amount of a composition of Claim 27 for lowering plasma concentrations of either or both TNF-.alpha. and IL-1.

35. A use of an effective amount of a composition of Claim 27 for the production of a medicament for lowering plasma concentrations of either or both TNF-.alpha. and IL-1.

36. A use of an effective amount of a compound of any one of Claims 1 to 26 for lowering plasma concentrations of either or both IL-6 and IL-8.

37. A use of an effective amount of a compound of any one of Claims 1 to 26 for the production of a medicament for lowering plasma concentrations of either or both IL-6 and IL-8.

38. A use of an effective amount of a composition of Claim 27 for lowering plasma concentrations of either or both-IL-6 and IL-8.

39. A use of an effective amount of a composition of Claim 27 for the production of a medicament for lowering plasma concentrations of either or both IL-6 and IL-8.

40. A use of an effective amount of a compound according to any one of Claims 1 to 26 to produce a glucagon antagonist effect for prophylaxis or treatment of diabetes disease in a mammal in need thereof.

41. A use of an effective amount of a compound according to any one of Claims 1 to 26 to produce a glucagon antagonist effect for the production of a medicament for prophylaxis or treatment of diabetes disease in a mammal in need thereof.

42. A use of an effective amount of a pharmaceutical composition according to Claim 27 to produce a glucagon antagonist effect for prophylaxis or treatment of diabetes disease in a mammal.

43. A use of an effective amount of a pharmaceutical composition according to Claim 27 to produce a glucagon antagonist effect for the production of a medicament for prophylaxis or treatment of diabetes disease in a mammal.

44. A use of an effective amount of a compound according to any one of Claims 1 o 26 for prophylaxis or treatment of a pain disorder in a mammal in need thereof.

45. A use of an effective amount of a compound according to any one of Claims 1 to 26 for the production of a medicament for prophylaxis or treatment of a pain disorder in a mammal in need thereof.

46. A use of an effective amount of a pharmaceutical composition according to Claim 27 for prophylaxis or treatment of a pain disorder in a mammal in need thereof.

47. A use of an effective amount of a pharmaceutical composition according to Claim 27 for the production of a medicament for prophylaxis or treatment of a pain disorder in a mammal in need thereof.

48. A use of an effective amount of a compound according to any one of Claims 1 to 26 for decreasing prostaglandins production in a mammal in need thereof.

49. A use of an effective amount of a compound according to any one of Claims 1 to 26 for the production of a medicament for decreasing prostaglandins production in a mammal in need thereof.

50. A use of an effective amount of a pharmaceutical composition according to Claim 27 for decreasing prostaglandins production in a mammal in need thereof.

51. A use of an effective amount of a pharmaceutical composition according to Claim 27 for the production of a medicament for decreasing prostaglandins production in a mammal in need thereof.

52. A use of an effective amount of a compound according to any one of Claims 1 to 26 for decreasing cyclooxygenase enzyme activity in a mammal in need thereof.

53. A use of an effective amount of a compound according to any one of Claims 1 to 26 for the production of a medicament for decreasing cyclooxygenase enzyme activity in a mammal in need thereof.

54. The use of Claim 52 or 53 wherein the cyclooxygenase enzyme is COX-2.

55. A use of an effective amount of a pharmaceutical composition according to Claim 27 for decreasing cyclooxygenase enzyme activity in a mammal in need thereof.

56. A use of an effective amount of a pharmaceutical composition according to Claim 27 for the production of a medicament for decreasing cyclooxygenase enzyme activity in a mammal in need thereon.

57. ~The use of Claim 55 or 56 wherein the cyclooxygenase enzyme is COX-2.
CA002274093A 1996-12-05 1997-12-04 Substituted pyrimidinone and pyridinone compounds and their use Expired - Fee Related CA2274093C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US3212896P 1996-12-05 1996-12-05
US60/032,128 1996-12-05
US5095097P 1997-06-13 1997-06-13
US60/050,950 1997-06-13
US97605397A 1997-11-21 1997-11-21
US08/976,053 1997-11-21
PCT/US1997/022949 WO1998024780A2 (en) 1996-12-05 1997-12-04 Substituted pyrimidinone and pyridinone compounds and their use

Publications (2)

Publication Number Publication Date
CA2274093A1 CA2274093A1 (en) 1998-06-11
CA2274093C true CA2274093C (en) 2006-11-07

Family

ID=27364029

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002274093A Expired - Fee Related CA2274093C (en) 1996-12-05 1997-12-04 Substituted pyrimidinone and pyridinone compounds and their use

Country Status (13)

Country Link
EP (1) EP0948496A2 (en)
JP (1) JP2002514196A (en)
KR (1) KR100476586B1 (en)
CN (1) CN1328277C (en)
AU (1) AU735901C (en)
BG (1) BG65129B1 (en)
BR (1) BR9713863A (en)
CA (1) CA2274093C (en)
CZ (1) CZ9902016A3 (en)
HU (1) HUP0001140A3 (en)
IL (1) IL130181A0 (en)
NZ (1) NZ335992A (en)
WO (1) WO1998024780A2 (en)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410729B1 (en) * 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU1924699A (en) 1997-12-19 1999-07-12 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
AR023052A1 (en) * 1998-09-25 2002-09-04 Mitsuharu Yoshimura Milton DERIVATIVES OF PIRIMIDONA
ES2212657T3 (en) 1998-11-04 2004-07-16 Smithkline Beecham Corporation REPLACED PIRAZINAS PIRIDIN-4-IL OR PIRIMIDIN-4-IL.
GB9910378D0 (en) * 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
US6403596B1 (en) 1999-06-28 2002-06-11 Merck & Co., Inc. Substituted pyridones having cytokine inhibitory activity
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US6982270B1 (en) 1999-11-23 2006-01-03 Smithkline Beecham Corporation 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
WO2001038314A1 (en) 1999-11-23 2001-05-31 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
EP1136493A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-(Thienopyridinyl)pyrimidone, 2-(furopyridinyl)pyrimidone 2-(isoquinolinyl)pyrimidone, 2-(pyridoindolyl)pyrimidone and 2-(benzofuropyridinyl)pyrimidone derivatives
EP1136099A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-(Indolylalkylamino)pyrimidone derivatives as GSK3beta inhibitors
JP2005289808A (en) * 2000-03-23 2005-10-20 Sanofi-Aventis 3-substituted-4-pyrimidone derivative
EP1136482A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
HUP0300927A2 (en) 2000-04-26 2003-07-28 Eisai Co., Ltd. Medicinal compositions promoting bowel movement, containing new pyrimidine derivatives
DE60137426D1 (en) 2000-06-12 2009-03-05 Eisai R&D Man Co Ltd 1,2-Dihydropyridine compounds, process for their preparation and their use
JP2004509867A (en) * 2000-09-19 2004-04-02 サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、（セーエヌエルエス） Pyridinone and pyridinethione derivatives having HIV inhibitory properties
GB0024808D0 (en) * 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
US6821960B2 (en) 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
US6706744B2 (en) 2000-11-17 2004-03-16 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU2002223500A1 (en) 2000-11-17 2002-05-27 Novo-Nordisk A/S Glucagon antagonists/inverse agonists
EP1295885A1 (en) * 2001-09-21 2003-03-26 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives
EP1295884A1 (en) * 2001-09-21 2003-03-26 Sanofi-Synthelabo 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives
EP1674456B1 (en) 2001-09-21 2008-07-16 Sanofi-Aventis Use of 2-fluoro- 3-ketoesters for preparing 3-fluoro-6,7,8,9-tetrahydro-4-H-pyrimdo[1,2-a]pyrimidin-4-ones
AU2002337498B2 (en) 2001-09-21 2006-08-10 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
DE60206946T2 (en) * 2001-09-21 2006-07-27 Sanofi-Aventis SUBSTITUTED 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO [1,2-A] PYRIMIDIN-4-ON- AND 7-PYRIMIDINYL-2,3-DIHYDROIMIDAZO [1,2-A] PYRIMIDIN-5 (1H) ON DERIVATIVES AGAINST NEURODEEGENERATIVE DISEASES
TWI330183B (en) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
TWI301834B (en) * 2001-10-22 2008-10-11 Eisai R&D Man Co Ltd Pyrimidone compound and pharmaceutical composition including the same
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
US20050070555A1 (en) * 2001-12-21 2005-03-31 Bayer Healthcare Ag Aroyl pyridinones
AU2003216585A1 (en) * 2002-04-10 2003-10-20 Orchid Chemicals And Pharmaceuticals Limited Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases
WO2003099808A1 (en) * 2002-05-21 2003-12-04 Amgen Inc. Substituted heterocyclic compounds and methods of use
EP1534282B1 (en) 2002-07-09 2006-12-27 Boehringer Ingelheim Pharma GmbH & Co.KG Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
EA009027B1 (en) 2002-12-16 2007-10-26 Мицубиси Фарма Корпорейшн 3-substituted-4-pirimidone derivatives
TWI357408B (en) 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives
US20070167621A1 (en) 2003-04-03 2007-07-19 Pharmacia Corporation Substituted pyrimidinones
US7183287B2 (en) * 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
AU2004261587B2 (en) * 2003-07-25 2008-02-21 Amgen Inc. Substituted pyridones and pyrimidinones with antiinflammatory properties
CN1867560A (en) * 2003-08-13 2006-11-22 武田药品工株式会社 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
CA2535644A1 (en) 2003-08-20 2005-03-03 Amgen Inc. Substituted pyrimdinone derivatives and methods of use
SE0302486D0 (en) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
EP1557417B1 (en) * 2003-12-19 2007-03-07 Sanofi-Aventis Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006040649A1 (en) 2004-10-13 2006-04-20 Pharmacia & Upjohn Company Llc Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6h)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide
JP2008524233A (en) * 2004-12-16 2008-07-10 バーテックス ファーマシューティカルズ インコーポレイテッド Pyrid-2-ones useful as inhibitors of TEC family protein kinases for the treatment of inflammatory, proliferative and immune-mediated diseases
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
NZ566799A (en) 2005-09-14 2011-04-29 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors for treating diabetes
WO2007035629A2 (en) 2005-09-16 2007-03-29 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
AR059898A1 (en) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv DERIVATIVES OF 3-CIANO-PIRIDONA 1,4-DISUSTITUTED AND ITS USE AS ALLOSTERIC MODULATORS OF MGLUR2 RECEIVERS
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
WO2008104752A1 (en) * 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropyridones as elastase inhibitors
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
KR101520086B1 (en) 2007-09-14 2015-05-14 얀센 파마슈티칼스 인코포레이티드 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1'H-[1,4']bipyridinyl-2'-ones
NZ584152A (en) 2007-09-14 2011-11-25 Ortho Mcneil Janssen Pharm 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
CA2703996A1 (en) 2007-11-06 2009-05-14 Astrazeneca Ab Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
CA2735764C (en) 2008-09-02 2016-06-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
JP5592388B2 (en) * 2008-10-31 2014-09-17 メルク・シャープ・アンド・ドーム・コーポレーション Technical field of P2X3 receptor antagonist for the treatment of pain
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
BRPI1012870B8 (en) 2009-05-12 2021-05-25 Addex Pharmaceuticals Sa 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors and pharmaceutical composition
EA020671B1 (en) 2009-05-12 2014-12-30 Янссен Фармасьютикалз, Инк. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF mGluR2 RECEPTORS
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP2013506649A (en) 2009-10-02 2013-02-28 アストラゼネカ・アクチエボラーグ 2-pyridone compounds used as inhibitors of neutrophil elastase
PT2649069E (en) 2010-11-08 2015-11-20 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
NZ611529A (en) 2010-12-23 2015-06-26 Pfizer Glucagon receptor modulators
CN104744370A (en) 2011-02-08 2015-07-01 辉瑞大药厂 Glucagon receptor modulators
RU2013143839A (en) 2011-02-28 2015-04-10 Эррэй Биофарма Инк. SERIN / THREONINE KINASE INHIBITORS
BR112014000288A2 (en) 2011-07-22 2017-01-10 Pfizer quinolinyl glucagon receptor modulators
BR112014002675A2 (en) 2011-08-04 2017-02-21 Array Biopharma Inc "Quinazoline as serine / threonine kinase inhibitors, their uses, and composition"
UA108713C2 (en) 2011-11-11 2015-05-25 2-Thiopyrimidinones
CN103130787B (en) * 2011-11-24 2015-06-10 南开大学 Pyrimidone amide compound, and preparation method, anti-HIV activity and anti-TMV activity thereof
HUE037423T2 (en) 2012-03-01 2018-08-28 Array Biopharma Inc Serine/threonine kinase inhibitors
CN105143200B (en) 2012-08-27 2018-10-16 阵列生物制药公司 Serine/threonine kinase inhibitor for treating excess proliferative disease
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
ME03518B (en) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
KR102502485B1 (en) 2014-01-21 2023-02-21 얀센 파마슈티카 엔.브이. Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
KR101693781B1 (en) * 2014-10-06 2017-01-09 한양대학교 에리카산학협력단 Method for producing difluoroalkylated amromatics
EP3292109A1 (en) 2015-05-05 2018-03-14 Pfizer Inc 2-thiopyrimidinones
CN107200731B (en) * 2017-06-11 2020-10-23 湖南科技大学 Thiazole ring-containing pyridone derivative and preparation method and application thereof
CN110078674B (en) * 2019-04-10 2022-11-01 昆明理工大学 Preparation method of 2-alkyl amino pyrimidone
JP7254246B2 (en) 2019-11-25 2023-04-07 アムジエン・インコーポレーテツド Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use
CN115650906A (en) * 2022-11-04 2023-01-31 苏州艾缇克药物化学有限公司 Preparation method of 2-aminoisonicotinic acid
US11993580B1 (en) 2022-12-02 2024-05-28 Neumora Therapeutics, Inc. Methods of treating neurological disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1271116B (en) * 1965-05-04 1968-06-27 Bayer Ag Process for the preparation of 4-hydroxypyrimidines
JPS6163680A (en) * 1984-09-05 1986-04-01 Kanto Ishi Pharma Co Ltd Pyrimido(1,2-a)benzimidazole derivative and its preparation
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
CZ292707B6 (en) * 1995-10-06 2003-11-12 Merck & Co., Inc Imidazole derivatives and pharmaceutical formulation in which the derivatives are comprised
EP0859771A4 (en) * 1995-10-31 2000-03-15 Merck & Co Inc Substituted pyridyl pyrroles, compositions containing such compounds and methods of use

Also Published As

Publication number Publication date
CZ9902016A3 (en) 1999-11-17
WO1998024780A2 (en) 1998-06-11
CA2274093A1 (en) 1998-06-11
HUP0001140A3 (en) 2002-05-28
AU735901C (en) 2004-02-12
EP0948496A2 (en) 1999-10-13
BG65129B1 (en) 2007-03-30
BG103521A (en) 2000-07-31
AU5525498A (en) 1998-06-29
HUP0001140A2 (en) 2001-04-28
KR20000069329A (en) 2000-11-25
JP2002514196A (en) 2002-05-14
KR100476586B1 (en) 2005-03-18
IL130181A0 (en) 2000-06-01
AU735901B2 (en) 2001-07-19
WO1998024780A3 (en) 1998-07-30
BR9713863A (en) 2000-03-14
NZ335992A (en) 2001-09-28
CN1246857A (en) 2000-03-08
CN1328277C (en) 2007-07-25

Similar Documents

Publication Publication Date Title
CA2274093C (en) Substituted pyrimidinone and pyridinone compounds and their use
US6420385B1 (en) Substituted pyrimidinone and pyridone compounds and methods of use
US6610698B2 (en) Substituted pyrimidine compounds and methods of use
AU755421B2 (en) Substituted pyridine and pyridazine compounds and their pharmaceutical use
WO1998024782A2 (en) Substituted pyrimidine compounds and their use
US6174901B1 (en) Substituted pyridine and pyridazine compounds and methods of use
US6440973B1 (en) Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
WO1998022457A9 (en) Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
CA2274063C (en) Substituted pyrimidine compounds and their use
AU8142901A (en) Substituted pyrimidinone and pyridone compounds and methods of use
EP1314731A2 (en) Substituted pyrimidine compounds and their use
MXPA99005168A (en) Substituted pyrimidine compounds and their use
KR20000069328A (en) Substituted pyrimidine compounds and their use

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed